REFERENCES FOR DRUGS IN CATEGORY A ALLOPURINOL

Transcription

REFERENCES FOR DRUGS IN CATEGORY A
ALLOPURINOL
Simmons F, Feldman B, Gerety D. Granulomatous hepatitis in a
patient receiving allopurinol. Gastroenterology 1972; 62: 101-4.
Young JL, Boswell RB, Nies AS. Severe allopurinol hypersensitivity.
Association with thiazides and prior renal compromise. Arch Intern
Med 1974; 134: 553-8.
McMenamin RA, Davies LM, Craswell PW. Drug induced interstitial
nephritis, hepatitis and exfoliative dermatitis. Aust N Z J Med 1976;
6: 583-7.
Boyer TD, Sun N, Reynolds TB. Allopurinol-hypersensitivity
vasculitis and liver damage. West J Med 1977; 126: 143-7.
Espiritu CR, Alalu J, Glueckauf LG, Lubin J. Allopurinol-induced
granulomatous hepatitis. Am J Dig Dis 1976; 21: 804-6.
Chawla SK, Patel HD, Parrino GR, Soterakis J, Lopresti PA, D'Angelo
WA. Allopurinol hepatotoxicity. Case report and literature review.
Arthritis Rheum 1977; 20: 1546-9.
Butler RC, Shah SM, Grunow WA, Tester EC. Massive hepatic
necrosis in a patient receiving allopurinol. JAMA 1977; 237: 473-4.
Shah SM, Butler RC, Grunow WA, Texter EC Jr. Massive hepatic
necrosis in a patient receiving concomitant medication. JAMA 1977;
237: 2036.
Swank LA, Chejfec G, Nemchausky BA. Allopurinol-induced
granulomatous hepatitis with cholangitis and a sarcoid-like reaction.
Arch Intern Med 1978; 138: 997-8.
Male PJ, Schaer B, Posternak R. Reaction d'hypersensibilite a
l'allopurinol. Schweiz Med Wochenschr 1978; 108: 661-3.
Medline A, Cohen LB, Tobe BA, Sellers EM. Liver granulomas and
allopurinol. Br Med J 1978; 108: 681-2.
Korting HC, Lesch R. Acute cholangitis after allopurinol treatment.
Lancet 1978; 1: 275-6.
Haughey DB, Lanse S, Imhoff T, Tobin M, Schentag JJ. Allopurinol
sensitivity: report of two cases. Am J Hosp Pharm 1979; 36: 137780.
Lang PG. Severe hypersensitivity reactions to allopurinol. South Med
J 1979; 72: 1361-8.
Olsen H, Mrland J. [Hepatic damages caused by allopurinol] Tidsskr
Nor Laegeforen 1980; 100: 562-3.
Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG.
Allopurinol hepatotoxicity. Report of two cases and review of
literature. Ann Intern Med 1981; 95: 588-90.
Shah KA, Levin J, Rosen N, Greenwald E, Zumoff B. Allopurinol
hepatotoxicity potentiated by tamoxifen. N Y State J Med 1982; 82:
1745-6.
Ramond MJ, Nouel O, Degott C, Lebrec D, Benhamou JP.
[Allopurinol-induced hepatitis. Report of a case and review of the
literature (author's transl)] Gastroenterol Clin Biol 1982; 6: 138-42.
Raper R, Ibels L, Lauer C, Barnes P, Lunzer M. Fulminant hepatic
failure due to allopurinol. Aust NZ J Med 1984; 14: 63-5.
Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity.
Description and guidelines for prevention in patients with renal
insufficiency. Am J Med 1984; 76: 47-56.
Ohsawa T, Ohtsubo M. Hepatitis associated with allopurinol. Drug
Intell Clin Pharm 1985; 19: 431-3.
Mousson C, Justrabo E, Tanter Y, Chalopin JM, Rifle G. [Acute
granulomatous interstitial nephritis and hepatitis caused by drugs.
Possible role of an allopurinol-furosemide combination] Nephrologie
1986; 7: 199-203.
Vanderstigel M, Zafrani ES, Lejonc JL, Schaeffer A, Portos JL.
Allopurinol hypersensitivity syndrome as a cause of hepatic fibrinring granulomas. Gastroenterol 1986; 90: 188-90.
Pewsner D, Bachmann C, Müller U. [Allopurinol-induced kidney
failure with hepatitis and squamous dermatitis in pre-existing
kidney insufficiency] Schweiz Med Wochenschr 1987; 117: 139-41.
Olmos M, Guma C, Colombato LO, Lami G, Miyashiro R, Alvarez E.
[Hepatic lesions induced by drugs. Report of 26 cases] Acta
Gastroenterol Latinoam 1987; 17: 105-11. Spanish.
Stricker BH, Blok AP, Babany G, Benhamou JP. Fibrin ring
granulomas and allopurinol. Gastroenterology 1989; 96: 1199-203.
González Ramallo VJ, Rodríguez Gorostiza FJ, Muiño Míguez A,
López de la Riva M. [Severe cholestasis caused by allopurinol] Rev
Esp Enferm Apar Dig 1989; 75: 317-8. Spanish.
Tam S, Carroll W. Allopurinol hepatotoxicity. Am J Med 1989; 86:
357-8.
Arellano F, Sacristán JA. Allopurinol hypersensitivity syndrome: a
review. Ann Pharmacother 1993; 27: 337-43
Berbegal J, Morera J, Andrada E, Navarro V, Lluch V, López-Benito
I. [Syndrome of allopurinol hypersensitivity. Report of a new case
and review of the Spanish literature] Med Clin (Barc) 1994; 102:
178-80. Spanish.
Lee SS, Lin HY, Wang SR, Tsai YY. Allopurinol hypersensitivity
syndrome. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi.
1994; 27: 140-7.
González U, Reyes E, Kershenovich J, Orozco-Topete RL.
[Hypersensitivity syndrome caused by allopurinol. A case of massive
hepatic necrosis] Rev Invest Clin 1995; 47: 409-13. Spanish.
Paitel JF, Trechot P, Stockemer V, Dorvaux V, Lederlin P. [Acute
liver disease during treatment with pipobroman and allopurinol]
Presse Med. 1995; 24:460.
Urban T, Maquarre E, Housset C, Chouaid C, Devin E, Lebeau B.
[Allopurinol hypersensitivity. A possible cause of hepatitis and
mucocutaneous eruptions in a patient undergoing antitubercular
treatment] Rev Mal Respir 1995; 12: 314-6.
Wade B, Klotz F, Debonne JM, Aubert M. [Fatal hepatitis due to
allopurinol in Dakar] Med Trop (Mars) 1995; 55: 186-7.
Andrade RJ, de la Mata M, Lucena MI, López-Rubio F, Corrales MA.
[Severe acute hepatitis due to allopurinol in a patient with
asymptomatic hyperuricemia and kidney failure. A review of the
literature and an analysis of the risk factors] Gastroenterol Hepatol
1997; 20: 353-6.
Pluim HJ, van Deuren M, Wetzels JFM. The allopurinol
hypersensitivity syndrome. Neth J Med 1998; 52: 107-110.
Kluger E. [Fatal outcome in allopurinol hypersensitivity syndrome]
Ugeskr Laeger 1998; 160: 1179-80. Danish.
Pereira S, Almeida J, Silva AO, Quintas M, Candeias O, Freitas F.
[Fatal liver necrosis due to allopurinol] Acta Med Port 1998; 11:
1141-4. Portuguese.
Khoo BP, Leow YH. A review of inpatients with adverse drug
reactions to allopurinol. Singapore Med J 2000; 41: 156-60.
Hammer B, Link A, Wagner A, Böhm M. [Hypersensitivity syndrome
during therapy with allopurinol in asymptomatic hyperuricemia with
a fatal outcome] Dtsch Med Wochenschr 2001; 126: 1331-4.
German.
Descamps V, Valance A, Edlinger C, Fillet AM, Crossin M, LerunVignes B, Belatch S, et al. Association of human herpesvirus 6
infection with drug reaction with eosinophilia and systemic
symptoms. Arch Dermatol 2001; 137: 301-4.
Vázquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R.
Relation between adverse events associated with allopurinol and
renal function in patients with gout. Ann Rheum Dis 2001; 60: 9813.
Muller P, Dubreil P, Mahé A, Lamaury I, Salzer B, Deloumeaux J,
Strobel M. Drug hypersensitivity syndrome in a West-Indian
population. Eur J Dermatol 2003; 13: 478-81.
Descamps V, Mahe E, Houhou N, Abramowitz L, Rozenberg F,
Ranger-Rogez S, Crickx B. Drug-induced hypersensitivity syndrome
associated with Epstein-Barr virus infection. Br J Dermatol 2003;
148: 1032-4.
Mete N, Yilmaz F, Gulbahar O, Avdin A, Sin A, Kokuludaq A, Yuce G,
Sebik F. Allopurinol hypersensitivity syndrome as a cause of hepatic
centrilobular hemorrhagic necrosis. J Investig Allergol Clin Immunol
2003; 13: 281-3.
Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver
transplantation for acute liver failure from drug-induced liver injury
in the United States. Liver Transpl 2004; 10: 1018-23.
Gutiérrez-Macías A, Lizarralde-Palacios E, Martínez-Odriozola P,
Miguel-De la Villa F. Fatal allopurinol hypersensitivity syndrome
after treatment of asymptomatic hyperuricaemia. BMJ 2005; 331:
623-4.
Saxena R, Loghmanee F. Fatal drug reaction due to allopurinol
therapy in a 72-year-old man. Arch Pathol Lab Med 2005; 129:
e183-4.
Choi SH, Yang SH, Song YB, Kim HJ, Seo YT, Choi DS, Moon KH, et
al. Allopurinol therapy and vanishing bile duct syndrome. Korean J
Hepatol 2005; 11: 80-85
Chiou CC, Yang LC, Hung SI, Chang YC, Kuo TT, Ho HC, Hu S, et al.
Clinicopathological features and prognosis of drug rash with
eosinophilia and systemic symptoms: a study of 30 cases in Taiwan.
J Eur Acad Dermatol Venereol 2008; 22: 1044-9.
Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck
JN, Sidoroff A, Naldi L, et al; EuroSCAR Study Group. Allopurinol is
the most common cause of Stevens-Johnson syndrome and toxic
epidermal necrolysis in Europe and Israel. J Am Acad Dermatol
2008; 58: 25-32.
Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K,
Sawada J, et al; JSAR research group. HLA-B locus in Japanese
patients with anti-epileptics and allopurinol-related Stevens-Johnson
syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008;
9: 1617-22.
Shalom R, Rimbroth S, Rozenman D, Markel A. Allopurinol-induced
recurrent DRESS syndrome: pathophysiology and treatment. Ren
Fail 2008; 30: 327-9.
Khanlari B, Bodmer M, Terracciano L, Heim MH, Fluckiger U,
Weisser M. Hepatitis with fibrin-ring granulomas. Infection 2008;
36: 381-3.
Yoon JY, Min SY, Park JY, Hong SG, Park SJ, Paik SY, Park YM. [A
case of allopurinol-induced granulomatous hepatitis with ductopenia
and cholestasis] Korean J Hepatol 2008; 14: 97-101.
Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, Naldi L,
et al; RegiSCAR study group. A European study of HLA-B in
Stevens-Johnson syndrome and toxic epidermal necrolysis related
to five high-risk drugs. Pharmacogenet Genomics 2008; 18: 99107.
Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J,
Reddy KR, Watkins PB, Navarro V, Barnhart H, Gu J, Serrano J
Features and Outcomes of 889 Patients with Drug-induced Liver
Injury: The DILIN Prospective Study. Gastroenterology. 2015 Mar 6.
pii: S0016-5085(15)00311-X.
Tausche AK, Aringer M, Schroeder HE, Bornstein SR, Wunderlich C,
Wozel G. The Janus faces of allopurinol-allopurinol hypersensitivity
syndrome. Am J Med 2008 ; 121: e3-4.
Eshki M, Allanore L, Musette P, Milpied B, Grange A, Guillaume JC,
Chosidow O, et al. Twelve-year analysis of severe cases of drug
reaction with eosinophilia and systemic symptoms: a cause of
unpredictable multiorgan failure. Arch Dermatol 2009; 145: 67-72.
Gyotoku E, Iwamoto T, Ochi M. [A fatal case of drug-induced
hypersensitivity syndrome due to allopurinol]. Arerugi 2009; 58:
560-6. Japanese.
Um SJ, Lee SK, Kim YH, Kim KH, Son CH, Roh MS, Lee MK. Clinical
features of drug-induced hypersensitivity syndrome in 38 patients. J
Investig Allergol Clin Immunol 2010; 20: 556-62.
Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group.
Drug-induced acute liver failure: results of a U.S. multicenter,
prospective study. Hepatology 2010; 52: 2065-76.
Botelho LF, Higashi VS, Padilha MH, Enokihara MM, Porro AM.
DRESS: clinicopathological features of 10 cases from an University
Hospital in São Paulo. An Bras Dermatol 2012; 87: 703-7.
Yaylacı S, Demir MV, Temiz T, Tamer A, Uslan MI. Allopurinolinduced DRESS syndrome. Indian J Pharmacol 2012; 44: 412-4.
Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C,
Dalbeth N. Starting dose is a risk factor for allopurinol
hypersensitivity syndrome: a proposed safe starting dose of
allopurinol. Arthritis Rheum 2012; 64: 2529-36.
Wongkitisophon P, Chanprapaph K, Rattanakaemakorn P,
Vachiramon V. Six-year retrospective review of drug reaction with
eosinophilia and systemic symptoms. Acta Derm Venereol 2012;
92: 200-5.
Bollaert M, Jeulin H, Waton J, Gastin I, Tréchot P, Rabaud C,
Schmutz JL, Barbaud A. [Six cases of spring DRESS]. Ann Dermatol
Venereol 2012; 139: 15-22.
Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer
D, Sidoroff A, et al; The RegiSCAR study group. Drug Reaction with
Eosinophilia and Systemic Symptoms (DRESS): an original
multisystem adverse drug reaction. Results from the prospective
RegiSCAR study. Br J Dermatol 2013; 169: 1071-80.
Ramasamy SN, Korb-Wells CS, Kannangara DR, Smith MW, Wang
N, Roberts DM, Graham GG, Williams KM, Day RO. Allopurinol
Hypersensitivity: A Systematic Review of All Published Cases, 19502012. Drug Saf 2013; 36: 954-80.
Walsh S, Diaz-Cano S, Higgins E, Morris-Jones R, Bashir S, Bernal
W, Creamer D. Drug reaction with eosinophilia and systemic
symptoms: is cutaneous phenotype a prognostic marker for
outcome? A review of clinicopathological features of 27 cases. Br J
Dermatol 2013; 168: 391-401.
Choi HG, Byun J, Moon CH, Yoon JH, Yang KY, Park SC, Han CJ.
Allopurinol-induced DRESS syndrome mimicking biliary obstruction.
Clin Mol Hepatol 2014; 20: 71-5.
Gonçalo M, Coutinho I, Teixeira V, Gameiro AR, Brites MM, Nunes R,
Martinho A. HLA-B*58:01 is a risk factor for allopurinol-induced
DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis
in a Portuguese population. Br J Dermatol 2013; 169: 660-5.
AMIODARON
Lim PK, Trewby PN, Storey GC, Hole DW. Neuropathy and fatal
hepatitis in a patient receiving amiodarone. Br Med J (Clin Res Ed)
1984; 288: 1638-9.
Poucell S, Ireton J, Valencia-Mayoral P, Downar E, Larratt L,
Patterson J, Blendis L, Phillips MJ. Amiodarone-associated
phospholipidosis and fibrosis of the liver. Light,
immunohistochemical, and electron microscopic studies.
Gastroenterology 1984; 86: 926-36.
Simon JB, Manley PN, Brien JF, Armstrong PW. Amiodarone
hepatotoxicity simulating alcoholic liver disease. N Engl J Med 1984;
311: 167-72.
Jones WP, Shin MS, Stanley RJ, Duncan-Myers J. Dense liver in a
72-year-old woman with congestive heart failure. Invest Radiol
1985; 20: 911-5.
Tordjman K, Katz I, Bursztyn M, Rosenthal T. Amiodarone and the
liver. Ann Intern Med 1985; 102: 411-2.
Varma RR, Troup PJ, Komorowski RA, Sarna T. Clinical and
morphologic effects of amiodarone on the liver. Gastroenterology
1985; 88: 1091-3.
Yagupsky P, Gazala E, Sofer S, Maor E, Abarbanel J. Fatal hepatic
failure and encephalopathy associated with amiodarone therapy. J
Pediatr 1985; 107: 967-70.
Dake MD, Madison JM, Montgomery CK, Shellito JD, Hinchcliffe WA,
Winkler ML, Bainton DF. Electron microscopic demonstration of
lysosomal inclusion bodies in lung, liver, lymph nodes, and blood
leukocytes of patients with amiodarone pulmonary toxicity. Am J
Med 1985; 78: 506-12.
Babany G, Mallat A, Zafrani ES, Saint-Marc Girardin MF, Carcone B,
Dhumeaux D. Chronic liver disease after low daily doses of
amiodarone. Report of three cases. J Hepatol 1986; 3: 228-32.
Lupon-Roses J, Simo-Canonge R, Lu-Cortez L, Permanyer-Miralda
G, Allende-Monclus H. Probable early acute hepatitis with parenteral
amiodarone. Clin Cardiol 1986; 9: 223-5.
Rigas B, Rosenfeld LE, Barwick KW, Enriquez R, Helzberg J, Batsford
WP, Josephson ME, Riely CA. Amiodarone hepatotoxicity. A
clinicopathologic study of five patients. Ann Intern Med 1986; 104:
348-51.
Rinder HM, Love JC, Wexler R. Amiodarone hepatotoxicity. N Engl J
Med 1986; 314: 318-9.
Rumessen JJ. Hepatotoxicity of amiodarone. Acta Med Scand 1986;
219: 235-9.
Shepherd NA, Dawson AM, Crocker PR, Levison DA. Granular cells
as a marker of early amiodarone hepatotoxicity: a pathological and
analytical study. J Clin Pathol 1987; 40: 418-23.
Gilinsky NH, Briscoe GW, Kuo CS. Fatal amiodarone hepatoxicity.
Am J Gastroenterol 1988; 83: 161-3.
Morse RM, Valenzuela GA, Greenwald TP, Eulie PJ, Wesley RC,
McCallum RW. Amiodarone-induced liver toxicity. Ann Intern Med
1988; 109: 838-40.
Pye M, Northcote RJ, Cobbe SM. Acute hepatitis after parenteral
amiodarone administration. Br Heart J 1988; 59: 690-1.
Jones DB, Mullick FG, Hoofnagle JH, Baranski B. Reye's syndromelike illness in a patient receiving amiodarone. Am J Gastroenterol
1988; 83: 967-9.
Bach N, Schultz BL, Cohen LB, Squire A, Gordon R, Thung SN,
Schaffner F. Amiodarone hepatotoxicity: progression from steatosis
to cirrhosis. Mt Sinai J Med 1989; 56: 293-6.
Flaharty KK, Chase SL, Yaghsezian HM, Rubin R. Hepatotoxicity
associated with amiodarone therapy. Pharmacotherapy 1989; 9:
39-44.
Lewis JH, Ranard RC, Caruso A, Jackson LK, Mullick F, Ishak KG,
Seeff LB, Zimmerman HJ. Amiodarone hepatotoxicity: prevalence
and clinicopathologic correlations among 104 patients. Hepatology
1989; 9: 679-85.
Roche JF, Netter P, Gay G. [Amiodarone-induced hepatitis:
biological, histological diagnosis, development and role of
associated factors. Review of the literature. Report of 2 cases] Rev
Med Interne 1989; 10: 497-501. French.
Stevenson RN, Nayani TH, Davies JR. Acute hepatic dysfunction
following parenteral amiodarone administration. Postgrad Med J
1989; 65: 707-8.
Lwakatare JM, Morris-Jones S, Knight EJ. Fatal fulminating liver
failure possibly related to amiodarone treatment. Br J Hosp Med
1990; 44: 60-1.
Lewis JH, Mullick F, Ishak KG, Ranard RC, Ragsdale B, Perse RM,
Rusnock EJ, et al. Histopathologic analysis of suspected amiodarone
hepatotoxicity. Hum Pathol 1990; 21: 59-67.
Simon JP, Zannad F, Trechot P, Thisse JY, Houplon M, Aliot E. Acute
hepatitis after a loading dose of intravenous amiodarone.
Cardiovasc Drugs Ther 1990; 4: 1467-8.
Benbassat C, Shahar A. [Acute fulminant hepatic failure after shortterm amiodarone] Harefuah 1991; 121: 378-80. Hebrew.
Kalantzis N, Gabriel P, Mouzas J, Tiniakos D, Tsigas D, Tiniakos G.
Acute amiodarone-induced hepatitis. Hepatogastroenterology 1991;
38: 71-4.
Morelli S, Guido V, De Marzio P, Aguglia F, Balsano F. Early hepatitis
during intravenous amiodarone administration. Cardiology 1991;
78: 291-4.
Fornaciari G, Monducci I, Barone A, Bassi C, Beltrami M, Tomasi C.
Amiodarone-induced acute hepatitis: case report. J Clin
Gastroenterol 1992; 15: 271-3.
Harrison RF, Elias E. Amiodarone-associated cirrhosis with hepatic
and lymph node granulomas. Histopathology 1993; 22: 80-2.
Rhodes A, Eastwood JB, Smith SA. Early acute hepatitis with
parenteral amiodarone: a toxic effect of the vehicle? Gut 1993; 34:
565-6.
Macarri G, Feliciangeli G, Berdini V, Jezequel AM, Benedetti A.
Canalicular cholestasis due to amiodarone toxicity. A definite
diagnosis obtained by electron microscopy. Ital J Gastroenterol
1995; 27: 436-8.
Rene JM, Buenestado J, Pais B, Pinol MC. [Cirrhosis caused by
amiodarone] Rev Esp Enferm Dig 1995; 87: 399-402. Spanish.
Richer M, Robert S. Fatal hepatotoxicity following oral
administration of amiodarone. Ann Pharmacother 1995; 29: 582-6.
Snir Y, Pick N, Riesenberg K, Yanai-Inbar I, Zirkin H, Schlaeffer F.
Fatal hepatic failure due to prolonged amiodarone treatment. J Clin
Tosetti C, Ongari M, Evangelisti A, Lolli R, Napoli A. [Acute
hepatotoxicity from amiodarone] Minerva Med 1995; 86: 387-90.
Italian.
Paniagua Clusells J, Arcusa Gavalda R, Goma Masip F, Pons
Masanes S, Soler Masana JM. [Acute hepatitis caused by
intravenous amiodarone.] Rev Esp Cardiol 1996; 49: 384-5.
Spanish.
Pillans PI. Drug associated hepatic reactions in New Zealand: 21
years’ experience. N Z Med J 1996; 109: 315-9.
James PR, Hardman SM. Acute hepatitis complicating parenteral
amiodarone does not preclude subsequent oral therapy. Heart
1997; 77: 583-4.
Josephson SA, Kessel ER. Amiodarone hepatotoxicity. Dig Dis 1997;
15: 312.
Pierce DR, Skaehill, PA. Case of fatal amiodarone hepatotoxicity.
Hosp Pharm 1997; 32: 1133-5.
Tagliamonte E, Cice G, Ducceschi V, Mayer MS, Iacono A. [Acute
hepatitis following amiodarone administration] Minerva Cardioangiol
1997; 45: 451-6. Italian.
Breuer HW, Bossek W, Haferland C, Schmidt M, Neumann H,
Gruszka J. Amiodarone-induced severe hepatitis mediated by
immunological mechanisms. Int J Clin Pharmacol Ther 1998; 36:
350-2.
Chang CC, Petrelli M, Tomashefski JF Jr, McCullough AJ. Severe
intrahepatic cholestasis caused by amiodarone toxicity after
withdrawal of the drug: a case report and review of the literature.
Arch Pathol Lab Med 1999; 123: 251-6.
Iliopoulou A, Giannakopoulos G, Mayrikakis M, Zafiris E,
Stamatelopoulos S. Reversible fulminant hepatitis following
intravenous amiodarone loading. Amiodarone hepatotoxicity. Int J
Clin Pharmacol Ther 1999; 37: 312-3.
Latorre G, Lucas I, Herrero JI, Sangro B, Quiroga J, Sola JJ, Díaz L,
Prieto J. [Severe hepatotoxicity caused by amiodarone: description
of a case] Rev Med Univ Navarra 1999; 43: 86-91. Spanish.
Lopez-Gomez D, Nicolas J, Frigola JM, Manito N, Esplugas E. [The
use of oral amiodarone as a chronic treatment in a patient with
prior fulminant hepatitis due to intravenous amiodarone] Rev Esp
Cardiol 1999; 52: 201-3. Spanish.
Jain D, Bowlus CL, Anderson JM, Robert ME. Granular cells as a
marker of early amiodarone hepatotoxicity. J Clin Gastroenterol
2000; 31: 241-3.
Jmelnitzky AC, Guidi M, Bologna A, Viola M, Soccini C, Barbero R,
Belloni P, Apraiz M. [Clinic-epidemiological significance of drug
hepatotoxicity in liver disease consultation] Acta Gastroenterol
Latinoam 2000; 30: 77-84. Spanish.
Luengo O, Montero J, Alegre J, Fernandez Sevilla T. [Toxic hepatitis
caused by intravenous amiodarone] Med Clin (Barc). 2000; 115:
798-9. Spanish.
Agozzino F, Picca M, Pelosi G. Acute hepatitis complicating
intravenous amiodarone treatment. Ital Heart J 2002; 3: 686-8.
Giannattasio F, Salvio A, Varriale M, Picciotto FP, Di Costanzo GG,
Visconti M. Three cases of severe acute hepatitis after parenteral
administration of amiodarone: the active ingredient is not the only
agent responsible for hepatotoxicity. Ann Ital Med Int 2002; 17:
180-4.
Gonzalez Galilea A, Garcia Sanchez MV, la Mata Garcia M, Mino
Fugarolas G. [Early-onset acute toxic hepatitis induced by
intravenous amiodarone administration] Gastroenterol Hepatol
2002; 25: 392-4. Spanish.
Gregory SA, Webster JB, Chapman GD. Acute hepatitis induced by
parenteral amiodarone. Am J Med 2002; 113: 254-5.
MacFadyen RJ, Palmer TJ, Hisamuddin K. Rapidly fatal acute
amiodarone hepatitis occurring in the context of multiple organ
failure. Int J Cardiol 2003; 91: 245-7.
Singhal A , Ghosh P, Khan SA. Low Dose amiodarone causing
pseudo-alcoholic cirrhosis. Age Ageing 2003; 32: 224-5.
Iba-Ba J, Tilea M, Balligand JL, Lefebvre C. [Amiodarone liver
toxicity about two cases and review of literature] Rev Med Interne
2004; 25: 386-9. French.
Maker AV, Orgill DP. Rapid acute amiodarone-induced
hepatotoxicity in a burn patient. J Burn Care Rehabil 2005; 26:
341-3.
Oikawa H, Maesawa C, Sato R, Oikawa K, Yamada H, Oriso S, Ono
S, et al. Liver cirrhosis induced by long-term administration of a
daily low dose of amiodarone: a case report. World J Gastroenterol
2005; 11: 5394-7.
Puli SR, Fraley MA, Puli V, Kuperman AB, Alpert MA. Hepatic
cirrhosis caused by low-dose oral amiodarone therapy. Am J Med
Sci 2005; 330: 257-61.
Rätz Bravo AE, Drewe J, Schlienger RG, Krähenbühl S, Pargger H,
Ummenhofer W. Hepatotoxicity during rapid intravenous loading
with amiodarone: Description of three cases and review of the
literature. Crit Care Med 2005; 33: 128-34; discussion 245-6.
Galan MV, Potts JA, Silverman AL, Gordon SC. The burden of acute
nonfulminant drug-induced hepatitis in a United States tertiary
referral center [corrected]. J Clin Gastroenterol 2005; 39: 64-7.
Erratum in: J Clin Gastroenterol 2005; 39: 176.
Rizzioli E, Incasa E, Gamberini S, Savelli S, Zangirolami A, Tampieri
M, Manfredini R. Acute toxic hepatitis after amiodarone intravenous
loading. Am J Emerg Med 2007; 25: 1082.e1-4.
Sharma JR, Sathanandam S, Rao SP, Acharya S, Flood V.
Ventricular tachycardia in acute fulminant myocarditis: medical
management and follow-up. Pediatr Cardiol 2007;
Collins AM, Winter DC, McCormick AP, Cottell DC, Geoghegan JG.
Amiodarone hepatotoxicity complicating obstructive jaundice due to
ampullary cancer. Hepatobiliary Pancreat Dis Int 2007; 6: 435-7.
Kang HM, Kang YS, Kim SH, Seong JK, Kang DY, Lee HY, Lee BS.
Amiodarone-induced hepatitis and polyneuropathy. Korean J Intern
Med 2007; 22: 225-9.
Dedhia V, Munsi SC. Acute amiodarone hepatotoxicity. Indian Heart
J 2007; 59: 491-3.
pii: S0016-5085(15)00311-X.
Cataldi A, Gonella D, Robutti N, Siri M, Buonocore S, Odetti P.
Hepatotoxicity after intravenous amiodarone. Aging Clin Exp Res
2008; 20: 593-6.
Chan AL, Hsieh HJ, Hsieh YA, Lin SJ. Fatal amiodarone-induced
hepatotoxicity: a case report and literature review. Int J Clin
Pharmacol Ther 2008; 46: 96-101.
Li L, Yang J, Ding JW. [Acute amiodarone-induced hepatotoxicity in
a patient]. Zhonghua Xin Xue Guan Bing Za Zhi 2008; 36: 464.
Chinese
Raja K, Thung SN, Fiel MI, Chang C. Drug-induced steatohepatitis
leading to cirrhosis: long-term toxicity of amiodarone use. Semin
Liver Dis 2009; 29: 423-8.
Llanos L, Moreu R, Peiró AM, Pascual S, Francés R, Such J, Horga
JF, et al. Causality assessment of liver injury after chronic oral
amiodarone intake. Pharmacoepidemiol Drug Saf 2009; 18: 291300.
Arkun A, Van Deusen SK, Grau T, Birkhahn RH. Hepatic dysfunction
and neurotoxicity in a patient receiving long-term low-dose
amiodarone therapy. J Emerg Med 2010; 38: 337-9.
Gassanov N, Caglayan E, Erdmann E, Er F. [Amiodarone-induced
liver dysfunctions]. Dtsch Med Wochenschr 2010; 135: 1372-4.
German.
Ishida S, Sugino M, Hosokawa T, Sato T, Furutama D, Fukuda A,
Kimura F,
K
- u w a b a ra H , S h ib a
induced liver cirrhosis and
p arkin so n ism : a ca se
Neuropathol 2010; 29: 84-8.
Verhovez A, Elia F, Riva A, Ferrari G, Aprà F. Acute liver injury after
intravenous amiodarone: a case report. Am J Emerg Med 2011; 29:
843.e5-6.
von Vital JM, Karachristos A, Singhal A, Thomas R, Jain A. Acute
amiodarone hepatotoxicity after liver transplantation.
Transplantation 2011; 91: e62-4.
Joghetaei N, Weirich G, Huber W, Büchler P, Estner H. Acute liver
failure associated with dronedarone. Circ Arrhythm Electrophysiol
2011; 4: 592-3.
Sung PS, Yoon SK. Amiodarone hepatotoxicity. Hepatology 2012;
55: 325-6.
Grecian R, Ainslie M. Acute hepatic failure following intravenous
amiodarone. BMJ Case Rep 2012; 2012.
Kicker JS, Haizlip JA, Buck ML. Hepatotoxicity after continuous
amiodarone infusion in a postoperative cardiac infant. J Pediatr
Lahbabi M, Aqodad N, Ibrahimi A, Lahlou M, Aqodad H. Acute
hepatitis secondary to parenteral amiodarone does not preclude
subsequent oral therapy. World J Hepatol 2012; 4: 196-8.
Ben Chaabane N, Hellara O, Safer L, Melki W, Bdioui F, Zakhama A,
Saffar H. Cirrhosis with increased density of the liver: amiodaroneinduced hepatotoxicity. Tunis Med 2012; 90: 487-8.
Thiele RH, Williams J, Moylan CA, Rao SV, Bennett-Guerrero E.
CASE 6--2012: suspected amiodarone hepatotoxicity after cardiac
surgery. J Cardiothorac Vasc Anesth 2012; 26: 729-32.
Rao U, Agarwal A. Amiodarone-induced acute hepatotoxicity. Eur J
Clin Pharmacol 2012; 68: 449-50.
Akbal E, Batgi H, Koçak E, Canatan T, Köklü S. Low-dose
amiodarone-induced
Epub.
fata l live r fa ilu re .
Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S.
Incidence, presentation and outcomes in patients with drug-induced
liver injury in the general population of Iceland. Gastroenterology
2013; 144: 1419-25.
Cimic A, Sirintrapun J. Amiodarone hepatotoxicity with absent
phospholipidosis and steatosis: a case report and review of
amiodarone toxicity in various organs. Case Rep Pathol 2013; 2013:
201095.
Nasser M, Larsen TR, Waanbah B, Sidiqi I, McCullough PA.
Hyperacute drug-induced hepatitis with intravenous amiodarone:
case report and review of the literature. Drug Healthc Patient Saf
2013; 5: 191-8.
AMOXICILLIN/CLAVULANIC ACID
van den Broek JW, Buennemeyer BL, Stricker BH. [Cholestatic
hepatitis caused by a combination of amoxicillin and clavulanic acid
(Augmentin)]. Ned Tijdschr Geneeskd 1988; 132: 1495-7. Dutch.
Verhamme M, Ramboer C, Van de Bruaene P, Inderadjaja N.
Cholestatic hepatitis due to an amoxycillin/clavulanic acid
preparation. J Hepatol 1989; 9: 260-4.
Schneider JE, Kleinman MS, Kupiec JW. Cholestatic hepatitis after
therapy with amoxicillin/clavulanate potassium. N Y State J Med
1989; 89: 355-6.
Dowsett JF, Gillow T, Heagerty A, Radcliffe M, Toadi R, Isle I,
Russell RCG. Amoxycillin/clavulanic acid (Augmentin)-induced
intrahepatic cholestasis. Dig Dis Sci 1989; 34: 1290-3.
Reddy KR, Brillant P, Schiff ER. Amoxicillin-clavulanate potassiumassociated cholestasis. Gastroenterology 1989; 96: 1135-41.
Stricker BH, Van den Broek JW, Keuning J, Eberhardt W , Houben
HGJ, Johnson M, Blok APR. Cholestatic hepatitis due to antibacterial
combination of amoxicillin and clavulanic acid (augmentin). Dig Dis
Sci. 1989; 34: 1576-80.
Cleau D, Jobard JM, Alves T, Gury S, Rey B, Vuillemard M, Noirot A,
et al. [Cholestatic hepatitis induced by the amoxicillin-clavulanic
acid combination. A case and review of the literature].
Gastroenterol Clin Biol 1990; 14: 1007-9. French.
Pelletier G, Ink O, Fabre M, Hagège H. [Hepatic cholestasis probably
due to the combination of amoxicillin and clavulanic acid].
Gastroenterol Clin Biol 1990; 14: 601. French.
Michielsen PP, Van Outryve MJ, Van Marck EA, De Maeyer MH,
Pelckmans PA, Van Maercke YM. Amoxycillin/clavulanic acid induced
cholestasis. J Hepatol 1990; 11: 392.
Escallier F, Dalac S, Caillot D, Boulitrop C, Collet E, Lambert D.
[Erythema multiforme, aplasia, cholestatic hepatitis during
treatment with Augmentin (amoxicillin + clavulanic acid)]. Rev Med
Interne 1990; 11: 73-5. French.
Alexander P, Roskams T, Van Steenbergen W, Peetermans W,
Desmet V, Yap SH. Intrahepatic cholestasis induced by
amoxicillin/clavulanic acid (Augmentin): a report on two cases. Acta
Clin Belg 1991; 46: 327-32.
Wong FS, Ryan J, Dabkowski P, Dudley FJ, Sewell RB, Smallwood
RA. Augmentin-induced jaundice. Med J Aust 1991; 154: 698-701.
Silvain C, Fort E, Levillain P, Labat-Labourdette J, Beauchant M.
Granulomatous hepatitis due to combination of amoxicillin and
clavulanic acid. Dig Dis Sci 1992; 37: 150-2.
Ryan J, Dudley FJ. Cholestasis with ticarcillin-potassium clavulanate
(Timentin). Med J Aust 1992; 156: 291.
Cabelleria Rovira E, Masso Ubeda RM, Arago López JV, Sanchís
Closa A. [Cholestatic hepatitis from amoxicillin-clavulanic acid]. An
Med Interna 1992 Jul; 9(7): 360-1. Spanish.
Larrey D, Vial T, Micaleff A, Babany G, Morichau-Beauchant M,
Michel H, Benhamou JP. Hepatitis associated with amoxycillinclavulanic acid combination report of 15 cases. Gut 1992; 33: 36871.
Hebbard GS, Smith KG, Gibson PR, Bhathal PS. Augmentin-induced
jaundice with a fatal outcome. Med J Aust 1992; 156: 285-6.
Peroux JL, Peroux E, Jais F, Philit F, Chichmanian RM. [Augmentin
hepatotoxicity: responsibility of clavulanic acid? Apropos of a case]
Gastroenterol Clin Biol 1992; 16: 102-3. French
Yap I, Gwee KA, Wee A. Augmentin-induced cholestatic jaundice--a
case report. Singapore Med J 1993; 34: 464-5.
Horsmans Y; Geubel AP. Amoxycillin-clavulanic acid-erythromycin
cross-liver toxicity: a case report. J Hepatol 1994; 21: 911-2.
Hanssens M, Mast A, Van Maele V, Pauwels W. [Cholestatic jaundice
caused by amoxicillin-clavulanic acid in 4 patients]. Ned Tijdschr
Geneeskd 1994; 138: 1481-3. Dutch.
Thomson JA, Fairley CK, Ugoni AM, Forbes AB, Purcell PM, Desmond
PV, Smallwood RA, McNeil JJ. Risk factors for the development of
amoxycillin-clavulanic acid associated jaundice. Med J Aust 1995;
162: 638-40.
Watteeuw G, Vasilevski D, Hautekeete M, Taton G, Lambilliotte JP,
François E, Adler M. [Cholestatic hepatitis and amoxicillin-clavulanic
acid combination. Personnel case report and literature review]. Rev
Med Brux 1995; 16: 391-3. French.
Galindo C, Buenestado J, Rene JM, Pinol MC. [Acute pancreatitis
associated with hepatotoxicity induced by amoxicillin-clavulanic
acid] Rev Esp Enferm Dig 1995; 87: 597-600. Spanish.
Pedro-Botet J, Supervía A, Barranco C, Solá R, Bruguera M.
Intrahepatic cholestasis without hepatitis induced by
amoxycillin/clavulanic acid. J Clin Gastroenterol 1996; 23: 137-8.
Bralet MP, Zafrani ES.[Hepatitis caused by the amoxicillin-clavulanic
acid combination. An example of drug-induced biliary
hepatotoxicity] Ann Pathol 1996; 16: 425-9. French.
Bustamante Balén M, Pérez Aguilar F, Rayón Martín M, García
Herola A, Berenguer Lapuerta J. [Cholestatic hepatitis caused by
amoxycillin-clavulanic acid. Report of a new case]. Gastroenterol
Hepatol 1997; 20: 187-9. Spanish.
Caballero Plasencia AM, Valenzuela Barranco M, Martin Ruiz JL,
Guilarte Lopez-Manas J. [Hepatotoxicity caused by amoxicillin,
clavulanic acid or both?] Gastroenterol Hepatol 1997; 20: 45-6.
Spanish.
de Haan F, Stricker BH. [Liver damage associated with the
combination drug amoxicillin-clavulanic acid (Augmentin)]. Ned
Tijdschr Geneeskd 1997; 141: 1298-301. Dutch
Barrio J, Castiella A, Lobo C, Indart A, López P, García-Bengoechea
M, Cosme A, et al. [Cholestatic acute hepatitis induced by
amoxycillin-clavulanic acid combination. Role of ursodeoxycholic
acid in drug-induced cholestasis] Rev Esp Enferm Dig 1998; 90:
523-6. Spanish.
Nathani MG, Mutchnick MG, Tynes DJ, Ehrinpreis MN. An unusual
case of amoxicillin/clavulanic acid-related hepatotoxicity. Am J
Ballester Fayos J, Rodríguez Gil FJ, Paredes Arquiola JM, García del
Castillo G, Antón-Conejero MD, Añón Rodríguez R, Moreno-Osset E.
[Amoxicillin-clavulanic acid hepatotoxicity]. Gastroenterol Hepatol
1998; 21: 114-5. Spanish.
Julve R, García A, Gómez A, Primo J, Molés JR, Hinojosa J. [Acute
hepatocellular lesion induced by amoxicillin-clavulanic acid].
Gastroenterol Hepatol 1998; 21: 92-4. Spanish.
Beurton I, Germanese JC, Becker MC, Koch S, Carbillet JP, Miguet
JP, Bresson-Hadni S. [Acute hepatitis and destructive cholangitis
probably induced by amoxicillin-clavulanic acid combination].
Soza A, Riquelme F, Alvarez M, Duarte I, Glasinovic JC, Arrese M.
[Hepatotoxicity by amoxicillin/clavulanic acid: case report] Rev Med
Chil 1999; 127: 1487-91. Spanish.
Hautekeete ML, Horsmans Y, Van Waeyenberge C, Demanet C,
Henrion J, Verbist L, Brenard R, et al. HLA association of amoxicillinclavulanate--induced hepatitis. Gastroenterology 1999; 117: 11816.
Limauro DL, Chan-Tompkins NH, Carter RW, Brodmerkel GJ Jr,
Agrawal RM. Amoxicillin/clavulanate-associated hepatic failure with
progression to Stevens-Johnson syndrome. Ann Pharmacother
1999; 33: 560-4.
Maggini M, Raschetti R, Agostinis L, Cattaruzzi C, Troncon MG,
Simon G. Use of amoxicillin and amoxicillin-clavulanic acid and
hospitalization for acute liver injury. Ann Ist Super Sanita. 1999;
35: 429-33.
O'Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, MacSween
RN, Mills PR. Co-amoxiclav jaundice: clinical and histological
features and HLA class II association. Gut 2000; 47: 717-20.
Bolzan H, Spatola J, Castelletto R, Curciarello J. [Intrahepatic
cholestasis induced by amoxicillin alone]. Gastroenterol Hepatol
2000; 23: 237-9. Spanish.
Chawla A; Kahn E; Yunis EJ; Daum F. Rapidly progressive
cholestasis: An unusual reaction to amoxicillin/clavulanic acid
therapy in a child.J Pediatr 2000; 136: 121-3.
Katsinelos P, Vasiliadis T, Xiarchos P, Patakiouta F, Christodoulou K,
Pilpilidis I, Eugenidis N. Ursodeoxycholic acid (UDCA) for the
treatment of amoxycillin-clavulanate potassium (Augmentin)induced intra-hepatic cholestasis: report of two cases. Eur J
Gastroenterol Hepatol 2000; 12: 365-8.
Gresser U. Amoxicillin-clavulanic acid therapy may be associated
with severe side effects--review of the literature. Eur J Med Res
2001; 6: 139-49.
Berg P, Hahn EG. Hepatotoxic reactions induced by beta-lactamase
inhibitors. Eur J Med Res 2001; 6: 535-42.
Schey R, Avni Y, Bruck R, Shirin H. History of drug-induced hepatitis
and risk of amoxicillin/clavulanate-induced hepatotoxicity. Ann
Pharmacother 2001; 35: 1142-3.
Andrade RJ, Lucena MI, Fernández MC, Vega JL, Camargo R.
Hepatotoxicity in patients with cirrhosis, an often unrecognized
problem: lessons from a fatal case related to amoxicillin/clavulanic
acid. Dig Dis Sci 2001; 46: 1416-9
Jordán T, González M, Casado M, Suárez JF, Pulido F, Guerrero E,
Esteban J. [Amoxicillin-clavulanic acid induced hepatotoxicity with
progression to cirrhosis.] Gastroenterol Hepatol 2002; 25: 240-3.
Spanish.
Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C,
Lenoir C, et al. Incidence of drug-induced hepatic injuries: a French
population-based study. Hepatology 2002; 36: 451-5.
Ibáñez L, Pérez E, Vidal X, Laporte JR; Grup d'Estudi Multicènteric
d'Hepatotoxicitat Aguda de Barcelona (GEMHAB). Prospective
surveillance of acute serious liver disease unrelated to infectious,
obstructive, or metabolic diseases: epidemiological and clinical
features, and exposure to drugs. J Hepatol 2002; 37: 592-600.
Zaidi SA. Hepatitis associated with amoxicillin/clavulanic acid and/or
ciprofloxacin. Am J Med Sci 2003; 325: 31-3.
Martí J. [Cholestatic hepatitis due to amoxicillin-clavulanic acid with
positive re-exposure]. Enferm Infecc Microbiol Clin 2003; 21: 3223. Spanish.
de Abajo FJ, Montero D, Madurga M, García Rodríguez LA. Acute
and clinically relevant drug-induced liver injury: a population based
case-control study. Br J Clin Pharmacol 2004; 58: 71-80.
Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K,
García-Ruiz E, García-Muñoz B, et al.; Spanish Group for the Study
of Drug-Induced Liver Disease. Drug-induced liver injury: an
analysis of 461 incidences submitted to the Spanish registry over a
10-year period. Gastroenterology 2005; 129: 512-21.
Fontana RJ, Shakil AO, Greenson JK, Boyd I, Lee WM. Acute liver
failure due to amoxicillin and amoxicillin/clavulanate. Dig Dis Sci
2005; 50: 1785-90.
Andrade RJ, Lucena MI, Kaplowitz N, García-Munoz B, Borraz Y,
Pachkoria K, García-Cortés M, et al. Outcome of acute idiosyncratic
drug-induced liver injury: long-term follow-up in a hepatotoxicity
registry. Hepatology 2006; 44: 1581-8.
Lucena MI, Andrade RJ, Fernández MC, Pachkoria K, Pelaez G,
Durán JA, Villar M, et al.; Spanish Group for the Study of DrugInduced Liver Disease (Grupo de Estudio para las Hepatopatías
Asociadas a Medicamentos (GEHAM)). Determinants of the clinical
expression of amoxicillin-clavulanate hepatotoxicity: a prospective
series from Spain. Hepatology 2006; 44: 850-6.
Cundiff J, Joe S. Amoxicillin-clavulanic acid-induced hepatitis. Am J
Otolaryngol 2007; 28: 28-30.
Jakab SS, West AB, Meighan DM, Brown RS Jr, Hale WB.
Mycophenolate mofetil for drug-induced vanishing bile duct
syndrome. World J Gastroenterol 2007; 13: 6087-9.
pii: S0016-5085(15)00311-X.
Domínguez Jiménez JL, Marín Moreno M, Bernal Blanco E, Puente
Gutiérrez JJ, Guiote Malpartida S, de la Mata García M. [Acute
cholestatic hepatitis induced by amoxicillin-clavulanic acid].
Gastroenterol Hepatol 2008; 31: 46. Spanish.
Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D,
Adarsh CK. Single-center experience with drug-induced liver injury
from India: causes, outcome, prognosis, and predictors of mortality.
Herrero-Herrero JI, García-Aparicio J. Corticosteroid therapy in a
case of severe cholestasic hepatitis associated with amoxicillinclavulanate. J Med Toxicol 2010; 6: 420-3.
Studniarz M, Czubkowski P, Cielecka-Kuszyk J, Jankowska I,
Teisseyre M, Kamińska D, Markiewicz M, et al. Amoxicillin/clavulanic
acid-induced cholestatic liver injury after pediatric liver
transplantation. Ann Transplant 2012; 17: 128-31.
Sánchez-Ruiz-Granados E, Bejarano-García A, Uceda-Torres E.
Recurrent cholestasis by amoxicillin-clavulanic acid: the importance
of a correct diagnosis of hepatotoxicity. Rev Esp Enferm Dig 2012;
104: 616-7.
2013; 144: 1419-25.
Sistanizad M, Peterson GM. Drug-induced liver injury in the
Australian setting. J Clin Pharm Ther 2013; 38: 115-20.
Beraldo DO, Melo JF, Bonfim AV, Teixeira AA, Teixeira RA, Duarte
AL. Acute cholestatic hepatitis caused by amoxicillin/clavulanate.
World J Gastroenterol 2013; 19: 8789-92.
Hernández N, Bessone F, Sánchez A, di Pace M, Brahm J, Zapata R,
A Chirino R, et al. Profile of idiosyncratic drug induced liver injury in
Latin America. An analysis of published reports. Ann Hepatol 2014;
13: 231-9.
ATORVASTATIN
Jiminez-Alonso J, Osorio JM, Gutierrez-Cabello F, Lopez de la Osa A,
Leon L, Mediavilla Garcia JD. Atorvastatin-induced cholestatic
hepatitis in a young woman with systemic lupus erythematosus.
Arch Intern Med 1999; 159: 1811-2.
Nakad A, Bataille L, Hamoir V, Sempoux C, Horsman Y.
Atorvastatin-induced hepatitis with the absence of cross-toxicity
with simvastatin. Lancet 1999; 353: 1763-4.
Sreenarasinhaiah J, Shiels P, Lisker-Melman M. Multiorgan failure
induced by atorvastatin. Am J Med 2002; 113: 348-9.
Lewin JJ 3rd, Nappi JM, Taylor MH. Rhabdomyolysis with concurrent
atorvastatin and diltiazem. Ann Pharmacother 2002; 36: 1546-9.
Ridruejo E, Mando OG. Acute cholestatic hepatitis after reinitiating
treatment with atorvastatin. J Hepatol 2002; 37: 165-6.
Graziadei IW, Obermoser GE, Sepp NT, Erhart KH, Vogel W. Druginduced lupus-like syndrome associated with severe autoimmune
hepatitis. Lupus 2003; 12: 409-12.
Pelli N, Setti M, Ceppa P, Toncini C, Indiveri F. Autoimmune
hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol
2003; 15: 921-4.
Perger L, Kohler M, Fattinger K, Flury R, Meier PJ, Pauli-Magnus C.
Fatal liver failure with atorvastatin. J Hepatol 2003; 39: 1096-7.
Gershovich OE, Lyman AE Jr. Liver function test abnormalities and
pruritus in a patient treated with atorvastatin: case report and
review of the literature. Pharmacotherapy 2004; 24: 150-4.
Geoghegan M, Smith V, Green JRB. Acute cholestatic hepatitis
associated with atorvastatin. Gut 2004; 53(Suppl.3): A123.
van Heyningen C. Drug-induced acute autoimmune hepatitis during
combination therapy with atorvastatin and ezetimibe. Ann Clin
Biochem 2005; 42: 402-4.
Andrade RJ, Lucena MI, Kaplowitz N, García-Munoz B, Borraz Y,
Pachkoria K,
G a rcía M, et al. Outcome of acute idiosyncratic
-Cortés
drug-induced liver injury: Long-term follow-up in a hepatotoxicity
registry. Hepatology 2006; 44: 1581-8
Clarke AT, Mills PR. Atorvastatin associated liver disease. Dig Liver
Dis 2006; 38: 772-7.
Alla V, Abraham J, Siddiqui J, Raina D, Wu GY, Chalasani NP,
Bonkovsky HL. Autoimmune hepatitis triggered by statins. J Clin
de Castro ML, Hermo JA, Baz A, de Luaces C, Perez R, Clofent J.
[Acute cholestatic hepatitis after atorvastatin
reintroduction](Spanish). Gastroenterol Hepatol 2006; 29: 21-4.
Rahier JF, Rahier J, Leclercq I, Geubel AP. Severe acute cholestatic
hepatitis with prolonged cholestasis and bile-duct injury following
atorvastatin therapy: a case report. Acta Gastroenterol Belg 2008;
71: 318-20.
pii: S0016-5085(15)00311-X.
Minha S, Golzman G, Adar I, Rapoport M. Cholestatic jaundice
induced by atorvastatin: a possible association with
antimitochondrial antibodies. Isr Med Assoc J 2009; 11: 440-1.
Liu Y, Cheng Z, Ding L, Fang F, Cheng KA, Fang Q, Shi GP.
Atorvastatin-induced acute elevation of hepatic enzymes and the
absence of cross-toxicity of pravastatin. Int J Clin Pharmacol Ther
2010; 48: 798-802.
Merli M, Bragazzi MC, Giubilo F, Callea F, Attili AF, Alvaro D.
Atorvastatin-induced prolonged cholestasis with bile duct damage.
Clin Drug Investig 2010; 30: 205-9.
Drug-induced acute
liver results
ilure:
fa
of a U.S. multicenter,
prospective study. Hepatology 2010;
5 2 : 2 0 6 5
-76.
Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated
with statins: reports of idiosyncratic liver injury post-marketing. J
Hepatol 2012; 56:374-80.
2013; 144: 1419-25.
AZATHIOPRINE/6-MERCAPTOPURINE
McIlvanie SK, MacCarthy JD. Hepatitis in association with prolonged
6-mercaptopurine therapy. Blood 1959; 14: 80-90.
Clark PA, Hsia YE, Huntsman RG. Toxic complications of treatment
with 6-mercaptopurine: two cases with hepatic necrosis and
intestinal ulceration. Br Med J 1960; 1: 393-5.
Einhorn M, Davidsohn I. Hepatotoxicity of mercaptopurine. JAMA
1964; 188: 802-6.
Krawitt EL, Stein JH, Kirkendall WM, Clifton JA. Mercaptopurine
hepatotoxicity in a patient with chronic active hepatitis. Arch Intern
Med. 1967; 120: 729-34.
Shorey J, Schenker S, Suki WN, Combes B. Hepatotoxicity of
mercaptopurine. Arch Intern Med 1968; 122: 54-8.
Lascari AD, Givier RL, Saper RT, Hill LF. Portal hypertension in a
case of acute leukemia treated with antimetabolites for 10 years. N
Engl J Med 1968; 279: 303-6.
Sparberg M, Simon N, Del Greco F. Intrahepatic cholestasis due to
azathioprine. Gastroenterology 1969; 57: 439-41.
Lehmann GW. [Intrahepatic cholestasis caused by 6mercaptopurine]. Kinderarztl Prax 1969; 37: 506-11. German.
Drinkard JP, Stanley TM, Dornfeld L, Austin RC, Barnett EV, Pearson
CM, Vernier RL, et al. Azathioprine and prednisone in the treatment
of adults with lupus nephritis. Medicine(Baltimore) 1970; 49: 41132.
Zarday A, Veith FJ, Gliedman ML, Soberman R. Irreversible liver
damage after azathioprine. JAMA 1972; 222: 690-1.
Marubbio AT, Danielson B. Hepatic veno-occlusive disease in a renal
transplant patient receiving azathioprine. Gastroenterology 1975;
69: 739-43.
Griner PF, Elbadawi A, Packman CH. Veno-occlusive disease of the
liver after chemotherapy of acute leukemia. Report of two cases.
Ann Intern Med 1976; 85: 578-82.
DePinho RA, Goldberg CS, Lefkowitch JH. Azathioprine and the
liver: evidence favoring idiosyncratic, mixed cholestatichepatocellular injury in man. Gastroenterology 1984; 86: 162-5.
Eisenhauer T, Hartmann H, Rumpf KW, Helmchen U, Scheler F,
Creutzfeldt W. Favorable outcome of hepatic veno-occlusive disease
in a renal transplant patient receiving azathioprine, treated by
portacaval shunt: report of a case and review of the literature.
Digestion 1984; 30: 185-90.
Watanabe A, Obata T, Nagashima H, Sakagami K, Orita K.
Nonicteric liver damage with a gamma-glutamyl transpeptidase
level of 5,609 units/l in a renal-transplant recipient receiving
azathioprine. Acta Med Okayama 1984; 38: 533-9.
Gerlag PG, Labatty S, Driessen WM, Deckers PFL, Van Hooff JP,
Schroder E, Assmann KM, et al. Hepatic sinusoidal dilatation with
portal hypertension during azathioprine treatment after kidney
transplantation. J Hepatol 1986; 1: 339-48.
Read AE, Wiesner RH, La Brecque DR, Tifft JG, Mullen KD, Sheer RL,
Petrelle M, et al. Hepatic veno-occlusive disease associated with
renal transplantation and azathioprine therapy. Ann Intern Med
1986; 104: 651-6.
Lemarchand P, Desrumeaux B, Bercoff E, Manchon ND, Chassagne
P, Deshayes P,
H ém e t J, B o u rre
dilatation following treatment with azathioprine]. Gastroenterol Clin
Biol 1986; 10: 853-4. French.
Katzka DA, Saul SH, Jorkasky D, Sigal H, Reynolds JC, Soloway RD.
Azathioprine and hepatic venoocclusive disease in renal transplant
patients. Gastroenterology 1986; 90: 446-54.
Cooper C, Cotton DW, Minihane N, Cawley MI. Azathioprine
hypersensitivity manifesting as acute focal hepatocellular necrosis. J
R Soc Med 1986; 79: 171-3.
Barrowman JA, Kutty PK, Mu RA, Huang SN. Sclerosing hepatitis
and azathioprine. Dig Dis Sci 1986; 31: 221-2.
Adler M, Delhaye M, Deprez C, Hardy N, Gelin M, DePauw L,
Vererstraeten P, et al. Hepatic vascular disease after kidney
transplantation: report of two cases and review of the literature.
Nephrol Dialysis Transplant 1987; 2: 183-8.
Fonseca V, Havard CW. Portal hypertension secondary to
azathioprine in myasthenia gravis. Postgrad med J 1988; 64: 9502.
Haboubi MB, Hiam H, Whitwell HL, Ackrill P. Role of endothelial cell
injury in the spectrum of azathioprine-induced liver disease after
renal transplant: light microscopy and ultrastructural observations.
Buffet C, Cantarovitch M, Pelletier G, Fabre M, Martin E, Charpentier
B, Etienne JP, et al. Three cases of nodular regenerative hyperplasia
of the liver following renal transplantation. Nephrol Dial Transplant
1988; 3: 327-30.
Jones MC, Best PV, Catto GRD. Is nodular regenerative hyperplasia
of the liver associated with azathioprine therapy after renal
transplantation. Nephrol Dial Transplant 1988; 3: 330-3.
Lemley DE, Delacy LM, Seeff LB, Ishak KG, Nashel DJ. Azathioprine
induced hepatic veno-occlusive disease in rheumatoid arthritis. Ann
Rheum Dis 1989; 48: 342-6
Small P, Lichter M. Probable azathioprine hepatotoxicity: a case
report. Ann Allergy 1989; 62: 518-20.
Ramalho HJ, Terra EG, Cartapatti E, Barberato JB, Alves VA,
Gayotto LC, Abbud-Filho M. Hepatotoxicity of azathioprine in renal
transplant recipients. Transplant Proc 1989; 21(1 Pt 2): 1716-7.
Horsmans Y, Rahier J, Geubel AP. Reversible cholestasis with bile
duct injury following azathioprine therapy. A case report. Liver
1991; 11: 89-93
Sterneck M, Wiesner R, Ascher N, Roberts J, Ferrell L, Ludwig J,
Lake J. Azathioprine hepatotoxicity after liver transplantation.
Hepatology 1991; 14: 806-10.
Mion F, Napoleon B, Berger F, Chevallier M, Bonvoisin S, Descos L.
Azathioprine induced liver disease: nodular regenerative hyperplasia
of the liver and perivenous fibrosis in a patient treated for multiple
sclerosis. Gut 1991; 32: 715-7.
Laidlaw ST, Reilly JT, Suvarna SK. Fatal hepatotoxicity associated
with 6-mercaptopurine therapy. Postgrad Med J 1995; 71: 639.
Romagnuolo J, Sadowski DC, Lalor E, Jewell L, Thomson AB.
Cholestatic hepatocellular injury with azathioprine: a case report
and review of the mechanisms of hepatotoxicity. Can J
Kontorinis N, Agarwal K, Gondolesi G, Fiel MI, O'Rourke M, Schiano
TD. Diagnosis of 6 mercaptopurine hepatotoxicity post liver
transplantation utilizing metabolite assays. Am J Transplant 2004;
4: 1539-42.
de Boer NK, Mulder CJ, van Bodegraven AA. Myelotoxicity and
hepatotoxicity during azathioprine therapy. Neth J Med 2005; 63:
444-6.
Daniel F, Cadranel JF, Seksik P, Cazier A, Duong Van Huyen JP, Ziol
M, Coutarel P, et al. Azathioprine induced nodular regenerative
hyperplasia in IBD patients. Gastroenterol Clin Biol 2005; 29: 60034.
García-Ruiz E, García-Muñoz B, et al. Drug-induced liver injury: an
analysis of 461 incidences submitted to the Spanish Registry over a
Bryant DL, Miles CJ, Gearry RB. Nodular regenerative hyperplasia of
the liver secondary to azathioprine in a patient with inflammatory
bowel disease. N Z Med J 2010; 123: 74-6.
López-Martín C, de la Fuente-Fernández E, Corbatón P, Sánchez
MC, Gisbert JP. [Nodular regenerative hyperplasia: azathioprineinduced hepatotoxicity in a patient with Crohn's disease].
Blogowski W, Marlicz W, Smereczynski A, Lawniczak M, Lewosiuk A,
Starzynska T. Nodular regenerative liver hyperplasia as a
complication of azathioprine-containing immunosuppressive
treatment for Crohn's disease. Immunopharmacol Immunotoxicol
2011; 33: 398-402.
Choudhary NS, Gupta S, Chawla YK, Duseja A, Dhiman RK, Das A.
Azathioprine induced liver injury: a case report. Dig Dis Sci 2012;
57: 1717-8.
Incidence, presentation, and outcomes in patients with druginduced liver injury in the general population of Iceland.
Ruiz-Clavijo D, Arín A, Vila JJ, Albéniz E, Picazo R, Casi M.
[Azathioprine-induced hepatotoxicity in a patient with Crohn's
disease]. An Sist Sanit Navar 2013; 36: 353-6. Spanish.
Appell ML, Wagner A, Hindorf U. A skewed thiopurine metabolism is
a common clinical phenomenon that can be successfully managed
with a combination of low-dose azathioprine and allopurinol. J
Crohns Colitis 2013; 7: 510-3.
BUSULFAN
Kyle RA, Dameshek W. Porphyria cutanea tarda associated with
chronic granulocytic leukemia treated with busulfan(Myleran). Blood
1964; 23: 776-85.
Underwood JC, Shahani RT, Blackburn EK. Cholestatic jaundice
following treatment of chronic granulocytic leukemia with
busulphan. J Clin Pathol 1970; 23: 827.
Key NS, Kelly PM, Emerson PM, Chapman RW, Allan NC, McGee JO.
Oesophageal varices associated with busulphan-thioguanine
combination therapy for chronic myeloid leukaemia. Lancet 1987;
2: 1050-2.
Morris LE, Guthrie TH Jr. Busulfan-induced hepatitis. Am J
Brugieres L, Hartmann O, Benhamou E, Patte C, Kalifa C, Lemerle J.
[Hepatic complications after high-dose chemotherapy and bone
marrow autograft in solid tumors in children]. Presse Med 1988; 17:
1305-8. French.
Adang RP, Breed WP. [Liver damage during busulfan therapy]. Ned
Tijdschr Geneeskd 1989; 133: 1515-8. Dutch.
Vassal G, Hartmann O, Benhamou E. Busulfan and veno-occlusive
disease of the liver. Ann Intern Med 1990; 112: 881.
Ozkaynak MF, Weinberg K, Kohn D, Sender L, Parkman R, Lenarsky
C. Hepatic veno-occlusive disease post-bone marrow
transplantation in children conditioned with busulfan and
cyclophosphamide: incidence, risk factors, and clinical outcome.
Bone Marrow Transplant 1991; 7: 467-74.
Kasai M, Kiyama Y, Watanabe M, Seto K, Matsuura A, Tanaka J,
Takeda H, et al. Toxicity of high-dose busulfan and
cyclophosphamide as a preparative regimen for bone marrow
transplantation. Transplant Proc 1992; 24: 1529-30.
Méresse V, Hartmann O, Vassal G, Benhamou E, Valteau-Couanet
D, Brugieres L,
Lem e rle J. R isk facto rs fo r
-occlusive
disease after high-dose busulfan-containing regimens followed by
autologous bone marrow transplantation: a study in 136 children.
Bone Marrow Transplant 1992; 10: 135-41.
Atra A, Whelan JS, Calvagna V, Shankar AG, Ashley S, Shepherd V,
Souhami RL, et al. High-dose busulphan/melphalan with autologous
stem cell rescue in Ewing's sarcoma. Bone Marrow Transplant 1997;
20: 843-6.
Diaz MA, Vicent MG, Madero L. High-dose busulfan/melphalan as
conditioning for autologous PBPC transplantation in pediatric
patients with solid tumors. Bone Marrow Transplant 1999; 24:
1157-9
Lee JL, Gooley T, Bensinger W, Schiffman K, McDonald GB. Venoocclusive disease of the liver after busulfan, melphalan, and
thiotepa conditioning therapy: incidence, risk factors, and outcome.
Biol Blood Marrow Transplant 1999; 5: 306-15.
Foschi FG, Savini P, Marano G, Musardo G, Bedeschi E, Girelli F,
Emiliani F, et al. Focal nodular hyperplasia after busulfan treatment.
Dig Liver Dis 2005; 37: 619-21.
Ulrickson M, Aldridge J, Kim HT, Hochberg EP, Hammerman P, Dube
C, Attar E, Ballen KK, Dey BR, McAfee SL, Spitzer TR, Chen YB.
Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen
for autologous stem cell transplantation in patients with nonHodgkin lymphoma: a single-institution experience. Biol Blood
Marrow Transplant 2009; 15: 1447-54.
CARBAMAZEPINE
Brukker AB, Joustra UH. [Liver damage caused by carbamazepine]
Ned Tijdschr Geneeskd 1966; 110: 1181-3. Dutch.
Ramsay ID. Carbamazepine-induced jaundice. Br Med J 1967; 4:
155.
Fellows WR. A case of aplastic anemia and pancytopenia with
tegretol therapy. Headache 1969; 9: 92-5.
Zucker P, Daum F, Cohen MI. Fatal carbamazepine hepatitis. J
Pediatr 1977; 91: 667-8.
Hopen G, Nesthus I, Laerum OD. Fatal carbamazepine-associated
hepatitis. Report of two cases. Acta Med Scand 1981; 210: 333-5.
Ponte CD. Carbamazepine-induced thrombocytopenia, rash, and
hepatic dysfunction. Drug Intell Clin Pharm 1983; 17: 642-4.
Soffer EE, Taylor RJ, Bertram PD, Haggitt RC, Levinson MJ.
Carbamazepine-induced liver injury. South Med J 1983; 76: 681-3.
Rigau Cañardo J, Bruguera M, Sese J, Morlans G. [Acute cholestatic
hepatitis due to carbamazepine]. Gastroenterol Clin Biol 1984; 8:
769-70. French.
Diaz-Torres MA, Caraballo R, Ollero M, Lissen E. [Hepatitis caused
by carbamazepine] Med Clin(Barc) 1984; 83: 823. Spanish.
Bastús JB. [Hepatitis caused by carbamazepine] Med Clin(Barc)
1985; 84: 543. Spanish.
Okada Y, Watanabe T, Kajiwara E, Tsuji H, Murai K, Akagi K,
Onoyama K, Omae T. [Two cases of carbamazepine induced
hepatitis] Nippon Naika Gakkai Zasshi 1984; 73: 1189-94.
Japanese.
Davion T, Capron JP, Andrejak M, Geoffroy P, Capron-Chivrac D,
Quénum C. [Acute hepatitis due to carbamazepine (Tegretol). Study
of a case and review of the literature]. Gastroenterol Clin Biol 1984;
8: 52-6. French.
Moore NC, Lerer B, Meyendorff E, Gershon S. Three cases of
carbamazepine toxicity. Am J Psychiatry 1985; 142: 974-5
Davion T, Capron-Chivrac D, Andrejak M, Capron JP. [Hepatitis due
to antiepileptic agents] Gastroenterol Clin Biol 1985; 9: 117-26.
French.
Galeone D, Lamontanara G, Torelli D. Acute hepatitis in a patient
treated with carbamazepine. J Neurol 1985; 232: 301-3.
Costa JF, Sramek JJ, Herrera JM. Hepatic reaction to
carbamazepine. J Clin Psychopharmacol 1986; 6: 251-2.
Luke DR, Rocci ML Jr, Schaible DH, Gerguson RK. Acute
hepatotoxicity after excessively high doses of carbamazepine on
two occasions. Pharmacother 1986; 6: 108-111.
Swinburn BA, Croxson MS, Miller MV, Crawford KB. Carbamazepine
induced granulomatous hepatitis. N Z Med J 1986; 99:167.
Larrey D, Hadengue A, Pessayre D, Choudat L, Degott C, Benhamou
J-P. Carbamazepine-induced acute cholangitis. Dig Dis Sci 1987;
32: 554-7.
Noguerado A, Isasia T, Martínez MC, García-Sánchez A.
[Granulomatous hepatitis caused by carbamazepine] Rev Clin Esp
1987; 181:116. Spanish.
Robbie MJ, Scurry JP, Stevenson P. Carbamazepine-induced severe
systemic hypersensitivity reaction with eosinophilia. Drug Intell Clin
Pharm 1988; 22: 783-4.
Matsukura H, Suzuki Y. A case of hepatitis associated with
carbamazepine therapy. Eur J Pediatr 1988; 147: 666.
Horowitz S, Patwardhan R, Marcus E. Hepatotoxic reactions
associated with carbamazepine therapy. Epilepsia 1988; 29: 14954.
Frey B, Schubiger G, Musy JP. Transient cholestatic hepatitis in a
neonate associated with carbamazepine exposure during pregnancy
and breast-feeding. Eur J Pediatr 1990; 150: 136-8.
Rivey MP, Stone JD. Carbamazepine hypersensitivity reaction. Brain
Inj 1991; 5: 57-62.
Kleier RS, Breneman DL, Boiko S. Generalized pustulation as a
manifestation of the anticonvulsant hypersensitivity syndrome. Arch
Dermatol 1991; 127: 1361-4.
Merlob P, Mor N, Litwin A. Transient hepatic dysfunction in an infant
of an epileptic mother treated with carbamazepine during
pregnancy and breastfeeding. Ann Pharmacother 1992; 26: 1563-5.
Forbes GM, Jeffrey GP, Shilkin KB, Reed WD. Carbamazepine
hepatotoxicity: another cause of the vanishing bile duct syndrome.
Pirmohamed M, Kitteringham NR, Breckenridge AM, Park BK.
Detection of an autoantibody directed against human liver
microsomal protein in a patient with carbamazepine
hypersensitivity. Br J Clin Pharmacol 1992; 33: 183-6.
Handfield-Jones SE, Jenkins RE, Whittaker SJ, Besse CP, McGibbon
DH. The anticonvulsant hypersensitivity syndrome. Br J Dermatol
1993; 129: 175-7.
Froomes PR, Stewart MR. A reversible parkinsonian syndrome and
hepatotoxicity following addition of carbamazepine to sodium
valproate. Aust N Z J Med 1994; 24: 413-4.
Kong KH. Carbamazepine-induced hepatitis in a patient with cervical
myelopathy. Arch Phys Med Rehabil 1996; 77: 305-6.
Martínez P, González de Etxabarri S, Ereño C, López G, Hinojal C,
Teira R. [Acute severe hepatic insufficiency caused by
carbamazepine]. Rev Esp Enferm Dig 1993; 84: 124-6. Spanish.
Dertinger S, Dirschmid K, Vogel W, Drexel H. Immunosuppressive
therapy for carbamazepine-induced hypersensitivity syndrome and
hepatitis. J Hepatol 1998; 28: 356-7.
Nathan DL, Belsito DV. Carbamazepine-induced pseudolymphoma
with CD-30 positive cells. J Am Acad Dermatol 1998; 38: 806-9.
Morales-Diaz M, Pinilla-Roa E, Ruiz I. Suspected carbamazepineinduced hepatotoxicity. Pharmacotherapy 1999; 19: 252-5.
Nari G. [Carbamazepine-induced hepatitis. A case report] Acta
Gastroenterol Latinoam 1999; 29: 277-8. Spanish. PubMed Citation
Hamer HM, Morris HH. Successful treatment with gabapentin in the
presence of hypersensitivity syndrome to phenytoin and
carbamazepine: a report of three cases. Seizure 1999; 8: 190-2.
Haukeland JW, Jahnsen J, Raknerud N. [Carbamazepine-induced
hepatitis] Tidsskr Nor Laegeforen 2000; 120: 2875-7. Norwegian.
PubMed Citation
Grieco A, Alfei B, Di Rocco P, Miele L, Biolcati G, Griso D, Vecchio
FM, et al. Non-alcoholic steatohepatitis induced by carbamazepine
and variegate porphyria. Eur J Gastroenterol Hepatol 2001; 13:
973-5.
Queyrel V, Catteau B, Michon-Pasturel U, et al. [DRESS syndrome
after sulfasalazine and carmazepine: report of two cases]. Rev Med
Yamaki M, Yoshida I. [A case of acute renal failure and liver
dysfunction induced by carbamazepine (CBZ)] Nippon Jinzo Gakkai
Shi 2001; 43: 357-61. Japanese.
Nashed MH, Liao L. Possible atypical cross-sensitivity between
phenytoin and carbamazepine in the anticonvulsant hypersensitivity
syndrome. Pharmacother 2001; 21: 502-5.
Garcia M, Mhanna MJ, Chung-Park MJ, Davis PH, Srivastava MD.
Efficacy of early immunosuppressive therapy in a child with
carbamazepine-associated vanishing bile duct and Stevens-Johnson
syndromes. Dig Dis Sci 2002; 47: 177-82.
Ramos AMO, Gayotto LCC, Clemente CM, Mello EA, Luz KG, Freitas
ML. Reversible vanishing bile duct syndrome induced by
carbamazepine. Eur J Gastroenterol Hepatol 2002; 14: 1019-22.
Frey B, Braegger CP, Ghelfi D. Neonatal cholestatic hepatitis from
carbamazepine exposure during pregnancy and breast feeding. Ann
Bin-Nakhi HA, Sadeq S, Pinto RG, Habeeb Y. Anticonvulsant
hypersensitivity syndrome: report of 2 cases from Kuwait. Med
Princ Pract 2003; 12: 197-9
Parikh S, Dillon LC, Scharf SL. Hepatotoxicity possibly due to
paracetamol with carbamazepine. Intern Med J 2004; 34: 441-2.
Durán-Ferreras E, Mir-Mercader J, Morales-Martínez MD, MartínezParra C. [Anticonvulsant hypersensitivity syndrome with severe
repercussions in the skin and kidneys due to carbamazepine] Rev
Neurol 2004; 38: 1136-8. Spanish.
Björnsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant druginduced hepatic failure leading to death or liver transplantation in
Sweden. Scand J Gastroenterol 2005; 40: 1095-101.
Wadhawan M, Tyagi P, Malhotra V, Sakhuja P, Puri AS. Reversible
cholestatic hepatitis due to carbamazepine in an adolescent. Indian
J Gastroenterol 2005; 24: 172-3.
Syn WK, Naisbitt DJ, Holt AP, Pirmohamed M, Mutimer DJ.
Carbamazepine-induced acute liver failure as part of the DRESS
syndrome. Int J Clin Pract 2005; 59: 988-91.
Skopp G, Schmitt HP, Pedal I. [Fulminant liver failure in a patient
on carbamazepine and levetiracetam treatment associated with
status epilepticus]. Arch Kriminol 2006; 217: 161-75. German.
Réaud S, Oberti F, Leclech C, Calès P. [Hepatotoxicity of
carbamazepine: a case of "DRESS syndrome"]. Gastroenterol Clin
Biol 2007; 31: 205-6. French.
Fsadni C, Fsadni P, Piscopo T, Mallia Azzopardi C. Carbamazepineinduced drug reaction with eosinophilia and systemic symptoms
syndrome in a 35-year-old man with epilepsy. Clin Neuropharmacol
2008; 31: 295-8.
Crespo Pérez L, Moreira Vicente V, Cano Ruiz A, Gobernado Serrano
JM, Cobo Ibañez N, Milicua Salamero JM. [Anticonvulsant
hypersensitivity syndrome: an entity to be remembered].
Aouam K, Ben Romdhane F, Loussaief C, Salem R, Toumi A,
Belhadjali H, Chaabane A, et al. Hypersensitivity syndrome induced
by anticonvulsants: possible cross-reactivity between
carbamazepine and lamotrigine. J Clin Pharmacol 2009; 49: 148891.
Teng P, Tan B. Carbamazepine-induced DRESS syndrome in a child:
rapid response to pulsed corticosteroids. Dermatol Online J 2013;
19: 18170.
Mehta M, Shah J, Khakhkhar T, Shah R, Hemavathi KG.
Anticonvulsant hypersensitivity syndrome associated with
carbamazepine administration: Case series. J Pharmacol
CHLORPROMAZINE
Zatuchni J, Miller G. Jaundice during chlorpromazine therapy. N
Engl J Med 1954; 251: 1003-6.
Boardman RH. Fatal case of toxic hepatitis implicating
chlorpromazine. BMJ 1954; 2: 579.
Hartnett BS. Liver damage and eosinophilia following
chlorpromazine therapy: report of a case. BMJ 1955; 1: 1458-9.
Isaacs B, MacArthur JG, Taylor RM. Jaundice in relation to
chlorpromazine therapy. BMJ 1955; 2; 1122-3.
Van Ommen R, Brown C. Obstructive-type jaundice due to
chlorpromazine(thorazine); report of three cases. JAMA 1955; 157:
321-5.
Movitt E, Meyer M, Snell A, Goldman M, Gibson J, Sullivan B,
Webster J, et al. Jaundice associated with the administration of
chlorpromazine, SKF-2601-A (thorazine); report of three cases,
with biopsies of the liver. Gastroenterology 1955; 28: 901-13.
Werther JL, Korelitz BI. Chlorpromazine jaundice: analysis of
twenty-two cases. Am J Med 1957; 22: 351-66.
Dickes R, Schenker V, Deutsch L. Serial liver function and blood
studies in patients receiving chlorpromazine. N Engl J Med 1957;
256: 1-7.
Hollister L. Allergy to chlorpromazine manifested by jaundice. Am J
Med 1957; 23: 870-9.
Graham GS. Chlorpromazine jaundice in a general hospital. BMJ
1957; 2:1080-1.
Zelman S. Liver cell necrosis in chlorpromazine jaundice(allergic
cholangitis): a serial study of 26 needle biopsy specimens in nine
patients. Am J Med 1959; 27: 708-29.
Melrose AG, Roy JR. Late prognosis of chlorpromazine jaundice. BMJ
1959; 1: 818-9.
Mackay EV. Progressive chlorpromazine jaundice during pregnancy.
Med J Aust 1960; 47: 209-12.
Stewart WR. Chlorpromazine jaundice. Am J Surg 1960; 100: 4957.
Urbinati G, Figliuzzi M. [Jaundice caused by chlorpromazine.] Clin
Ter 1960; 18: 611-39. Italian.
Gaulhofer WK, van der Helm H. [Jaundice caused by
chlorpromazine.] Ned Tijdschr Geneeskd 1961; 105: 477-81. Dutch.
Read AE, Harrison CV, Sherlock S. Chronic chlorpromazine jaundice:
with particular reference to its relationship to primary biliary
cirrhosis. Am J Med 1961; 31: 249-58.
Waitzkin L. Prolonged hepatic dysfunction after clinical recovery
from chlorpromazine jaundice. Gastroenterology 1962; 43: 337-9.
Ranek L. [A fatal case of prolonged chlorpromazine jaundice.].
Dereux J, Dereux JF, Carbonnelle B, Guffroy M, Cacheux S.
[Jaundice due to chlorpromazine]. J Sci Med Lille 1965; 83: 565-72.
French.
Levine RA, Briggs GW, Lowell DM. Chronic chlorpromazine
cholangiolitic hepatitis. Report of a case with immunofluorescent
studies. Gastroenterology 1966; 50: 665-70.
Walker CO, Combes B. Biliary cirrhosis induced by chlorpromazine.
Bolton BH. Prolonged chlorpromazine jaundice. Am J Gastroenterol
1967; 48: 497-503.
Cheongvee EM, Hurst L, Smith RH. Agranulocytosis and jaundice
associated with chlorpromazine. Br J Clin Pract 1967; 21: 95-6.
L'hirondel J, Venezia R, Rousselot P, Daridon F, Fellouse JC.
[Neonatal jaundice due to chlorpromazine]. Arch Fr Pediatr 1968;
25: 1171-7. French
Russell RI, Allan JG, Patrick R. Active chronic hepatitis after
chlorpromazine ingestion. Br Med J 1973; 1: 655-6.
Nartowicz A, Mirska K, Slowik J. [Jaundice following administration
of chlorpromazine to a 21/2-month-old infant]. Pediatr Pol 1977;
52: 217-8. Polish
Døssing M, Andreasen PB. Drug-induced liver disease in Denmark.
An analysis of 572 cases of hepatotoxicity reported to the Danish
Board of Adverse Reactions to Drugs. Scand J Gastroenterol 1982;
17: 205-11.
Bach N, Thung SN, Schaffner F, Tobias H. Exaggerated cholestasis
and hepatic fibrosis following simultaneous administration of
chlorpromazine and sodium valproate. Dig Dis Sci 1989; 34: 13037.
Sidi Y, Douer D, Pinkhas J. Simultaneous appearance of
agranulocytosis and cholestatic jaundice following chlorpromazine
treatment. Med Interne 1989; 27: 69-71.
Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost
R, Schmid M. Chlorpromazine-induced vanishing bile duct syndrome
leading to biliary cirrhosis. Hepatology 1994; 20: 1437-41
Wang CK, Liu JD, Lin SY, Liao LY, Cheng NY, Wang CS, Siauw CP, et
al. Drug-induced liver disease--a review of 14 cases. Gaoxiong Yi
Xue Ke Xue Za Zhi 1995; 11: 213-9.
Chlumská, CuríR, Boudová, Mukensnabl P, Klvana P.
Chlorpromazine-induced cholestatic liver disease with ductopenia.
Cesk Patol 2001; 37: 118-22.
Minondo Amuchasteguia L, Egiguren Urrosolo L, Zapata Morcillo E,
Castiella Eguzkiza A. [Chlorpromazine-induced cholestatic hepatitis
in intractable hiccups]. Gastroenterol Hepatol 2007; 30: 103.
Spanish.
Sabaté, Ibánez L, Pérez E, Vidal X, Buti M, Xiol X, Mas A, et al. Risk
of acute liver injury associated with the use of drugs: a multicentre
population survey. Aliment Pharmacol Ther 2007; 25: 1401-9.
Jaiprakash H, Narayana S, Mohanraj J. Drug-induced hepatotoxicity
in a tertiary care hospital in rural South India. N Am J Med Sci
2012; 4: 90-3.
DANTROLENE
Cornette M, Gillard C, Borlee-Hermans G. (Fatal toxic hepatitis
associated with administration of dantrolene.) Acta Neurol Belg
1980; 80: 336-47. French.
Ogburn RM, Myers RL, Burdick GE. Hepatitis associated with
dantrolene sodium. Ann Intern Med 1976; 84: 53-4.
Schneider R, Mitchell D. Dantrolene hepatitis. JAMA 1976;
235:1590-1.
Wilkinson SP, Portmann B, Williams R. Hepatitis from dantrolene
sodium. Gut 1979; 20: 33-6.
Utili R, Boitnott JK, Zimmerman HJ. Dantrolene-associated hepatic
injury. Incidence and character. Gastroenterology 1977;72:
610-6.
Chan CH. Dantrolene sodium and hepatic injury. Neurology 1990;
40:1427-32.
DICLOFENAC
Dunk AA, Walt RP, Jenkins WJ, Sherlock SS. Diclofenac hepatitis. Br
Med J(Clin Res Ed) 1982; 284: 1605-6.
Babany G, Pessayre D, Benhamou JP. [Hepatitis caused by
diclofenac] Gastroenterol Clin Biol 1983; 7: 316. French.
Deshayes P, Leloet X, Bercoff E, Fouin-Fortunet H. [Diclofenac
hepatitis. A case] Presse Med 1984; 13: 1847. French.
Lascar G, Grippon P, Lévy VG. [Acute fatal hepatitis during
treatment with diclofenac(Voltarène)] Gastroenterol Clin Biol 1984;
8: 881-2. French.
Babany G, Bernuau J, Danan G, Rueff B, Benhamou JP.
[Fulminating hepatitis in a woman taking glafenine and diclofenac]
Paret Masana A, Guarga Rojas A, Urrutia de Diego A, Sabriá Leal M.
[Acute hepatitis and diclofenac sodium] Rev Clin Esp 1986; 179:
476. Spanish.
Breen EG, McNicholl J, Cosgrove E, McCabe J, Stevens FM. Fatal
hepatitis associated with diclofenac. Gut. 1986; 27:1390-3.
Schapira D, Bassan L, Nahir AM, Scharf Y. Diclofenac-induced
hepatotoxicity. Postgrad Med J. 1986; 62: 63-5.
Snijder RJ, Dinant HJ, Stricker BH. [Fatal liver damage during use of
diclofenac] Ned Tijdschr Geneeskd 1987; 131: 2088-90. Dutch.
Llorca G, Larbre JP, Collet Ph, Ravault A, Lejeune E. Changing the
class of NSAID in cases of hepatotoxicity. Ann Rheum Dis 1988;
791.
Hovette P, Touze JE, Debonne JM, Delmarre B, Rogier C, Schmoor
P, et al. [Cholestatic hepatitis and acute kidney insufficiency during
treatment with diclofenac] Ann Gastroenterol Hepatol(Paris) 1989;
25: 257-8. French
Mazeika PK, Ford MJ. Chronic active hepatitis associated with
diclofenac sodium therapy. Br J Clin Pract 1989; 43: 125-6.
Helfgott SM, Sandberg-Cook J, Zakim D, Nestler J. Diclofenacassociated hepatotoxicity. JAMA 1990; 264: 2660-2.
Iveson TJ, Ryley NG, Kelly PM, Trowell JM, McGee JO, Chapman RW.
Diclofenac associated hepatitis. J Hepatol 1990; 10: 85-9.
Ouellette GS, Slitzky BE, Gates JA, Lagarde S, West AB. Reversible
hepatitis associated with diclofenac. J Clin Gastroenterol 1991; 13:
205-10.
Sallie RW, McKenzie T, Reed WD, Quinlan MF, Shilkin KB. Diclofenac
hepatitis. Aust N Z J Med 1991; 21: 251-5.
Adebajo AO, Eastmond CJ. Hepatotoxicity to several nonsteroidal
anti-inflammatory drugs with diclofenac induced histological
changes. Clin Rheumatol 1992; 11: 120-1.
Nos P, Palau J, Pérez-Aguilar F, Berenguer J. [Hepatitis associated
with taking diclofenac] Rev Esp Enferm Dig 1992; 81: 367. Spanish.
Selz F, Cereda JM. [Fatal sub-fulminant hepatitis due to diclofenac]
Rev Med Suisse Romande 1993; 113: 985-7. French.
Scully LJ, Clarke D, Barr RJ. Diclofenac induced hepatitis. 3 cases
with features of autoimmune chronic active hepatitis. Dig Dis Sci
1993; 38: 744-51.
Ramakrishna B, Viswanath N. Diclofenac-induced hepatitis: case
report and literature review. Liver 1994; 14: 83-4.
Banks AT, Zimmerman HJ, Ishak KG, Harter JG. Diclofenacassociated hepatotoxicity: analysis of 180 cases reported to the
Food and Drug Administration as adverse reactions. Hepatology
1995; 22: 820-7.
Zaragoza Marcet A, Alfonso Moreno V, Roig Catala E. [NSAIDinduced hepatotoxicity: aceclofenac and diclofenac] Rev Esp Enferm
Dig 1995; 87: 472-5. Spanish.
Hernández Beriain J, Segura García C. [Aceclofenac-induced
hepatitis] Rev Esp Enferm Dig 1995; 87: 550-1. Spanish.
Pérez Moreno JM, Puertas Montenegro M, Fernández Ruiz A,
Fernández González MA. [Toxic hepatitis caused by aceclofenac]
Rev Esp Enferm Dig 1996; 88: 815-6. Spanish.
Prieto de Paula JM, Romero Castro R, Villamandos Nicás YV.
[Hepatic toxicity caused by aceclofenac] Gastroenterol Hepatol
1997; 20: 165. Spanish.
Vilà Santasuana A, Cid Pañella R, Roure Nuez C, Martínez Montauti
J, Ortega Enciso YL. [Acute hepatitis caused by diclofenac]
Hackstein H, Mohl W, Püschel W, Stallmach A, Zeitz M. [Diclofenacassociated acute cholestatis hepatitis] Z Gastroenterol 1998; 36:
385-9. German.
Bhogaraju A, Nazeer S, Al-Baghdadi Y, Rahman M, Wrestler F, Patel
N. Diclofenac-associated hepatitis. South Med J 1999; 92: 711-3.
Dierkes-Globisch A, Schäfer R, Mohr HH. [Asymptomatic diclofenacinduced acute hepatitis] Dtsch Med Wochenschr 2000; 125: 797800. German.
Fernández-Avala Novo M, Penado Nadela S, Nan Nan DN, González
Macías J. [Toxic hepatitis caused by aceclofenac] Rev Clin Esp
2001; 201: 616-7. Spanish.
Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JB, Alexander G,
et al. Hepatic adducts, circulating antibodies, and cytokine
polymorphisms in patients with diclofenac hepatotoxicity.
Hepatology 2004; 39: 1430-40.
Sweden. Scand J Gastroentero 2005; 40: 1095-101.
Yerly G, Cereda JM. Severe hepatitis due to percutaneous
diclofenac. Gastroenterol Clin Biol 2008; 32: 824-5.
2013; 144: 1419-25.
DIDANOSINE
Lai KK, Gang DL, Zawacki JK, Cooley TP. Fulminant hepatic failure
associated with 2.,3.-dideoxyinosine(ddI). Ann Intern Med 1991;
115: 283-4.
Bissuel F, Bruneel F, Habersetzer F, Chassard D, Cotte L, Chevallier
M, Bernuau J, et al. Fulminant hepatitis with severe lactate acidosis
in HIV-infected patients on didanosine therapy. J Intern Med 1994;
235: 367-71.
Lacaille R, Ortigao MB, Debré, Rouzioux C, Brousse N, Blanche S.
Hepatic toxicity associated with 2.3.-dideoxyinosine in children with
AIDS. J Pediatr Gastroenterol Nutr 1995; 20: 287-90
ter Hofstede HJ, de Marie S, Foudraine NA, Danner SA, Brinkman K.
Clinical features and risk factors of lactic acidosis following longterm antiretroviral therapy: 4 fatal cases. Int J STD AIDS 2000; 11:
611-6.
Brivet F, Nion I, Mérbane B, Slama A, Brivet M, Rustin P, Munnich A.
Fatal lactic acidosis and liver steatosis associated with didanosine
and stavudine treatment: a respiratory chain dysfunction? J Hepatol
2000; 32: 364-5.
Claessens Y-E, Cariou A, Chiche J-D, Dauriat G, Dhainaut J-F. Lcarnitine as a treatment of life-threatening lactic acidosis induced
by nucleoside analogues. AIDS 2000; 14: 472-3.
Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC.
Hyperlactatemia and hepatic abnormalities in 10 human
immunodeficiency virus-infected patients receiving nucleoside
analogue combination regimens. Clin Infect Dis 2000; 31: 162-6.
Ware AJ, Berggren RA, Taylor WE. Didanosine-induced hepatitis.
Lederman JC, Nawaz H. Toxic interaction of didanosine and
acetaminophen leading to severe hepatitis and pancreatitis: a case
report and review of the literature. Am J Gastroenterol 2001; 96:
3474-5.
Carr A, Morey A, Mallon P, Williams D, Thorburn DR. Fatal portal
hypertension, liver failure, and mitochondrial dysfunction after HIV1 nucleoside analogue-induced hepatitis and lactic acidaemia.
Lancet 2001; 357: 1412-4.
Church JA, Mitchell WG, Gonzalez-Gomez I, Christensen J, Vu TH,
Dimauro S, Boles RG. Mitochondrial DNA depletion, near-fatal
metabolic acidosis, and liver failure in an HIV-infected child treated
with combination antiretroviral therapy. J Pediatr 2001; 138: 74851.
Clark S, Creighton S, Portmann B, Taylor C, Wendon J, Cramp M.
Acute liver failure associated with antiretroviral treatment for HIV: a
report of six cases. J Hepatol 2002; 36: 295-301.
Koch RO, Graziadel IW, Zangerle R, Romani N, Maier H, Vogel W.
Acute hepatic failure and lactic acidosis associated with
antiretroviral treatment for HIV. Wien Klin Wochenschr 2003; 115:
135-40.
Masiá, Gutiéez F, Padilla S, Ramos JM, Pascual J. Severe toxicity
associated with the combination of tenofovir and didanosine: case
report and review. Int J STD AIDS 2005; 16: 646-8.
Podevin P, Spiridon G, Terris B, Chauvelot-Moachon L, Guillevin L,
Chaussade S, Sogni P, Salmon-Ceron D. Nodular regenerative
hyperplasia of the liver after IL-2 therapy in an HIV-infected
patient. AIDS 2006; 20: 313-5.
Mallet V, Blanchard P, Verkarre V, Vallet-Pichard A, Fontaine H,
Lascoux-Combe C, Pol S. Nodular regenerative hyperplasia is a new
cause of chronic liver disease in HIV-infected patients. AIDS 2007;
21: 187-92.
Arey B, Markov M, Ravi J, Prevette E, Batts K, Nadir A. Nodular
regenerative hyperplasia of liver as a consequence of ART. AIDS
2007; 21: 1066-8.
Sandrine PF, Sylvie A, André E, Abdoulaye D, Bernard L, André C.
Nodular regenerative hyperplasia: a new serious antiretroviral drugs
side effect? AIDS 2007; 21: 1498-9.
Garvey LJ, Thomson EC, Lloyd J, Cooke GS, Goldin RD, Main J.
Response to Mallet et al., 'Nodular regenerative hyperplasia is a
new cause of chronic liver disease in HIV-infected patients'. AIDS
2007; 21: 1494-5.
Mallet V, Blanchard P, Verkarre V, Vallet-Pichard A, Fontaine H,
Lascoux-Combe C, Pol S. Nodular regenerative hyperplasia is a new
cause of chronic liver disease in HIV-infected patients. AIDS 2007;
21: 187-92.
Thoden J, Lebrecht D, Venhoff N, Neumann J, Muller K, Walker UA.
Highly active antiretroviral HIV therapy-associated fatal lactic
acidosis: quantitative and qualitative mitochondrial DNA lesions with
mitochondrial dysfunction in multiple organs. AIDS 2008; 22: 10934. 28% in muscle and 72% in heart).
Saifee S, Joelson D, Braude J, Shrestha R, Johnson M, Sellers M,
Galambos MR, Rubin RA. Noncirrhotic portal hypertension in
patients with human immunodeficiency virus-1 infection. Clin
Gastroenterol Hepato. 2008; 6: 1167-9.
Tateo M, Sebagh M, Bralet MP, Teicher E, Azoulay D, Mallet V, Pol
S, et al. A new indication for liver transplantation: nodular
regenerative hyperplasia in human immunodeficiency virus-infected
patients. Liver Transpl 2008; 14: 1194-8.
Vispo E, Maida I, Barreiro P, Moreno V, Soriano V. Upper
gastrointestinal bleeding may unmask didanosine-associated portal
hepatopathy in HIV/HCV co-infected patients. HIV Clin Trials 2008;
9: 440-4.
Panos G, Farouk L, Stebbing J, Holmes P, Valero S, Randell P,
Bower M, et al. Cryptogenic pseudocirrhosis: a new clinical
syndrome of noncirrhotic portal hypertension (unassociated with
advanced fibrosis) that can be detected by transient elastography in
patients with HIV. J Acquir Immune Defic Syndr 2009; 52: 525-7.
Chang PE, Miquel R, Blanco JL, Laguno M, Bruguera M, Abraldes JG,
Bosch J, Garcia-Pagan JC. Idiopathic portal hypertension in patients
with HIV infection treated with highly active antiretroviral therapy.
Am J Gastroenterol 2009; 104: 1707-14
Mendizabal M, Craviotto S, Chen T, Silva MO, Reddy KR.
Noncirrhotic portal hypertension: another cause of liver disease in
HIV patients. Ann Hepatol 2009; 8: 390-5.
Kovari H, Ledergerber B, Peter U, Flepp M, Jost J, Schmid P, Calmy
A, et al; Swiss HIV Cohort Study. Association of noncirrhotic portal
hypertension in HIV-infected persons and antiretroviral therapy with
didanosine: a nested case-control study. Clin Infect Dis 2009; 49:
626-35.
Mendizabal M, Craviotto S, Chen T, Silva MO, Reddy KR.
Noncirrhotic portal hypertension: another cause of liver disease in
HIV patients. Ann Hepatol 2009; 8: 390-5.
Vispo E, Moreno A, Maida I, Barreiro P, Cuevas A, Albertos S,
Soriano V. Noncirrhotic portal hypertension in HIV-infected patients:
unique clinical and pathological findings. AIDS 2010; 24: 1171-6.
Reuben A, Koch DG, Lee WM; Acute Liver Failure Study
Group. Drug-induced acute liver failure: results of a U.S.
multicenter, prospective study. Hepatology 2010; 52: 2065-76.
Scourfield A, Jackson A, Waters L, Gazzard B, Nelson M. The value
of screening HIV-infected individuals for didanosine-related liver
disease? Antivir Ther 2011; 16(6): 941-2.
Alvarez Díaz H, Mariño Callejo A, García Rodríguez JF. Non-cirrhotic
portal hypertension in human immunodeficiency virus-infected
patients: a new challenge in antiretroviral therapy era. Open AIDS J
2011; 5: 59-61.
Scourfield A, Waters L, Holmes P, Panos G, Randell P, Jackson A,
Mandalia S, Gazzard B, Nelson M. Non-cirrhotic portal hypertension
in HIV-infected individuals. Int J STD AIDS 2011; 22: 324-8.
Hofmaenner D, Kovari H, Weber A, Weishaupt D, Speck RF. Nodular
regenerative hyperplasia of the liver associated with didanosine
persists for years even after its interruption. BMJ Case Rep 2011;
2011.
Schiano TD, Uriel A, Dieterich DT, Fiel MI. The development of
hepatoportal sclerosis and portal hypertension due to didanosine
use in HIV. Virchows Arch 2011; 458: 231-5.
Cotte L, Bénet T, Billioud C, Miailhes P, Scoazec JY, Ferry T,
Brochier C, Boibieux A, Vanhems P, Chevallier M, Zoulim F. The role
of nucleoside and nucleotide analogues in nodular regenerative
hyperplasia in HIV-infected patients: a case control study. J Hepatol
2011; 54: 489-96.
Schouten JN, Van der Ende ME, Koëter T, Rossing HH, Komuta M,
Verheij J, van der Valk M, et al. Risk factors and outcome of HIVassociated idiopathic noncirrhotic portal hypertension. Aliment
Giacomet V, Viganò A, Penagini F, Manfredini V, Maconi G, Camozzi
M, Zuccotti GV. Splenomegaly and variceal bleeding in a ten-yearold HIV-infected girl with noncirrhotic portal hypertension. Pediatr
Infect Dis J 2012; 31: 1059-60.
Saison J, Cotte L, Chidiac C, Ferry T. Fatal cumulative toxicities of
HAART in a stable, AIDS-free, HIV-infected patient. BMJ Case Rep
2012; 2012.
Chang HM, Tsai HC, Lee SS, Wann SR, Chen YS. Noncirrhotic portal
hypertension associated with didanosine: a case report and
literature review. Jpn J Infect Dis 2012; 65: 61-5.
Hui YT, Lam WY, Lee MP, Lam TW, Li P. An unusual cause of
oesophageal variceal bleeding in a Chinese human
immunodeficiency virus-infected patient. Hong Kong Med J 2013;
19: 77-9.
DISULFIRAM
Knutsen B. [Complications of Antabuse therapy]. Tidsskr Nor
Laegeforen 1949; 69: 436-7.
Keeffe EB, Smith FW. Disulfiram hypersensitivity hepatitis. JAMA
1974; 230: 435-6.
Eisen HJ, Ginsberg AL. Letter: Disulfiram hepatotoxicity. Ann Intern
Med 1975; 83: 673-5.
Ranek L, Buch Andreasen P. Disulfiram hepatotoxicity. Br Med J
1977; 2: 94-6.
Morris SJ, Kanner R, Chiprut RO, Schiff ER. Disulfiram hepatitis.
Kristensen ME. Toxic hepatitis induced by disulfiram in a nonalcoholic. Acta Med Scand 1981; 209: 335-6.
Kobborg N, Søgaard PE. [Disulfiram hepatitis]. Ugeskr Laeger 1981;
143: 624. Danish.
Holm-Bentzen M, Almbjerg F, Ranek L. [Drug-induced liver
damage]. Ugeskr Laeger 1981; 143: 1213-6. Danish.
Wise JD. Disulfiram toxicity--a review of the literature. J Ark Med
Soc 1981; 78: 87-92.
Schade RR, Gray JA, Dekker A, Varma RR, Shaffer RD, Van Thiel
DH. Fulminant hepatitis associated with disulfiram. Report of a case.
Arch Intern Med 1983; 143: 1271-3.
Vázquez JJ, Diaz de Otazu R, Guillen FJ, Zozaya J, Pardo FJ.
Hepatitis induced by drugs used as alcohol aversion therapy. Diagn
Histopathol 1983; 6: 29-37.
Nässberger L. Disulfiram-induced hepatitis--report of a case and
review of the literature. Postgrad Med J 1984; 60: 639-41.
Nässberger L. Hepatotoxicity due to disulfiram. J Toxicol Clin Toxicol
1984; 22: 403-8.
Sundkvist T, Johansson B. [Disulfiram-induced hepatitis].
Lakartidningen 1984; 81: 4837. Swedish.
Bartle WR, Fisher MM, Kerenyi N. Disulfiram-induced hepatitis.
Report of two cases and review of the literature. Dig Dis Sci 1985;
30: 834-7.
Nässberger L. [Liver injury due to disulfiram]. Lakartidningen.
1985; 82: 4520-1. Swedish.
Black JL, Richardson JW. Disulfiram hepatotoxicity: case report. J
Clin Psychiatry 1985; 46: 67-8.
Nathan RS, Hill SY, Smith L. Disulfiram and hepatotoxicity.
Psychiatr J Univ Ott 1985; 10: 87-8
Barth R, Resnick RH, Smoller B. Disulfiram and fulminant hepatitis.
Dig Dis Sci 1987; 32: 1059.
Wright C 4th, Vafier JA, Lake CR. Disulfiram-induced fulminating
hepatitis: guidelines for liver-panel monitoring. J Clin Psychiatry
1988; 49: 430-4.
Cereda JM, Bernuau J, Degott C, Rueff B, Benhamou JP. Fatal liver
failure due to disulfiram. J Clin Gastroenterol 1989; 11: 98-100.
Mason NA. Disulfiram-induced hepatitis: case report and review of
the literature. DICP 1989; 23: 872-5.
Vanjak D, Samuel D, Gosset F, Derrida S, Moreau R, Soupison T,
Soulier A, et al. [Fulminant hepatitis induced by disulfiram in a
patient with alcoholic cirrhosis. Survival after liver transplantation].
Senerath Yapa RS. Danger of antabuse therapy. Practitioner 1989;
233: 13-4.
Kahn S, Farnum JB, Thomas E. Disulfiram-induced hepatitis. South
Med J 1990; 83: 833-6.
Knudsen TE, Nielsen-Kudsk JE. [Fatal hepatitis caused by
disulfiram]. Ugeskr Laeger 1990; 152: 1457-8. Danish.
Bell H, Raknerud N. [Fulminating hepatitis after treatment with
naproxen and/or disulfiram?]. Tidsskr Nor Laegeforen 1991; 111:
322-3. Norwegian.
Zala G, Schmid M, Bühler H. [Fulminant hepatitis caused by
disulfiram]. Dtsch Med Wochenschr 1993; 118: 1355-60. German.
Forns X, Caballería J, Bruguera M, Salmerón JM, Vilella A, Mas A,
Parés A, et al. Disulfiram-induced hepatitis. Report of four cases
and review of the literature. J Hepatol 1994; 21: 853-7.
Kerkhof SC, de Doelder PF, Harinck HI, Stricker BH. [Liver damage
attributed to the use of disulfiram]. Ned Tijdschr Geneeskd 1995;
139: 2378-81. Dutch.
Carniato A, Fuser R, Vaglia A. [Disulfiram-induced hepatitis]. Infez
Med 1998; 6: 102-103. Italian.
Eliasson E, Stål P, Oksanen A, Lytton S. Expression of
autoantibodies to specific cytochromes P450 in a case of disulfiram
hepatitis. J Hepatol 1998; 29: 819-25.
Rabkin JM, Corless CL, Orloff SL, Benner KG, Flora KD, Rosen HR,
Olyaei AJ. Liver transplantation for disulfiram-induced hepatic
failure. Am J Gastroenterol 1998; 93: 830-1.
Masiá M, Gutiérrez F, Jimeno A, Navarro A, Borrás J, Matarredona J,
Martín-Hidalgo A. Fulminant hepatitis and fatal toxic epidermal
necrolysis(Lyell disease) coincident with clarithromycin
administration in an alcoholic patient receiving disulfiram therapy.
Arch Intern Med 2002; 162: 474-6.
Mohanty SR, LaBrecque DR, Mitros FA, Layden TJ. Liver
transplantation for disulfiram-induced fulminant hepatic failure. J
Clin Gastroenterol 2004; 38: 292-5.
De Valle MB, Av Klinteberg V, Alem N, Olsson R, Björnsson E. Druginduced liver injury in a Swedish University hospital out-patient
hepatology clinic. Aliment Pharmacol Ther 2006; 24: 1187-95.
Björnsson E, Nordlinder H, Olsson R. Clinical characteristics and
prognostic markers in disulfiram-induced liver injury. J Hepatol
2006; 44: 791-7.
Verge C, Lucena MI, López-Torres E, Puche-Garcia MJ, Fraga E,
Romero-Gomez M, Andrade RJ. Adverse hepatic reactions
associated with calcium carbamide and disulfiram therapy: is there
still a role for these drugs? World J Gastroenterol 2006; 12: 507880.
pii: S0016-5085(15)00311-X.
multicenter, prospective study. Hepatology 2010; 52: 2065-76
ERYTHROMYCIN
Johnson DF Jr, Hall WH. Allergic hepatitis caused by propionyl
erythromycin ester of lauryl sulfate. N Engl J Med 1961; 265: 12002.
Kohlstaedt KG. Propionyl erythromycin ester lauryl sulfate and
jaundice. JAMA 1961; 178: 89-90.
Dittler EL. Upper abdominal pain and intrahepatic cholestasis as
manifestations of sensitivity to Ilosone. Am J Gastroenterol 1962;
38: 691-2.
Gilbert FI Jr. Cholestatic hepatitis caused by esters of erythromycin
and oleandomycin. JAMA 1962; 182: 1048-50.
Havens WP Jr. Cholestatic jaundice in patients treated with
erythromycin estolate. JAMA 1962; 180: 30-2.
Masel MA. Erythromycin hepato-sensitivity: a preliminary report of
two cases. Med J Aust 1962; 49: 560-2.
Reed C, Ritchie F. Toxic jaundice due to propionyl erythromycin
ester lauryl sulfate (“Ilosone”). Med J Aust 1962; 49: 810-2.
Riley WA. Hepatitis following administration of Ilosome. Case report.
N C Med J 1962; 23: 362.
Robinson MM. Demonstration by "challenge" of hepatic dysfunction
associated with propionyl erythromycin ester lauryl sulfate. Antibiot
Chemother 1962; 12: 147-51.
Robinson MM. Hepatic dysfunction associated with
triacetyloleandomycin and propionyl erythromycin ester lauryl
sulfate. Am J Med Sci 1962; 243: 502-10.
Farmer CD, Hoffman HN 2nd, Shorter RG, Thurber DL, Bartholomew
LG. Intrahepatic cholestasis associated with the ingestion of
erythromycin estolate (Ilosone). Gastroenterology 1963; 45: 15860.
Fischer HW, Hoak JC. Mimicry of acute cholecystitis by erythromycin
estolate reactions. Report of 2 cases. Am J Med Sci 1964; 247: 2835.
Fukayak TG. [Case of hypersensitive hepatitis due to propionyl
erythromycin lauryl sulfate] Naika 1964; 14: 741-4. Japanese
McKenzie I, Doyle A. Two cases of jaundice following "Ilosone". Med
J Aust 1966; 1: 349-51.
Braun P. Hepatotoxicity of erythromycin. J Infect Dis 1969; 119:
300-6.
Kosenow W, Stollenwerk F. [Jaundice following erythromycinestolate therapy] Dtsch Med Wochenschr 1971; 96: 1836 passim.
German.
Oliver LE, Iser JH, Stening GF, Smallwood RA. Abdominal pain and
erythromycin estolate. Lancet 1972; 2: 980.
The erythromycins. A further report from the Australian Drug
Evaluation Committee. Med J Aust 1973; 2: 192-3.
[Erythromycin estolate and liver toxicity] Ugeskr Laeger 1974; 136:
2093-4. Danish.
Buchanec J, Krajnák V. [Liver damage during erythromycin therapy
in 3 children] Cesk Pediatr 1974; 29: 76-8. Slovak.
Tolman KG, Sannella JJ, Freston JW. Chemical structure of
erythromycin and hepatotoxicity. Ann Intern Med 1974; 81: 58-60.
Lunzer MR, Huang SN, Ward KM, Sherlock S. Jaundice due to
erythromycin estolate. Gastroenterology 1975; 68(5 Pt 1): 128491.
Pessayre D, Marie C, Benhamou JP. [Hepatitis due to erythromycin
propionate (author's transl)] Arch Fr Mal App Dig 1976; 65: 405-8.
French.
Cacace LG, Schweigert BF, Gildon AM. Erythromycin estolate
induced hepatotoxicity: report of a case and review of the literature.
Drug Intell Clin Pharm 1977; 11: 22-25.
Cooksley WG, Powell LW. Erythromycin jaundice: diagnosis by an in
vitro challenge test. Aust N Z J Med 1977; 7: 291-3.
Lloyd-Still JD, Sherman JO, Boggs J, Demers LM. Erythromycin
estolate hepatotoxicity. Am J Dis Child 1978; 132: 320.
Rodríguez Cuartero A, Rodríguez Cuartero F, Alonso Fernández J,
Castillo Higueras PL. [Acute hepatitis caused by erythromycin] Rev
Esp Enferm Apar Dig 1978; 54: 533-6. Spanish.
Gafter U, Mandel EM, Weiss S, Djaldetti M. Erythromycin estolateinduced hepatitis. Ultrastructural study of liver. N Y State J Med
1979; 79: 87-9
Viteri AL, Greene JF Jr, Dyck WP. Erythromycin ethylsuccinateinduced cholestasis. Gastroenterology 1979; 76(5 Pt 1): 1007-8.
Zafrani ES, Ishak KG, Rudzki C. Cholestatic and hepatocellular
injury associated with erythromycin esters: report of nine cases. Dig
Dis Sci 1979; 24: 385-96
Sullivan D, Csuka ME, Blanchard B. Erythromycin ethylsuccinate
hepatotoxicity. JAMA 1980; 243: 1074.
Bachman BA, Boyd WP Jr, Brady PG. Erythromycin ethylsuccinateinduced cholestasis. Am J Gastroenterol 1982; 77: 397-400.
Cocchi P, Silenzi M, Salvi G, Calabri G, Tamburini M, Alvisi P.
[Hepatotoxic syndrome caused by erythromycin ethyl succinate]
Minerva Pediatr 1982; 34: 68-9. Italian.
Funck-Brentano C, Danan G, Pessayre D, Benhamou JP. [Hepatitis
due to erythromycin ethylsuccinate] Gastroenterol Clin Biol 1982;
6: 1044-5. French
Keeffe EB, Reis TC, Berland JE. Hepatotoxicity to both erythromycin
estolate and erythromycin ethylsuccinate. Dig Dis Sci 1982; 27:
701-4.
Ponsot P, Théodore C, Larrey D, Breil P, Hugentobler JP, Paolaggi
JA. [Acute hepatitis caused by erythromycin propionate]
Funck-Brentano C, Pessayre D, Benhamou JP. [Hepatitis caused by
various derivatives of erythromycin] Gastroenterol Clin Biol 1983;
7: 362-9. French.
Hosker JP, Jewell DP. Transient, selective factor X deficiency and
acute liver failure following chest infection treated with
erythromycin BP. Postgrad Med J 1983; 59: 514-5.
Paliard P, Stremsdoerfer N, Moindrot H. [Acute hepatitis caused by
erythromycin esters (propionate and ethylsuccinate)] Gastroenterol
Clin Biol 1983; 7: 100-1. French.
Phillips KG. Hepatotoxicity of erythromycin ethylsuccinate in a child.
Can Med Assoc J 1983; 129: 411-2.
Diehl AM, Latham P, Boitnott JK, Mann J, Maddrey WC. Cholestatic
hepatitis from erythromycin ethylsuccinate. Am J Med 1984; 76:
931-4
Ortuño JA, Olaso V, Berenguer J. [Cholestasis hepatitis caused by
erythromycin propionate] Med Clin (Barc) 1984; 82: 912. Spanish.
Patel J, Schneider R. Hepatotoxic reaction to erythromycin
ethylsuccinate. South Med J 1984; 77: 1343-4.
García Monzón C, Noguerado A, Hidalgo S, Escudero V. [Cholestatic
hepatitis caused by erythromycin estolate] Rev Clin Esp 1985; 177:
420-1. Spanish.
Pessayre D, Larrey D, Funck-Brentano C, Benhamou JP. Drug
interactions and hepatitis produced by some macrolide antibiotics. J
Antimicrob Chemother 1985; 16 Suppl A: 181-94.
Simon C, Roul G, Chabrier G, Schlienger JL, Imler M. [Hepatic
involvement induced by erythromycin propionate] Rev Med Interne
1985; 6: 84-5. French.
Alcalay J, Halevy S, Theodor E, Sandbank M. Asymptomatic liver
injury due to erythromycin stearate. Drug Intell Clin Pharm 1986;
20: 601-2.
Swayne LC, Kolc J. Erythromycin hepatotoxicity. A rare cause of a
false-positive technetium-99m DISIDA study. Clin Nucl Med 1986;
11: 10-2.
Perrier M, Portier G, de Calan L, et al. [Erythromycin-induced
hepatitis] Cah Anesthesiol 1987; 35: 237. French.
Geubel AP, Nakad A, Rahier J, Dive C. Prolonged cholestasis and
disappearance of interlobular bile ducts following chlorpropamide
and erythromycin ethylsuccinate. Case of drug interaction? Liver
1988; 8: 350-3.
Luherne JY, Pariente EA, Maitre F. [Crossed hepatotoxicity of
erythromycin propionate and troleandomycin?] Gastroenterol Clin
Biol 1988; 12: 869-70. French.
Rigauts HD, Selleslag DL, Van Eyken PL, Van Damme BJ, Fevery JM,
Marchal GJ. Erythromycin-induced hepatitis: simulator of
malignancy. Radiology 1988; 169: 661-2.
Dubois A, Nakache N, Raffanel C, Balmes JL. [Acute cholestatic
hepatitis after ingestion of roxithromycin] Gastroenterol Clin Biol
1989; 13: 317-8. French
García Buey L, García-Samaniego Rey J, González Estecha A,
Pajares García JM. [Hepatotoxicity of erythromycin] Rev Clin Esp
1989; 184: 158. Spanish.
Alemayehu G, Näslund I. [Erythromycin caused liver injury and
gallbladder inflammation] Lakartidningen 1990; 87: 2866. Swedish.
Dde Escalante B, Sampedro JA, Zabala S, Gracia P. [Cholestatic
hepatitis caused by erythromycin propionate] An Med Interna 1990;
7: 656. Spanish.
Gholson CF, Warren GH. Fulminant hepatic failure associated with
intravenous erythromycin lactobionate. Arch Intern Med 1990; 150:
215-6.
Serrano Heranz R, Ziad F. [Hepatotoxicity caused by erythromycin
ethylsuccinate] An Med Interna 1990; 7: 215. Spanish.
Caballeria Rovira E, Arago López JV, Masso Ubeda RM, Sanchis
Closa A. [Hepatotoxicity due to erythromycin ethylsuccinate] Rev
Esp Enferm Dig 1991; 80: 356. Spanish.
Saiz Santos S, Montero López L. [Hepatotoxicity from erythromycin
estolate] Aten Primaria 1992; 10: 1050. Spanish.
Carson JL, Strom BL, Duff A, et al. Acute liver disease associated
with erythromycins, sulfonamides, and tetracyclines. Ann Intern
Med 1993; 119(7 Pt 1): 576-83.
Derby LE, Jick H, Henry DA, Dean AD. Erythromycin-associated
cholestatic hepatitis. Med J Aust 1993; 158: 600-2.
Howe E, Howe E, Benn RA. Hepatotoxicity due to erythromycin
ethylsuccinate. Med J Aust 1993; 158: 142-4.
Gilbert FI Jr. Cholestatic hepatitis caused by esters of erythromycin
and oleandomycin. 1962. Hawaii Med J 1995; 54: 603-5.
years experience. N Z Med J 1996; 109: 315-9.
Wong PW, Dillard TA, Kroenke K. Multiple organ toxicity from
addition of erythromycin to long-term lovastatin therapy. South Med
J 1998; 91: 202-5.
Horn S, Aglas F, Horina JH. Cholestasis and liver cell damage due to
hypersensitivity to erythromycin stearate--recurrence following
therapy with erythromycin succinate. Wien Klin Wochenschr 1999;
111: 76-7.
Sweden. Scand J Gastroenterol 2005; 40: 1095-101
Karthik SV, Casson D. Erythromycin-associated cholestatic hepatitis
and liver dysfunction in children: the British experience. J Clin
EFAVIRENZ
Bossi P, Colin D, Dricaire F, Caumes E. Hypersensitivity syndrome
associated with efavirenz therapy. Clin Infect Dis 2000; 30: 227-8.
Verdon R, Six M, Rousselot P, Bazin C. Efavirenz-induced acute
eosinophilic hepatitis. J Hepatol. 2001; 34: 783-5.
Hill JB, Sheffield JS, Zeeman GG, Wendel GD Jr. Hepatotoxicity with
antiretroviral treatment of pregnant women. Obstet Gynecol 2001;
98: 909-11.
report of six cases. J Hepatol 2002; 36: 295-301
Verma S, Bhakta H, Nowain A, Pais S, Kanel G, Squires K, Squires
K. Severe cholestatic liver injury days after initiating antiretroviral
therapy in a patient with AIDS: drug toxicity or immune
reconstitution inflammatory syndrome? Dig Dis Sci 2005; 50: 18137.
Lattuada E, Lanzafame M, Carolo G, Gottardi M, Concia E, Vento S.
Does tenofovir increase efavirenz hepatotoxicity? AIDS 2008; 22:
995-6.
Leung JM, O'Brien JG, Wong HK, Winslow DL. Efavirenz-induced
hypersensitivity reaction manifesting in rash and hepatitis in a
Latino male. Ann Pharmacother 2008; 42: 425-9.
Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T,
Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network
(DILIN). Causes, clinical features, and outcomes from a prospective
study of drug-induced liver injury in the United States.
Qayyum S, Dong H, Kovacic D, Sohail S, Waters B, Thornton C,
Corbett CE. Combination therapy efavirenz/emtricitabine/tenofovir
disoproxil fumarate associated with hepatic failure. Curr Drug Saf
2012; 7: 391-3.
Elsharkawy AM, Schwab U, McCarron B, Burt AD, Daly AK, Hudson
M, Masson S. Efavirenz induced acute liver failure requiring liver
transplantation in a slow drug metaboliser. J Clin Virol 2013; 58:
331-3.
Fink DL, Bloch E. Liver transplantation for acute liver failure due to
efavirenz hepatotoxicity: the importance of routine monitoring. Int J
STD AIDS 2013; 24: 831-3.
Echenique IA, Rich JD. EFV/FTC/TDF-associated hepatotoxicity: a
case report and review. AIDS Patient Care STDS 2013; 27: 493-7.
Sonderup MW, Wainwright H, Hall P, Hairwadzi H, Spearman CW. A
clinicopathological cohort study of liver pathology in 301 patients
with human immunodeficiency virus/acquired immune deficiency
syndrome. Hepatology. 2015 Jan 16. doi: 10.1002/hep.27710.
[Epub ahead of print]
FLUCLOXACILLIN
Lobatto S, Dijkmans BA, Mattie H, Van Hooff JP. Flucloxacillinassociated liver damage. Neth J Med. 1982; 25: 47-8.
Bengtsson F, Florén CH, Hägerstrand I, Söderström C, Aberg T.
Flucloxacillin-induced cholestatic liver damage. Scand J Infect Dis
1985; 17: 125-8.
Tauris P, Jørgensen NF, Petersen CM, Albertsen K. Prolonged severe
cholestasis induced by oxacillin derivatives. A report on two cases.
Acta Med Scand 1985; 217: 567-9.
Victorino RM, Maria VA, Correia AP, de Moura C. Floxacillin-induced
cholestatic hepatitis with evidence of lymphocyte sensitization. Arch
Intern Med 1987; 147: 987-9.
[Risk of liver reactions after treatment with flucloxacillin]
Lakartidningen 1989; 86: 977-8. Swedish.
Turner IB, Eckstein RP, Riley JW, Lunzer MR. Prolonged hepatic
cholestasis after flucloxacillin therapy. Med J Aust 1989; 151: 7015.
Miros M, Kerlin P, Walker N, Harris O. Flucloxacillin induced delayed
cholestatic hepatitis. Aust N Z J Med 1990; 20: 251-3.
Fairley CK, Boyd I, Purcell P, McNeil J. Flucloxacillin jaundice. Lancet
1992; 339: 679.
Olsson R, Wiholm BE, Sand C, Zettergren L, Hultcrantz R, Myrhed
M. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J
Hepatol 1992; 15: 154-61.
Derby LE, Jick H, Henry DA, Dean AD. Cholestatic hepatitis
associated with flucloxacillin. Med J Aust 1993; 158: 596-600.
Jick H, Derby LE, Dean AD, Henry DA. Flucloxacillin and cholestatic
hepatitis. Med J Aust 1994; 160: 525.
Eckstein RP, Dowsett JF, Lunzer MR. Flucloxacillin induced liver
disease: histopathological findings at biopsy and autopsy. Pathology
1993; 25: 223-8.
Fairley CK, McNeil JJ, Desmond P, Smallwood R, Young H, Forbes A,
Purcell P, et al. Risk factors for development of flucloxacillin
associated jaundice. BMJ 1993; 306: 233-5.
Koek GH, Stricker BH, Blok AP, Schalm SW, Desmet VJ.
Flucloxacillin-associated hepatic injury. Liver 1994; 14: 225-9.
Desmond PV. Flucloxacillin hepatitis--an Australian epidemic. Aust N
Z J Med 1995; 25: 195-6.
Devereaux BM, Crawford DH, Purcell P, Powell LW, Roeser HP.
Flucloxacillin associated cholestatic hepatitis. An Australian and
Swedish epidemic? Eur J Clin Pharmacol 1995; 49: 81-5.
Sweden. Scand J Gastroenterol 2005; 40: 1095-101
Dobson JL, Angus PW, Jones R, Crowley P, Gow PJ. Flucloxacillininduced aplastic anaemia and liver failure. Transpl Int 2005; 18:
487-9.
Hussaini SH, O'Brien CS, Despott EJ, Dalton HR. Antibiotic therapy:
a major cause of drug-induced jaundice in southwest England. Eur J
Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A,
Daly MJ, et al. HLA-B*5701 genotype is a major detrminant of druginduced liver injury due to flucloxacillin. Nature Genetics 2009; 41:
816-9.
Björnsson E, Olsson R. Outcome and prognostic markers in severe
drug-induced liver disease. Hepatology 2005; 42: 481-489.
FLUTAMIDE
Hart W, Stricker BH. Flutamide and hepatitis. Ann Intern Med 1989;
110: 943-4.
Møller S, Iversen P. [Severe toxic hepatitis during flutamide
(Eulexin) treatment] Ugeskr Laeger 1989; 151: 173-4. Danish.
Coppéré H, Perraud Y, Gérard F, Jouffre C, David A, Barthélémy C,
Audigier JC. [A case of acute hepatitis caused by flutamide]
Møller S, Iversen P, Franzmann MB. Flutamide-induced liver failure.
J Hepatol 1990; 10: 346-9.
Alperine M, Cohen L, Cocheton JJ, Lecomte I, Meyniel D. [Acute
hepatitis caused by flutamide] Presse Med 1991; 20: 1459-60.
French.
Corkery JC, Bihrle W 3rd, McCaffrey JA, Whitcomb FF, Levy C, Ellis
R. Flutamide-related fulminant hepatic failure. J Clin Gastroenterol
1991; 13: 364-5.
Dankoff JS. Near fatal liver dysfunction secondary to administration
of flutamide for prostate cancer. J Urol 1992; 148: 1914.
Martínez Bruna MS, Velila Alcubilla JP, Abinzano M, Martínez Velasco
C, García Mauriz ME, Urbieta Echezareta M. [Hepatotoxicity and
flutamide] An Med Interna 1993; 10: 566. Spanish.
Rosman AS, Frissora-Rodeo C, Marshall AT, Reiter BP, Paronetto F.
Cholestatic hepatitis following flutamide. Dig Dis Sci 1993; 38:
1756-9.
Wallace C, Lalor EA, Chik CL. Hepatotoxicity complicating flutamide
treatment of hirsutism. Ann Intern Med 1993; 119: 1150
Wysowski DK, Freiman JP, Tourtelot JB, Horton ML 3rd. Fatal and
nonfatal hepatotoxicity associated with flutamide. Ann Intern Med
1993; 118: 860-4.
Caballería E, Aragó JV, Sanchís A. [Hepatotoxicity due to flutamide]
Med Clin (Barc) 1994; 102: 434. Spanish.
Dourakis SP, Alexopoulou AA, Hadziyannis SJ. Fulminant hepatitis
after flutamide treatment. J Hepatol 1994; 20: 350-3.
Prattichizzo FA. Acute cholestatic hepatitis secondary to flutamide
therapy. Am J Med 1994; 96: 392-3.
Kosar Y, Sasmaz N, Oguz P, Küçükbas S. Hepatic insufficiency
developing as a result of flutamide treatment. Am J Gastroenterol
1995; 90: 1027-8.
Andréjak M, Nguyen-Khac E, Decocq G, Capron JP. [Fulminant
hepatitis caused by flutamide] Gastroenterol Clin Biol 1996; 20:
121-2. French.
Cicognani C, Malavolti M, Morselli-Labate AM, Sama C, Barbara L.
Flutamide-induced toxic hepatitis.
Crownover RL, Holland J, Chen A, Krieg R, Young BK, Roach M III,
Fu KK. Flutamide-induced liver toxicity including fatal hepatic
necrosis. Int J Radiat Oncol Biol Phys 1996; 34: 911-5.
Lee HW, Chung JP, Lee KS, Kim KC, Lee KS, Chon CY, Park IS, Kim
HG. A case of flutamide-induced acute cholestatic hepatitis--a case
report. Yonsei Med J 1996; 37: 225-9.
Patel H, Rhee E, Zimmern PE. [Hepatic encephalopathy induced by
flutamide administered for the treatment of prostatic cancer] J Urol
(Paris) 1996; 102: 123-5. French
Rosenthal SA, Linstadt DE, Leibenhaut MH, Andras EJ, Brooks CP,
Stickney DR, Chang GC, et al. Flutamide-associated liver toxicity
during treatment with total androgen suppression and radiation
therapy for prostate cancer. Radiology 1996; 199: 451-5.
Cantalejo Moreira M, García Espinosa V, Martín Gutiérrez JC, García
Puig J. [Hepatotoxicity from flutamide] Med Clin (Barc) 1997; 109:
819-20. Spanish.
Fernández Peña CM, Morano Amado LE, Montes Santiago J, Fachal
C. [Fulminant liver failure with a fatal outcome due to flutamide]
Med Clin (Barc) 1997; 108: 237-8. Spanish.
García-Gascó P, Morata Aldea C, Segura Huertas A, Aparicio
Urtasun J. [Fulminant hepatitis associated with treatment with
flutamide] Med Clin (Barc) 1997; 109: 820. Spanish.
Guzmán Martínez-Valls PL, Ferrero Doria R, Morga Egea JP, Ros R,
Galiano R, Gutierrez A, Franco G, et al. [Liver failure caused by
flutamide] Actas Urol Esp 1997; 21: 278-82. Spanish
Wietzke P, Münke H, Hartmann H, Ramadori G. [Hepatotoxicity of
flutamide] Z Gastroenterol 1997; 35: 631-5. German.
Chu CW, Hwang SJ, Luo JC, et al. Flutamide-induced liver injury: a
case report. Zhonghua Yi Xue Za Zhi (Taipei) 1998; 61: 678-82.
Cuevas Campos MA, Pareja Llorens G, García Romero E, Bertomeu
Blanch F. [Toxic hepatitis caused by flutamide] Gastroenterol
Mena FJ, Goyeneche ML, Velicia R, González JM, Bellido J, CaroPatón A. [Acute cholestatic hepatitis secondary to flutamide] Rev
Esp Enferm Dig 1998; 90: 376-7. Spanish.
Pontiroli L, Sartori M, Pittau S, Morelli S, Boldorini R, Albano E.
Flutamide-induced acute hepatitis: investigation on the role of
immunoallergic mechanisms. Ital J Gastroenterol Hepatol 1998; 30:
310-4.
Andrade RJ, Lucena MI, Fernández MC, Suarez F, Montero JL, Fraga
E, Hidalgo F. Fulminant liver failure associated with flutamide
therapy for hirsutism. Lancet 1999; 353: 983.
Cetin M, Demirci D, Unal A, Altinbas M, Güven M, Unlühizarci K.
Frequency of flutamide induced hepatotoxicity in patients with
prostate carcinoma. Hum Exp Toxicol 1999; 18: 137-40.
Nakagawa Y, Koyama M, Matsumoto M. [Flutamide-induced hepatic
disorder and serum concentrations of flutamide and its metabolites
in patients with prostate cancer] Hinyokika Kiyo 1999; 45: 821-6.
Japanese.
Nicolás D, Pérez-EbrI ML, Sarrión JV, Nos P. [Acute flutamideinduced hepatitis] Gastroenterol Hepatol 1999; 22: 262-3. Spanish.
Román Llorente FJ, Alvarez Navascués C, Suárez González A,
González Bernal AC. [Toxic hepatitis caused by flutamide and
hirsutism] Gastroenterol Hepatol 2000; 23: 258. Spanish.
García Cortés M, Andrade RJ, Lucena MI, Sanchez Martinez H,
Fernandez MC, Ferrer T, Martin-Vivaldi R, et al. Flutamide-induced
hepatotoxicity: report of a case series. Rev Esp Enferm Dig 2001;
93: 423-32.
Kraus I, Vitezic D, Oguic R. Flutamide-induced acute hepatitis in
advanced prostate cancer patients. Int J Clin Pharmacol Ther 2001;
39: 395-9.
Ruiz R, Casañ R, Juan O. [Hepatotoxicity due to flutamide] Aten
Primaria 2001; 28: 565. Spanish.
Ruiz-Rebollo M, Atienza-Sánchez R, López-García E. [Hirsutism,
flutamide and hepatotoxicity] Gastroenterol Hepatol 2001; 24: 218.
Spanish.
Ashar U, Desai D, Bhaduri A. Flutamide-induced hepatotoxicity with
possible potentiation by simvastatin. J Assoc Physicians India 2003;
51: 75-7.
Famularo G, De Simone C, Minisola G, Nicotra GC. Flutamideassociated acute liver failure. Ann Ital Med Int 2003; 18: 250-3.
Kackar RR, Desai HG. Hepatic failure with flutamide. Indian J
Lübbert C, Wiese M, Haupt R, Ruf BR. [Toxic hepatitis and liver
failure under therapy with flutamide] Internist (Berl) 2004; 45:
333-40. German.
Manolakopoulos S, Bethanis S, Armonis A, Economou M, Avgerinos
A, Tzourmakliotis D. Toxic hepatitis after sequential administration
of flutamide and cyproterone acetate. Dig Dis Sci 2004; 49: 462-5.
Vázquez Romero M, Gil Grande L, López Serrano P, Alemán
Villanueva S, García Plaza A. [Liver toxicity associated with
flutamide] An Med Interna 2004; 21: 307-8. Spanish.
Bengoechea Gallastegui L, Vita Garay A, Castiella Eguzkiza A, Egido
Arroyo JF. [Toxic hepatitis after flutamide treatment] Aten Primaria
2005; 36: 112. Spanish.
Papaioannides D, Korantzopoulos P, Bouropoulos C, Latsi P, Fotinou
M, Orphanidou D. Microscopic polyangiitis complicated by the
development of prostate cancer and flutamide-induced hepatitis. Int
Urol Nephrol 2005; 37: 515-20.
Ramírez R, Ruiz MA, Auguet T, Richart C. [Severe acute hepatitis
due to flutamide and elevated CA 19.9] Gastroenterol Hepatol
2005; 28: 433. Spanish.
Osculati A, Castiglioni C. Fatal liver complications with flutamide.
Lancet 2006; 367: 1140-1.
Miquel M, Soler A, Vaqué A, Ojanguren I, Costa J, Planas R.
Suspected cross-hepatotoxicity of flutamide and cyproterone
acetate. Liver Int 2007; 27: 1144-7.
Wang YP, Shi B, Chen YX, Xu J, Jiang CF, Xie WF. Drug-induced
liver disease: an 8-year study of patients from one
gastroenterological department. J Dig Dis 2009; 10: 195-200.
A Chirino R, et al. Profile of idiosyncratic drug induced liver injury in
Latin America. An analysis of published reports. Ann Hepatol 2014
Mar-Apr; 13(2): 231-9.
FLOXURIDINE
Kemeny MM, Battifora H, Blayney DW, Cecchi G, Goldberg DA,
Leong LA, Margolin KA, et al. Sclerosing cholangitis after continuous
hepatic artery infusion of FUDR. Ann Surg 1985; 02: 176-81.
Shepard KV, Levin B, Karl RC, Faintuch J, DuBrow RA, Hagle M,
Cooper RM, et al. Therapy for metastatic colorectal cancer with
hepatic artery infusion chemotherapy using a subcutaneous
implanted pump. J Clin Oncol 1985; 3: 161-9.
Pien EH, Zeman RK, Benjamin SB, Barth KH, Jaffe MH, Choyke PL,
Clark LR, Paushter DM. Iatrogenic sclerosing cholangitis following
hepatic arterial chemotherapy infusion. Radiology. 1985; 156: 32930.
Shea WJ Jr, Demas BE, Goldberg HI, Hohn DC, Ferrell LD, Kerlan
RK. Sclerosing cholangitis associated with hepatic arterial FUDR
chemotherapy: radiographic-histologic correlation. AJR Am J
Roentgenol 1986; 146: 717-21.
Doria MI Jr, Shepard KV, Levin B, Riddell RH. Liver pathology
following hepatic arterial infusion chemotherapy. Hepatic toxicity
with FUDR. Cancer 1986; 58: 855-61.
Pettavel J, Gardiol D, Bergier N, Schnyder P. Fatal liver cirrhosis
associated with long-term arterial infusion of floxuridine. Lancet
1986; 2(8516): 1162-3.
Bolton JS, Bowen JC. Biliary sclerosis associated with hepatic artery
infusion of floxuridine. Surgery 1986; 99: 119-22
Laughlin EH. Common duct stricture associated with hepatic artery
infusion of FUDR. J Surg Oncol 1986; 31: 56-9.
Bergmann JF, Rougier P, Liguory C, Zafrani ES, Méeau JM,
Dhumeaux D. [Sclerosing cholangitis after chemotherapy by
continuous hepatic intra-arterial infusion of fluorodeoxyuridine].
Gastroenterol Clin Biol 1986; 10: 177-9. French
Shepard KV, Levin B, Faintuch J, Doria MI, DuBrow RA, Riddell RH.
Hepatitis in patients receiving intraarterial chemotherapy for
metastatic colorectal carcinoma. Am J Clin Oncol 1987; 10: 36-40.
Clark RA, Gallant TE. Bile duct strictures associated with hepatic
arterial infusion chemotherapy. Gastrointest Radiol 1987; 12: 14851.
Ludwig J, Kim CH, Wiesner RH, Krom RA. Floxuridine-induced
sclerosing cholangitis: an ischemic cholangiopathy? Hepatology
1989; 9: 215-8.
Wagman LD, Kemeny MM, Leong L, Terz JJ, Hill LR, Beatty JD,
Kokal WA, et al. A prospective, randomized evaluation of the
treatment of colorectal cancer metastatic to the liver. J Clin Oncol
1990; 8: 1885-93.
Pozniak MA, Babel SG, Trump DL. Complications of hepatic arterial
infusion chemotherapy. Radiographics 1991; 11: 67-79.
Rougier P, Laplanche A, Huguier M, Hay JM, Ollivier JM, Escat J,
Salmon R, et al. Hepatic arterial infusion of floxuridine in patients
with liver metastases from colorectal carcinoma: long-term results
of a prospective randomized trial. J Clin Oncol 1992; 10: 1112-8.
Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF,
Bertino JR, et al. Hepatic arterial infusion of chemotherapy after
resection of hepatic metastases from colorectal cancer. N Engl J
Med 1999; 341: 2039-48.
Aldrighetti L, Arru M, Ronzoni M, Salvioni M, Villa E, Ferla G.
Extrahepatic biliary stenoses after hepatic arterial infusion(HAI) of
floxuridine(FUdR) for liver metastases from colorectal cancer.
Hepatogastroenterology 2001; 48: 1302-7.
Phongkitkarun S, Kobayashi S, Varavithya V, Huang X, Curley SA,
Charnsangavej C. Bile duct complications of hepatic arterial infusion
chemotherapy evaluated by helical CT. Clin Radiol 2005; 60: 700-9.
Sandrasegaran K, Alazmi WM, Tann M, Fogel EL, McHenry L,
Lehman GA. Chemotherapy-induced sclerosing cholangitis. Clin
Radiol 2006; 61: 670-8.
Alazmi WM, McHenry L, Watkins JL, Fogel EL, Schmidt S, Sherman
S, Lehman GL. Chemotherapy-induced sclerosing cholangitis: longterm response to endoscopic therapy. J Clin Gastroenterol. 2006;
40: 353-7.
Ito K, Ito H, Kemeny NE, Gonen M, Allen PJ, Paty PB, Fong Y, et al.
Biliary sclerosis after hepatic arterial infusion pump chemotherapy
for patients with colorectal cancer liver metastasis: incidence,
clinical features, and risk factors. Ann Surg Oncol 2012; 19: 160917.
Ang C, Jhaveri K, Patel D, Gewirtz A, Seidman A, Kemeny N.
Hepatic arterial infusion and systemic chemotherapy for breast
cancer liver metastases. Breast J 2013; 19: 96-9.
GOLD SALTS
Moeschlin S, Siegenthaler P. [Cholestatic hepatitis caused by gold;
analogy to chlorpromazine and androgen icterus.] Helv Med Acta
1960; 27: 707-15.
Wiontzek H, Schmidt J. [Allergic cholestatic hepatosis following gold
treatment of a seronegative, chronic progressive polyarthritis]. Z
Rheumaforsch 1970; 9: 46-8. German.
Kornreich H, Malouf NN, Hanson V. Acute hepatic dysfunction in
juvenile rheumatoid arthritis. J Pediatr 1971; 79: 27-35.
Ghisolfi J, Rumeau JL, Rolland M, Dalous A. [Cholestatic syndrome
following massive chrysotherapy]. Arch Fr Pediatr 1972; 29: 1097106. French.
Iuel J. [Deaths from gold therapy in Denmark during 1960-64].
Schenker S, Olson KN, Dunn D, Breen KJ, Combes B. Intrahepatic
cholestasis due to therapy of rheumatoid arthritis. Gastroenterology
1973; 64: 622-9.
Favreau M, Tannenbaum H, Lough J. Hepatic toxicity associated
with gold therapy. Ann Intern Med 1977; 87: 717-9.
Prichanond S, Skosey JL. Gold and liver biopsy. Ann Intern Med
1978; 88: 579.
Ghishan FK, LaBrecque DR,Younoszai K. Intrahepatic cholestasis
after gold therapy in juvenile rheumatoid arthritis. J Pediatr 1978;
93: 1042-3.
Pessayre D, Feldmann G, Degott C, Ulmann A, Roger W, Erlinger S,
Benhamou JP. Gold salt-induced cholestasis. Digestion 1979; 19:
56-64.
Griffin AJ. Cholestatic hepatitis induced by gold. Rheumatol Rehabil
1979; 18: 174-6.
Alcalay M, Touchard G, Patte F, Babin P, Reboux JF, Thomas P,
Patte D, et al. [Simultaneous nephropathy, lung disease and liver
disease caused by gold salts, with an ultrastructural study of
pulmonary and renal lesions]. Rev Rhum Mal Osteoartic 1979; 46:
491-8. French.
Charhon S, Rouillat M, Bouvier M. [Hepatitis caused by gold
therapy: a case]. Rev Rhum Mal Osteoartic 1980; 47: 205. French.
Frigerio G, Terruzzi V, Butti GC, Minoli G, Rossini A. [Toxic
cholestatic hepatitis secondary to chrysotherapy]. Minerva Med
1981; 72: 1941-4. Italian.
Le Bodic MF, Degott C, Barrier J, Chekroun G, Gaillard F, Couprie F,
Mussini-Montpellier J. [Anatomo-pathologic aspects of gold-salt
induced cholestasis. Report of two cases with ultrastructural study
(author's transl)]. Arch Anat Cytol Pathol 1981; 29: 98-104. French.
Howrie DL, Gartner JC Jr. Gold-induced hepatotoxicity: case report
and review of the literature. J Rheumatol 1982; 9: 727-9.
17: 205-11.
Sanchis Closa A, Caballeria Rovira E, Arago Lopez JV, Sune Gispert
S. [Submassive hepatic necrosis due to treatment with gold salts].
Edelman J, Donnelly D, Graham N, Percy JS. Liver dysfunction
associated with gold therapy for rheumatoid arthritis. J Rheumatol
1983; 10: 510-1.
Lewis D, Madhok R, Capell H. Liver dysfunction associated with gold
therapy for RA. J Rheumatol 1984; 11: 395-6.
Shaban MR, Golding DN, Letcher RG. Fatal intrahepatic cholestasis
and interstitial lung fibrosis following gold therapy for rheumatoid
arthritis. J R Soc Med 1984; 77: 960-1.
Schapira D, Nahir M, Scharf Y, Pollack S. Cholestatic jaundice
induced by gold salts treatment clinical and immunological
aspects—report of one case and review of the literature. J
Rheumatol 1984; 11: 843-5.
Jaeger A, Porte A, Sauder P, Stoeckel ME, Mantz JM. [Hepatitis
secondary to a gold salt overdose]. Gastroenterol Clin Biol 1984; 8:
660-6. French.
Lowthian PJ, Cleland LG, Vernon-Roberts B. Hepatotoxicity with
aurothioglucose therapy. Arthritis Rheum 1984; 27: 230-2.
Harats N, Ehrenfeld M, Shalit M, Lijovetzky G. Gold-induced
granulomatous hepatitis. Isr J Med Sci 1985; 21: 753-6.
Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic,
and neurologic manifestations in juvenile rheumatoid arthritis:
possible relationship to drugs or infection. J Pediatr 1985; 106:
561-6.
Hanissian AS, Rothschild BM, Kaplan S. Gold: hepatotoxic and
cholestatic reactions. Clin Rheumatol 1985; 4: 183-8.
Smith MD. Hepatitis and neutropenia secondary to gold thiomalate
therapy for rheumatoid arthritis. Aust N Z J Med 1986; 16: 72-4.
Farre JM, Perez T, Hautefeuille P, Tonnel F, Colombel JF, Duquesnoy
B, Delcambre B. Cholestasis and pneumonitis induced by gold
therapy. Clin Rheumatol 1989; 8: 538-40.
Watkins PB, Schade R, Mills AS, Carithers RL Jr, Van Thiel DH. Fatal
hepatic necrosis associated with parenteral gold therapy. Dig Dis Sci
1988; 33: 1025-9.
González Pérez JA, Calvo Catala J, Herrera Bataller A, Hortelano
Martínez E, Folgado Montesinos J, López Maldonado MD. [Mixed
hepatopathy due to parenteral gold salts]. An Med Interna 1990; 7:
477-9. Spanish.
Hansen RM, Varma RR, Hanson GA. Gold induced hepatitis and pure
red cell aplasia. Complete recovery after corticosteroid and Nacetylcysteine therapy. J Rheumatol 1991; 18: 1251-3.
Van Linthoudt D, Buss W, Beyner F, Ott H. [Fatal hepatic necrosis
due to a treatment course of rheumatoid arthritis with gold salts].
Schweiz Med Wochenschr. 1991; 121: 1099-1102. French.
Fleischner GM, Morecki R, Hanaichi T, Hayashi H, Quintana N,
Sternlieb I. Light- and electron-microscopical study of a case of gold
salt-induced hepatotoxicity. Hepatology 1991; 14: 422-5.
Yamanishi Y, Takeda M, Honjo N, Aoi K, Ishibe Y, Yamana S. [Goldinduced severe cholestatic jaundice in rheumatoid arthritis patient
and effect of repeated steroid pulse therapy]. Ryumachi 1992; 32:
475-82. Japanese.
Friis H, Andreasen PB. Drug-induced hepatic injury: an analysis of
1100 cases reported to the Danish Committee on Adverse Drug
Reactions between 1978 and 1987. J Intern Med 1992; 232: 133-8.
Rye B, Krusinski PA. Hepatonecrosis resulting from parenteral gold
therapy in pemphigus vulgaris. J Am Acad Dermatol 1993; 28: 99101.
Nisar M, Winfield J. Gold induced colitis and hepatic toxicity in a
patient with rheumatoid arthritis. J Rheumatol 1994; 21: 938-9.
Bendix G, Bjelle A. A 10 year follow up of parenteral gold therapy in
patients with rheumatoid arthritis. Ann Rheum Dis 1996; 55: 16976.
Tilelli JA, Heinrichs MM. Adverse reactions to parenteral gold salts.
Lancet 1997; 349: 853.
Ben-Ami H, Pollack S, Nagachandran P, Lashevsky I, Yarnitsky D,
Edoute Y. Reversible pancreatitis, hepatitis, and peripheral
polyneuropathy associated with parenteral gold therapy. J
Rheumatol 1999; 26: 2049-50.
te Boekhorst PA, Barrera P, Laan RF, van de Putte LB.
Hepatotoxicity of parenteral gold therapy in rheumatoid arthritis: a
case report and review of the literature. Clin Exp Rheumatol 1999;
17: 359-62.
Uhm WS, Yoo DH, Lee JH, Kim TH, Jun JB, Lee IH, Bae SC, et al.
Injectable gold-induced hepatitis and neutropenia in rheumatoid
arthritis. Korean J Intern Med. 2000; 15: 156-9.
Wu ML, Tsai WJ, Ger J, Deng JF, Tsay SH, Yang MH. Cholestatic
hepatitis caused by acute gold potassium cyanide poisoning. J
Toxicol Clin Toxicol 2001; 39: 739-43.
Basset C, Vadrot J, Denis J, Poupon J, Zafrani ES. Prolonged
cholestasis and ductopenia following gold salt therapy. Liver Int
2003; 23: 89-93.
HALOTHANE
Brody GL, Sweet RB. Halothane anesthesia as a possible cause of
massive hepatic necrosis. Anesthesiology 1963; 24: 29-37.
Lindenbaum J, Leifer E. Hepatic necrosis associated with halothane
anesthesia. N Engl J Med 1963; 268: 525-30.
Slater EM, Gibson JM, Dykes MH, Walzer SG. Postoperative hepatic
necrosis. Its incidence and diagnostic value in association with the
administration of halothane. N Engl J Med 1964; 270: 983-7.
Summary of the National Halothane Study. Possible association
between halothane anesthesia and postoperative hepatic necrosis.
JAMA 1966; 197: 775-88.
Klein NC, Jeffries GH. Hepatotoxicity after methoxyflurane
administration. JAMA 1966; 197: 1037-9.
Babior BM, Davidson CS. Postoperative massive liver necrosis. A
clinical and pathological study. N Engl J Med 1967; 276: 645-52.
Gall EA. Report of the pathology panel. National Halothane Study.
Anesthesiology 1968; 29: 233-48.
Klatskin G, Kimberg DV. Recurrent hepatitis attributable to
halothane sensitization in an anesthetist. N Engl J Med 1969; 280:
515-22.
Klion FM, Schaffner F, Popper H. Hepatitis after exposure to
halothane. Ann Intern Med 1969; 71: 467-77.
Peters RL, Edmondson HA, Reynolds TB, Meister JC, Curpey TJ.
Hepatic necrosis associated with halothane anesthesia. Am J Med
1969; 47: 748-64.
Hughes M, Powell LW. Recurrent hepatitis in patients receiving
multiple halothane anesthetics for radium treatment of carcinoma of
the cervix uteri. Gastroenterology 1970; 58: 790-7.
Paull A, Grant AK. Halothane hepatitis--a report of five cases. Med J
Aust 1974; 1: 954-7.
Moult PJ, Sherlock S. Halothane-related hepatitis. A clinical study of
twenty-six cases. Q J Med 1975; 44: 99-114.
Wright R, Eade OE, Chisholm M, Hawksley M, Lloyd B, Moles TM,
Edwards JC, Gardner MJl. Controlled prospective study of the effect
on liver function of multiple exposures to halothane. Lancet 1975;
1: 817-20.
Hoft RH, Bunker JP, Goodman HI, Gregory PB. Halothane hepatitis
in three pairs of closely related women. N Engl J Med 1981; 304:
1023-4.
17: 205-11.
Benjamin SB, Goodman ZD, Ishak KG, Zimmerman HJ, Irey NS.
The morphologic spectrum of halothane-induced hepatic injury:
analysis of 77 cases. Hepatology 1985; 5: 1163-71.
in the United States. Liver Transpl 2004; 10: 1018-23
Qureshi MA, Saeed F, Hussain T. Halothane induced fulminant
hepatic failure. J Coll Physicians Surg Pak 2007; 17: 103-4.
Eghtesadi-Araghi P, Sohrabpour A, Vahedi H, Saberi-Firoozi M.
Halothane hepatitis in Iran: a review of 59 cases. World J
Gastroenterol. 2008; 14: 5322-6.
Multicenter, prospective study. Hepatology 2010; 52: 2065-76.
HYDRALAZINE
Jori GP, Peschile C. Hydralazine disease associated with transient
granulomas in the liver. A case report. Gastroenterology 1973; 64:
1163-7.
Perry HM. Late toxicity to hydralazine resembling systemic lupus
erythematosus or rheumatoid arthritis. Am J Med 1973; 54: 58-72.
Irias JJ. Hydralazine-induced lupus erythematosus-like syndrome.
Am J Dis Child 1975; 129: 862-4.
Knoblauch M, Cueni B, Spycher M, Schmid M. [Dihydralazineinduced acute hepatitis with IgM deficiency]. Schweiz Med
Wochenschr 1977; 107: 651-6. German.
Bartoli E, Massarelli G, Solinas A, Faedda R, Chiandussi L. Acute
hepatitis with bridging necrosis due to hydralazine intake. Report of
a case. Arch Intern Med 1979; 139: 698-9.
Itoh S, Yamaba Y, Ichinoe A, Tsukada Y. Hydralazine-induced liver
injury. Dig Dis Sci 1980; 25: 884-7.
Barnett DB, Hudson SA, Golightly PW. Hydralazine-induced
hepatitis? Br Med J 1980; 280: 1165-6.
Mölleken K, Rüger K. [Rare liver damage caused by
antihypertensive and anti-arrhythmic agents]. Z Gesamte Inn Med
1980; 35: 296-9. German.
Forster HS. Hepatitis from hydralazine. N Engl J Med 1980; 302:
1362.
Itoh S, Ichinoe A, Tsukada Y, Itoh Y. Hydralazine-induced hepatitis.
Hepatogastroenterology 1981; 28: 13-6
Stewart GW, Peart WS, Boylston AW. Obstructive jaundice,
pancytopenia and hydralazine. Lancet 1981; 8231: 1207
Pariente EA, Pessayre D, Bernuau J, Degott C, Benhamou JP.
Dihydralazine hepatitis: report of a case and review of the
literature. Digestion 1983; 27: 47-52.
Roschlau G. [Dihydralazine-induced hepatitis with bridging necrosis.
A clinico-pathologic survey of 20 cases]. Zentralbl Allg Pathol 1983;
127: 385-93. German.
Rice D, Burdick CO. Granulomatous hepatitis from hydralazine
therapy. Arch Intern Med 1983; 143: 1077.
Myers JI, Augur NA. Hydralazine-induced cholangitis.
Reinhardt M, Machnik G, Krombholz B, Jahn G. [The so-called
dihydralazine hepatitis. A contribution to the pathogenesis]. Dtsch Z
Verdau Stoffwechselkr 1985; 45: 283-94.
Kunze KD, Porst H, Tschöpel L. [Morphology and pathogenesis of
liver injury produced by dihydralazine, propranolol and
ketophenylbutazone]. Zentralbl Allg Pathol 1985; 130: 509-18.
Hod M, Friedman S, Schoenfeld A, Theodor E, Ovadia J.
Hydralazine-induced hepatitis in pregnancy. Int J Fertil. 1986; 31:
352-5.
Machnik G, Bergert A, Justus J, Kunze P, Müller R, Reinhardt M,
Schulz H, et al. [Drug-induced hepatitis after dihydralazine
treatment with fatal consequences]. Zentralbl Allg Pathol 1988;
134: 167-77. German.
Roschlau G, Hass S, Schmehl V. [Chronic drug-induced hepatitis
caused by dihydralazine]. Dtsch Z Verdau Stoffwechselkr 1988; 48:
41-6. German.
Shaefer MS, Markin RS, Wood RP, Shaw BW Jr. Hydralazine-induced
cholestatic jaundice following liver transplantation. Transplantation
1989; 47: 203-4.
Bourdi M, Larrey D, Nataf J, Bernuau J, Pessayre D, Iwasaki M,
Guengerich FP, et al. Anti-liver endoplasmic reticulum
autoantibodies are directed against human cytochrome P-450IA2. A
specific marker of dihydralazine-induced hepatitis. J Clin Invest
1990; 85: 1967-73.
Roschlau G, Baumgarten R, Fengler JD. [Dihydralazine hepatitis.
Morphologic and clinical criteria for diagnosis]. Zentralbl Allg Pathol
1990; 136: 127-34. German.
Stumpf JL. Fatal hepatotoxicity induced by hydralazine or labetalol.
Pharmaco-therapy 1991; 11: 415-8.
Bourdi M, Gautier JC, Mircheva J, Larrey D, Guillouzo A, Andre C,
Belloc C, et al. Anti-liver microsomes autoantibodies and
dihydralazine-induced hepatitis: specificity of autoantibodies and
inductive capacity of the drug. Mol Pharmacol 1992; 42: 280-5.
Tameda Y, Hamada M, Takase K, Nakano T, Kosaka Y. Fulminant
hepatic failure caused by ecarazine hydrochloride (a hydralazine
derivative). Hepatology 1996; 23: 465-70.
Hassan A, Hammad R, Cucco R, Niranjan S. Hydralazine-induced
cholestatic hepatitis. Am J Ther 2009; 16: 371-3.
IBUPROFEN
Gasparetto P. [A case of hepatocellular jaundice during treatment
with ibuprofen] Minerva Pediatr 1974; 26: 531-3. Italian.
Mandell B, Shen HS, Hepburn B. Letter: Fever from ibuprofen in a
patient with lupus erythematosus. Ann Intern Med 1976; 85: 20910.
Bravo JF, Jacobson MP, Mertens BF. Fatty liver and pleural effusion
with ibuprofen therapy. Ann Intern Med 1977; 87: 200-1.
Stempel DA, Miller JJ 3rd. Lymphopenia and hepatic toxicity with
ibuprofen. J Pediatr 1977; 90: 657-8.
Sonnenblick M, Abraham AS. Ibuprofen hypersensitivity in systemic
lupus erythematosus. Br Med J 1978; 1: 619-20.
Sternlieb P, Robinson RM. Stevens-Johnson syndrome plus toxic
hepatitis due to ibuprofen. N Y State J Med 1978; 78: 1239-43.
Vigouroux C, Fitoussi D, Cariou D, Aerts J, Pasquier P. [Disclosure of
systemic lupus erythematosus in a case of hepatitis caused by
ibuprofen] Rev Med Interne 1993; 14: 856-9. French.
Alam I, Ferrell LD, Bass NM. Vanishing bile duct syndrome
temporally associated with ibuprofen use. Am J Gastroenterol 1996;
91: 1626-30.
Srivastava M, Perez-Atayde A, Jonas MM. Drug-associated acuteonset vanishing bile duct and Stevens-Johnson syndromes in a
child. Gastroenterology 1998; 115: 743-6.
Laurent S, Rahier J, Geubel AP, Lerut J, Horsmans Y. Subfulminant
hepatitis requiring liver transplantation following ibuprofen
overdose. Liver 2000; 20: 93-4.
Borel I, Hedelius F, Baumgartner C, Vial T, Scoazec JY, Dumortier J.
[Severe acute hepatitis associated with ibuprofen treatment]
Morelli MS, O'Brien FX. Stevens-Johnson Syndrome and cholestatic
hepatitis. Dig Dis Sci 2001; 46: 2385-8.
Andrade RJ, Lucena MI, García-Cortés M, García-Ruiz E, FernándezBonilla E, Vázquez L. Chronic hepatitis C, ibuprofen, and liver
damage. Am J Gastroenterol 2002; 97: 1854-5.
Javier Rodríguez-González F, Montero JL, Puente J, Fraga E, Costan
G, Barrera P, Muntane J, et al. Orthotopic liver transplantation after
subacute liver failure induced by therapeutic doses of ibuprofen. Am
Taghian M, Tran TA, Bresson-Hadni S, Menget A, Felix S, Jacquemin
E. Acute vanishing bile duct syndrome after ibuprofen therapy in a
child. J Pediatr 2004; 145: 273-6.
García-Ruiz E, García-Muñoz B, et al.; Spanish Group for the Study
Tyagi P, Sharma BC, Sarin SK. Cholestatic liver injury due to
ibuprofen. Indian J Gastroenterol 2005; 24: 77-8.
Barreales M, Pérez-Carreras M, Meizoso T, Garrido M, Masedo A,
Colina F, Solís JA. [Epstein-Barr virus infection and acute cholestatic
hepatitis] An Med Interna 2006; 23: 483-6. Spanish.
Elkrief L, Chryssostalis A, Moachon L, Franck N, Terris B, Chaussade
S, Sogni P. [Severe cholestatic hepatitis associated with StevensJohnson syndrome after taking ibuprofen]. Gastroenterol Clin Biol
2007; 31: 1043-5. French.
Bennett WE Jr, Turmelle YP, Shepherd RW. Ibuprofen-induced liver
injury in an adolescent athlete. Clin Pediatr (Phila) 2009; 48: 84-6.
Hotermans C, Belachew S, Moonen G, Delwaide J. Severe liver
dysfunction in a patient with multiple sclerosis: the guilty party is
not always the disease-modifying therapy. Mult Scler 2009; 15:
1378-9.
Leoz MK, Concejo FB, Fernández JM, Urmeneta JM, Peñuela AM.
[Ibuprofen-induced cholestatic hepatitis]. Gastroenterol Hepatol
2011; 34: 660-1. Spanish
Nayudu SK, Kavuturu S, Niazi M, Daniel M, Dev A, Kumbum K. A
rare coexistence: drug induced hepatitis and meningitis in
association with Ibuprofen. J Clin Med Res 2013; 5: 243-6.
Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic
characterization of idiosyncratic drug-induced liver injury: the
influence of age and gender. Hepatology 2009; 49: 2001–2009.
et al. Profile of idiosyncratic drug induced liver injury in Latin
America: an analysis of published reports. Ann Hepatol. 2014;13:
231-9.
pii: S0016-5085(15)00311-X.
INFLIXIMAB
Menghini VV, Arora AS. Infliximab-associated reversible cholestatic
liver disease. Mayo Clin Proc 2001; 76: 84-6.
Saleem G, Li SC, MacPherson BR, Cooper SM. Hepatitis with
interface inflammation and IgG, IgM, and IgA anti-double-stranded
DNA antibodies following infliximab therapy: comment on the article
by Charles et al. Arthritis Rheum 2001; 44: 1966-8.
Germano V, Picchianti Diamanti A, Baccano G, Natale E, Onetti
Muda A, Priori R, Valesini G. Autoimmune hepatitis associated with
infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005;
64: 1519-20.
Ierardi E, Della Valle N, Nacchiero MC, De Francesco V, Stoppino G,
Panella C. Infliximab single administration followed by acute liver
injury. Inflamm Bowel Dis 2006; 12: 1089-91.
Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W.
Subfulminant hepatitis B after infliximab in Crohn's disease: need
for HBV-screening? World J Gastroenterol 2006; 12: 974-6.
Soto-Fernández S, González-Carro P, De Pedro-Esteban A, LegazHuidobro ML, Pérez-Roldán F, Roncero GarciíEscribano O, ValbuenaGonzález M, et al. [Infliximab-induced hepatitis in a patient with
Crohn's disease]. Gastroenterol Hepatol 2006; 29: 321-2. Spanish.
Wahie S, Alexandroff A, Reynolds NJ. Hepatitis: a rare, but
important, complication of infliximab therapy for psoriasis. Clin Exp
Dermatol 2006; 31: 460-1.
Ozorio G, McGarity B, Bak H, Jordan AS, Lau H, Marshall C.
Autoimmune hepatitis following infliximab therapy for ankylosing
spondylitis. Med J Aust 2007; 187: 524-6.
Tobon GJ, Cañas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver
disease induced by infliximab. Clin Rheumatol 2007; 26: 578-81.
Moum B, Konopski Z, Tufteland KF, Jahnsen J. Occurrence of
hepatoxicity and elevated liver enzymes in a Crohn's disease patient
treated with infliximab. Inflamm Bowel Dis 2007; 13: 1584-6.
Thiéfen G, Morelet A, Heurgué A, Diebold MD, Eschard JP.
Infliximab-induced hepatitis: absence of cross-toxicity with
etanercept. Joint Bone Spine 2008; 75: 737-9.
García-Simón S, Saliente Callén S, López Avila A, Rabell Iñigo S.
[Hepatic cytolysis from infliximab]. Farm Hosp 2008; 32: 250-2.
Spanish.
Becker H, Willeke P, Domschke W, Gaubitz M. Etanercept tolerance
in a patient with previous infliximab-induced hepatitis. Clin
Rheumatol 2008; 27: 1597-8.
Marques M, Magro F, Cardoso H, Carneiro F, Portugal R, Lopes J,
Costa Santos C. Infliximab-induced lupus-like syndrome associated
with autoimmune hepatitis. Inflamm Bowel Dis 2008; 14: 723-5.
Carlsen KM, Riis L, Madsen OR. Toxic hepatitis induced by infliximab
in a patient with rheumatoid arthritis with no relapse after switching
to etanercept. Clin Rheumatol 2009; 28: 1001-3.
Fairhurst DA, Sheehan-Dare R. Autoimmune hepatitis associated
with infliximab in a patient with palmoplantar pustular psoriasis.
Clin Exp Dermatol 2009; 34: 421-2.
Kluger N, Girard C, Guillot B, Bessis D. Efficiency and safety of
etanercept after acute hepatitis induced by infliximab for psoriasis.
Acta Derm Venereol 2009; 89: 332-4.
Massarotti M, Marasini B. Successful treatment with etanercept of a
patient with psoriatic arthritis after adalimumab-related
hepatotoxicity. Int J Immunopathol Pharmacol 2009; 22: 547-9.
Mancini S, Amorotti E, Vecchio S, Ponz de Leon M, Roncucci L.
Infliximab-related hepatitis: discussion of a case and review of the
literature. Intern Emerg Med 2010.
Poulin Y, Thérien G. Drug-induced hepatitis and lupus during
infliximab treatment for psoriasis: case report and literature review.
J Cutan Med Surg 2010; 14: 100-4.
Haennig A, Bonnet D, Thebault S, Alric L. Infliximab-induced acute
hepatitis during Crohn's disease therapy: absence of cross-toxicity
with adalimumab. Gastroenterol Clin Biol 2010; 34: e7-8.
Cravo M, Silva R, Serrano M. Autoimmune hepatitis induced by
infliximab in a patient with Crohn's disease with no relapse after
switching to adalimumab. BioDrugs 2010; 24 Suppl 1:25-7.
Goujon C, Dahel K, Bérd F, Guillot I, Gunera-Saad N, Nicolas JF.
Autoimmune hepatitis in two psoriasis patients treated with
inflixmab. J Am Acad Dermatol 2010; 63: e43-4.
Ferrajolo C, Capuano A, Verhamme KM, Schuemie M, Rossi F,
Stricker BH, Sturkenboom MC. Drug-induced hepatic injury in
children: a case/non-case study of suspected adverse drug
reactions in VigiBase. Br J Clin Pharmacol 2010; 70: 721-8
Doyle A, Forbes G, Kontorinis N. Autoimmune hepatitis during
infliximab therapy for Crohn's disease: a case report. J Crohns
Colitis 2011; 5: 253-5.
Goldfeld DA, Verna EC, Lefkowitch J, Swaminath A. Infliximabinduced autoimmune hepatitis with successful switch to adalimumab
in a patient with Crohn's disease: the index case. Dig Dis Sci 2011;
56: 3386-8.
Subramaniam K, Chitturi S, Brown M, Pavli P. Infliximab-induced
autoimmune hepatitis in Crohn's disease treated with budesonide
and mycophenolate. Inflamm Bowel Dis. 2011; 17: E149-50.
Kinnunen U, Färkkilä M, Mäkisalo H. A case report: ulcerative colitis,
treatment with an antibody against tumor necrosis factor
(infliximab), and subsequent liver necrosis. J Crohns Colitis 2012;
6: 724-7.
Caussé S, Bouquin R, Wylomanski S, Flamant M, Joubert M, Dréno
B, Quéreux G. [Infliximab-induced hepatitis during treatment of
vulvar Crohn's disease]. Ann Dermatol Venereol 2013; 140: 46-51.
French.
Arai O, Omoto K, Notohara K, Shibata N, Kuboki M, Ikeda H. A case
of infliximab-related liver damage -case report and literature
review-. Nihon Shokakibyo Gakkai Zasshi 2013; 110: 104-11.
Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner
DE, Serrano J, et al; U.S. Drug-Induced Liver Injury Network. Liver
injury from tumor necrosis factor-α antagonists: analysis of thirtyfour cases. Clin Gastroenterol Hepatol 2013; 11: 558-564
Colina F, Molero A, Casís B, Martínez-Montiel P. Infliximab-related
hepatitis: a case study and literature review. Dig Dis Sci 2013; 58:
3362-7.
Carvalheiro J, Mendes S, Sofia C. Infliximab induced liver injury in
Crohn's disease: A challenging diagnosis. J Crohns Colitis 2013 Nov
29. [Epub ahead of print]
Dang LJ, Lubel JS, Gunatheesan S, Hosking P, Su J. Drug-induced
lupus and autoimmune hepatitis secondary to infliximab for
psoriasis. Australas J Dermatol 2014 55: 75-9.
Björnsson ES,, Gunnarsson BI, Gröndal G, Jonasson JG, Einarsdottir
R, Ludviksson BR, Gudbjörnsson B, Olafsson O. The risk of druginduced liver injury from Tumor Necrosis Factor (TNF)-alphaantagonists. Clin Gastroenterol Hepatol. 2014; Aug 15. pii: S15423565(14)01151-3.
INTERFERON BETA
Yoshida EM, Rasmussen SL, Steinbrecher UP, Erb SR, Scudamore
CH, Chung SW, Oger JJ, Hashiomoto SA. Fulminant liver failure
during interferon beta treatment of multiple sclerosis. Neurology
2001; 56: 1416.
Duccini A. Autoimmune hepatitis and interferon beta-1a for
multiple sclerosis. Am J Gastroenterol 2002; 97: 767-8.
Wallack EM, Callon R. Liver injury associated with the betainterferons for MS. Neurology 2004; 63: 1142-3; author reply
1142-3. Review.
Yuce B, Gulberg V, Diebold J, Gerbes AL. Hepatitis induced by Noni
juice from Morinda citrifolia: a rare cause of hepatotoxicity or the tip
of the iceberg? Digestion. 2006; 73 (2-3): 167-70.
West BJ. Hepatotoxicity from interferon-beta, not noni
juice. Digestion 2006; 74: 47-8.
Byrnes V, Afdhal N, Challies T, Greenstein PE. Drug induced liver
injury secondary to interferon-beta (IFN-ß) in multiple
sclerosis. Ann Hepatol 2006; 5: 56-9
Pulichen M, Koteish A, DeBusk K, Calabresi PA. Unmasking of
autoimmune hepatitis in a patient with MS following interferon beta
therapy. Neurology 2006; 66: 1954-5.
Montero JL, Cerezo A, Fraga E, Barrera P, López-Cillero P, Costán G,
Poyato A, et al. Acute liver failure in a patient with multiple sclerosis
treated with interferon-beta. Mult Scler 2007; 13: 820
Grieco A, Montalto M, Vero V, Maria Vecchio F, Gasbarrini G. Severe
acute hepatitis after resumption of interferon-Beta therapy for
multiple sclerosis: a word of caution. Am J Gastroenterol 2007;
102: 2606-7.
Behrbolm J, Neid M, Stolzel U, Wittekind C, Hauss JP, Tillmann
HL. Improvement of multiple sclerosis on tacrolimus plus
mycophenolate mofetil after liver transplantation. Transplant Int
2007; 20: 1077-9
Pietrosi G, Mandala L, Vizzini GB, Gruttadauria S, Minervini MI,
Burgio G, Spadaro A, et al. Fulminant hepatic failure and
autoimmune disorders in patient with multiple sclerosis on
interferon beta 1a: a fatal combination? Transpl Int 2008; 21: 5024.
pii: S0016-5085(15)00311-X.
Hotermans C, Belachew S, Moonen G, Delwaide J. Severe liver
dysfunction in a patient with multiple sclerosis: the guilty party is
not always the disease-modifying therapy. Multiple Sclerosis 2009;
15: 1378-9.
Tremlett H, Fu P, Yoshida E, Hashimoto S. Symptomatic liver injury
(hepatotoxicity) associated with administration of complementary
and alternative products (Ayurveda-AP-Mag Capsules(®)) in a betainterferon-treated multiple sclerosis patient. Eur J Neurol 2011; 18:
e78-9.
Tamura S, Warabi Y, Matsubara S. Severe liver dysfunction possibly
caused by the combination of interferon beta-1b therapy and melilot
(sweet clover) supplement. J Clin Pharm Ther 2012; 37: 724-5.
2013 ; 144: 1419-25.
Fontana RJ, Hayashi P, Bonkovsky HL, Kleiner DE, Kochhar S, Gu J,
Ghabril M. Presentation and Outcomes with Clinically Apparent
Interferon Beta Hepatotoxicity. Dig Dis Sci 2013; 58: 1766-75.
ISONIAZID
Randolph H, Joseph S. Toxic hepatitis with jaundice occurring in a
patient treated with isoniazid. JAMA 1953; 152: 38-40.
Gellis SN, Murphy RV. Hepatitis following isoniazid. Dis Chest 1955;
28: 462-4
Paine D. Fatal hepatic necrosis associated with aminosalicylic acid:
review of literature and report of case. JAMA 1958; 167: 285-9.
Merritt AD, Fetter BF. Toxic hepatic necrosis(hepatitis) due to
isoniazid: report of a case with cirrhosis and death due to
hemorrhage from esophageal varices. Ann Intern Med 1959; 50:
804-10.
Haber E, Osorne RK. Icterus and febrile reactions in response to
isonicotinic acid hydrazine; report of two cases and review of the
literature. N Engl J Med 1959; 260: 417-20.
Gillis S, Texler K. Unusual reactions to antituberculous
chemotherapy. Med J Aust 1960; 2: 99-101.
Davies D, Glowinski JJ. Jaundice due to isoniazid. Tubercle 1961;
42: 504-6.
Cohen R, Kalser MH, Thompson RV. Fatal hepatic necrosis
secondary to isoniazid therapy. JAMA 1961; 176: 877-9.
Reynolds E. Isoniazid jaundice and its relationship to iproniazid
jaundice. Tubercle 1962; 43: 375-81.
Berger HW, Berte SJ. Hypersensitivity to isoniazid. Report of a case
with discussion of management and oral desensitization. Am Rev
Respir Dis 1962 Jan; 85: 100-4.
Gokecen M Zinneman HH. Liver “autoantibodies” in a case of druginduced jaundice. Gastroenterology 1963; 44: 69-72.
O'Sullivan DC. Isoniazid jaundice during the treatment of
genitourinary tuberculosis. Tubercle 1966; 47: 221-4.
Bruno MS, Ober WB. Acute fulminant hepatic failure with bilateral
tuberculous cavitation. N Y State J Med 1968; 68: 2934-40.
Lederman RJ, Davis FB, Davis PJ. Exchange transfusion as
treatment of acute hepatic failure due to antituberculosis drugs.
Ann Intern Med 1968; 68: 830-8.
Assem ES, Ndoping N, Nicholson H, Wade JR. Liver damage and
isoniazid allergy. Clin Exp Immunol 1969; 5: 439-42.
Grossman LA, Kaplan HJ, Brittingham TE. Jaundice and death from
isoniazid. J Tenn Med Assoc 1970; 63: 23-8.
Martin CE, Arthaud JB. Hepatitis after isoniazid administration. N
Engl J Med 1970; 282: 433-4.
Moss JD, Lewis JE, Knauer CM. Isoniazid-associated hepatitis. A
study of five cases. Am Rev Respir Dis 1972; 106: 849-56.
Bailey WC, Thompson DH, Carson B, Greenberg HB. Fatal hepatic
necrosis in a woman receiving chemoprophylaxis with isoniazid. Am
Rudoy R, Stuemky J, Poley JR. Isoniazid administration and liver
injury. Am J Dis Child 1973; 125: 733-6.
Maddrey WC, Boitnott JK. Isoniazid hepatitis. Ann Intern Med 1973;
79: 1-12.
Stead WW, Texter EC Jr. Isoniazid hepatitis: backlash of progress.
Ann Intern Med 1973; 79: 125-7.
Gould DB, Falcao H, Galdabini J. Letter: Isoniazid hepatotoxicity.
Ann Intern Med 1973; 79: 902-3.
Rolla AR. Letter: Isoniazid hepatoxicity. Ann Intern Med 1974; 80:
278-9.
Swasey LK. Hepatotoxicity to isoniazid. A case report. Ariz Med
1974; 31: 17-9.
Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazidassociated hepatitis in 114 patients. Gastroenterology 1975; 69:
289-302.
Vanderhoof JA, Ament ME. Fatal hepatic necrosis due to isoniazid
chemoprophylaxis in a 15-year-old girl. J Pediatr 1976; 88: 867-8.
Brasfield DM, Goodloe TB, Tiller RE. Isoniazid hepatotoxicity in
childhood. Pediatrics 1976; 58: 291.
Allue X, Sanjurjo P, Fidalgo I, Bilbao F. Hepatic toxicity of
antituberculous drugs in children. Helv Paediatr Acta 1976; 31:
381-7.
Bhandari B, Sharda B. Isoniazid hepatotoxicity: report of two cases.
Indian Pediatr 1977; 14: 859-60.
Walker SH, Park-Hah JO. Possible isoniazid-induced hepatotoxicity
in a two-year-old child. J Pediatr 1977; 91: 344-5.
Pessayre D, Bentata M, Degott C, Nouel O, Miguet JP, Rueff B,
Benhamou JP. Isoniazid-rifampin fulminant hepatitis. A possible
consequence of the enhancement of isoniazid hepatotoxicity by
enzyme induction. Gastroenterology 1977; 72: 284-9.
Chapoy P, Ferracci JP, Mattei JF, Granjon B, Louchet E. [Severe
hepatitis induced by chemotherapy with antitubercular agents in
childhood. 2 cases]. Pediatrie 1978; 3: 637-45. French.
Poupon RY, Meyniel D, Petit J, Gustot P, Darnis F. [Cholestatic
hepatitis during treatment with I.N.H. and rifampicin: arguments in
favour of the hepatotoxicity of rifampicin]. Ann Med Interne (Paris)
1979; 130 (6-7): 371-5. French.
Stein MT, Liang D. Clinical hepatotoxicity of isoniazid in children.
Pediatrics 1979; 64: 499-505.
Graham WG, Dundas GR. Isoniazid-related liver disease. Occurrence
with portal hypertension, hypoalbuminemia, and hypersplenism.
JAMA 1979; 242: 353-4.
Bistritzer T, Barzilay Z, Jonas A. Isoniazid-rifampin--induced
fulminant liver disease in an infant. J Pediatr 1980; 97: 480-2.
Danielides IC, Constantoulakis M, Daikos GK. Hepatitis on high dose
isoniazid: reintroduction of the drug in severe tuberculous
meningitis. Am J Gastroenterol 1983; 78: 378-80.
Gal AA, Klatt EC. Fatal isoniazid hepatitis in a child. Pediatr Infect
Dis 1986; 5: 490-1.
Kasantikul V. Isoniazid-rifampicin-induced submassive hepatic
necrosis. J Med Assoc Thai 1989; 72: 56-8
Veale KS, Huff ES, Nelson BK, Coffman DS. Pure red cell aplasia and
hepatitis in a child receiving isoniazid therapy. J Pediatr 1992; 120:
146-8.
Israel HL, Gottlieb JE, Maddrey WC. Perspective: preventive
isoniazid therapy and the liver. Chest 1992; 101: 1298-301.
Farrell FJ, Keeffe EB, Man KM, Imperial JC, Esquivel CO. Treatment
of hepatic failure secondary to isoniazid hepatitis with liver
transplantation. Dig Dis Sc 1994; 39: 2255-9.
Nolan MC, Sandblom RE, Thummel KE, Slattery JT, Nelson SD.
Hepatotoxicity associated with acetaminophen usage in patients
receiving multiple drug therapy for tuberculosis. Chest 1994; 105:
408-11.
Palusci VJ, O'Hare D, Lawrence RM. Hepatotoxicity and
transaminase measurement during isoniazid chemoprophylaxis in
children. Pediatr Infect Dis J 1995; 14: 144-8.
Girotto L, Gjonovich A, Preciso G. [Fulminant liver failure caused by
antitubercular drugs. Report of a clinical case]. Minerva Anestesiol
2000; 66: 249-51. Italian.
Marra F, Cox VC, FitzGerald JM, Moadebi S, Elwood RK. Successful
treatment of multidrug-resistant tuberculosis following drug-induced
hepatic necrosis requiring liver transplant. Int J Tuberc Lung Dis
2004; 8: 905-9.
pii: S0016-5085(15)00311-X.
Semfke A, Wackernagel C, Vier H, Schütz A, Wiechmann V, Gillissen
A. Histologically proven isoniazid hepatoxicity in complicated
tuberculous salpingitis. Ther Adv Respir Dis 2009; 3: 159-62.
Molleston JP, Fontana RJ, Lopez MJ, Kleiner DE, Gu J, Chalasani N;
Drug-induced Liver Injury Network. Characteristics of idiosyncratic
drug-induced liver injury in children: results from the DILIN
prospective study. J Pediatr Gastroenterol Nutr 2011; 53: 182-9.
Sheen E, Huang RJ, Uribe LA, Nguyen MH. Isoniazid Hepatotoxicity
Requiring Liver Transplantation. Dig Dis Sci 2014 Feb 27. [Epub
ahead of print]
KETOCONAZOLE
Heiberg JK, Svejgaard E. Toxic hepatitis during ketoconazole
treatment. Br Med J (Clin Res Ed) 1981; 283: 825-6.
Firebrace DAJ. Hepatitis and ketoconazole therapy. Br Med J (Clin
Res Ed) 1981; 283; 1058-9.
Adams JG. Jaundice and other drug reactions to ketoconazole.
Australas J Dermatol 1982; 23: 90.
Svejgaard E, Ranek L. Hepatic dysfunction and ketoconazole
therapy. Ann Intern Med 1982; 96(6 Pt 1): 788-9.
Strauss JS. Ketaconazole and the liver. J Am Acad Dermatol 1982;
6: 546-7.
Tkach JR, Rinaldi MG. Severe hepatitis associated with ketoconazole
therapy for chronic mucocutaneous candidiasis. Cutis 1982; 29:
482-4.
van Dijke CP. [Hepatitis during the administration of ketoconazole
(Nizoral)]. Ned Tijdschr Geneeskd 1983; 127: 339-41.
Boëtius G, Peeters JP, Peters JH. [Toxic hepatitis caused by
ketoconazole (Nizoral)]. Ned Tijdschr Geneeskd 1983; 127: 341-3.
Dutch.
Kramer NJ, Montnor LP, Berghuis PH. [Toxic hepatitis during the
administration of ketoconazole(Nizoral)]. Ned Tijdschr Geneeskd
1983; 127: 343-4.
Bekkers GAH. [Toxic hepatitis due to ketoconazole]. Toxische
hepatitis door ketoconazol. Ned Tijdschr Geneesk 1983; 127: 11145.
Boughton K. Ketoconazole and hepatic reactions. S Afr Med J 1983;
63: 955.
Henning H, Kasper B, Lüders CJ. [Ketoconazole-induced hepatitis.
Case report]. Z Gastroenterol 1983; 21: 709-15.
Janssen PA, Symoens JE. Hepatic reactions during ketoconazole
treatment. Am J Med 1983; 74: 80-5.
Pegram S, Kerns FT, Wasilauskas BL, Hampton KD, Scharyj M,
Bruke JG. Successful ketoconazole treatment of protothecosis with
ketoconazole associated hepatotoxicity. Arch Intern Med 1983; 143:
1802-5.
Okumura H, Aramaki T, Satomura K, Iizuka K, Ohta M, Katsuta Y,
Akaike M, et al. Severe hepatitis during ketoconazole therapy.
Gastroenterol Jpn 1983; 18: 142-7.
Rollman O, Lööf L. Hepatic toxicity of ketoconazole. Br J Dermatol
1983; 108: 376-8.
Duarte PA, Chow CC, Simmons F, Ruskin J. Fatal hepatitis
associated with ketoconazole therapy. Arch Intern Med 1984; 144:
1069-70.
Lewis JH, Zimmerman HJ, Benson GD, Ishak KG. Hepatic injury
associated with ketoconazole therapy. Analysis of 33 cases.
Pérez-Mateo M, Sillero C, Vázquez N. [Is ketoconazole hepatotoxic
at high doses?]. Med Clin (Barc) 1984; 83: 780.
Roudot-Thoraval F, Dhumeaux D. [Hepatitis during treatment with
ketoconazole]. Gastroenterol Clin Biol 1984; 8: 92.
Svedhem A. Toxic hepatitis following ketoconazole treatment. Scand
J Infect Dis 1984; 16: 123-5.
Bercoff E, Bernau J, Degott C, Kalis B, Lemaire A, Tilly H, Rueff B,
et al. Ketoconazole-induced fulminant hepatitis. Gut 1985; 26: 6368.
Caballería Rovira E, Massó Ubeda RM, Aragó López JV, Sanchis
Closa A. [Ketoconazole hepatotoxicity. Apropos of a case]. Med Clin
(Barc) 1986; 86: 303-4.
Krivoy N, Bassan L. [Ketoconazole-induced acute liver necrosis].
Harefuah 1986; 110: 346-7.
Navarro Villena M. [Ketoconazole hepatotoxicity]. Med Clin (Barc)
1986; 87: 694.
Leal-Cerro A, García-Luna PP, Jiménez Mejías E, Astorga R.
[Hepatotoxicity of ketoconazole in patients with adrenal pathology].
Med Clin(Barc) 1987; 88: 519. Spanish.
Stricker BH, Blok AP, Bronkhorst FB, Van Parys GE, Desmet VJ.
Ketoconazole-associated hepatic injury. A clinicopathological study
of 55 cases. J Hepatol 1986; 3: 399-406.
Lake-Bakaar G, Scheuer PJ, Sherlock S. Hepatic reactions
associated with ketoconazole in the United Kingdom. Br Med J(Clin
Res Ed). 1987; 294: 419-22.
McCance DR, Ritchie CM, Sheridan B, Atkinson AB. Acute
hypoadrenalism and hepatotoxicity after treatment with
ketoconazole. Lancet 1987; 1: 573.
Meiring PD, Whitelaw DA. Ketoconazole induced hepatitis. S Afr Med
J 1987; 72: 577-8.
van Parys G, Evenepoel C, van Damme B, Desmet VJ.
Ketoconazole-induced hepatitis: a case with a definite cause-effect
relationship. Liver 1987; 7: 27-30.
Bensaude RJ, Furet Y, Autret E, Brottes H, Billard JL, Breteau M.
[Cholestatic hepatitis caused by ketoconazole]. Ann Gastroenterol
Hepatol(Paris) 1988; 24: 55-7. French.
Benson GD, Anderson PK, Combes B, Ishak KG. Prolonged jaundice
following ketoconazole-induced hepatic injury. Dig Dis Sci 1988; 33:
240-6.
Vilela MP, Ferraz ML, Franco DR. [Toxic hepatitis caused by
ketoconazole: a report of 4 cases]. Rev Paul Med 1989; 107: 57-8.
Portuguese.
Gradon JD, Sepkowitz DV. Massive hepatic enlargement with fatty
change associated with ketoconazole. DICP 1990; 24: 1175-6.
Brusko C, Marten J. Ketoconazole hepatotoxicity in a patient treated
for environmental illness and systemic candidiasis. DCIP 1991; 25:
1321-5.
Knight T, Shikuma C, Knight J. Ketoconazole-induced fulminant
hepatitis necessitating liver transplantation. J Am Acad Dermatol
1991; 25: 398-400.
Findor JA, Sorda JA, Igartua EB, Avagnina A. Ketoconazole-induced
liver damage. Medicina 1998; 58: 277-81.
Van Puijenbroek EP, Metselaar HJ, Berghuis PH, Zondervan PE,
Stricker BH. [Acute hepatocytic necrosis during ketoconazole
therapy for treatment of onchomycosis. National Foundation for
Registry and Evaluation of Adverse Effects]. Ned Tijdschr Geneeskd
1998; 142: 2416-8. Dutch.
Chien RN, Sheen IS, Liaw YF. Unintentional rechallenge resulting in
a causative relationship between ketoconazole and acute liver
injury. Int J Clin Pract 2003; 57: 829-30.
Kim TH, Kim BH, Kim YW, Yang DM, Han YS, Dong SH, Kim HJ, et
al. Liver cirrhosis developed after ketoconazole-induced acute
hepatic injury. J Gastroenterol Hepatol 2003; 18: 1426-9.
Stein CA, Goel S, Ghavamian R. Hepatitis and rhabdomyolysis in a
patient with hormone refractory prostate cancer on ketoconazole
and concurrent lovastatin therapy. Invest New Drugs 2007; 25:
277-8.
Lin C, Hu J, Yang S, Shin C, Huang S. Unexpected emergence of
acute hepatic injury in patients treated repeatedly with
ketoconazole. J Clin Gastroenterol 2008; 42: 432-3.
pii: S0016-5085(15)00311-X.
METHOTREXATE
http://livertox.nih.gov
METHYLDOPA
Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and
other chemicals on the liver. 2nd edition. Philadelphia: Lippincott
Williams & Wilkins, 1999. p. 656-8.
Zarday Z, Rosenthal WS, Wolff FW. Severe liver toxicity after
methyldopa. N Y State J Med 1967; 67: 1897-9.
Elkington SG, Schreiber WM, Conn HO. Hepatic injury caused by Lalpha-methyldopa. Circulation 1969; 40: 589-95.
Eliastam M, Holmes AW. Hepatitis, arthritis and lupus cell
phenomena caused by methyldopa. Am J Dig Dis 1971; 16: 1014-8.
Tysell JE Jr, Knauer M. Hepatitis induced by methyldopa (aldomet).
Report of a case and a review of the literature. Am J Dig Dis 1971;
16: 848-55.
Wong ML. Hepatocellular damage due to methyldopa. Med J Malaya
1971; 25: 218-9.
Brouillard RP, Barret O Jr. Methyldopa associated hepatitis. JAMA
1973; 224: 904.
Goldstein GB, Lam KC, Mistilis SP. Drug-induced active chronic
hepatitis. Am J Dig Dis 1973; 18: 177-84.
Hoyumpa AM Jr, Connell AM. Methyldopa hepatitis. Report of three
cases. Am J Dig Dis 1973; 18: 213-22.
Rehman OU, Keith TA, Gall EA. Methyldopa-induced submassive
hepatic necrosis. JAMA 1973; 224: 1390-2.
Torres Gomez JM. Intrahepatic cholestasis due to alphamethyldopa: a case report. Bol Asoc Med P R 1973; 65: 212-4.
Hoffbrand BI, Fry W, Bunton GL. Cholestatic jaundice due to
methyldopa. Br Med J 1974; 3: 559.
Schweitzer IL, Peters RL. Acute submassive hepatic necrosis due to
methyldopa. A case demonstrating possible initiation of chronic liver
disease. Gastroenterology 1974; 66: 1203-11.
Toghill PJ, Smith PG, Benton P, Brown RC, Matthews HL.
Methyldopa liver damage. Br Med J 1974; 3: 545-8.
Maddrey WC, Boitnott JK. Severe hepatitis from methyldopa.
Sataline L, Lowell D. Delayed hepatotoxicity from methyldopa. Conn
Med 1975; 39: 775-6.
Bonkowsky HL, Brisbane J. Colitis and hepatitis caused by
methyldopa. JAMA 1976; 236: 1602-3.
Miller AC Jr, Reid WM. Methyldopa-induced granulomatous hepatitis.
JAMA 1976; 235: 2001-2.
Rodman JS, Deutsch DJ, Gutman SI. Methyldopa Hepatitis. A report
of six cases and review of the literature. Am J Med 1976; 60: 9418.
Thomas E. Methyldopa liver injury. J Assoc Physicians India 1976;
24: 851-3.
Thomas E, Bhuta S, Rosenthal WS. Methyldopa-induced liver injury.
Rapid progression to fatal postnecrotic cirrhosis. Arch Pathol Lab
Med 1976; 100: 132-5.
Puppala AR, Steinheber FU. Fulminant hepatic failure associated
with methyldopa. Am J Gastroenterol 1977; 68: 578-81.
Sakamaki H, Dan K, Onozawa Y, Adachi Y, Ukishima H. [A case of
alpha-methyldopa-induced hemolytic anemia with cholestasis
(author's transl)] Rinsho Ketsueki 1977; 18: 821-7. Japanese.
Sotaniemi EA, Hokkanen OT, Ahokas JT, Pelkonen RO, Ahlqvist J.
Hepatic injury and drug metabolism in patients with alphamethyldopa-induced liver damage. Eur J Clin Pharmacol 1977; 12:
429-35.
Thomas E, Rosenthal WS, Zapiach L, Micci D. Spectrum of
methyldopa liver injury. Am J Gastroenterol 1977; 68: 125-33.
Furhoff AK. Adverse reactions with methyldopa--a decade's reports.
Acta Med Scand 1978; 203: 425-8.
Hokkanen OT, Sotaniemi EA. Liver injury and multiple drug therapy.
Arch Toxicol Suppl 1978; (1): 173-6.
Delpre G, Grinblat J, Kadish U, Livni E, Shoha B. Case report.
Immunological studies in a case of hepatitis following methyldopa
administration. Am J Med Sci 1979; 277: 207-13.
Seggie J, Saunders SJ, Kirsch RE, Campbell JAH, Gitlin N, Clain D,
Terblanche J. Patterns of hepatic injury induced by methyldopa. S
Afr Med J 1979; 55: 75-83.
Shashaty GG. Cryptogenic cirrhosis associated with methyldopa.
South Med J 1979; 72: 364-6.
Arranto AJ, Sotaniemi EA. Morphologic alterations in patients with
alpha-methyldopa-induced liver damage after short- and long-term
exposure. Scand J Gastroenterol 1981; 16: 853-63.
Arranto AJ, Sotaniemi EA. Histologic follow-up of alpha-methyldopainduced liver injury. Scand J Gastroenterol 1981; 16: 865-72.
Balázs M, Kovách G. Chronic aggressive hepatitis after methyldopa
treatment. Case report with electron-microscopic study.
Bezahler GH. Fatal methyldopa-associated granulomatous hepatitis
and myocarditis. Am J Med Sci 1982; 283: 41-5.
Breland BD, Hicks GS Jr. Hepatitis and hemolytic anemia associated
with methyldopa therapy. Drug Intell Clin Pharm 1982; 16: 489-92.
Dossing M, Andreasen PB. Drug-induced liver disease in Denmark.
17: 205-11.
Shalev O, Mosseri M, Ariel I, Stalnikowicz R. Methyldopa-induced
immune hemolytic anemia and chronic active hepatitis. Arch Intern
Med 1983; 143: 592-3.
Neuberger J, Kenna JG, Nouri Aria K, Williams R. Antibody mediated
hepatocyte injury in methyl dopa induced hepatotoxicity. Gut 1985;
26: 1233-9.
Otsuka M, Fujimura M, Koshino T, Ueda M, Otake S, Funada H,
Harada M, et al. [A case of autoimmune hemolytic anemia,
interstitial pneumonia and liver injury occurred during one month's
medication of small dose of alpha-methyldopa] Rinsho Ketsueki
1985; 26: 1647-53. Japanese.
Sakurai S, Yamada S, Nagamine T, Takezawa J, Ichikawa K, Arai T,
Takagi H, et al. [A male case of methyldopa-induced liver injury
with positive lupus cell preparation] Nippon Shokakibyo Gakkai
Zasshi 1985; 82: 2134-8. Japanese.
Minakami H, Ohkusa T, Kimura K, Tamada T, Hirota N. [Hepatic
injury caused by methyldopa in a pre-eclamptic patient] Nippon
Sanka Fujinka Gakkai Zasshi 1986; 38: 139-42. Japanese.
Rao KV. Cholestatic jaundice associated with methyldopa. Minn Med
1986; 69: 720-1.
Stanley P, Mijch A. Methyldopa: an often overlooked cause of fever
and transient hepatocellular dysfunction. Med J Aust 1986; 144:
603-5.
Lee WM, Denton WT. Chronic hepatitis and indolent cirrhosis due to
methyldopa: the bottom of the iceberg? J S C Med Assoc 1989; 85:
75-9
Moses A, Zahger D, Amir G. Cholestatic liver injury after prolonged
exposure to methyldopa. Digestion 1989; 42: 57-60.
Picaud A, Walter P, de Préville G, Nicolas P. [Fatal toxic hepatitis in
pregnancy. A discussion of the role of methyldopa] J Gynecol Obstet
Biol Reprod (Paris) 1990; 19: 192-6. French.
Mirada Canals A, Monteagudo Jimenez M, Sole Villa J, Rodriguez
Moreno C. Methyldopa-induced granulomatous hepatitis. DICP
1991; 25: 1269-70.
Daghfous R, el Aidli S, Loueslati MH, Sakka T, Takhal M, Ben Mami
N, Ben Khelifa H, et al. [Methyldopa-induced hepatitis: 3 case
reports] Tunis Med 1994; 72: 47-50. French.
Thomas LA, Cardwell MS. Acute reactive hepatitis in pregnancy
induced by alpha-methyldopa. Obstet Gynecol 1997; 90: 658-9.
Fernández-Marcote Menor EM, Pérez-Bedmar Delgado J.
[Methyldopa-induced acute toxic hepatitis] Rev Esp Enferm Dig
2005; 97: 840-1. Spanish.
Phadnis SV, Sangay MR, Sanusi FA. Alpha-methyldopa-induced acute
hepatitis in pregnancy. Aust N Z J Obstet Gynaecol 2006; 46: 256-7.
pii: S0016-5085(15)00311-X.
Ali T, Srinivasan N, Le V, Rizvi S. Alpha-methyldopa hepatotoxicity
in pregnancy. J Coll Physicians Surg Pak 2009; 19: 125-6.
Slim R, Ben Salem C, Hmouda H, Bouraoui K. Hepatotoxicity of
alpha-methyldopa in pregnancy. J Clin Pharm Ther 2010; 35: 3613.
MINOCYCLINE
Boudreaux JP, Hayes DH, Mizrahi S, Hussey J, Regenstein F, Balart
L. Fulminant hepatic failure, hepatorenal syndrome, and necrotizing
pancreatitis after minocycline hepatotoxicity.
Transplant Proc. 1993 Apr;25(2):1873.
Goldstein NS, Bayati N, Silverman AL, Gordon SC.
Minocycline as a cause of drug-induced autoimmune hepatitis.
Report of four cases and comparison with autoimmune hepatitis.
Am J Clin Pathol. 2000 Oct;114(4):591-8.
Pohle T, Menzel J, Domschke W. Minocycline and fulminant hepatic
failure necessitating liver transplantation.
Am J Gastroenterol. 2000 Feb;95(2):560-1.
Kettaneh A, Fain O, Ziol M, Lejeune F, Eclache-Saudreau V, Biaggi
A, Guettier-Bouttier C, Thomas M. Minocycline-induced systemic
adverse reaction with liver and bone marrow granulomas and
Sezary-like cells. Am J Med. 2000 Mar;108(4):353-4.
Kiessling S, Forrest K, Moscow J, Gewirtz A, Jackson E, Roszman T,
Goebel J. Interstitial nephritis, hepatic failure, and systemic
eosinophilia after minocycline treatment. Am J Kidney Dis. 2001
Dec;38(6):E36.
Seaman HE, Lawrenson RA, Williams TJ, MacRae KD, Farmer RD.
The risk of liver damage associated with minocycline: a comparative
study. J Clin Pharmacol. 2001 Aug;41(8):852-60.
Bamberg C, Laskowski J, Zimmermann R, Gross G.[Cutaneous
xanthomas associated with minocycline-induced cholestatic
jaundice]. Hautarzt. 2003 Sep;54(9):864-8. German.
Losanoff JE, Holder-Murray JM, Ahmed EB, Cochrane AB, Testa G,
Millis JM. Minocycline toxicity requiring liver transplant.
Dig Dis Sci. 2007 Nov;52(11):3242-4.
Favrolt N, Bonniaud P, Collet E, Fayard M, Rabec C, Camus C, Bour
JB, Camus P. [Severe drug rash with eosinophilia and systemic
symptoms after treatment with minocycline].
Rev Mal Respir. 2007 Sep;24(7):892-5. French.
Otto M, Hansen SH, Dalgaard L, Dubois J, Badolo L. Development of
an in vitro assay for the investigation of metabolism-induced drug
hepatotoxicity. Cell Biol Toxicol. 2008 Jan;24(1):87-99.
Kuhn , Weiler-Normann C, Schramm C, Kluge S, Behne MJ, Lohse
AW, Benten D. Acute liver failure following minocycline treatment a case report and review of the literature.
Z Gastroenterol. 2012 Aug;50(8):771-5.
pii: S0016-5085(15)00311-X.
Björnsson E , Talwalkar J, Treeprasertsuk S, Kamath PS, Takahashi
N, Sanderson S, Neuhauser M, Lindor KD. Drug-induced
Autoimmune Hepatitis: Clinical characteristics and prognosis.
Hepatology 2010; 51: 2040-8.
NEVIRAPINE
Reiter GS. Hepatitis in an HIV-infected man. AIDS Clin Care 1997;
9: 78,81.
Warren KJ, Boxwell DE, Kim NY, Drolet BA. Nevirapine-associated
Stevens-Johnson syndrome. Lancet 1998; 351: 567.
Bourezane Y, Salard D, Hoen B, Vandel S, Drobacheff C, Laurent R.
DRESS (drug rash with eosinophilia and systemic symptoms)
syndrome associated with nevirapine therapy. Clin Infect Dis 1998;
27: 1321-2.
Leitze Z, Nadeem A, Choudhary A, Saul Z, Roberts I, Manthous CA.
Nevirapine-induced hepatitis treated with corticosteroids? AIDS
1998; 12: 1115-7.
Ho TTY, Wong KH, Chan KCW, Lee SS. AIDS 1998; 12: 2082-3.
Cattelan AM, Erne E, Salatino A, Trevenzoli M, Carretta G,
Meneghetti F, Cadrobbi P. Severe hepatic failure related to
nevirapine treatment. Clin Infect Dis 1999; 29: 455-6.
Wetterwald E, Le Cleach I, Michel C, David F, Pevuz J. Nevirapineinduced overlap Stevens-Johnson syndrome/toxic epidermal
necrolysis. Br J Dermatol 1999; 140: 980-2
Johnson S, Baraboutis JG. Adverse effects associated with use of
nevirapine in HIV postexposure prophylaxis for 2 health care
workers. JAMA 2000; 284: 2722.
Sha BE, Proia LA, Kessler HA. Adverse effects associated with use of
nevirapine in HIV postexposure prophylaxis for 2 health care
workers. JAMA 2000; 284: 2723.
Piroth L, Grappin M, Sgro C, Buisson M, Duong M, Chavanet P.
Recurrent NNRTI-induced hepatotoxicity in an HIV-HCV-coinfected
patient. Ann Pharmacother 2000; 34: 534-5.
Sissoko D, Ajana F, de la Tribonniere X, Baclet V, Mouton Y.
Manifestations cutanees, hepatiques et hematologiques liees a la
nevirapine: DRESS syndrome? Presse Med 2000; 29: 1041-2.
Clarke S, Harrington P, Barry M, Mulcahy F. The tolerability of
efavirenz after nevirapine-related adverse events. Clin Infect Dis
2000; 31: 806-7
Clarke S, Harrington P, Condon C, Kelleher D, Smith OP, Mulcahy F.
Late onset hepatitis and prolonged deterioration in hepatic function
associated with nevirapine therapy. Int J STD AIDS 2000; 11: 3367.
García Fernández D, García-Patos Briones V, Mollet Sánchez J,
Castells Rodellas A. [Stevens-Johnson syndrome due to nevirapine]
Rev Clin Esp 2000; 200: 179-80.
Bundow D, Rosoff L, Aboulafia DM. Optimal treatment of nevirapineassociated hepatotoxicity remains uncertain. AIDS Read. 2001; 11:
577-80.
Piliero PJ, Purdy B. Nevirapine-induced hepatitis: a case series and
review of the literature. AIDS Read 2001; 11: 379-82.
Prakash M, Poreddy V, Tiyyagura L, Bonacini M. Jaundice and
hepatocellular damage associated with nevirapine therapy. Am J
Claudio GA, Martin AF, de Dios Perrino S, Velasco AA. DRESS
syndrome associated with nevirapine therapy. Arch Intern Med
2001; 161: 2501-2.
Gökengin D, Yamazhan T. Hepatic adverse events during highly
active antiretroviral therapy containing nevirapine: a case report.
Ann Clin Microbiol Antimicrob 2002; 1:1.
Dodi F, Alessandrini A, Camera M, Lorenzo G, Morandi N, Pagano G.
Stevens-Johnson syndrome in HIV patients treated with nevirapine:
two case reports. AIDS 2002; 16: 1197-8.
Knudtson E, Para M, Boswell H, Fan-Havard P. Drug rash with
eosinophilia and systemic symptoms syndrome and renal toxicity
with a nevirapine-containing regimen in a pregnant patient with
human immunodeficiency virus. Obstet Gynecol 2003; 101 (5 Pt 2):
1094-7.
Claes P, Wintzen M, Allard S, Simons P, De Coninck A, Lacor P.
Nevirapine-induced toxic epidermal necrolysis and toxic hepatitis
treated successfully with a combination of intravenous
immunoglobulins and N-acetylcysteine. Eur J Intern Med 2004; 15:
255-258.
Fields KS, Petersen MJ, Chiao E, Tristani-Firouzi P. Case reports:
treatment of nevirapine-associated dress syndrome with
intravenous immune globulin(IVIG). J Drugs Dermatol 2005; 4:
510-3.
Buyse S, Vibert E, Sebagh M, Antonini T, Ichai P, Castaing D,
Samuel D, et al. Liver transplantation for fulminant hepatitis related
to nevirapine therapy. Liver Transpl 2006; 12: 1880-2.
Maniar JK, Shah SR, Verma R, Kamath R, Gupte P, Maniar A.
Nevirapine-induced fulminant hepatitis. J Assoc Physicians India
2006; 54: 957-8.
pii: S0016-5085(15)00311-X.
Ferrajolo C, Capuano A, Verhamme KM, Schuemie M, Rossi F,
Stricker BH, Sturkenboom MC. Drug-induced hepatic injury in
children: a case/non-case study of suspected adverse drug
reactions in VigiBase. Br J Clin Pharmacol 2010; 70: 721-8.
Jao J, Sturdevant M, del Rio Martin J, Schiano T, Fiel MI, Huprikar S.
Nevirapine-induced Stevens Johnson-syndrome and fulminant
hepatic failure requiring liver transplantation. Am J Transplant
2010; 10: 1713-6.
Lopez-Delgado JC, Mendiluce RM, Pinol TS, Fernández XP, Sanchez
L, Vicente RG. Urgent liver transplantation for nevirapine-induced
acute liver failure: report of a case and review of the literature. Ann
Transplant 2012; 17: 122-7.
NIMESULIDE
Van Steenbergen W, Peeters P, De Bondt J, Staessen D, Büscher H,
Laporta T, Roskams T, Desmet V. Nimesulide-induced acute
hepatitis: evidence from six cases. J Hepatol. 1998 Jul;29(1):13541.
Grignola JC, Arias L, Rondan M, Sola L, Bagnulo H. Hepatoxicity
associated to nimesulide [Revision of five cases]. Arch Med Int
1998; 20: 13-18
Weiss P, Mouallem M, Bruck R, Hassin D, Tanay A, Brickman CM,
Farfel Z, Bar-Meir S. Nimesulide-induced hepatitis and acute liver
failure. Isr Med Assoc J. 1999 Oct;1(2):89-91.
Romero Gómez M, Nevado Santos M, Fobelo MJ, Castro Fernández
M. [Nimesulide acute hepatitis: description of 3 cases] Med Clin
(Barc) 1999; 113: 357-358
McCormick PA, Kennedy F, Curry M, Traynor O. COX 2 inhibitor and
fulminant hepatic failure. Lancet. 1999 Jan 2;353(9146):40-1.
Romero-Gómez M, Nevado Santos M, Otero Fernández MA, Fovelo
MJ, Suárez-García E, Castro Fernández M. Acute cholestatic
hepatitis induced by nimesulide. Liver. 1999 Apr;19(2):164-5.
Rodrigues de Oliveira J, Correia J, Silvestre F, Meirelles A, Bernardo
A. [Severe acute hepatitis probably induced by
nimesulide].Gastroenterol Clin Biol. 2000 May;24(5):592-3.
Bessone F, Tanno H. [Hepatotoxicity induced by non-steroidal
anti-inflammatory drugs] Gastroenterol Hepatol 2000; 23: 200-205
Andrade RJ, Lucena MI, Fernández MC, González M.Fatal hepatitis
associated with nimesulide. J Hepatol. 2000 Jan;32(1):174. No
abstract available.
Schattner A, Sokolovskaya N, Cohen J.Fatal hepatitis and renal
failure during treatment with nimesulide. J Intern Med. 2000
Jan;247(1):153-5.
Montesinos S, Hallal H, Rausell V, Conesa F, López A.
[Nimesulide-induced acute hepatitis]. Gastroenterol Hepatol. 2001
Apr;24(4):219-20.
Pérez-Moreno J, Llerena Guerrero RM, Puertas Montenegro M,
Jiménez Arjona MJ. [Nimesulide toxic hepatitis in pregnancy].
Gastroenterol Hepatol. 2000 Dec;23(10):498-9.
Pérez-Moreno J, Llerena Guerrero RM, Puertas Montenegro M,
Jiménez Arjona MJ. [Nimesulide toxic hepatitis in pregnancy]
Gastroenterol Hepatol 2000; 23: 498-499
Tejos S, Torrejón N, Reyes H, Meneses M. [Bleeding gastric ulcers
and acute hepatitis: 2 simultaneous adverse reactions due to
nimesulide in a case] Rev Med Chil 2000; 128: 1349-1353
Ferreiro C, Vivas S, Jorquera F, Domínguez AB, Espinel J, Muñoz F,
Herrera A, Fernández MJ, Olcoz JL, Ortiz de Urbina J. [Toxic
hepatitis caused by nimesulide, presentation of a new case and
review of the literature]. Gastroenterol Hepatol. 2000
Nov;23(9):428-30.
Sbeit W, Krivoy N, Shiller M, Farah R, Cohen HI, Struminger L,
Reshef R.Nimesulide-induced acute hepatitis. Ann Pharmacother.
2001 Sep;35(9):1049-52.
Dourakis SP, Sevastianos VA, Petraki K, Hadziyannis SJ. Nimesulide
induced acute icteric hepatitis. Iatriki 2001; 79: 275-278
Merlani G, Fox M, Oehen HP, Cathomas G, Renner EL, Fattinger K,
Schneemann M, Kullak-Ublick GA. Fatal hepatoxicity secondary to
nimesulide. Eur J Clin Pharmacol. 2001 Jul;57(4):321-6.
Gallego Rojo FJ, Fernández Pérez F, Fernández Pérez R, Porcel A,
Blas JM, Díez F. [Nimesulide-induced hepatotoxicity].
Rev Esp Enferm Dig. 2002 Jan;94(1):41-2. Spanish
Maciá MA, Carvajal A, del Pozo JG, Vera E, del Pino A.
Hepatotoxicity associated with nimesulide: data from the Spanish
Pharmacovigilance System. Clin Pharmacol Ther 2002; 72: 596597.
Dumortier J, Borel I, Delafosse B, Vial T, Scoazec JY, Boillot O.
[Subfulminant hepatitis associated with nimesulide treatment
requiring liver transplantation]. Gastroenterol Clin Biol. 2002
Apr;26(4):415-6. French.
Rodrigo L, de Francisco R, Pérez-Pariente JM, Cadahia V, Tojo R,
Rodriguez M, Lucena MI, Andrade RJ. Nimesulide- induced severe
hemolytic anemia and acute liver failure leading to liver
transplantation. Scand J Gastroenterol 2002; 37: 1341-1343
Stadlmann S, Zoller H, Vogel W, Offner FA. COX-2 inhibitor
(nimesulide) induced acute liver failure. Virchows Arch. 2002
May;440(5):553-5.
Gallego Rojo FJ, Fernández Pérez F, Fernández Pérez R, Porcel A,
Blas JM, Díez F. [Nimesulide-induced hepatotoxicity]. Rev Esp
Enferm Dig. 2002 Jan;94(1):41-2.
Ozgür O, Hacihasanoğlu A, Karti SS, Ovali E. Nimesulide- induced
fulminant hepatitis. Turk J Gastroenterol 2003; 14: 208-210
Papaioannides D, Korantzopoulos P, Athanassiou E, Sinapi- dis D.
Nimesulide-induced acute hepatotoxicity. Indian J Gastroenterol
2003; 22: 239
Polimeni G, Salvo F, Cutroneo P, Morreale I, Patrizio Caputi A.
Adverse reactions induced by NSAIDs and antibacterials: analysis of
spontaneous reports from the Sicilian regional database. Drug Saf.
2006;29(5):449-59.
Dastis SN, Rahier J, Lerut J, Geubel AP. Liver transplantation for
nonsteroidal anti-inflammatory drug-induced liver failure:
nimesulide as the first implicated compound. Eur J Gastroenterol
Hepatol. 2007 Nov;19(11):919-22.
Tan HH, Ong WM, Lai SH, Chow WC. Nimesulide-induced
hepatotoxicity and fatal hepatic failure. Singapore Med J. 2007
Jun;48(6):582-5.
Walker SL, Kennedy F, Niamh N, McCormick PA. Nimesu-lide
associated fulminant hepatic failure. Pharmacoepidemiol Drug Saf
2008; 17: 1108-1112
Koller T, Banárová A, Ondrias F, Kollerová J, Payer J.[Acute
cholestasis following treatment with nimesulide and oral
contraception: case report and review]. Vnitr Lek. 2008
Jun;54(6):665-9. Slovak.
Chatterjee S, Pal J, Biswas N. Nimesulide-induced hepatitis and
toxic epidermal necrolysis. J Postgrad Med. 2008 AprJun;54(2):150-1.
Lukić S, Krstić M, Damjanov N, Boricić I, Popović D, Djuranović S,
Kovacević N, Tomanović N. [Cholestatic hepatitis associated with
nimesulide--a case report]. Srp Arh Celok Lek. 2009 SepOct;137(9-10):550-3.
Wang YP, Shi B, Chen YX, Xu J, Jiang CF, Xie WF. Drug-induced
liver disease: an 8-year study of patients from one
gastroenterological department. J Dig Dis. 2009 Aug;10(3):195-200
Altwegg R. [Acute liver failure due to a treatment by nimesulide].
Ann Fr Anesth Reanim. 2009 Mar;28(3):262-3
Licata A, Calvaruso V, Cappello M, Craxì A, Almasio PL. Clinical
course and outcomes of drug-induced liver injury: nimesulide as the
first implicated medication. Dig Liver Dis 2010; 42: 143-148 , n=14
Bessone F, Colombato L, Fassio E, Reggiardo MV, Vorobioff J, Tanno
H. The spectrum of nimesulide-induced-hepatotoxicity. AntiInflamm & Anti-Allergy Agents Med Chem 2010; 9: 355-365
A Chirino R, Dávalos M, Méndez-Sánchez N, Arrese M, Schinoni M,
Lucena MI, Andrade RJ. Profile of idiosyncratic drug induced liver
injury in Latin America: an analysis of published reports. Ann Hepatol.
2014 Mar-Apr;13(2):231-9.
NITROFURANTOIN
Ernaelsteen D, Williams R. Jaundice due to
nitrofurantoin. Gastroenterology 1961; 41: 590-3.
Cook GC, Sherlock S. Jaundice and its relation to therapeutic
agents. Lancet 1965; 1(7378): 175-9.
Jokela S. Liver disease due to nitrofurantoin. Gastroenterology
1967; 53: 306-11.
Jowers LV, Shannon SR. Jaundice due to nitrofurantoin. J S C Med
Assoc 1967; 63: 357-8.
Wasowska T, Krus S. Jaundice induced by furadantin treatment:
case description. Pol Med J 1968; 7: 322-7.
Murphy KJ, Innis MD. Hepatic disorder and severe bleeding
diathesis following nitrofurantoin ingestion. JAMA 1968; 204: 396-7.
Bhagwat AG, Warren RE. Hepatic reaction to nitrofurantoin. Lancet
1969; 2(7634): 1369.
Lamberger B, von Schenck H. [Nitrofurantoin induced icterus]
Lakartidningen 1973; 70: 2655. Swedish.
Goldstein LI, Ishak KG, Burns W. Hepatic injury associated with
nitrofurantoin therapy. Am J Dig Dis 1974; 19: 987-98.
Selroos O, Edgren J. Lupus-like syndrome associated with
pulmonary reaction to nitrofurantoin. Report of three cases. Acta
Med Scand 1975; 197: 125-9
Klemola H, Penttilä O, Runeberg L, Tallqvist G. Anicteric liver
damage during nitrofurantoin medication. Scand J Gastroenterol
1975; 10: 501-5.
Engel JJ, Vogt TR, Wilson DE. Cholestatic hepatitis after
administration of furan derivatives. Arch Intern Med 1975;
135: 733-5.
Fagrell B, Strandberg I, Wengle B. A nitrofurantoin-induced disorder
simulating chronic active hepatitis. A case report. Acta Med Scand
1976; 199: 237-9.
Strömberg A, Wengle B. Letter: Chronic active hepatitis induced by
nitrofurantoin. Br Med J 1976; 2(6028): 174-5.
Strohscheer H, Wegener HH. [Nitrofurantoin-induced granulomatous
hepatitis]. MMW Munch Med Wochenschr 1977; 119: 1535-6.
German.
Hokkanen OT, Sotaniemi EA. Liver injury and multiple drug therapy.
Arch Toxicol Suppl 1978; (1): 173-6.
Hatoff DE, Cohen M, Schweigert BF, Talbert WM. Nitrofurantoin:
another cause of drug-induced chronic active hepatitis? A report of
a patient with HLA-B8 antigen. Am J Med 1979; 67:117-21.
Iwarson S, Lindberg J, Lundin P. Nitrofurantoin-induced chronic liver
disease. Clinical course and outcome of five cases. Scand J
Gastroenterol 1979; 14(4): 497-502.
Holmberg L, Boman G, Böttiger LE, Eriksson B, Spross R, Wessling
A. Adverse reactions to nitrofurantoin. Analysis of 921 reports. Am J
Med 1980; 69: 733-8.
Black M, Rabin L, Schatz N. Nitrofurantoin-induced chronic active
hepatitis. Ann Intern Med 1980; 92: 62-4.
Sharp JR, Ishak KG, Zimmerman HJ. Chronic active hepatitis and
severe hepatic necrosis associated with nitrofurantoin. Ann Intern
Med 1980; 92: 14-9.
Sippel PJ, Agger WA. Nitrofurantoin-induced granulomatous
hepatitis. Urology 1981 ; 18: 177-8.
Spoelstra P, Janssens AR, Ruiter DJ, de Vries RR. [Chronic active
hepatitis caused by nitrofurantonin]. Ned Tijdschr Geneeskd 1981;
125: 61-3. Dutch.
Anttinen H, Ahonen A, Leinonen A, Kallioinen M, Heikkinen ES.
Diagnostic imaging of focal nodular hyperplasia of the liver
developing during nitrofurantoin therapy. Acta Med Scand 1982;
211: 227-32.
Miller AR, Addis BJ, Clarke PD. Nitrofurantoin and chronic active
hepatitis. Ann Intern Med 1982; 97: 452.
Berry WR, Warren GH, Reichen J. Nitrofurantoin-induced cholestatic
hepatitis from cow's milk in a teenaged boy. West J Med 1984; 140:
278-80.
Baetens P, Ramboer C. Chronic active hepatitis due to
hydroxymethyl-nitrofurantoin in a male patient. Acta Clin Belg
1984; 39: 85-91.
Young TL, Achkar E, Tuthill R, Ferguson DR. Chronic active hepatitis
induced by nitrofurantoin. Cleve Clin Q 1985; 52: 253-6.
Stricker BH, Blok AP, Claas FH, Van Parys GE, Desmet VJl. Hepatic
injury associated with the use of nitrofurans: a clinicopathological
study of 52 reported cases. Hepatology 1988 ; 8: 599-606.
Kursbaum A, Rottenstreich E. [Acute hepatitis and pneumonitis
associated with nitrofurantoin]. Harefuah 1990; 119: 427-8.
Hebrew.
Mollison LC, Angus P, Richards M, Jones RMcL, Ireton J. Hepatitis
due to nitrofurantoin. Med J Aust 1992; 156: 347-9.
Paiva LA, Wright PJ, Koff RS. Long-term hepatic memory for
hypersensitivity to nitrofurantoin. Am J Gastroenterol 1992; 87:
891-3.
Reinhart HH, Reinhart E, Korlipara P, Peleman R. Combined
nitrofurantoin toxicity to liver and lung. Gastroenterology 1992; 102
(4 Pt 1):1396-9.
Hebert MF, Roberts JP. Endstage liver disease associated with
nitrofurantoin requiring liver transplantation. Ann Pharmacother
1993; 27: 1193-4.
Mulberg AE, Bell LM. Fatal cholestatic hepatitis and multisystem
failure associated with nitrofurantoin. J Pediatr Gastroenterol Nutr
1993; 17: 307-9.
Burgert SJ, Burke JP, Box TD. Reversible nitrofurantoin-induced
chronic active hepatitis and hepatic cirrhosis in a patient awaiting
liver transplantation. Transplantation 1995; 59: 448-9.
Yalcin S, Sahin A, Yalcin B, Altinok G. Nitrofurantoin toxicity to both
liver and lungs. Liver 1997; 17: 166-7.
Kelly BD, Heneghan MA, Bennani F, Connolly CE, O'Gorman
TA. Nitrofurantoin-induced hepatotoxicity mediated by CD8+ T
cells. Am J Gastroenterol 1998; 93: 819-21.
Yalcin S, Sahin A, Yalcin B, Altinok G. Nitrofurantoin toxicity to both
liver and lungs. Liver 1997; 17: 166-7
Kelly BD, Heneghan MA, Bennani F, Connolly CE, O'Gorman
TA. Nitrofurantoin-induced hepatotoxicity mediated by CD8+ T
cells. Am J Gastroenterol 1998; 93: 819-21.
Schattner A, Von der Walde J, Kozak N, Sokolovskaya A, Knobler H.
Nitrofurantoin-induced immune-mediated lung and liver disease.
Am J Med Sci 1999; 317: 336-40.
Dam-Larsen S, Kromann-Andersen H. [Hepatic toxicity of
nitrofurantoin. Cases reported to the Center for Monitoring Adverse
Drug Reactions 1968-1998]. Ugeskr Laeger 1999; 161: 6650-2.
Danish.
Edoute Y, Karmon Y, Roguin A, Ben-Ami H. Fatal liver necrosis
associated with the use of nitrofurantoin. Isr Med Assoc J 2001; 3:
382-3.
Amit G, Cohen P, Ackerman Z. Nitrofurantoin-induced chronic active
hepatitis. Isr Med Assoc J 2002; 4: 184-6.
Linnebur SA, Parnes BL. Pulmonary and hepatic toxicity due to
nitrofurantoin and fluconazole treatment. Ann Pharmacother. 2004;
38: 612-6.
Galan MV, Potts JA, Silverman AL, Gordon SC. The burden of acute
nonfulminant drug-induced hepatitis in a United States tertiary
referral center. J Clin Gastroenterol 2005; 39: 64-7.
García-Ruiz E, García-Muñoz B, et al.; Spanish Group for the Study
Salle V, Lafon B, Smail A, Cévallos R, Chatelain D, Andréjak M,
Ducroix JP. [Nitrofurantoin-induced lupus-like syndrome associated
with hepatitis]. Rev Med Interne 2006; 27: 344-6.
Koulaouzidis A, Bhat S, Moschos J, Tan C, De Ramon A.
Nitrofurantoin-induced lung- and hepatotoxicity. Ann Hepatol 2007;
6: 119-21.
Aksamija A, Horvat G, Habek D, Zalac D, Jendris E. Nitrofurantoininduced acute liver damage in pregnancy. Arh Hig Rada Toksikol
2009; 60: 357-61.
Beigel R, Perets R, Mouallem M. Acute kidney injury, hepatitis, and
CPK elevation associated with nitrofurantoin therapy. Am J Med Sci
2009; 337: 132-3.
Cetti RJ, Venn S, Woodhouse CR. The risks of long-term
nitrofurantoin prophylaxis in patients with recurrent urinary tract
infection: a recent medico-legal case. BJU Int 2009; 103: 567-9.
Björnsson E, Talwalkar J, Treeprasertsuk S, Kamath PS, Takahashi
N, Sanderson S, Neuhauser M, et al. Drug-induced autoimmune
hepatitis: clinical characteristics and prognosis. Hepatology 2010;
51: 2040-8.
Appleyard S, Saraswati R, Gorard DA. Autoimmune hepatitis
triggered by nitrofurantoin: a case series. J Med Case Reports
2010; 4: 311.
Incidence, Presentation and Outcomes in Patients with DrugInduced Liver Injury in the General Population of Iceland.
PHENYTOIN
Pezzimenti FJ, Hahn AL. Anicteric hepatitis induced by
diphenylhydantoin. Arch Intern Med 1970; 125: 118-120.
Dhar GJ, Ahamed PN, Pierach CA, Howard RB. Diphenylhydantoininduced hepatic necrosis. Postgrad Med 1974; 56: 128-134.
Weedon AP. Diphenylhydantoin sensitivity. A syndrome resembling
infectious mononucleosis with a morbilliform rash and cholestatic
hepatitis. Aust NZ J Med 1975; 5: 561-3.
Kleckner HB, Yakulis V, Heller P. Severe hypersensitivity to
diphenylhydantoin with circulating antibodies to the drug. Ann
Intern Med 1975; 83: 522-23.
Lee TJ, Carney CN, Lapis JL, Higgins T, Fallon HJ.
Diphenylhydantoin-induced hepatic necrosis. A case study.
Charlesworth EN. Phenytoin-induced pseudolymphoma syndrome.
An immunologic study. Arch Derm 1977; 113: 477-80.
Campbell CB, McGuffie C, Weedon AP, Powell LW. Cholestatic liver
disease associated with diphenylhydantoin therapy. Possible
pathogenic importance of altered bile salt metabolism. Am J Dig Dis
1977; 22: 255-62.
Parker WA, Shearer CA. Phenytoin hepatotoxicity: a case report and
review. Neurology 1979; 29: 175-7.
Mullick FG, Ishak KG. Hepatic injury associated with
diphenylhydantoin therapy: a clinicopathologic study of 20 cases.
Am J Clin Pathol 1980; 74: 442-52.
Cook IF, Shilkin KB, Reed WD. Phenytoin induced granulomatous
hepatitis. Aust NZ J Med 1981; 11: 539-41.
Spechler SJ, Sperber H, Doos WG, Koff RS. Cholestasis and toxic
epidermal necrolysis associated with phenytoin sodium ingestion:
the role of bile duct injury. Ann Intern Med 1981; 95: 455-6.
Cacatian AA, Rando J. Diphenylhydantoin-induced pseudolymphoma
syndrome. With severe thrombocytopenia. NY State J Med 1981;
81: 1085-7.
Ting S, Dunsky EH. Diphenylhydantoin-induced hepatitis. Ann
Allergy 1982; 48: 331-2.
Rosenthal CJ, Noguera CA, Coppola A, Kapelner SN.
Pseudolymphoma with mycosis fungoides manifestations,
hyperresponsiveness to diphenylhydrantoin, and lymphocyte
disregulation. Cancer 1982; 49: 2305-14.
Tomsick RS. The phenytoin syndrome. Cutis 1983; 32: 535-41.
Taylor JW, Stein MN, Murphy MJ, Mitros FA. Cholestatic liver
dysfunction after long-term phenytoin therapy. Arch Neurol 1984;
41: 500-01.
Kahn HD, Faguet GB, Agee JF, Middleton HM. Drug-induced liver
injury. In vitro demonstration of hypersensitivity to both phenytoin
and phenobarbital. Arch Intern Med 1984; 144; 1677-9.
Aaron JS, Bank S, Ackert G. Diphenylhydantoin-induced
hepatotoxicity. Am J Gastroenterol 1985; 80: 200-2.
Wolf R, Kahane E, Sandbank M. Mycosis fungoides-like lesions
associated with phenytoin therapy. Arch Derm 1985; 121: 1181-2.
Riera Velasco JR, Rodrigo Saez LR, Perez Alvarez M, Gonzalez G.
Hepatitis cronica activa por difenilhidantoinas. Med Clin(Barc) 1986;
87: 214.
Brown M, Schubert T. Phenytoin hypersensitivity hepatitis and
mononucleosis syndrome. J Clin Gastroenterol 1986; 4: 469-77.
Engel JN, Mellul VG, Goodman DBP. Phenytoin hypersensitivity: a
case of severe acute rhabdomyolysis. Am J Med 1986; 81: 928-30.
Sherertz EF, Jegasothy BV, Lazarus GS. Phenytoin hypersensitivity
reaction presenting with toxic epidermal necrolysis and severe
hepatitis. Report of a patient treated with corticosteroid “pulse
therapy”. J Am Acad Dermatol 1985; 12: 178-81.
Howard PA, Engen PL, Dunn MI. Phenytoin hypersensitivity
syndrome: a case report. Ann Pharmacother 1991; 25: 929-32.
Kleier RS, Breneman DL, Boiko S. Generalized pustulation as a
manifestation of the anticonvulsant hypersensitivity syndrome. Arch
Dermatol 1991; 127: 1361-4.
Gennis MA, Vemuri R, Burns EA, Hill JV, Miller MA, Spielberg SP.
Familial occurrence of hypersensitivity to phenytoin. Am J Med
1991; 91: 6341-4.
Roy AK, Mahoney HC, Levine RA. Phenytoin-induced chronic
Handfield-Jones SE, Jenkins RE, Whittaker SJ, Besse CP, McGibbon
DH. The anticonvulsant hypersensitivity syndrome. Br J Dermatol
1993; 129: 175-7.
Garcia-Samaniego J, Soriano V, Soto J, Munoz F. [Phenytoin
hypersensitivity syndrome]. An Med Interna 1994; 11: 541-2.
Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome.
Arch Intern Med 1995; 155: 2285-90.
de la Serna Higuera C, Gil Grande LA, Barcena Marugan R. [Toxic
cholestatic hepatitis due to phenytoin]. Gastroenterol Hepatol 1995;
18: 471-3.
Schneider S, Charles F, Chichmanian RM, Montoya ML, Rampal P.
[Acute hepatitis associated with microvesicular steatosis induced by
Atrium] Gastroenterol Clin Biol 1995; 19: 1064-5.
Conger LA Jr, Grabski WJ. Dilantin hypersensitivity reaction. Cutis
1996; 57: 223-6.
Gloria L, Serejo F, Cruz E, freitas J, Costa A, Ramalho F, Batista A,
Carneiro de Moura M. Diphenylhydantoin-induced hepatitis: a case
report. Hepatogastroenterol 1998; 45: 411-4.
Kakar A, Byotra SP. Phenytoin induced severe agranulocytosis and
hepatitis. J Assoc Physicians India 1999; 47: 644.
Nashed MH, Liao L. Possible atypical cross-sensitivity between
phenytoin and carbamazepine in the anticonvulsant hypersensitivity
syndrome. Pharmacother 2001; 21: 502-5.
Gungor E, Alli N, Comoglu S, Comcuoglu C. Phenytoin
hypersensitivity syndrome. Neurol Sci 2001; 22: 261-5.
Bessmertny O, Hatton RC, Gonzalez-Peralta RP. Antiepileptic
hypersensitivity syndrome in children. Ann Pharmacother 2001; 35:
533-8.
Kaur S, Sarkar R, Thami GP, Kanwar AJ. Anticonvulsant
hypersensitivity syndrome. Pediatr Dermatol 2002; 19: 142-5.
Altuntas Y, Ozturk B, Erdem L, Gunes G, Karul S, Ucak S, Senul A.
Phenytoin-induced toxic cholestatic hepatitis in a patient with skin
lesions: case report. South Med J 2003; 96: 201-3.
Choi TS, Doh KS, Kim SH, Jang MS, Suh KS, Kim ST.
Clinicopathological and genotypic aspects of anticonvulsant-induced
pseudolymphoma syndrome. Brit J Dermatol 2003; 148: 730-6.
transplantation for acute liver failure from drug induced liver injury
in the United States. Liver Transplant 2004; 10: 1018-23.
Ito S, Shioda M, Sasaki K, Imai K, Oguni H, Osawa M.
Agranulocytosis following phenytoin-induced hypersensitivity
syndrome. Brain Develop 2009; 31: 449-51
Franciotta D, Kwan P, Perucca E. Genetic basis for idiosyncratic
reactions to antiepileptic drugs. Curr Opin Neurol 2009; 22: 144-9.
Newell BD, Moinfar M, Mancini AJ, Nopper AJ. Retrospective analysis
of 32 pediatric patients with anticonvulsant hypersensitivity
syndrome (ACHSS). Pediatr Dermatol 2009; 26: 536-46.
for the Drug-Induced Liver Injury Network. Characteristics of
idiosyncratic drug-induced liver injury in children: results from the
DILIN Prospective Study. J Pediatr Gastroenterol Nutr 2011; 53:
182-189.
Ghabril M, Fontana R, Rockey D, Jiezhun G, Chalasani N. Druginduced liver injury caused by intravenously administered
medications: The Drug-induced Liver Injury Network experience. J
Clin Gastroenterol 2013; 47: 553-8
PROPYLTHIOURACIL
Livingston HJ, Livingston SF. Agranulocytosis and hepatocellular
jaundice: toxic reactions following propylthiouracil therapy. JAMA
1947; 135: 422-4. Oct 18.
Juliar B, Harris TL. Fatal agranulocytosis occurring during
propylthiouracil therapy: report of a case. JAMA 1949; 139: 646-7.
Colwell AR Jr, Sando DE, Lang SJ. Propylthiouracil-induced
agranulocytosis, toxic hepatitis, and death. JAMA 1952; 148: 63941.
Eisen MJ. Fulminant hepatitis during treatment with propylthiouracil.
N Engl J Med 1953; 249: 814-6.
Parker LN. Hepatitis and propylthiouracil. Ann Intern Med 1975; 82:
228-9.
Fedotin MS, Lefer LG. Liver disease caused by propylthiouracil. Arch
Intern Med 1975; 135: 319-21.
Mihas AA, Holley P, Koff RS, Hirschowitz BI. Fulminant hepatitis and
lymphocyte sensitization due to propylthiouracil. Gastroenterology
1976; 70: 770-4.
Reddy CM. Propylthiouracil and hepatitis: a case report. J Natl Med
Assoc1979; 71: 1185-6.
Jacobsen BB. [Liver involvement in propylthiouracil treatment of
juvenile thyrotoxicosis]. Ugeskr Laeger 1979; 141: 3171-2. Danish.
Nielsen HK, Iversen TO. [Propylthiouracil-induced hepatitis and
agranulocytosis]. Ugeskr Laeger 1980; 142: 3189-90. Danish.
Weiss M, Hassin D, Bank H. Propylthiouracil-induced hepatic
damage. Arch Intern Med 1980; 140: 1184-5.
Pacini F, Sridama V, Refetoff S. Multiple complications of
propylthiouracil treatment: granulocytopenia, eosinophilia, skin
reaction and hepatitis with lymphocyte sensitization. J Endocrinol
Invest 1982; 5: 403-7.
Parker WA. Propylthiouracil-induced hepatotoxicity. Clin Pharm
1982; 1: 471-4.
Safani MM, Tatro DS, Rudd P. Fatal propylthiouracil-induced
hepatitis. Arch Intern Med 1982; 142: 838-9.
Hanson JS. Propylthiouracil and hepatitis. Two cases and a review of
the literature. Arch Intern Med 1984; 144: 994-6.
Bloch CA, Jenski LJ, Balistreri WF, Dolan LM. Propylthiouracilassociated hepatitis. Arch Intern Med 1985; 145: 2129-30.
Garty BZ, Kauli R, Ben-Ari J, Lubin E, Nitzan M, Laron Z. Hepatitis
associated with propylthiouracil treatment. Drug Intell Clin Pharm
1985; 19: 740-2.
Cofré C, Valdés E, Tapia A, Rodríguez J. [Cholestatic hepatitis
secondary to propylthiouracil]. Rev Med Chil 1986; 114: 42-4.
Spanish.
Seidman DS, Livni E, Ilie B, Blum I. Propylthiouracil-induced
cholestatic jaundice. J Toxicol Clin Toxicol 1986; 24: 353-60.
Limaye A, Ruffolo PR. Propylthiouracil-induced fatal hepatic
necrosis. Am J Gastroenterol 1987; 82: 152-4
Jonas MM, Eidson MS. Propylthiouracil hepatotoxicity: two pediatric
cases and review of the literature. J Pediatr Gastroenterol Nutr
1988; 7: 776-9.
Yao JD, Gross JB Jr, Ludwig J, Purnell DC. Cholestatic jaundice in
hyperthyroidism. Am J Med 1989; 86: 619-20.
Maggiore G, Larizza D, Lorini R, De Giacomo C, Scotta MS, Severi F.
Propylthiouracil hepatotoxicity mimicking autoimmune chronic
active hepatitis in a girl. J Pediatr Gastroenterol Nutr 1989; 8: 5478.
Baker B, Shapiro B, Fig LM, Woodbury D, Sisson JC, Beierwaltes
WH. Unusual complications of antithyroid drug therapy: four case
reports and review of literature. Thyroidology 1989; 1: 17-26.
Werner MC, Romaldini JH, Bromberg N, Werner RS, Farah CS.
Adverse effects related to thioamide drugs and their dose regimen.
Am J Med Sci 1989; 297: 716-9.
Kirkland JL. Propylthiouracil-induced hepatic failure and
encephalopathy in a child. DICP 1990; 24: 470-1.
Hayashida CY, Duarte AJ, Sato AE, Yamoshuro-Kanasbiro EH.
Neonatal hepatitis and lymphocyte sensitization by placental
transfer of propylthiouracil. J Endocrinol Invest 1991; 13: 937-41.
Peter SA. Propylthiouracil-associated hepatitis. J Natl Med Assoc
1991; 83: 75-7.
Levy M. Propylthiouracil hepatotoxicity. A review and case
presentation. Clin Pediatr(Phila) 1993; 32: 25-9.
Westphal SA. Hepatotoxicity from propylthiouracil. South Med J
1994; 87: 943-7.
Hoffman DM, Burgess J, Hill P. Agranulocytosis and hepatic
dysfunction following propylthiouracil treatment. Aust N Z J Med
1994; 24: 409-10.
Singh A, Thakur R. Scintigraphic study of propylthiouracil induced
submassive hepatic necrosis. Clin Nucl Med 1995; 20: 132-5.
Deidiker R, deMello DE. Propylthiouracil-induced fulminant hepatitis:
case report and review of the literature. Pediatr Pathol Lab Med
1996; 16: 845-52.
Hardee JT, Barnett AL, Thannoun A, Eghtesad B, Wheeler D, Jamal
MM. Propylthiouracil-induced hepatotoxicity. West J Med 1996; 165:
144-7.
Ozenírler S, Tuncer C, Boztepe U, Akyol G, Alkim H, Cakir N, et al.
Propylthiouracil-induced hepatic damage. Ann Pharmacother 1996;
30: 960-3.
Williams KV, Nayak S, Becker D, Reyes J, Burmeister LA. Fifty years
of experience with propylthiouracil-associated hepatotoxicity: what
have we learned? J Clin Endocrinol Metab 1997; 82: 1727-33.
Lock DR, Sthoeger ZM. Severe hepatotoxicity on beginning
propylthiouracil therapy. J Clin Gastroenterol 1997; 24: 267-9.
Khovidhunkit W, Farese RV Jr. Resolution of propylthiouracilinduced hepatic failure after treatment of thyrotoxicosis. West J Med
1997; 167: 353-6.
Ichiki Y, Akahoshi M, Yamashita N, Morita C, Maruyama T, Horiuchi
T, et al. Propylthiouracil-induced severe hepatitis: a case report and
review of the literature. J Gastroenterol 1998; 33: 747-50.
Parolin MB, Lopes RW, Telles JE, Ioshii SO, Hajar N. [Acute
cholestatic hepatitis induced by propylthiouracil. Case report]. Arq
Gastroenterol 2000; 37: 129-32. Portuguese.
De Castro JJ, Nobre EL, Garcia e Costa J, Galvão-Teles A.
[Asymptomatic hepatitis induced by propylthiouracil]. Acta Med Port
2001; 14: 523-7. Portuguese.
Kim HJ, Kim BH, Han YS, Yang I, Kim KJ, Dong SH, et al. The
incidence and clinical characteristics of symptomatic
propylthiouracil-induced hepatic injury in patients with
hyperthyroidism: a single-center retrospective study. Am J
Ruiz JK, Rossi GV, Vallejos HA, Brenet RW, Lopez IB, Escribano AA.
Fulminant hepatic failure associated with propylthiouracil. Ann
Testa G, Trevino J, Bogetti D, Layden T, Wiley T, Sankary H, et al.
Liver transplantation for propylthiouracil-induced acute hepatic
failure. Dig Dis Sci 2003; 48: 190-1.
Aydemir S, Ustundag Y, Bayraktaroglu T, Tekin IO, Peksoy I, Unal
AY. Fulminant hepatic failure associated with propylthiouracil: a
case report with treatment emphasis on the use of plasmapheresis.
J Clin Apheresis 2005; 20: 235-8.
Sipe WEB, Su M, Posselt A, Kim GE, Quiros JA, Rosenthal P.
Propylthiouracil-associated liver failure presenting as probable
autoimmune hepatitis in a child with Graves' disease. Pediatr
Transplant 2006; 10: 525-8.
Casallo Blanco S, Valero MA, Marcos Sánchez F, de Matías Salces L,
Blanco González JJ, Martín Barranco MJ. [Methimazole and
propylthiouracil induced acute toxic hepatitis]. Gastroenterol
Benyounes M, Sempoux C, Daumerie C, Rahier J, Geubel AP.
Propylthiouracyl-induced severe liver toxicity: an indication for
alanine aminotransferase monitoring? World J Gastroenterol 2006;
12: 6232-4.
Moral Moral P, Rodríguez Soler M, Mancheño Franch N, Aguilera
Sánchez-Tello V, Todolí Parra J, Ponce García J, et al. [Acute
cholestatic hepatitis due to propylthiouracil]. Gastroenterol Hepatol
2008; 31: 474-5. Spanish.
Grzywa M, Orłowska-Florek R, Grzywa-Celińska A. [Two cases of
serious hepatic injury caused by antithyroid drugs]. Endokrynol Pol
2009; 60 396-400. Polish.
Livadas S, Xyrafis X, Economou F, Boutzios G, Christou M, Zerva A,
Karachalios A, Palioura H, Palimeri S, Diamanti-Kandarakis E. Liver
failure due to antithyroid drugs: report of a case and literature
review. Endocrine 2010; 38: 24-8
Carrion AF, Czul F, Arosemena LR, Selvaggi G, Garcia MT, Tekin A,
Tzakis AG, et al. Propylthiouracil-induced acute liver failure: role of
liver transplantation. Int J Endocrinol 2010; 2010: 910636.
Primeggia J, Lewis JH. Gone (from the Physicians' desk reference)
but not forgotten: propylthiouracil-associated hepatic failure: a call
for liver test monitoring. J Natl Med Assoc 2010; 102: 531-4.
de Campos Mazo DF, de Vasconcelos GB, Pereira MA, de Mello ES,
Bacchella T, Carrilho FJ, et al. Clinical spectrum and therapeutic
approach to hepatocellular injury in patients with hyperthyroidism.
Clin Exp Gastroenterol 2013; 6: 9-17.
PYRAZINAMIDE
Aquinas SM. Reactions to antituberculosis drugs among Chinese in
Hong Kong. Tubercle 1964; 45: 181-7.
Simpson AJ, Mirza AM, Martin JF, O'Brien TF Jr. Hepatitis secondary
to pyrazinamide toxicity: accompaniments of transient
hypolipoproteinemia, acanthocytosis, and changes in stomach and
small bowel. South Med J 1970; 63: 138-44.
Singapore Tuberculosis Service/British Medical Research Council.
Clinical trial of six-month and four-month regimens of
chemotherapy in the treatment of pulmonary tuberculosis. Am Rev
Respir Dis 1979; 119: 579-85.
Danan G, Pessayre D, Larrey D, Benhamou JP. Pyrazinamide
fulminant hepatitis: an old hepatotoxin strikes again. Lancet 1981;
2: 1056-7
van Aalderen WMC, Knoester H, Knol K. Fulminant hepatitis during
treatment with rifampicin, pyrazinamide and ethambutol. Eur J
Pediatr 1987; 146: 290-1.
Roden S, Lagneau M, Homasson JP. [Fulminant hepatitis induced by
pyrazinamide]. Rev Pneumol Clin 1990; 46: 43. French.
Kshirsagar NA, Karande SC, Potkar CN. A prospective survey of
drug induced hepatotoxicity in a large hospital. Indian J
Altman C, Biour M, Grangé JD. [Hepatic toxicity of antitubercular
agents. Role of different drugs. 199 cases]. Presse Med 1993; 22:
1212-6. French.
van der Kooi K, Mottet JJ, Regamey C. Isoniazid is not always the
cause of hepatitis during treatment of tuberculosis. Clin Infect Dis
1994; 19: 987-8.
Corbella X, Vadillo M, Cabellos C, Fernandez-Viladrich P, Rufi G.
Hypersensitivity hepatitis due to pyrazinamide. Scand J Infect Dis
1995; 27: 93-4.
al Sarraf KA, Michielsen PP, Hauben EI, Lefebure A, Ramon AM, Van
Marck EA, Pelckmans PA. Hepatotoxicity after a short course of lowdose pyrazinamide. Acta Gastroenterol Belg 1996; 59: 251-3.
Knobel B, Buyanowsky G, Dan M, Zaidel L. Pyrazinamide-induced
granulomatous hepatitis. J Clin Gastroenterol 1997; 24: 264-6.
Tahaoğlu K, Ataç G, Sevim T, Tärün T, Yazicioğlu O, Horzum G,
Gemci I, et al. The management of anti-tuberculosis drug-induced
hepatotoxicity. Int J Tuberc Lung Dis 2001; 5: 65-9.
Teleman MD, Chee CB, Earnest A, Wang YT. Hepatotoxicity of
tuberculosis chemotherapy under general programme conditions in
Singapore. Int J Tuberc Lung Dis 2002; 6: 699-705.
Kunimoto D, Warman A, Beckon A, Doering D, Melenka L. Severe
hepatotoxicity associated with rifampin-pyrazinamide preventative
therapy requiring transplantation in an individual at low risk for
hepatotoxicity. Clin Infect Dis 2003; 36: e158-61.
Younossian AB, Rochat T, Ketterer JP, Wacker J, Janssens JP. High
hepatotoxicity of pyrazinamide and ethambutol for treatment of
latent tuberculosis. Eur Respir J 2005; 26: 462-4.
Potolidis E, Mantadakis E, Zeniodi MH, Samonis G. Rifampin plus
pyrazinamide-induced hepatitis requiring hospitalization in a 30-yold male with latent tuberculosis. Scand J Infect Dis 2005; 37: 1557.
pii: S0016-5085(15)00311-X.
QUINIDINE
Colding H. Et tilfaelde af kinidinallergi med feber og leverpavirkning.
[A case of quinine-allergy with fever and liver injury]. Ugeskr
Laeger 1969; 131: 1657-8.
Deisseroth A, Morganroth J, Winokour S. Quinidine-induced liver
disease. Ann Intern Med 1972; 77: 595-7.
Murphy RJ, Rymer W. Quinidine induced liver disease? Ann Intern
Med 1973; 78: 460.
Chajek T, Lehrer B, Geltner D, Levij IS. Quinidine-induced
granulomatous hepatitis. Ann Intern Med 1974; 81: 774-6.
Chajek T. Quinidine and granulomatous hepatitis. Ann Intern Med
1975; 82: 282.
Handler SD, Hirsch NR, Hass K, Davidson FZ. Quinidine hepatitis.
Arch Intern Med 1975; 135: 871-2.
Koch MJ, Seeff LB, Crumley CE, Rabin L, Burns WA. Quinidine
hepatitis: a report of a case and review of the literature.
Dzur JR. Letter: Quinidine hepatotoxicity. JAMA 1976; 235: 908.
Rotmensch HH, Rubinstein A, Livni E, Liron M, Ilie B. [Quinidineinduced subclinical hepatitis]. Harefuah. 1980; 98: 211-2. Hebrew.
Bramlet DA, Posalaky Z, Olson R. Granulomatous hepatitis as a
manifestation of quinidine hypersensitivity. Arch Intern Med 1980;
140: 395-7.
Tiliakos N, Waites TF. Multiform quinidine toxicity. South Med J
1981; 74: 1267-8.
Slezak P. Quinidine hepatotoxicity. Med J Aust 1981; 1: 139..
Karoly R, Ferenc S. [An unusual side effect of quinidine: liver
damage, pneumonia]. Orv Hetil 1983; 124: 055-6. Hungarian.
Urdahl P, Bjørkheim A. [Quinidine-induced hepatitis. A case report
and review of the literature]. Tidsskr Nor Laegeforen 1983; 103:
760-3. Norwegian.
Smally AJ. When to leave well enough alone—two cases. Hosp Pract
1985; 20: 48-9.
Tanaka N, Matsushita E, Morimoto H, Kobayashi K, Hattori N. [Toxic
hepatitis induced by cardiovascular agents]. Nippon Rinsho 1985;
43: 1172-5. Japanese.
Knobler H, Levij IS, Gavish D, Chajek-Shaul T. Quinidine-induced
hepatitis: a common and reversible hypersensitivity reaction. Arch
Intern Med 1986; 146: 526-8.
Pariente EA, Maitre F, Marchand JP. [Hepatitis caused by quinidine.
Study of a case and review of the literature]. Gastroenterol Clin Biol
1986; 10: 255-8. French.
Bourlière M, Bernuau J, Rueff B, Benhamou JP. Quinidine
phenylethyl-barbiturate-induced fulminant hepatitis in a pregnant
woman. A case report. J Hepatol 1988; 6: 214-6.
Alix M, Mosquet B, Adrien A, Cuny G, Raffy P, Moulin M. [Cholestatic
hepatitis caused by quinidine phenylethylbarbiturate, and
sarcoidosis. Apropos of a case]. Therapie 1989; 44: 69. French.
RIFAMPIN
Lees AW, Asgher B, Hashem MA, Sinha BN. Jaundice after
rifampicin. Br J Dis Chest 1970; 64: 90-5.
Hollins PJ, Simmons AV. Jaundice associated with rifampicin.
Tubercle 1970; 51: 328.
Marche J, Hugues FC, Graisely B, Marche J. [Hepatitis caused by the
combination of rifampicin and isoniazid]. Ann Med Interne(Paris)
1971; 122: 1045-54.
Abeledo Mezquita G, Otero Reigada MC. [Toxic hepatitis caused by
rifampin and isoniazid in treatment of tuberculosis]. An Esp Pediatr
1977; 10: 167-70. Spanish.
Di Piazza S, Cottone M, Craxi A, Gatto G, Pinzelle G, Pagliaro L.
Severe rifampicin-associated liver failure in patients with
compensated cirrhosis. Lancet 1978; 1: 774.
Gutman L. More adverse reactions to rifampicin. J Antimicrob
Chemother 1978; 4: 283.
Poupon RY, Meyniel D, Petit J, Gustot P, Darnis F. [Cholestatic
hepatitis during treatment with I.N.H. and rifampicin: arguments in
favour of the hepatotoxicity of rifampicin]. Ann Med Interne(Paris).
1979; 130: 371-5. French.
Taillan B, Chichmanian RM, Fuzibet JG, Vinti H, Taillan F,
Dellamonica P, Dujardin P. [Jaundice caused by rifampicin: 3 cases]
Rev Med Interne 1989; 10: 409-11.
McNeill L, Allen M, Estrada C, Cook P. Pyrazinamide and rifampin vs
isoniazid for the treatment of latent tuberculosis: improved
completion rates but more hepatotoxicity. Chest 2003; 123: 102-6.
Centers for Disease Control and Prevention(CDC). Update: Fatal and
severe liver injuries associated with rifampin and pyrazinamide
treatment for latent tuberculosis infection. MMWR Morb Mortal Wkly
Rep 2002; 51: 998-9.
Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K,
Garcia-Ruiz E, Garcia-Munoz B, et al. Drug-induced liver injury: an
Ijaz K, Jereb JA, Lambert LA, Bower WA, Spradling PR, McElroy PD,
Iademarco MF, et al. Severe or fatal liver injury in 50 patients in the
United States taking rifampin and pyrazinamide for latent
tuberculosis infection. Clin Infect Dis 2006; 42: 346-55.
Fountain FF, Tolley EA, Jacobs AR, Self TH. Rifampin hepatotoxicity
associated with treatment of latent tuberculosis infection. Am J Med
Sci 2009; 337: 317-20.
SIMVASTATIN
Feydy P, Bogomoletz WV. [A case of hepatitis caused by
simvastatin] [French]. Gastroenterol Clin Biol 1991; 15: 94-5.
Ballare M, Campanini M, Catania E, Bordin G, Zaccala G,
Monteverde A. Acute cholestatic hepatitis during simvastatin
administration. Recento Prog Med 1991; 82: 233-5.
England JD, Viles A, Labib S. Liver side effects associated with
simvastatin therapy. Med J Aust 1991; 155: 61.
Roblin X, Becot F, Piquemal A, Baziz A. [Simvastatin-induced
hepatitis]. Gastroenterol Clin Biol 1992; 16: 101. French.
Koornstra JJ, Ottervanger JP, Fehmers MC, Stricker BH. [Clinically
manifest liver lesions during use of simvastatin] Ned Tijdschr
Geneeskd 1996; 140: 846-8. Dutch.
Heuer T, Gerards H, Pauw M, Gabbert HE, Reis HE. [Toxic liver
damage caused by HMG-CoA reductase inhibitor]. Med Klin(Munich)
2000; 95: 642-4. German.
Kanathur N, Mathai MG, Byrd RP Jr, Fields CL, Roy TM. Simvastatindiltiazem drug interaction resulting in rhabdomyolysis and hepatitis.
Tenn Med 2001; 94: 339-41
Punthakee Z, Scully LJ, Guindi MM, OOi TC. Liver fibrosis attributed
to lipid lowering medications: two cases. J Intern Med 2001; 250:
294.
Cokça F, Ozkan S, Nergisoglu G, Memikoglu O, Azap A. Statin
toxicity: a situation that mimics viral hepatitis. Int J Clin Pharmacol
Ther 2005; 43: 543-5.
Lata S, Chudy B. [Acute cholestatic hepatitis caused by simvastatin
in a 67-year-old patient]. Przegl Lek 2006; 63(suppl 7): 97-8.
Polish.
Alla V, Abraham J, Siddiqui J, Raina D, Wu GY, Chalasani NP,
Bonkovsky HL. Autoimmune hepatitis triggered by statins. J Clin
Tuteja S, Pyrsopoulos NT, Wolowich WR, Khanmoradi K, Levi DM,
Selvaggi G, Weisbaum G, et al. Simvastatin-ezetimibe-induced
hepatic failure necessitating liver transplantation. Pharmacotherapy
2008; 28: 1188-93.
Hepatol 2012; 56:374-80.
prospective study. Hepatology 2010; 52: 2065-76.
2013; 144: 1419-25.
Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K,
Garcia-Ruiz E, Garcia-Munoz B, et al. Drug-induced liver injury: an
Sulfamethoxazole/Trimethoprim
Tönder M, Nordöy A, Elgjo K. Sulfonamide-induced chronic liver
disease. Scand J Gastroenterol 1974; 9: 93-6.
Colucci CF, Lo Cicero M. Hepatic necrosis and trimethoprimsulfamethoxazole. JAMA 1975; 233: 952-3.
Brøckner J, Bøisen E. Fatal multisystem toxicity after cotrimoxazole. Lancet 1978; 1: 831.
Stevenson DK, Christie DL, Haas JE. Hepatic injury in a child
caused by Trimethoprim-Sulfamethoxazole. Pediatrics 1978; 61:
864-6.
Nair SS, Kaplan JM, Levine LH, Geraci K. Trimethoprimsulfamethoxazole-induced intrahepatic cholestasis. Ann Intern Med
1980; 92: 511-2.
Ogilvie AL, Toghill PJ. Cholestatic jaundice due to co-trimoxazole.
Postgrad Med J 1980; 56: 202-4.
Abi-Mansur P, Ardiaca MC, Allam C, Shamma'a M. Trimethoprimsulfamethoxazole-induced cholestasis. Am J Gastroenterol 1981;
76: 356-9.
Coto H, McGowan WR, Pierce EH Jr, Thomas E. Intrahepatic
cholestasis due to trimethoprim-sulfamethoxazole. South Med J
1981; 74: 897-8.
Ransohoff DF, Jacobs G. Terminal hepatic failure following a small
dose of sulfamethoxazole-trimethoprim. Gastroenterology 1981;
80: 816-9.
Ghishan FK. Trimethoprim-sulfamethoxazole-induced intrahepatic
cholestasis. Clin Pediatr (Phila) 1983; 22: 212-4
Horák J, Mertl L, Hrabal P. Severe liver injuries due to
sulfamethoxazole-trimethoprim and sulfamethoxydiazine.
Thies PW, Dull WL. Trimethoprim-sulfamethoxazole-induced
cholestatic hepatitis. Inadvertent rechallenge. Arch Intern Med
1984; 144: 1691-2.
Bartlett JC, Park H, Moe R. Hepatic toxicity associated with
trimethoprim-sulfamethoxazole: report of a case. J Am Osteopath
Assoc 1985; 85: 381-2.
Oliver RM, Rickenbach MA, Thomas MR, Neville E. Intrahepatic
cholestasis associated with co-trimoxazole. Br J Clin Pract 1987; 41:
975-6.
Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L.
Fulminant liver failure and pancreatitis associated with the use of
sulfamethoxazole-trimethoprim. Am J Gastroenterol 1989; 84:
1577-9.
Muñoz SJ, Martinez-Hernandez A, Maddrey WC. Intrahepatic
cholestasis and phospholipidosis associated with the use of
trimethoprim-sulfamethoxazole. Hepatology 1990; 12: 342-7.
Kowdley KV, Keeffe EB, Fawaz KA. Prolonged cholestasis due to
trimethoprim sulfamethoxazole. Gastroenterology 1992; 102: 214850.
Ristikankare M, Tarssanen L.[Trimethoprim-sulfadiazine-induced
cholestasis]. Duodecim. 1993;109(2):139-42. Finnish.
Altraif I, Lilly L, Wanless IR, Heathcote J. Cholestatic liver disease
with ductopenia (vanishing bile duct syndrome) after administration
of clindamycin and trimethoprim-sulfamethoxazole. Am J
Pickert CB, Belsha CW, Kearns GL. Multi-organ disease secondary
to sulfonamide toxicity. Pediatrics 1994; 94: 237-9.
Baciewicz AM, Hapke RJ, Todd CY. Cholestasis: hepatocellular
reaction to trimethoprim/sulfamethoxazole. Ann Pharmacother.
1994 Nov;28(11):1310-1.
Simma B, Meister B, Deutsch J, Sperl W, Fend F, Ofner D,
Margreiter R, Vogel W. Fulminant hepatic failure in a child as a
potential adverse effect of trimethoprim-sulphamethoxazole.
Eur J Pediatr. 1995 Jul;154(7):530-3.
Cario E, Rünzi M, Becker EW, Gröger G, Ali A, Rehbehn K, Goebell
H, Layer P. [Trimethoprim-sulfamethoxazole-induced cholestatic
hepatitis. Clinico-immunological demonstration of its allergic origin].
Dtsch Med Wochenschr. 1996 Feb 2;121(5):129-32.
[Prolonged cholestasis following single dose of cotrimoxazole++].
Ruiz-Irastorza G, Montejo M, Ituarte J, Aguirre C.
Rev Clin Esp. 1996 Dec;196(12):879-80. Spanish.
Yao F, Behling CA, Saab S, Li S, Hart M, Lyche KD. Trimethoprimsulfamethoxazole-induced vanishing bile duct syndrome. Am J
Brett AS, Shaw SV. Simultaneous pancreatitis and hepatitis
associated with trimethoprim-sulfamethoxazole. Am J Gastroenterol
1999; 94: 267-8.
Ilario MJ, Ruiz JE, Axiotis CA. Acute fulminant hepatic failure in a
woman treated with phenytoin and trimethoprim-sulfamethoxazole.
Arch Pathol Lab Med 2000; 124: 1800-3.
Windecker R, Steffen J, Cascorbi I, Thürmann PA. Co-trimoxazoleinduced liver and renal failure. Case report. Eur J Clin Pharmacol
2000; 56: 191-3.
Mainra RR, Card SE. Trimethoprim-sulfamethoxazole-associated
hepatotoxicity - part of a hypersensitivity syndrome. Can J Clin
Pharmacol 2003; 10: 175-8.
Zaman F, Ye G, Abreo KD, Latif S, Zibari GB. Successful orthotopic
liver transplantation after trimethoprim-sulfamethoxazole
associated fulminant liver failure. Clin Transplant 2003; 17: 461-4.
Karnsakul W, Arkachaisri T, Atisook K, Wisuthsarewong W,
Sattawatthamrong Y, Aanpreung P. Vanishing bile duct syndrome in
a child with toxic epidermal necrolysis: an interplay of unbalanced
immune regulatory mechanisms. Ann Hepatol. 2006 AprJun;5(2):116-9.
Kouklakis G, Mpoumponaris A, Zezos P, Moschos J, Koulaouzidis A,
Nakos A, Pehlivanidis A, et al. Cholestatic hepatitis with severe
systemic reactions induced by trimethoprim-sulfamethoxazole. Ann
Hepatol 2007; 6: 63-5.
pii: S0016-5085(15)00311-X.
Crowell CS, Melin-Aldana H, Tan TQ. Fever, rash, and hepatic
dysfunction in a 3-year-old child: a case report. Clin Pediatr (Phila)
2008; 47: 517-20.
Faria LC, Resende CC, Couto CA, Couto OF, Fonseca LP, Ferrari TC.
Severe and prolonged cholestasis caused by trimethoprimsulfamethoxazole: a case report. Clinics (Sao Paulo).
2009;64(1):71-4.
Hanses F, Zierhut S, Schölmerich J, Salzberger B, Wrede CE. Severe
and long lasting cholestasis after high-dose co-trimoxazole
treatment for Pneumocystis pneumonia in HIV-infected patients--a
report of two cases. Int J Infect Dis 2009; 13: e467-9.
Bell TL, Foster JN, Townsend ML. Trimethoprim-sulfamethoxazoleinduced hepatotoxicity in a pediatric patient. Pharmacotherapy
2010; 30: 539.
Chisholm-Burns MA, Patanwala AE, Spivey CA. Aseptic meningitis,
hemolytic anemia, hepatitis, and orthostatic hypotension in a
patient treated with trimethoprim-sulfamethoxazole. Am J Health
Syst Pharm 2010; 67: 123-7.
Sembera S, Lammert C, Talwalkar JA, Sanderson SO, Poterucha JJ,
Hay JE, Wiesner RH, Gores GJ, Rosen CB, Heimbach JK, Charlton
MR. Frequency, clinical presentation, and outcomes of drug-induced
liver injury after liver transplantation. Liver Transpl 2012; 18: 80310.
Cangemi DJ, Donovan ST, Johnson MM. 62-year-old man with
painless jaundice and hyponatremia. Mayo Clin Proc 2013; 88: e4953.
Ng CT, Tan CK, Oh CC, Chang JP. Successful extracorporeal liver
dialysis for the treatment of trimethoprim-sulfamethoxazoleinduced fulminant hepatic failure. Singapore Med J 2013; 54: e1136.
2013; 144: 1419-25.
SULPHASALAZINE
Sotolongo RP, Neefe LI, Rudzki C, Ishak KG. Hypersensitivity
reaction to sulfasalazine with severe
hepatotoxicity. Gastroenterology 1978; 75: 95-99.
Jacobs E, Paulet P, Rahier J. Hypersensitivity reaction to
sulfasalazine--another case. Gastroenterology 1978; 75: 1193.
Kanner RS, Tedesco FJ, Kalser MH. Azulfidine- (sulfasalazine-)
induced hepatic injury. Am J Dig Dis 1978; 23: 956-8.
Mihas AA, Goldenberg DJ, Slaughter RL. Sulfasalazine toxic
reactions. Hepatitis, fever, and skin rash with hypocomplementemia
and immune complexes. JAMA 1978; 239: 2590-1.
Gulley RM, Mirza A, Kelly CE. Hepatotoxicity of
salicylazosulfapyridine: a case report and review of the literature.
Losek JD, Werlin SL. Sulfasalazine hepatotoxicity. Am J Dis Child
1981; 135: 1070-2.
Namias A, Bhalotra R, Donowitz M. Reversible sulfasalazine-induced
granulomatous hepatitis. J Clin Gastroenterol 1981; 3: 193-8.
Larcan A, Lambert H, Janot C, Perarnaud J, Delorme N, Tonnel F.
[Fatal hepatitis during sulfasalazine treatment] Therapie 1982; 37:
315-9. French.
Smith MD, Gibson GE, Rowland R. Combined hepatotoxicity and
neurotoxicity following sulphasalazine administration. Aust N Z J
Med 1982; 12: 76-80.
Lennard TW, Farndon JR. Sulphasalazine hepatotoxicity after 15
years’ successful treatment for ulcerative colitis. Br Med J (Clin Res
Ed) 1983; 287: 96.
Fich A, Schwartz J, Braverman D, Zifroni A, Rachmilewitz D.
Sulfasalazine hepatotoxicity. Am J Gastroenterol 1984; 79: 401-2.
Farr M, Symmons DP, Bacon PA. Raised serum alkaline phosphatase
and aspartate transaminase levels in two rheumatoid patients
treated with sulphasalazine. Ann Rheum Dis 1985; 44: 798-800.
Haines JD Jr. Hepatotoxicity after treatment with sulfasalazine.
Postgrad Med 1986; 79: 193-4, 197-8.
Jennings PE, Blandford RL, Rosenthal FD. Acute sulphasalazine
hepatotoxicity. Postgrad Med J 1986; 62: 305-6.
Labadie H, Beaugrand M, Ferrier JP. [Hepatitis and mononucleosis
syndrome related to the ingestion of salazosulfapyridine]. Rev Med
MacGilchrist AJ, Hunter JA. Sulphasalazine hepatotoxicity: lack of a
hypersensitivity response. Ann Rheum Dis 1986; 45: 967-8.
Poland GA, Love KR. Marked atypical lymphocytosis, hepatitis, and
skin rash in sulfasalazine drug allergy. Am J Med 1986; 81: 707-8.
Ribe J, Benkov KJ, Thung SN, Shen SC, LeLeiko NS. Fatal massive
hepatic necrosis: a probable hypersensitivity reaction to
sulfasalazine. Am J Gastroenterol 1986; 81: 205-8.
Coumaros D, Georges C, Zerbe S. Salicylazosulfapyridine (SASP)
hepatitis: role of 5-aminosalicylic acid (5-ASA). Scand J
Gastroenterol 1989;24(suppl 158):132-133.
Brooks H, Taylor HG, Nichol FE. The three week sulphasalazine
syndrome. Clin Rheumatol 1992; 11: 566-8.
Hautekeete ML, Bourgeois N, Potvin P, Duville L, Reynaert H, Devis
G, Adler M, et al. Hypersensitivity with hepatotoxicity to mesalazine
after hypersensitivity to sulfasalazine. Gastroenterology 1992; 103:
1925-7.
Leroux JL, Ghezail M, Chertok P, Blotman F. Hypersensitivity
reaction to sulfasalazine: skin rash, fever, hepatitis and activated
lymphocytes. Clin Exp Rheumatol 1992; 10: 427.
Besnard M, Debray D, Durand P, Cézard JP, Navarro J.
Sulfasalazine-induced fulminant hepatitis in pediatric Crohn's
disease: report of two cases. J Pediatr Gastroenterol Nutr 1998; 26:
119-20.
Lau G, Kwan C, Chong SM. The 3-week sulphasalazine syndrome
strikes again. Forensic Sci Int 2001; 122: 79-84.
Descloux E, Argaud L, Dumortier J, Scoazec JY, Boillot O, Robert D.
Favourable issue of a fulminant hepatitis associated with
sulfasalazine DRESS syndrome without liver transplantation.
Intensive Care Med 2005; 31: 1727-8.
Teo L, Tan E. Sulphasalazine-induced DRESS. Singapore Med J.
2006; 47: 237-9.
Jobanputra P, Amarasena R, Maggs F, Homer D, Bowman S, Rankin
E, Filer A, Raza K, Jubb R. Hepatotoxicity associated with
sulfasalazine in inflammatory arthritis: A case series from a local
surveillance of serious adverse events. BMC Musculoskelet Disord
2008; 9: 48.
Yeşilova Z, Kantarcioğlu M, Erçin CN, Safalioğlu M, Kilciler G, Koç E,
Atli M, Uygun A. Sulfasalazine-induced hypersensitivity: a case
report of DRESS syndrome. Turk J Gastroenterol. 2009
Dec;20(4):298-9.
Gutierrez M, Filippucci E, Bugatti L, Bertolazzi C, Grassi W. [Severe
drug hypersensitivity syndrome due to sulphasalazine in patient
with rheumatoid arthritis]. Reumatismo 2009; 61: 65-8. Italian.
Lens S, Crespo G, Carrión JA, Miquel R, Navasa M. Severe acute
hepatitis in the DRESS syndrome: Report of two cases. Ann Hepatol
2010 Apr-Jun; 9(2): 198-201.
Pirklbauer M, Gruber J. [DRESS syndrome following sulfasalazine
treatment.]. Z Rheumatol. 2013 Dec 14. [Epub ahead of print]
German.
Girelli F, Bernardi S, Gardelli L, Bassi B, Parente G, Dubini A, Serra
L, Nizzoli M. A new case of DRESS syndrome induced by
sulfasalazine and triggered by amoxicillin. Case Rep Rheumatol
2013; 2013: 409152.
SULFONAMIDES
Fries J, Siragenian R. Sulfonamide hepatitis. Report of a case due to
sulfamethoxazole and sulfisoxazole. N Engl J Med 1966; 274: 95-7.
Dujovne CA, Chan CH, Zimmerman HJ. Sulfonamide hepatic injury.
Review of the literature and report of a case due to
sulfamethoxazole. N Engl J Med 1967; 277: 785-8.
Espiritu CR, Kim TS, Levine RA. Granulomatous hepatitis associated
with sulfadimethoxine hypersensitivity. JAMA 1967; 202: 985-8.
Mooney RA. Liver damage following the administration of
sulphatriad. J Ir Med Assoc. 1969
Millikan LE, Harrell ER. Drug reactions to the sulfones. Arch
Dermatol 1970; 102: 220-4.
Rafoth RJ. Systemic granulomatous reaction to
salicylazosulfapyridine (Azulfidine) in a patient with Crohn's disease.
Am J Dig Dis 1974; 19: 465-9.
Callen JP, Soderstrom RM. Granulomatous hepatitis associated with
salicylazosulfapyridine therapy. South Med J 1978; 71: 1159-60.
Chester AC, Diamond LH, Schreiner GE. Hypersensitivity to
salicylazosulfapyridine: renal and hepatic toxic reactions. Arch
Intern Med 1978; 138: 1138-9.
Iwarson S, Lundin P. Multiple attacks of jaundice associated with
repeated sulfonamide treatment. Acta Med Scand 1979; 206: 21922.
Steinbrecher UP, Mishkin S. Sulfamethoxazole-induced hepatic
injury. Dig Dis Sci 1981; 26: 756-9.
Geier B, Nousbaum JP, Cauvin JM, Rosaszkiewick M, Gouérou H.
[Acute hepatitis probably secondary to the treatment with
pyrimethamine-sulfadiazine combination]. Gastroenterol Clin Biol.
1992;16(8-9):724-5. French.
Barnard GF, Scharf MJ, Dagher RK. Sulfone syndrome in a patient
receiving steroids for pemphigus. Am J Gastroenterol 1994; 89:
2057-9.
Puri AS, Gupta R, Ghoshal UC, Khan E, Aggarwal R, Naik SR.
Hepatic injury in sulfone syndrome: hepatitis or cholestasis? Indian
J Gastroenterol 1995; 14: 20.
Morand JJ, Lightburn E, Coton T, Carré D, Chouc C, Debonne JM,
Jean-Pastor MJ. [Drug hypersensitivity syndrome rapidly resolving
after human immunoglobulin infusion]. Ann Dermatol Venereol.
2001 Dec;128(12):1351-3. French.
Itha S, Kumar A, Dhingra S, Choudhuri G. Dapsone induced
cholangitis as a part of dapsone syndrome: a case report. BMC
Gastroenterol. 2003 11;3:21.
Khalili H, Soudbakhsh A, Talasaz AH. Severe hepatotoxicity and
probable hepatorenal syndrome associated with sulfadiazine.
Am J Health Syst Pharm. 2011 May 15;68(10):888-92.
Frey HM, Gershon AA, Borkowsky W, Bullock WE. Fatal reaction to
dapsone during treatment of leprosy. Ann Intern Med 1981; 94:
777-9.
Tomecki KJ, Catalano CJ. Dapsone hypersensitivity. The sulfone
syndrome revisited. Arch Dermatol 1981; 117: 38-9.
Kromann NP, Vilhelmsen R, Stahl D. The dapsone syndrome. Arch
Dermatol 1982; 118: 531-2.
Jayalakshmi P, Ting HC. Dapsone-induced liver necrosis.
Histopathology 1990; 17: 89-91.
Mohle-Boetani J, Akula SK, Holodniy M, Katzenstein D, Garcia G.
The sulfone syndrome in a patient receiving dapsone prophylaxis for
Pneumocystis carinii pneumonia. West J Med 1992 Mar; 156: 303-6.
Lons T, Richardet JP, Machayekhi JP, Dalbergue B, Trinchet JC.
[Granulomatous hepatitis caused by dapsone]. Gastroenterol Clin
Biol 1992; 16: 293.
Prussick R, Shear NH. Dapsone hypersensitivity syndrome. J Am
Acad Dermatol 1996; 35(2 Pt 2): 346-9.
Alves-Rodrigues EN, Ribeiro LC, Silva MD, Takiuchi A, Fontes CJ.
Dapsone syndrome with acute renal failure during leprosy
treatment: case report. Braz J Infect Dis 2005; 9: 84-6.
Abidi MH, Kozlowski JR, Ibrahim RB, Peres E. The sulfone syndrome
secondary to dapsone prophylaxis in a patient undergoing unrelated
hematopoietic stem cell transplantation. Hematol Oncol 2006; 24:
164-5.
Ranawaka RR, Mendis S, Weerakoon HS. Dapsone-induced
haemolytic anaemia, hepatitis and agranulocytosis in a leprosy
patient with normal glucose-6-phosphate-dehydrogenase activity.
Lepr Rev 2008 Dec; 79(4): 436-40.
Sheen YS, Chu CY, Wang SH, Tsai TF. Dapsone hypersensitivity
syndrome in non-leprosy patients: a retrospective study of its
incidence in a tertiary referral center in Taiwan. J Dermatolog Treat
2009; 20: 340-3.
Vinod KV, Arun K, Dutta TK. Dapsone hypersensitivity syndrome: A
rare life threatening complication of dapsone therapy. J Pharmacol
Pharmacother. 2013; 4: 158-60.
SULINDAC
Zimmerman HJ. Drugs used to treat rheumatic and musculospastic
disease. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of
drugs and other chemicals on the liver. 2nd ed. Philadelphia:
Lippincott, 1999, pp. 517-553.
Anderson RJ. Severe reaction associated with sulindac
administration. N Engl J Med 1979; 300: 735-6.
Wolfe PB. Sulindac and jaundice. Ann Intern Med 1979; 91: 656.
Smith FE, Lindberg PJ. Life-threatening hypersensitivity to sulindac.
JAMA 1980; 244: 269-70.
Dhand AK, LaBrecque DR, Metzger J. Sulindac (Clinoril) hepatitis.
Kaul A, Reddy JC, Fagman E, Smith GF. Hepatitis associated with
use of sulindac in a child. J Pediatr 1981; 99: 650-1.
McIndoe GA, Menzies KW, Reddy J. Sulindac (Clinoril) and
cholestatic jaundice. N Z Med J 1981; 94: 430-1.
Giroux Y, Moreau M, Kass TG. Cholestatic jaundice caused by
sulindac. Can J Surg 1982; 25: 334-5.
Kammerer J, Sabardeil S, Rumeau JL, Salson A, El Hage A.
[Hepatitis due to Sulindac; a case with review of 3 precedents]
Park GD, Spector R, Headstream T, Goldberg M. Serious adverse
reactions associated with sulindac. Arch Intern Med 1982; 142:
1292-4.
Whittaker SJ, Amar JN, Wanless IR, Heathcote J. Sulindac
hepatotoxicity. Gut 1982; 23: 875-7.
Fagan EA, Walford N, Hodgson HJ. Sulindac hepatotoxicity. Gut
1983; 24: 1199.
Klein SM, Khan MA. Hepatitis, toxic epidermal necrolysis and
pancreatitis in association with sulindac therapy. J Rheumatol 1983;
10: 512-3.
Bodin F, Habibi B, Legendre C, Schaeffer-Plumet J, Riallin P, Darnis
F. [Hepatotoxicity of sulindac. A new case] Gastroenterol Clin Biol
1985; 9: 546-7. French.
Gallanosa AG, Spyker DA. Sulindac hepatotoxicity: a case report
and review. J Toxicol Clin Toxicol 1985; 23: 205-38. Erratum in: J
Toxicol Clin Toxicol 1985-86; 23: 617.
Wood LJ, Mundo F, Searle J, Powell LW. Sulindac hepatotoxicity:
effects of acute and chronic exposure. Aust N Z J Med 1985; 15:
397-401.
[Sulindac—a review of adverse effects. Liver reactions are the most
characteristics] Lakartidningen 1987; 84: 142, 144. Swedish.
Lerche A, Vyberg M, Kirkegaard E. Acute cholangitis and
pancreatitis associated with sulindac(clinoril). Histopathology 1987;
11: 647-53.
Daniele B, Pignata S, D'Agostino L, Vecchione R, Mazzacca G.
Sulindac-induced severe hepatitis. Am J Gastroenterol 1988; 83:
1429-31.
Tarazi EM, Harter JG, Zimmerman HJ, Ishak KG, Eaton RA.
Sulindac-associated hepatic injury: analysis of 91 cases reported to
the Food and Drug Administration. Gastroenterology 1993; 104:
569-74.
Garcia Rodriguez LA, Williams R, Derby LE, Dean AD, Jick H. Acute
liver injury associated with nonsteroidal anti-inflammatory drugs
and the role of risk factors. Arch Intern Med 1994; 154: 311-6.
TELITHROMYCIN
Moseley RH. Macrolide antibiotics. Hepatotoxicity of antimicrobials
and antifungal agents. In, Kaplowitz N, DeLeve LD, eds. Druginduced Liver Disease. 3rd ed. Amsterdam: Elsevier, 2013, pp.
466-7.
Clay KD, Hanson JS, Pope SD, Rissmiller RW, Purdum PP 3rd, Banks
PM. Brief communication: severe hepatotoxicity of telithromycin:
three case reports and literature review. Ann Intern Med 2006;
144: 415-20. Summary for patients in: Ann Intern Med 2006; 144:
I42.
Onur O, Guneysel O, Denizbasi A, Celikel C. Acute hepatitis attack
after exposure to telithromycin. Clin Ther 2007; 29: 1725-9.
Bolesta S, Roslund BP. Elevated hepatic transaminases associated
with telithromycin therapy: a case report and literature review. Am
J Health Syst Pharm 2008; 65: 37-41.
Brinker AD, Wassel RT, Lyndly J, Serrano J, Avigan M, Lee WM,
Seeff LB. Telithromycin-associated hepatotoxicity: Clinical spectrum
and causality assessment of 42 cases. Hepatology 2009; 49: 2507.
pii: S0016-5085(15)00311-X.
THIOGUANINE
Gill RA, Onstad GR, Cardamone JM, Maneval DC, Sumner HW.
Hepatic veno-occlusive disease caused by 6-thioguanine. Ann Intern
Med 1982; 96: 58-60.
Krivoy N, Raz R, Carter A, Alroy G. Reversible hepatic venoocclusive disease and 6-thioguanine. Ann Intern Med 1982; 96:
788.
Satti MB, Weinbren K, Gordon-Smith EC. 6-thioguanine as a cause
of toxic veno-occlusive disease of the liver. J Clin Pathol 1982; 3:
1086-91.
Larrey D, Freneaux E, Berson A, Babany G, DeGott C, Valla D,
Pessayre D, et al. Peliosis hepatic induced by 6-thioguanine
administration. Gut 1988; 29: 1265-9.
Kao NL, Rosenblate HJ. 6-thioguanine therapy for psoriasis causing
toxic hepatic venoocclusive disease. J Am Acad Dermatol 1993; 28:
1017-8.
Rulyak SJ, Saunders MD, Lee SD. Hepatotoxicity associated with 6thioguanine therapy for Crohn's disease. J Clin Gastroenterol 2003;
36: 234-7.
Stoneham S, Lennard L, Coen P, Lilleyman J, Saha V. Venoocclusive disease in patients receiving thiopurines during
maintenance therapy for childhood acute lymphoblastic leukaemia.
Br J Haematol 2003; 123: 100-2.
Piel B, Vaidya S, Lancaster D, Taj M, Pritchard-Jones K. Chronic
hepatotoxicity following 6-thioguanine therapy for childhood acute
lymphoblastic leukaemia. Br J Haematol 2004; 125: 410-1; author
reply 412.
Geller SA, Dubinsky MC, Poordad FF, Vasiliauskas EA, Cohen AH,
Abreu MT, Tran T, et al. Early hepatic nodular hyperplasia and
submicroscopic fibrosis associated with 6-thioguanine therapy in
inflammatory bowel disease. Am J Surg Pathol 2004; 28: 1204-11.
Broxson EH, Dole M, Wong R, Laya BF, Stork L. Portal hypertension
develops in a subset of children with standard risk acute
lymphoblastic leukemia treated with oral 6-thioguanine during
maintenance therapy. Pediatr Blood Cancer 2005; 44: 226-31.
De Bruyne R, Portmann B, Samyn M, Bansal S, Knisely A, MieliVergani G, Dhawan A. Chronic liver disease related to 6-thoguanine
in children with acute lymphoblastic leukaemia. J Hepatol 2006; 44:
407-10.
TICLOPIDINE
Biour M, Toussaint P, Duhamel G, Canuel C, Krulick M, Calmus Y.
[Ticlopidine: blood and liver involvement?]. Therapie 1982; 37:
222-4. French.
Deschamps JP, Lassègue A, Ottignon Y, Vuitton D, Allemand H,
Carayon P, Miguet JP. [Cholestatic jaundice associated with
ingestion of ticlopidine: apropos of the first 2 cases]. Gastroenterol
Saint-Marc Girardin MF, Cordonnier C. [Cholestatic icterus and
agranulocytosis due to ticlopidine]. Gastroenterol Clin Biol 1982; 6:
716-7. French.
Eugene C, Lefebvre JF, Gury B, Quevauvilliers J. [Cholestatic
hepatitis. Presumptive role of ticlopidine]. Sem Hop 1983; 59:
2923-4. French.
Mammarella A, Paoletti V, Moroni C, Cassone R. [Ticlopidineinduced cholestatic jaundice]. Clin Ter 1991; 138: 45-6. Italian.
Miyahara K, Kasahara N, Kondo Y, Imai Y, Matuzaki F. Changes in
plasma lipids and abnormal lipoproteins in a patient with druginduced cholestatic hepatitis. Jpn J Med 1991; 30: 354-9.
Greany JJ Jr, Hess DA, Mahoney CD. Ticlopidine-induced cholestatic
jaundice. Clin Pharm 1993; 12: 398-9.
Nurhussein MA. Ticlopidine-induced prolonged cholestasis. J Am
Geriatr Soc 1993; 41: 1371-2
Sondag D, Bader R, Claude P, Schreiber M. [Hepatitis due to
ticlopidine: a new case]. Ann Gastroenterol Hepatol(Paris) 1993;
29: 40-1. French.
Weber E, Donckier J. [Cholestatic jaundice due to ticlopidine: a new
case]. Acta Clin Belg 1994; 49: 309-10. French.
Yoder JD, Algozzine GJ, Hill GW. More ticlopidine-induced cholestatic
jaundice. Am J Hosp Pharm 1994; 51: 1821-2.
Grimm IS, Litynski JJ. Severe cholestasis associated with
ticlopidine. Am J Gastroenterol 1994; 89: 279-80.
Colvicchi F, Magnanimi S, Sebastiani F, Silvestri R, Magnanimi R.
Ticlopidine-induced chronic cholestatic hepatitis: a case report. Curr
Ther Res 1994; 55: 929-31.
Cassidy LJ, Schuster BG, Halparin LS. Probable ticlopidine-induced
cholestatic hepatitis. Ann Pharmacother 1995; 29: 30-2.
Ruiz-Valverde P, Zafon C, Segarra A, Ribera R, Piera L. Ticlopidineinduced granulomatous hepatitis. Ann Pharmacother 1995; 29:
633-4.
Miras Parra FJ, Gómez Jiménez FJ, García Contreras T, Valverde
Romera M. [Ticlopidine-induced cholestatic hepatitis]. Rev Esp
Enferm Dig 1995; 87: 414-5. Spanish.
Naschitz JE, Khamessi R, Elias N, Yeshurun D. Ticlopidine-induced
prolonged cholestasis. J Toxicol Clin Toxicol 1995; 33: 379-80.
López P, Castiella A, Bujanda L, Arenas JI. [Ticlopidine-induced
cholestatic hepatitis. A case report]. Rev Esp Enferm Dig 1995; 87:
735-7. Spanish.
Roy L, Plante M-A, Perreault H, Biron P. Cholestatic hepatitis:
ticlopidine suspected. Therapie 1995; 50: 587-95..
Pistone AM, Podesta F, Raviolo E, Testa D, Grosso B, Toselli P,
Nyffeneger G. [Cholestatic fatty liver of probably iatrogenic origin].
Recenti Prog Med 1986; 77: 188-90. Italian.
Pascual S, Sarrión JV, Jarque I, Argüello L, Berenguer J.
[Cholestatic hepatitis and anemia induced by ticlopidine].
Klepser TB, Jogerst GJ. Ticlopidine-induced elevated liver enzymes.
Pharmacotherapy 1997; 17: 819-21.
Díaz Fuenzalida A, Valdés Socín H, Laudano O, Avagnina A, Findor
JA. [Cholestasis associated with ticlopidine]. Gastroenterol Hepatol
1997; 20: 128-30. Spanish.
Yim HB, Lieu PK, Choo PW. Ticlopidine induced cholestatic jaundice.
Singapore Med J 1997; 38: 132-3.
Guzzini F, Banfi L, Gomitoni A, Marchegiani C, Novati P, Mesina M,
Frigerio B. [2 cases of acute cholestasis caused by ticlopidine].
Recenti Prog Med 1997; 88: 124-7. Italian.
Flamenbaum M, Zenut M, Castillo D, Costes-Charlet N, Kemeny JL,
Lavarenne J, Cassan P. [Granulomatous hepatitis and ticlopidine].
Therapie 1997; 52: 610-1. French.
Friedman ND, Sitlington R, Lodge RS. Thrombocytopenia and
hepatitis complicating ticlopidine therapy. Aust N Z J Med 1997; 27:
599.
San Juan Portugal F, Jiménez Saez J, Naya Manchado J, Fuentes
Solsona F. [Cholestatic hepatitis due to ticlopidine: a report of a
new case]. An Med Interna 1997; 14: 540-1. Spanish.
Sánchez-Bisonó JR, Gómez-Moli J, Escudero-Cantó M. Probable
ticlopidine-induced severe aplastic anemia and cholestatic hepatitis.
Haematologica 1997; 82: 639.
Artímez ML, Fernández E, Rodríguez M, González M, Rodrigo L.
[Toxic hepatitis by ticlopidine. Three new cases]. Rev Esp Enferm
Dig 1997; 89: 796-7. Spanish
Ceylan C, Kirimli O, Akarsu M, Undar B, Güneri S. Early ticlopidineinduced hepatic dysfunction, dermatitis and irreversible aplastic
anemia after coronary artery stenting. Am J Hematol 1998; 59:
260.
Sossai P, Corte GD, Marenzi R. Liver injury with the use of
ticlopidine. Ann Pharmacother 1998; 32: 1370-1.
Martínez Pérez-Balsa A, De Arce A, Castiella A, López P, Ruibal M,
Ruiz-Martínez J, López De Munain A, Martí Massó JF. Hepatotoxicity
due to ticlopidine. Ann Pharmacother 1998; 32: 1250-1.
Iqbal M, Goenka P, Young MF, Thomas E, Borthwick TR. Ticlopidineinduced cholestatic hepatitis: report of three cases and review of
the literature. Dig Dis Sci 1998; 43: 2223-6.
Wegmann C, Müaier R, Dormann AJ, Huchzermeyer H. [Ticlopidineinduced acute cholestatic hepatitis]. Dtsch Med Wochenschr 1998;
123: 146-50. German.
Grieco A, Vecchio FM, Greco AV, Gasbarrini G. Cholestatic hepatitis
due to ticlopidine: clinical and histological recovery after drug
withdrawal. Case report and review of the literature. Eur J
Carvajal García-Pando A, García Ortega P, Rueda de Castro AM,
García del Pozo
from the Spanish drug surveillance system]. Med Clin(Barc) 1999;
112: 557-8. Spanish.
Amaro P, Nunes A, Macoas F, Ministro P, Baranda J, Cipriano A,
Martins I, et al. Ticlopidine-induced prolonged cholestasis: a case
report. Eur J Gastroenterol Hepatol 1999; 11: 673-6.
Kubin CJ, Sherman O, Hussain KB, Feinman L. Delayed-onset
ticlopidine-induced cholestatic jaundice. Pharmacotherapy 1999;
19: 1006-10.
Torrano Larrión F. [Cholestatic hepatitis from ticlopidine]. Aten
Primaria 1999; 24: 115. Spanish.
Meyer MI, Kuhn M, Bühler H, Bertschinger P. [Ticlopidine-induced
cholestasis]. Schweiz Med Wochenschr 1999; 129: 1405-9.
German.
Zeolla MM, Carson JJ. Successful use of clopidogrel for
cerebrovascular accident in a patient with suspected ticlopidineinduced hepatotoxicity. Ann Pharmacoth 1999; 33: 939-41.
Remy AJ, Heran B, Galindo G, Tapie C, Khemissa F, Larrey D. [A
new drug responsible for microvesicular steatosis: ticlopidine].
Gastroenterol Clin Biol 1999; 23: 151-2.
Tsai MH, Tsai SL, Chen TC, Liaw YF. Ticlopidine-induced cholestatic
hepatitis with anti-nuclear antibody in serum. J Formos Med Assoc
2000; 99: 866-9.
Wu MS, Chan P, Lien GS, Cheng YS, Pan S. Ticlopidine-induced
J. [T iclo p id in e
severe cholestatic hepatitis. Zhonghua Yi Xue Za Zhi(Taipei) 2000;
63: 663-6.
Berent R, Hinterholzer G, Höng W, Auer J, Haidenthaler A, Knoflach
P. [Cholestatic hepatitis as a rare side effect of therapy with
ticlopidine]. Z Gastroenterol 2000; 38: 587-91. German.
Pizarro AE, Andrade RJ, García-Cortés M, Lucena MI, Pérez-Moreno
JM, Puertas
M , S á n ch H,
-Martínez
ez et al. [Acute hepatitis due to
ticlopidine. A report of 12 cases and review of the literature]. Rev
Neurol 2001; 33: 1014-20. Spanish.
Placci A, Melandri G, Cecilioni L, Valgimigli M, Bolondi L, Branzi A.
[Late-appearing cholestatic icterus after a month of treatment with
ticlopidine]. Ital Heart J Suppl 2001; 2: 1240-2. Italian.
López López M, Martín López A, Moreno Feliu R. [Ticlopidine,
cholestasis and hepatic nodules]. Med Clin(Barc) 2001; 117: 477.
Spanish.
Blanco JR, Márquez M, Salcedo J, Zabala M. [Early hepatopathy
induced by ticlopidine]. An Med Interna 2001; 18: 48-9. Spanish.
Chen LK, Hsieh BH, Chen WC, Tsai ST, Hou MC. Ticlopidine-induced
hepatitis. Zhonghua Yi Xue Za Zhi(Taipei) 2001; 64: 59-63.
García Ortega P, José Navarro J, Carvajal A, García del Pozo J.
[Cholestatic hepatitis by ticlopidin]. Med Clin(Barc) 2001; 116: 117.
Spanish.
Adams L, Jeffrey GP, Deboer B, Garas G. Ticlopidine-associated
cholestatic hepatitis. Intern Med J 2002; 32: 359-60.
Rivera Vaquerizo P, Solís García del Pozo J, Villanueva Hernández P.
[Ticlopidine-induced hepatitis. Report of a new case]. An Med
Interna 2002; 19: 99-100. Spanish.
Skurnik YD, Tcherniak A, Edlan K, Sthoeger Z. Ticlopidine-induced
cholestatic hepatitis. Ann Pharmacother 2003; 37: 371-6.
Gandolfi A, Mengoli M, Rota E, Tolomelli S, Zanghieri G, Bernini MV,
Lusetti L. [Ticlopidine-induced acute cholestatic hepatitis. A case
report]. Recenti Prog Med 2004; 95: 96-9. Italian.
García-Ruiz E,
G a rcía B, et al.; Spanish Group for the Study
-Muñoz
10-year period. Gastroenterology 2005; 129: 512-21
Sabaté M, Ibáñez L, Pérez E, Vidal X, Buti M, Xiol X, Mas A, et al.
Risk of acute liver injury associated with the use of drugs: a
multicentre population survey. Aliment Pharmacol Ther 2007;
25:1401-9.
Mambelli E, Mancini E, Casanova S, Di Felice A, Santoro A. Severe
ticlopidine-induced cholestatic syndrome. Blood Purif 2007; 25:
441-5.
Lee JY, Park EB, Ahn JH, Suh SJ, Jung YK, Kim JH, Shin BK, et al. [A
case of ticlopidine induced acute cholestatic hepatitis and pure red
cell aplasia]. Korean J Hepatol 2008; 14: 102-7. Korean
Previtera AM, Pagani R. Agranulocytosis and hepatic toxicity with
ticlopidine therapy: a case report. J Med Case Reports 2010; 4:
269.
Anselmino M, Moretti C, Ravera L, Sheiban I. Clopidogrel treatment
in a patient with ticlopidine-induced hepatitis following
percutaneous coronary stenting. Minerva Cardioangiol 2010; 58:
277-80.
VALPROATE
Suchy FJ, Balistreri WF, Buchino JJ, Sondheimer JM, Bates SR,
Kearns GL, Stull
JD , B o ve K E . A
the use of sodium valproate. Report of two fatal cases. N Engl J Med
1979; 300: 962-6
Donat JF, Bocchini JA Jr, Gonzalez E, Schwendimann RN. Valproic
acid and fatal hepatitis. Neurology 1979; 29: 273-4.
Gerber N, Dickinson RG, Harland RC, Lynn RK, Houghton LD,
Antonias JI, Schimschock JC. Reye-like syndrome associated with
valproic acid therapy. J Pediatr 1979; 95: 142-4.
Jacobi G, Thorbeck R, Ritz A, Janssen W, Schmidts HL. Fatal
hepatotoxicity in child on phenobarbitone and sodium valproate.
Lancet 1980; 1 (8170): 712-3.
Ware S, Millward-Sadler GH. Acute liver disease associated with
sodium valproate. Lancet 1980; 2 (8204): 1110-3.
Le Bihan G, Bourreille J, Sampson M, Leroy J, Szekely AM, Coquerel
A. Fatal hepatic failure and sodium valproate. Lancet 1980; 2
(8207): 1298-9.
Young RS, Bergman I, Gang DL, Richardson EP Jr. Fatal Reye-like
syndrome associated with valproic acid. Ann Neurol 1980; 7: 389.
Gastaut H, Noel P. A case of fatal toxic hepatitis: recommendations
for the administration of sodium valproate. Epilepsia 1981; 22: 7113.
Zimmerman HJ, Ishak KG. Valproate-induced hepatic injury:
analyses of 23 fatal cases. Hepatology 1982; 2: 591-7.
Zafrani ES, Berthelot P. Sodium valproate in the induction of
unusual hepatotoxicity. Hepatology 1982; 2: 648-9.
Stricker BH. [Liver damage caused by valproic acid]. Ned Tijdschr
Geneeskd 1982; 126: 2111-3. Dutch.
Itoh S, Yamaba Y, Matsuo S, Saka M, Ichinoe A. Sodium valproateinduced liver injury. Am J Gastroenterol 1982; 77: 875-9.
Böhles H, Richter K, Wagner-Thiessen E, Schafer H. Decreased
serum carnitine in valproate induced Reye syndrome. Eur J Pediatr
1982; 139: 185-6.
Sugimoto T, Nishida N, Yasuhara A, Ono A, Sakane Y, Matsumura T.
Reye-like syndrome associated with valproic acid. Brain Dev 1983;
5: 334-7.
Keene DL, Humphreys P, Carpenter B, Fletcher JP. Valproic acid
producing a Reye-like syndrome. J Canad Sci Neurol 1982; 435-7.
Blaw ME, Belknap WM. Valproate hepatotoxicity. Pediatr Neurol
1985; 1: 320.
Dickinson RG, Bassett ML, Searle J, Tyrer JH, Eadie MJ. Valproate
hepatotoxicity: a review and report of two instances in adults. Clin
Exp Neurol 1985; 21: 79-91.
Møller P, Henriksen O. [Severe liver involvement during use of
sodium valproate]. Tidsskr Nor Laegeforen 1986; 106: 940-1.
Norwegian.
Colletti RB, Trainer TD, Krawisz BR. Reversible valproate fulminant
hepatic failure. J Pediatr Gastroenterol Nutr 1986; 5: 990-4.
Schneffer D, König S, Rauterberg-Ruland I, Kochen W, Hofmann
WJ, Unkelbach S. Fatal liver failure in 16 children with valproate
therapy. Epilepsia 1988; 29: 530-42.
Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA,
Menander KB. Valproic acid hepatic fatalities: a retrospective
review. Neurology 1987; 37: 379-85.
Binek J, Hany A, Egloff B, Heer M. [Acute fatal liver insufficiency
due to valproic acid therapy]. Schweiz Med Wochenschr 1991; 121:
228-33. German.
Bell EA, Shaefer MS, Markin RS, Wood RP, Langnas AN, Stratta RJ,
Shaw BW Jr. Treatment of valproic acid-associated hepatic failure
with orthotopic liver transplantation. Ann Pharmacother 1992; 26:
18-21.
Murphy JV, Groover RV, Hodge C. Hepatotoxic effects in a child
receiving valproate and carnitine. J Pediatr 1993; 123: 318-20.
Plantin P, Cartier H, Le Bihan G, Clouard P, Lellouche F, Leroy JP.
[Drug hypersensitivity syndrome during treatment with valproic
acid]. Presse Med 1995; 24: 1624. French.
Krähenbühl S, Mang G, Kupferschmidt H, Meier PJ, Krause M.
Plasma and hepatic carnitine and coenzyme A pools in a patient
with fatal, valproate induced hepatotoxicity. Gut 1995; 37: 140-3.
Picart N, Périole B, Mazereeuw J, Bonafé JL. [Drug hypersensitivity
syndrome to valproic acid] Presse Med 2000; 29: 648-50.
Delarue A, Paut O, Guys JM, Montfort MF, Lethel V, Roquelaure B,
Pellissier JF, et al. Inappropriate liver transplantation in a child with
Alpers-Huttenlocher syndrome misdiagnosed as valproate-induced
acute liver failure. Pediatr Transplant 2000; 4: 67-71.
Kayihan N, Nennesmo I, Ericzon BG, Németh A. Fatal deterioration
of neurological disease after orthotopic liver transplantation for
valproic acid-induced liver damage. Pediatr Transplant 2000; 4:
211-4.
Thomson MA, Lynch S, Strong R, Shepherd RW, Marsh W.
Orthotopic liver transplantation with poor neurologic outcome in
valproate-associated liver failure: a need for critical risk-benefit
appraisal in the use of valproate. Transplant Proc 2000; 32: 200-3.
Spahr L, Negro F, Rubbia-Brandt L, Marinescu O, Goodman K,
Jordan M, Frossard JL, Hadenque A. Acute valproate-associated
microvesicular steatosis: could the [13C]methionine breath test be
useful to assess liver mitochondrial function? Dig Dis Sci 2001; 46:
2758-61.
Barrueto F Jr, Hack JB. Hyperammonemia and coma without hepatic
dysfunction induced by valproate therapy. Acad Emerg Med 2001;
8: 999-1001.
Bohan TP, Helton E, McDonald I, König SA, Gazitt S, Sugimoto T,
Scheffner D, et al. Effect of L-carnitine treatment for valproateinduced hepatotoxicity. Neurology 2001; 56: 1405-9.
Huang Y-L, Hong H-S, Wang Z-W, Kuo T-T. Fatal sodium valproateinduced hypersensitivity syndrome with lichenoid dermatitis and
fulminant hepatitis. J Am Acad Dermatol 2003; 49: 416-9.
Romero-Falcón A, de la Santa-Belda E, Garci;a-Contreras R, Varela
JM. A case of valproate-associated hepatotoxicity treated with Lcarnitine. Eur J Intern Med 2003; 14: 338-340.
Ee LC, Shepherd RW, Cleghorn GJ, Lewindon PJ, Fawcett J, Strong
RW, Lynch SV. Acute liver failure in children: A regional experience.
J Paediatr Child Health 2003; 39: 107-10.
Arévalo-Lorido JC, Carretero-Gómez J, Bureo-Dacal JC, MonteroLeal C, Bureo-Dacal P. Antiepileptic drug hypersensitivity syndrome
in a patient treated with valproate. Br J Clin Pharmacol 2003; 55:
415-6.
Bumb A, Diederich N, Beyenburg S. Adding topiramate to valproate
therapy may cause reversible hepatic failure. Epileptic Disord 2003;
5: 157-9.
Rahman M, Haider N. Anticonvulsant hypersensitivity syndrome
from addition of lamotrigine to divalproex. Am J Psychiatry 2005;
162:1021.
Björnsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-
induced hepatic failure leading to death or liver transplantation in
Bauer MS. Fatal hepatic failure and valproate. Am J Psychiatry
2005; 162: 192.
McFarland R, Hudson G, Taylor RW, Green SH, Hodges S, McKiernan
PJ, Chinnery PF, Ramesh V. Reversible valproate hepatotoxicity due
to mutations in mitochondrial DNA polymerase gamma(POLG1).
Arch Dis Child 2008; 93: 151-3.
pii: S0016-5085(15)00311-X.
Neyns B, Hoorens A, Stupp R. Valproic acid related idiosyncratic
drug induced hepatotoxicity in a glioblastoma patient treated with
temozolomide. Acta Neurol Belg 2008; 108: 131-4.
Mata Zubillaga D, Prieto Espuñes S, Ferrero de la Mano L, Herrero
Mendoza B. [Valproic acid induced-idiosyncratic hepatotoxicity].
An Pediatr (Barc) 2008; 69: 492-3. Spanish.
Verrotti A, Di Marco G, la Torre R, Pelliccia P, Chiarelli F.
Nonalcoholic fatty liver disease during valproate therapy. Eur J
Pediatr 2009; 168: 1391-4.
Nishri D, Blumkin L, Lev D, Leshinsky-Silver E, Abu-Rashid M, Birch
R, Zuberi SM, Lerman-Sagie T. Hepatic coma culminating in severe
brain damage in a child with a SCN1A mutation. Eur J Paediatr
Neurol 2010; 14: 456-9.
for the Drug-Induced Liver Injury Network. Characteristics of
idiosyncratic drug-induced liver injury in children: results from the
DILIN Prospective Study. J Pediatr Gastroenterol Nutr 2011; 53:
182-189.
Mindikoglu AL, King D, Magder LS, Ozolek JA, Mazariegos GV,
Shneider BL. Valproic acid-associated acute liver failure in children:
case report and analysis of liver transplantation outcomes in the
United States. J Pediatr 2011; 158: 802-7.
Schmid MM, Freudenmann RW, Keller F, Connemann BJ, Hiemke C,
Gahr M, Kratzer W, Fuchs M, Schönfeldt-Lecuona C. Non-Fatal and
Fatal Liver Failure Associated with Valproic Acid.
Pharmacopsychiatry 2012 Aug 22.
ANABOLIC STEROIDS
Werner SC, Hanger FM, Kritzler RA. Jaundice during
methyltestosterone therapy. Am J Med 1950; 8: 325-31.
Brick IB, Kyle LH. Jaundice of hepatic origin during the course of
methyltestosterone therapy. N Engl J Med 1952; 246: 176-9.
Almaden PJ, Ross SW. Jaundice due to methyl testosterone therapy.
Ann Intern Med 1954; 40: 146-52.
Kaplan AA. Jaundice due to methyltestosterone therapy.
Koszalka MF. Medical obstructive jaundice: report of a death due to
methyltestosterone. J Lancet 1957; 77: 51-4.
Seelen JC. Complications during administration of
methylestrenolone. J Clin Endocrinol 1958; 1137-8.
Schaffner F, Popper H, Chesrow E. Cholestasis produced by
administration of norethandrolone. Am J Med 1959; 26: 249-54.
Shaw RK, Gold GL. Jaundice associated with
norethandrolone(Nilevar) therapy. Ann Intern Med 1960; 52: 42834.
Perez-Mera RA, Shields CE. Jaundice associated with norethindrone
acetate therapy. N Engl J Med 1962; 267: 1137-8.
Wilder EM. Death due to liver failure following the use of
methandrostenolone. Can Med Assoc J 1962; 87: 768-9.
Gilbert EF, DaSilva AQ, Queen DM. Intrahepatic cholestasis with
fatal termination following norethandrolone therapy. JAMA 1963;
185: 538-9.
Glober GA, Wilkerson JA. Biliary cirrhosis following the
administration of methyltestosterone. JAMA 1968; 204: 170-3.
Slater SD, Davidson JF, Patrick RS. Jaundice induced by stanozolol
hypersensitivity. Postgrad Med J 1976; 52: 229-32.
Sweeney EC, Evans DJ. Hepatic lesions in patients treated with
synthetic anabolic steroids. J Clin Pathol 1976; 29: 626-33. FATAL
CASE.
Leong AS, Sage RE. Drug-induced hepatic injury. Aust N Z J Med
1977; 7: 537-9.
Boue F, Coffin B, Delfraissy JF. Danazol and cholestatic hepatitis.
Ann Intern Med 1986; 105:139-40.
Lucey MR, Moseley RH. Severe cholestasis associated with
methyltestosterone: a case report. Am J Gastroenterol 1987; 82:
461-2.
Evely RS, Triger DR, Milnes JP, Low-Beer TS, Williams R. Severe
cholestasis associated with stanozolol. Br Med J 1987; 294: 612-3.
Gurakar A, Caraceni P, Fagiuoli S, Van Thiel DH.
Androgenic/anabolic steroid-induced intrahepatic cholestasis: a
review with four additional case reports. J Okla State Med Assoc
1994; 87: 399-404.
Wood P, Yin JA. Oxymetholone hepatotoxicity enhanced by
concomitant use of cyclosporin A in a bone marrow transplant
patient. Clin Lab Haematol 1994; 16: 201-4.
Yoshida EM, Karim MA, Shaikh JF, Soos JG, Erb SR. At what price,
glory? Severe cholestasis and acute renal failure in an athlete
abusing stanozolol. CMAJ 1994; 151: 791-3.
Mork H, al-Taie O, Klinge O, Scheurlen M. Successful therapy of
persistent androgen-induced cholestasis with ursodeoxycholic acid.
Z Gastroenterol 1997; 35: 1087-91.
Habscheid W, Abele U, Dahm HH. [Severe cholestasis with kidney
failure from anabolic steroids in a body builder]. Dtsch Med
Stimac D, Milić S, Dintinjana RD, Kovac D, Ristić S.
Androgenic/Anabolic steroid-induced toxic hepatitis. J Clin
Capra F, Nicolini N, Morana G, Guglielmi A, Capelli P, Vantini I.
Vanishing bile duct syndrome and inflammatory pseudotumor
associated with a case of anabolic steroid abuse. Dig Dis Sci 2005;
50: 1535-7.
Clark BM, Schofield RS. Dilated cardiomyopathy and acute liver
injury associated with combined use of ephedra, gammahydroxybutyrate, and anabolic steroids. Pharmacotherapy 2005;
25: 756-61.
Jasiurkowski B, Raj J, Wisinger D, Carlson R, Zou L, Nadir A.
Cholestatic jaundice and IgA nephropathy induced by OTC muscle
building agent Superdrol. Am J Gastroenterol 2006; 101: 2659-62.
Kafrouni MI, Anders RA, Verma S. Hepatotoxicity associated with
dietary supplements containing anabolic steroids. Clin Gastroenterol
Hepatol 2007; 5: 809-12.
Sánchez-Osorio M, Duarte-Rojo A, Martínez-Benítez B, Torre A,
Uribe M. Anabolic-androgenic steroids and liver injury. Liver Int
2008; 28: 278-82.
Shah NL, Zacharias I, Khettry U, Afdhal N, Gordon FD. Methasteronassociated cholestatic liver injury: clinicopathologic findings in 5
cases. Clin Gastroenterol Hepatol 2008; 6: 255-8.
Singh V, Rudraraju M, Carey EJ, Byrne TJ, Vargas HE, Williams JE,
Balan V, et al. Severe hepatotoxicity caused by a methasteroncontaining performance-enhancing supplement. J Clin Gastroenterol
2009; 43: 287.
Nasr J, Ahmad J. Severe cholestasis and renal failure associated
with the use of the designer steroid Superdrol (methasteron): a
case report and literature review. Dig Dis Sci 2009; 54: 1144-6.
Masumori N, Ikeda H, Endo T. Acute hepatitis induced by
replacement oral testosterone product in a female-to-male patient
with gender identity disorder. Int J Urol 2009 May; 16(5): 530-1.
Krishnan PV, Feng ZZ, Gordon SC. Prolonged intrahepatic
cholestasis and renal failure secondary to anabolic androgenic
steroid-enriched dietary supplements. J Clin Gastroenterol 2009;
43: 672-5.
Rosenfeld GA, Chang A, Poulin M, Kwan P, Yoshida E. Cholestatic
jaundice, acute kidney injury and acute pancreatitis secondary to
the recreational use of methandrostenolone: a case report. J Med
Case Reports 2011; 5: 138.
Elsharkawy AM, McPherson S, Masson S, Burt AD, Dawson RT,
Hudson M. Cholestasis secondary to anabolic steroid use in young
men. BMJ 2012; 344: e468.
Hymel BM, Victor DW, Alvarez L, Shores NJ, Balart LA. Mastabol
induced acute cholestasis: A case report. World J Hepatol 2013; 5:
133-6.
2013; 144: 1419-25. Robles-Diaz M, Gonzalez-Jimenez A, Medina-Caliz I, Stephens C,
García-Cortes M, García-Muñoz B, Ortega-Alonso A, Blanco-Reina E,
Gonzalez-Grande R, Jimenez-Perez M, Rendón P, Navarro JM, Gines
P, Prieto M, Garcia-Eliz M, Bessone F, Brahm JR, Paraná R, Lucena
MI, Andrade RJ; Spanish DILI Registry; SLatinDILI Network. Distinct
phenotype of hepatotoxicity associated with illicit use of anabolic
androgenic steroids. Aliment Pharmacol Ther. 2015 Jan;41(1):11625.
ORAL CONTRACEPTIVES
Perez-Mera RA, Shields CE. Jaundice associated with norethindrone
acetate therapy. N Engl J Med 1962; 267: 1137-8.
Sotaniemi E, Kreus KE, Scheinin TM. Oral contraceptives and liver
damage. Br Med J 1964; 2: 1264-5.
Wetterberg L. Oral contraceptives and acute intermittent porphyria.
Lancet 1964; 2: 1178-9.
Boake WC, Schade SG, Morrissey JF, Schaffner F. Intrahepatic
cholestatic jaundice of pregnancy followed by Enovid-induced
cholestatic jaundice. Ann Intern Med 1965; 63: 302-8.
Culberg G, Lundstrom R, Stenram U. Jaundice during treatment
with an oral contraceptive, Lyndiol. Br Med J 1965; 1: 695-7.
Carlström H, Höglund S, Reizenstein P. Oral contraceptives and liver
damage. Br Med J 1965; 1: 993.
Larsson-Cohn U, Stenram U. Jaundice during treatment with oral
contraceptive agents. Report of two cases. JAMA 1965; 193: 422-6.
Oigaard A. [Jaundice following norethynodrel plus
mestranol(enovid)]. Ugeskr Laeger 1965; 127(45): 1444-6. Danish.
Elliott AJ, Hendry J. Cholestatic jaundice complicating pregnancy.
Recurrence after norethynodrel with ethynylestradiol (Enovid). Can
Med Assoc J 1965; 92: 344-5..
Baines GF. Jaundice in a patient taking norethisterone compound
tablets. Lancet 1965; 1 (7376): 108-9.
Holzbach RT, Sanders JH. Recurrent intrahepatic cholestasis of
pregnancy: observations on pathogenesis. JAMA 1965; 193: 542-4.
von Oldershausen, Eggstein M, Dold U, Knoerr K. [Icterus in
intrahepatic cholestasis following the administration of
contraceptive steroids]. Dtsch Med Wochenschr 1965; 90: 1290-4.
German.
Orellana-Alcalde JM, Dominguez JP. Jaundice and oral contraceptive
drugs. Lancet 1966; 2: 1278-80.
Thulin KE, Nermark J. Seven cases of jaundice in women taking oral
contraceptive, Anovlar. Br Med J 1966; 1: 584-6.
Somayaji BN, Paton A, Price JH, Harris AW, Flervett TH.
Norethisterone jaundice in two sisters. Br Med J 1968; 2: 281-3.
Dooner HP, Hoyl C, Aliaga C, Parada J. Jaundice and oral
contraceptives. Acta Hepatosplenol 1971; 18: 84-4.
Medline A, Ptak T, Gryfe A, Blenkinsop B. Pruritus of pregnancy and
jaundice induced by oral contraceptives. Am J Gastroenterol 1976;
65: 156-9.
Lieberman DA, Keefe LB, Stenzel P. Severe and prolonged oral
contraceptive jaundice. J Clin Gastroenterol 1984; 6: 145-8.
Wedén M, Glaumann H, Einarsson K. Protracted cholestasis
probably induced by oral contraceptive. J Intern Med 1992; 231:
561-5.
Lindgren A, Olsson R. Liver damage from low-dose oral
contraceptives. J Intern Med 1993; 234: 287-92.
Anand V, Gorard DA. Norethisterone-induced cholestasis. QJM
2005; 98: 232-4.
pii: S0016-5085(15)00311-X.
Elouni B, Ben Salem C, Zamy M, Ganne N, Beaugrand M, Bouraoui
K, Biour M. Cytolytic hepatitis possibly related to
levonorgestrel/ethinylestradiol oral contraceptive use: 2 case
reports. Ann Pharmacother 2010; 44: 2035-7.
ACARBOSE
Andrade RJ, Lucena MI, Rodríguez-Mendizábal M. Hepatic injury
caused by acarbose. Ann Intern Med 1996; 124: 931.
Carrascosa M, Pascual F, Aresti S. Acarbose-induced acute severe
hepatotoxicity. Lancet 1997; 349: 698-9.
Diaz-Gutierrez FL, Ladero JM, Diaz-Rubio M. Acarbose-induced
acute hepatitis. Am J Gastroenterol 1998; 93: 481.
Fujimoto Y, Ohhira M, Miyokawa N, Kitamori S, Kohgo Y. Acarboseinduced hepatic injury. Lancet 1998; 351: 340.
Andrade RJ, Lucena M, Vega JL, Torres M, Salmerón FJ, Bellot V,
García-Escaño
M D , et al. Ahepatotoxicity.
-associated
carb o se
Diabetes Care 1998; 21: 2029-30.
Mennecier D, Zafrani ES, Dhumeaux D, Mallat A. [Acarbose-induced
acute hepatitis]. Gastroenterol Clin Biol 1999; 23: 1398-9. French.
de la Vega J, Crespo M, Escudero JM, Sánchez L, Rivas LL.
[Acarbose-induced acute hepatitis. Report of two events in the
same patient]. Gastroenterol Hepatol 2000; 23: 282-4. Spanish.
Madonia S, Pietrosi G, Pagliaro L. Acarbose-induced liver injury in
an anti-hepatitis C virus positive patient. Dig Liver Dis 2001; 33:
615-6.
Benavente Fernández A, Maraver Gacía A, Talavera Fabuel A,
Barrios Merino A. [Acute hepatitis induced by acarbose]. Med Clin
(Barc) 2001; 117: 317-8. Spanish.
Hsiao SH, Liao LH, Cheng PN, Wu TJ. Hepatotoxicity associated with
acarbose therapy. Ann Pharmacother 2006; 40: 151-4.
AMITRYPTILINE
Cunningham ML. Acute hepatic necrosis following treatment with
amitriptyline and diazepam. Br J Psychiatry 1965; 111: 1107-9.
Biagi RW, Bapat BN. Intrahepatic obstructive jaundice from
amitriptyline. Br J Psychiatry 1967; 113: 1113-4.
Morgan DH. Jaundice associated with amitriptyline. Br J Psychiatry
1969; 115: 105-6.
Yon J, Anuras S. Hepatitis caused by amitriptyline therapy. JAMA
1975; 232: 833-4.
Anderson BN, Henrikson IR. Jaundice and eosinophilia associated
with amitriptyline. J Clin Psychiatry 1978; 39: 730-1.
Giller EL Jr, Bialos DS, Docherty JP, Jatlow P, Harkness L. Chronic
amitriptyline toxicity. Am J Psychiatry 1979; 136: 458-9
Danan G, Bernuau J, Moullot X, Degott C, Pessayre D. Amitriptylineinduced fulminant hepatitis. Digestion 1984; 30: 179-84.
Larrey D, Rueff B, Pessayre D, Algard M, Geneve J, Benhamou JP.
Cross hepatotoxicity between tricyclic antidepressants. Gut 1986;
87-90.
Larrey D, Amouyal G, Pessayre D, Degott C, Danne O, Machayekhi
JP, Feldmann G, et al. Amitriptyline-induced prolonged cholestasis.
Brems JJ, Merenda GO, Hayek ME, Kane RE, Flynn MF, Kaminski DL.
Orthotopic liver transplantation resulting in amitriptyline toxicity in
the recipient. Transplantation 1989; 48: 159-61
Remy AL, Larrey D, Pageaux GP, Desprez D, Ramos J, Michel H.
Cross hepatotoxicity between tricyclic antidepressants and
phenothiazines. Eur J Gastroenterol 1995; 7: 373-6
Randeva HS, Bangar V, Sailesh S, Hillhouse EW. Fatal cholestatic
jaundice associated with amitriptyline. Int J Clin Pract 2000; 54:
405-6.
Milionis HJ, Skopelitou A, Elisaf MS. Hypersensitivity syndrome
caused by amitriptyline administration. Postgrad Med J 2000; 76:
361-3.
Milkiewicz P, Chilton AP, Hubscher SG, Elias E. Antidepressant
induced cholestasis: hepatocellular redistribution of multidrug
resistant protein (MRP2). Gut 2003; 52: 300-3.
AMODIAQUINE
Glick L. Fatal agranulocytosis during treatment with amodiaquine.
Br Med J 1957; 1: 932.
Perry HO, Bartholomew LG, Hanlon DG. Nearly fatal reaction to
amodiaquine. JAMA 1962; 179: 598-601.
Gillespie P, Wagner F. Amodiaquine agranulocytosis. Med J Aust
1977; 1: 298-9.
Woodtli W, Vonmoos P, Siegrist P, Zollikofer H. [Amodiaquineinduced hepatitis with leukopenia]. Schweiz Med Wochenschr 1986;
116: 966-8. German.
Larrey D, Castot A, Pëssayre D, Merigot P, Machayekhy JP,
Feldmann G, Lenoir A, et al. Amodiaquine-induced hepatitis. A
report of seven cases. Ann Intern Med 1986; 104: 801-3.
Desaint B, Conrad M, Florent C, Legendre C, Levy VG. [Is
amodiaquine (Flavoquine) hepatotoxic?]. Gastroenterol Clin Biol
1986; 10: 440.
Amouretti M, Raymond JM, Baldit C, Dumas F, Couzigou P, Béraud
C. [Amodiaquine (Flavoquine) is hepatotoxic]. Gastroenterol Clin
Biol 1986; 10: 855. French.
Neftel KA, Woodtly W, Schmid M, Frick PG, Fehr J. Amodiaquineinduced agranulocytosis and liver damage. Br Med J 1986; 292:
721-3.
Charmot G, Goujon C. [Minor hepatitis probably caused by
amodiaquine]. Bull Soc Pathol Exot Filiales 1987; 80: 266-70.
Bernuau J, Larrey D, Campillo B, Degott C, Verdier F, Rueff B,
Pessayre D, et al. Amodiaquine-induced fulminant hepatitis. J
Hepatol 1988; 6:109-12.
Raymond JM, Dumas F, Baldit C, Couzigou P, Beraud C, Amouretti
M. Fatal acute hepatitis due to amodiaquine. J Clin Gastroenterol
1989; 11: 602-3.
Markham LN, Giostra E, Hadengue A, Rossier M, Rebsamen M,
Desmeules J. Emergency liver transplantation in amodiaquineinduced fulminant hepatitis. Am J Trop Med Hyg 2007; 77: 14-5.
Guévart E, Aguémon A. [Two cases of fulminant hepatitis during a
curative treatment with an artesunate-amodiaquine combination].
Med Mal Infect 2009; 39: 57-60. French.
AMOXICILLIN
Kim JS, Jang YR, Lee JW, Kim JY, Jung YK, Chung DH, Kwon OS,
Kim YS, Choi DJ, Kim JH. A case of amoxicillin-induced
hepatocellular liver injury with bile-duct damage. Korean J Hepatol.
2011 Sep;17(3):229-32
Ruiz Rebollo ML, Aller De La Fuente R, Macho Conesa A, Salado
Valdivieso I, Sainz Gil M, Carvajal A, Manuel González
J.[Amoxicillin-induced cholestatic hepatitis].Gastroenterol Hepatol.
2011 Aug-Sep;34(7):474-7.
Romney R, Biour M, Belloula D, Elbaz D, Carriere J, Cadranel
JF.[Amoxicillin induced acute hepatitis]. Gastroenterol Clin Biol.
2004 May;28(5):505-6. French
Bolzan H, Spatola J, Castelletto R, Curciarello J. [Intrahepatic
cholestasis induced by amoxicillin alone]. Gastroenterol Hepatol.
2000 May;23(5):237-9. Spanish.
Schwarze C, Schmitz V, Fischer HP, Sauerbruch T, Spengler
U.Vanishing bile duct syndrome associated with elevated pancreatic
enzymes after short-term administration of amoxicillin. Eur J
Gastroenterol Hepatol. 2002 Nov;14(11):1275-7.
Davies MH, Harrison RF, Elias E, Hübscher SG. Antibiotic-associated
acute vanishing bile duct syndrome: a pattern associated with
severe, prolonged, intrahepatic cholestasis. J Hepatol. 1994
Jan;20(1):112-6.
Fontana RJ, Shakil AO, Greenson JK, Boyd I, Lee WM. Acute liver
failure due to amoxicillin and amoxicillin/clavulanate. Dig Dis Sci
2005; 50: 1785-90.
Andrade RJ, Lucena MI, Kaplowitz N, Garcia-Munoz B, Borraz Y,
Pachkoria K, Garcia-Cortes M, et al. Outcome of acute idiosyncratic
Madroñero AB, Porcel JM, Bielsa S. [Hepatotoxicity induced by
amoxicillin].Rev Esp Enferm Dig. 2007 Mar;99(3):173-4. Spanish
pii: S0016-5085(15)00311-X.
ASPARAGINASE
Land VJ, Sutow WW, Fernbach DJ, Lane DM, Williams TE. Toxicity of
L-asparginase in children with advanced leukemia. Cancer 1972;
30: 339-47.
Woods WG, O'Leary M, Nesbit ME. Life-threatening neuropathy and
hepatotoxicity in infants during induction therapy for acute
lymphoblastic leukemia. J Pediatr 1981; 98: 642-5.
Jenkins R, Perlin E. Severe hepatotoxicity from Escherichia coli Lasparaginase. J Natl Med Assoc 1987; 79: 775, 779.
Sahoo S, Hart J. Histopathological features of L-asparaginaseinduced liver disease. Semin Liver Dis 2003; 23: 295-9.
Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krähenbühl
S. Fatal liver failure in an adult patient with acute lymphoblastic
leukemia following treatment with L-asparaginase. Digestion 2006;
74: 28-32.
Saison J, Berger F, Lebosse F, Audoual R, Thomas X, Michallet M.
Hepatomegaly and fever at the time of neutrophil recovery
revealing L-asparaginase toxicity in the treatment of acute
lymphoblastic leukemia. Am J Case Rep 2014; 15: 13-7.
AZITHROMYCIN
Longo G, Valenti C, Gandini G, Ferrara L, Bertesi M, Emilia G.
Azithromycin-induced intrahepatic cholestasis. Am J Med 1997;
102: 217-8.
Macaigne G, Mokbel M, Marty O, De La Lande P, Mallet L. [Acute
pseudoangiocholitic hepatitis probably induced by azithromycin]
Cascaval RI, Lancaster DJ. Hypersensitivity syndrome associated
with azithromycin. Am J Med 2001; 110: 330-1.
Chandrupatla S, Demetris AJ, Rabinovitz M. Azithromycin-induced
intrahepatic cholestasis. Dig Dis Sci 2002; 47: 2186-8.
Suriawinata A, Min AD. A 33-year-old woman with jaundice after
azithromycin use. Semin Liver Dis 2002; 22: 207-10.
Baciewicz AM, Al-Nimr A, Whelan P. Azithromycin-induced
hepatoxicity. Am J Med 2005; 118: 1438-9.
Danica J, Irena H, Davor R, Mate S, Marijana C, Boris V, Igor F.
Vanishing Bile Duct Syndrome Associated with Azithromycin in a 62Year-Old Man. Basic Clin Pharmacol Toxicol 2009.
Lockwood AM, Cole S, Rabinovich M. Azithromycin-induced liver
injury. Am J Health Syst Pharm 2010; 67: 810-4.
Caramaschi P, Mahamid H, Bambara LM, Biasi D. Liver impairment
after concomitant administration of bosentan and clarithromycin in
systemic sclerosis. Joint Bone Spine 2010; 77: 81-2.
Das BK. Azithromycin induced hepatocellular toxicity and hepatic
encephalopathy in asymptomatic dilated cardiomyopathy. Indian J
Pharmacol 2011; 43: 736-7.
Juricic D, Hrstic I, Radic D, Skegro M, Coric M, Vucelic B, Francetic
I. Vanishing bile duct syndrome associated with azithromycin in a
62-year-old man. Basic Clin Pharmacol Toxicol. 2010
Jan;106(1):62-5.
Martinez MA, Vuppalanchi R, Fontana RJ, Stolz A, Kleiner DE,
Hayashi PH, Gu J, Hoofnagle JH, Chalasani N. Clinical and Histologic
Features of Azithromycin-Induced Liver Injury.
Clin Gastroenterol Hepatol. 2014 Aug 9. N=18
CAPTOPRIL
Schattner A, Kozak N, Friedman J.Captopril-induced jaundice:
report of 2 cases and a review of 13 additional reports in the
literature. Am J Med Sci. 2001 Oct;322(4):236-40. Review.
Kocab MA, Coppola D, Hiotis S, Karl RC, Barthel JS.Captoprilassociated cholestasis complicating the management of pancreatic
cancer.Surg Endosc. 2000 Jul;14(7):681.
Martínez Gutiérrez A, Sierra Manzano JM, Tapia YR, Larumbe Sola
Y.[Hepatotoxicity caused by captopril]. Aten Primaria. 1998 May
15;21(8):586-7. Spanish.
Pérez Roldán F, González Carro PS, Legaz Huidobro ML, Saez Bravo
JM, Ruiz Carrillo F.[Cholestatic hepatitis caused by captopril]. Rev
Esp Enferm Dig. 1998 May;90(5):378-9. Spanish.
Deira JL, Corbacho L, Bondía A, Lerma JL, Gascón A, Martín B,
García P, Tabernero JM.Captopril hepatotoxicity in a case of renal
crisis due to systemic sclerosis. Nephrol Dial Transplant. 1997
Aug;12(8):1717-8..
Nissan A, Spira RM, Seror D, Ackerman Z.Captopril-associated
"pseudocholangitis'. A case report and review of the literature. Arch
Surg. 1996 Jun;131(6):670-1.
Hagley MT, Hulisz DT, Burns CM.Hepatotoxicity associated with
angiotensin-converting enzyme inhibitors. Ann Pharmacother. 1993
Feb;27(2):228-31. Review.
Alonso-Villaverde C, Ubiría J, Masana L, Prats E. [Cholestasis caused
by captopril].Med Clin (Barc). 1992 Nov 7;99(15):595.
Pedersen JH, Clementsen PS, Høyer S, Hansen BA.
[Captopril-induced toxic hepatitis].Ugeskr Laeger. 1992 Oct
12;154(42):2911-2.
Hagley MT, Benak RL, Hulisz DT.Suspected cross-reactivity of
enalapril- and captopril-induced hepatotoxicity.
Ann Pharmacother. 1992 Jun;26(6):780-1.
de Vega T, Rúa-Figueroa I, Soto J, Sacristán JA.
[Cholestatic jaundice induced by captopril].
Med Clin (Barc). 1992 Apr 4;98(13):518. Spanish.
Crantock L, Prentice R, Powell L.Cholestatic jaundice associated with
captopril therapy.J Gastroenterol Hepatol. 1991 Sep-Oct;6(5):52830. Review.
Putterman C, Livshitz T [Captopril-induced liver dysfunction].
Harefuah. 1991 Aug;121(3-4):92-3. Hebrew.
Hernández López R, Bravo Toledo R.[Captopril and the liver].
Aten Primaria. 1991 Jun;8(6):514.
Hagley MT. Captopril-induced cholestatic jaundice.
South Med J. 1991 Jan;84(1):100.
CEFAZOLIN
Ammann R, Neftel K, Hardmeier T, Reinhardt M. Cephalosporininduced cholestatic jaundice. Lancet 1982; 2: 337.
Benyounes M, Horsmans Y, Galand C, Lambert M. [Acute cytolytic
hepatitis caused by cefazolin and metronidazole] Gastroenterol Clin
Biol 1995; 19: 740-1. French.
Skoog SM, Smyrk TC, Talwalkar JA. Cephalexin-induced cholestatic
hepatitis. J Clin Gastroenterol 2004; 38: 833
Pacik PT. Augmentation mammaplasty: postoperative
cephalosporin-induced hepatitis. Plast Reconstr Surg 2007; 119:
1136-7.
Alqahtani SA, Kleiner DE, Ghabril M, Gu J, Hoofnagle JH, Rockey
DC. Identification and Characterization of Cefazolin-induced Liver
Injury.Clin Gastroenterol Hepatol. 2014 Dec 17. pii: S15423565(14)01824-2
CEFTRIAXONE
Longo F, Hastier P, Buckley MJ, Chichmanian RM, Delmont JP. Acute
hepatitis, autoimmune hemolytic anemia, and
erythroblastocytopenia induced by ceftriaxone. Am J Gastroenterol
1998; 93: 836-7.
Ravisha MS, Godambe SV. Ceftriaxone induced cholestasis in a
neonate: a case report. Indian J Med Sci 2004; 58: 73-4.
Bell MJ, Stockwell DC, Luban NL, et al. Ceftriaxone-induced
hemolytic anemia and hepatitis in an adolescent with hemoglobin
SC disease. Pediatr Crit Care Med 2005; 6: 363-6.
Rivkin AM. Hepatocellular enzyme elevations in a patient receiving
ceftriaxone. Am J Health Syst Pharm 2005; 62: 2006-10.
Peker E, Cagan E, Dogan M. Ceftriaxone-induced toxic hepatitis.
World J Gastroenterol 2009; 15: 2669-71.
Kaur I, Singh J. Cholestatic hepatitis with intravenous ceftriaxone.
Indian J Pharmacol 2011; 43: 474-5. doi:
Choi YY, Jung YH, Choi SM, Lee CS, Kim D, Hur KY. Gallbladder
pseudolithiasis caused by ceftriaxone in young adult. J Korean Surg
Soc 2011; 81:423-6.
Tomoda T, Ueki T, Saito S, Tatsukawa M, Nawa T, Hamamoto H,
Endo H, Yabushita K, Shimoe T, Sakaguchi K. [A case of
ceftriaxone-associated pseudolithiasis in an adult patient that
disappeared after the discontinuation of ceftriaxone]. Nihon
Tomoda T, Ueki T, Saito S, Tatsukawa M, Nawa T, Hamamoto H,
Endo H, Yabushita K, Shimoe T, Sakaguchi K. [A case of
ceftriaxone-associated pseudolithiasis in an adult patient that
disappeared after the discontinuation of ceftriaxone]. Shokakibyo
Gakkai Zasshi 2013; 110: 1481-6. Japanese.
von Martels JZ, Van de Meeberg EK, Holman M, Ligtenberg JJ, Ter
Maaten JC. Pseudolithiasis after recent use of ceftriaxone: an
unexpected diagnosis in a child with abdominal pain. Am J Emerg
Med 2013; 31: 1294. e5-6.
CELEOXIB
Carrillo-Jimenez R, Nurnberger M. Celecoxib-induced acute
pancreatitis and hepatitis: a case report. Arch Intern Med 2000;
160: 553-4.
Galan MV, Gordon SC, Silverman AL. Celecoxib-induced cholestatic
Nachimuthu S, Volfinzon L, Gopal L. Acute hepatocellular and
cholestatic injury in a patient taking celecoxib. Postgrad Med J
2001; 77: 548-50.
O'Beirne JP, Cairns SR. Drug Points: Cholestatic hepatitis in
association with celecoxib. BMJ 2001; 323: 23.
Alegria P, Lebre L, Chagas C. Celecoxib-induced cholestatic
hepatotoxicity in a patient with cirrhosis. Ann Intern Med 2002;
137: 75.
Grieco A, Miele L, Giorgi A, Civello IM, Gasbarrini G. Acute
cholestatic hepatitis associated with celecoxib. Ann Pharmacother
2002; 36: 1887-9.
Zinsser P, Meyer-Wyss B, Rich P. Hepatotoxicity induced by
celecoxib and amlodipine. Swiss Med Wkly 2004; 134: 201.
Chamouard P, Walter P, Baumann R, Poupon R. Prolonged
cholestasis associated with short-term use of celecoxib.
Tabibian JH, Tabibian N, Kaufman DM. Late-onset celecoxibinduced combined hepato-nephrotoxicity. BJCP 2008; 66: 150-1.
pii: S0016-5085(15)00311-X.
El Hajj, Malik SM, Alwakeel HR, Shaikh OS, Sasatomi E, Kandil
HM. Celecoxib-induced cholestatic liver failure requiring orthotopic
liver transplantation. World J Gastroenterol 2009; 15: 3937-9.
Famularo G, Gasbarrone L, Minisola G. Probable celecoxib-induced
hepatorenal syndrome. Ann Pharmacother 2012; 46: 610-1.
Nayudu SK, Badipatla S, Niazi M, Balar B. Cholestatic hepatitis with
small duct injury associated with celecoxib. Case Rep Med 2013;
2013: 315479.
CHLORPROPAMIDE
HAMFF LH, FERRIS HA, EVANS EC, WHITEMAN HW. The effects of
tolbutamide and chlorpropamide on patients exhibiting jaundice as
a result of previous chlorpropamide therapy.
Ann N Y Acad Sci. 1959 Mar 30;74(3):820-9.
TAUBMAN F, PETROPOULOS P. Intrahepatic jaundice produced by
chlorpropamide. J Am Med Assoc. 1959 Aug 22;170(17):2085-8. N
Y State J Med. 1959 Dec 1;59:4432-4.
BROWN G, ZOIDIS J, SPRING M. Hepatic damage during
chlorpropamide therapy. J Am Med Assoc. 1959 Aug
22;170(17):2085-8.
Grottum KA.[Liver damage due to phenylbutazone and
chlorpropamide].Tidsskr Nor Laegeforen. 1966 Aug
15;86(16):1096-8
Rigberg LA, Robinson MJ, Espiritu CR. Chlorpropamide-induced
granulomas. A probable hypersensitivity reaction in liver and bone
marrow. JAMA. 1976 Jan 26;235(4):409-10.
Gill MJ, Ratliff DA, Harding LK. Hypoglycemic coma, jaundice, and
pure RBC aplasia following Chlorpropamide therapy. Arch Intern
Med 1980; 140: 714-5.
Rumboldt Z, Bota B. Favorable effects of glibenclamide in a patient
exhibiting idiosyncratic hepatotoxic reactions to both
chlorpropamide and tolbutamide. Acta Diabetol Lat 1984; 21: 38791.
Schneider HL, Hornbach KD, Kniaz JL, Efrusy ME. Chlorpropamide
hepatotoxicity: report of a case and review of the literature. Am J
Gastroenterol. 1984 Sep;79(9):721-4.
Bell RL. Chlorpropamide hepatitis. Ala Med. 1984 Mar;53(9):20, 223.
Gupta R, Sachar DB. Chlorpropamide-induced cholestatic jaundice
and pseudomembranous colitis. Am J Gastroenterol 1985; 80: 3813.
Geubel AP, Nakad A, Rahier J, Dive C. Prolonged cholestasis and
disappearance of interlobular bile ducts following chlorpropamide
and erythromycin ethylsuccinate. Case of drug interaction?
Liver. 1988 Dec;8(6):350-3.
Crespo Valadés E, Ortega Gómez A, Alvarado Izquierdo MI, Magro
Ledesma D. [Hepatotoxic reaction associated with metformin and
chlorpropamide treatment]. Rev Clin Esp. 1999 Feb;199(2):118-9.
Spanish. No abstract available.
CHLORZOXAZON
Lindholm L. [Fever, skin and liver reactions in a patient treated with
Paraflex comp.] Lakartidningen 1979; 76: 2795-6. Swedish.
[Effects on liver of analgesics containing dextropropoxyphene
and/or chlorzoxazone.] Lakartidningen 1982; 79: 3823. Swedish.
Powers BJ, Cattau EL Jr, Zimmerman HJ. Chlorzoxazone hepatotoxic
reactions. An analysis of 21 identified or presumed cases. Arch
Intern Med 1986; 146: 1183-6.
Kronenberg A, Krohenbohl S, Zimmermann A, Streuli R. [Severe
hepatocellular damage after administration of paracetamol and
chlorzoxazone in therapeutic dosage.] Schweiz Rundsch Med Prax
1998; 87: 1356-60. German.
Bielecki JW, Schraner C, Briner V, Kuhn M. [Rhabdomyolysis and
cholestatic hepatitis under treatment with simvastatin and
chlorzoxazone.] Schweiz Med Wochenschr 1999; 129: 514-8.
German.
Jackson J, Anania FA. Chlorzoxazone as a cause of acute liver
failure requiring liver transplantation. Dig Dis Sci 2007; 52: 338991.
pii: S0016-5085(15)00311-X.
CIMETIDINE
Züchner H. [Cholestatic hepatitis under Cimetidine]. Dtsch Med
Lilly JR, Hitch DC, Javitt NB. Cimetidine cholestatic jaundice in
children. J Surg Res 1978; 24: 384-7
Villeneuve JP, Warner HA. Cimetidine hepatitis. Gastroenterology
1979; 77: 143-4
Ruiz Del Arbol L, Moreira V, Moreno A, Hernández Ranz F, Cano A,
García Plaza
A . B rid g in g h ep atic n ec
cimetidine. Am J Gastroenterol 1980; 74: 267-9.
Lorenzini I, Jezequel AM, Orlandi F. Cimetidine-induced hepatitis.
Electron microscopic observations and clinical pattern of liver injury.
Dig Dis Sci 1981; 26: 275-80.
Delpre G, Kadish U, Livni E. Hepatitis following cimetidine
administration. Am J Med Sci 1982; 283: 153-6.
Van Steenbergen W, Vanstapel MJ, Desmet V, Van Kerckvoorde L,
De Keyzer R, Brijs R, Fevery J, et al. Cimetidine-induced liver injury.
Report of three cases. J Hepatol 1985; 1: 359-68.
Schwartz JT, Gyorkey F, Graham DY. Cimetidine hepatitis. J Clin
Clarke B, Yoong A. Prolonged cholestasis and cimetidine. Dig Dis Sci
1987; 32: 333.
Vázquez Arnedo M, Pastor Fanco A, Bestue Fuster JM. [Cimetidine
and toxic hepatitis]. Rev Esp Enferm Apar Dig 1987; 71: 66-8.
Spanish.
Kadri AZ, Fisher R, Winterton MC. Cimetidine and paracetamol
hepatotoxicity. Hum Toxicol 1988; 7: 205.
Kimura H, Akamatsu K, Sakaue H, Nogawa M, Ohta Y. Fulminant
hepatitis induced by cimetidine. J Gastroenterol Hepatol 1988; 3:
223-6.
Boyd PT, Lepre F, Dickey JD. Chronic active hepatitis associated
with cimetidine. BMJ 1989; 298: 324-5.
Zaidenstein R, Cohen N, Golik A. [Cimetidine hepatitis]. Harefuah
1992; 123: 516-8, 572. Hebrew
Polunina TE, Fomichev VI, Vasil'ev AP. [Acute drug-induced
hepatitis in a patient with peptic ulcer]. Klin Med(Mosk) 1992; 70:
102-3. Russian.
Hashimoto F, Davis RL, Egli D. Hepatitis following treatments with
famotidine and then cimetidine. Ann Pharmacother 1994; 28: 37-9.
CIPROFLOXACIN
Slama TG. Serum sickness-like illness associated with ciprofloxacin.
Antimicrob Agents Chemother 1990; 34: 904-5.
Grassmick BK, Lehr VT, Sundareson AS. Fulminant hepatic failure
possibly related to ciprofloxacin. Ann Pharmacother 1992; 26: 636-
9.
Levison JR, Kumar A. Ciprofloxacin induced cholestatic jaundice: a
case report. Am J Gastroenterol 1993; 88: 1619.
Fuchs S, Simon Z, Brezin M. Fatal hepatic failure associated with
ciprofloxacin. Lancet 1994; 343: 738-9.
Sherman O, Beizer JL. Possible ciprofloxacin-induced acute
cholestatic jaundice. Ann Pharmacother 1994; 28: 1162-4.
Aggarwal A, Gurka J. Probable ciprofloxacin induced cholestasis.
Aust N Z J Med 1995; 25: 541-2.
Alcalde M, Donoso MS, Carcfa-Diaz M, Pascasio JM, Narvaez I. Liver
dysfunction due to ciprofloxacin. Acta Gastroenterol Belg 1995; 58:
475-6.
Hautekeete ML, Kockx MM, Naegels S, Holvoet JK, Hubens H,
Kloppel G. Cholestatic hepatitis related to quinolones: a report of
two cases. J Hepatol 1995; 23: 759-60.
Villeneuve JP, Davies C, Côté J. Suspected ciprofloxacin-induced
hepatotoxicity. Ann Pharmacother 1995; 29: 257-9.
Labowitz JK, Silverman WB. Cholestatic jaundice induced by
ciprofloxacin. Dig Dis Sci 1997; 42: 192-4.
Jones SF, Smith RH. Quinolones may induce hepatitis. BMJ 1997;
314(7084): 869.
Contreras MA, Luna R, Mulero J, Andreu JL. Severe ciprofloxacininduced acute hepatitis. Eur J Clin Microbiol Infect Dis 2001; 20:
434-5.
Bataille L, Rahier J, Geubel A. Delayed and prolonged cholestatic
hepatitis with ductopenia after long-term ciprofloxacin therapy for
Crohn's disease. J Hepatol 2002; 37: 696-9.
Goetz M, Galle PR, Schwarting A. Non-fatal acute liver injury
possibly related to high-dose ciprofloxacin. Eur J Clin Microbiol
Infect Dis 2003; 22: 294-6.
Zaidi SA. Hepatitis associated with amoxicillin/clavulanic acid and/or
ciprofloxacin. Am J Med Sci 2003; 325: 31-3.
Zimpfer A, Propst A, Mikuz G, Vogel W, Terracciano L, Stadlmann S.
Ciprofloxacin-induced acute liver injury: case report and review of
literature. Virchows Arch 2004; 444: 87-9.
Thakur BS, Jain AK, Sirkar S, Joshi G, Joshi R. Ciprofloxacin-induced
cholestatic jaundice. Indian J Gastroenterol 2007; 26(1): 51-2.
Bhagirath KM. A case report of highly suspected ciprofloxacininduced hepatotoxicity. Turk J Gastroenterol 2008; 19: 204-6.
Dichiara AJ, Atkinson M, Goodman Z, Sherman KE. Ciprofloxacininduced acute cholestatic liver injury and associated renal failure.
Case report and review. Minerva Gastroenterol Dietol 2008; 54:
307-15.
Cholongitas E, Georgousaki C, Spyrou S, Dasenaki M. Ciprofloxacininduced acute cholestatic hepatitis. Ann Hepatol 2009; 8: 400-1.
Alan C, Koçoglu H, Ersay AR, Ertung Y, Kurt HA. Unexpected severe
hepatotoxicity of ciprofloxacine: two case reports. Drug Chem
Toxicol 2011 Apr; 34(2): 189-91.
Orman ES, Conjeevaram HS, Vuppalanchi R, Freston JW, Rochon J,
Kleiner DE, Hayashi PH; DILIN Research Group. Clinical and
histopathologic features of fluoroquinolone-induced liver injury. Clin
Gastroenterol Hepatol 2011; 9: 517-523
CLARITHROMYCIN
Yew WW, Chau CH, Lee J, Leung CW. Cholestatic hepatitis in a
patient who received clarithromycin therapy for a Mycobacterium
chelonae lung infection. Clin Infect Dis 1994; 18: 1025-6.
Cadranel JF, Bachmeyer C, Pras V, Bouraya D, Pourvillain S, Biour
M, Mougeot-Martin M. [Acute symptomatic cytolytic hepatitis
probably related to clarithromycin] Gastroenterol Clin Biol 1996;
20: 1034-5. French.
Shaheen N, Grimm IS. Fulminant hepatic failure associated with
clarithromycin. Am J Gastroenterol 1996; 91: 394-5.
Sousa C, Correia J, Santos J, Silvestre F, Bernardo A. [Cholestatic
hepatitis probably induced by clarithromycin] Gastroenterol Clin Biol
1997; 21: 632-3. French.
Baylor P, Williams K. Interstitial nephritis, thrombocytopenia,
hepatitis, and elevated serum amylase levels in a patient receiving
clarithromycin therapy. Clin Infect Dis 1999; 29: 1350-1
Fox JC, Szyjkowski RS, Sanderson SO, Levine RA. Progressive
cholestatic liver disease associated with clarithromycin treatment. J
Clin Pharmacol 2002; 42: 676-80.
Masiá M, Gutiérrez F, Jimeno A, Navarro A, Borrás J, Matarredona
J,
M a rtín A. Fulminant hepatitis and fatal toxic epidermal
-Hidalgo
necrolysis (Lyell disease)coincident with clarithromycin
administration in an alcoholic patient receiving disulfiram therapy.
Arch Intern Med 2002; 162: 474-6.
Christopher K, Hyatt PA, Horkan C, Yodice PC. Clarithromycin use
preceding fulminant hepatic failure. Am J Gastroenterol 2002; 97:
489-90.
Tietz A, Heim MH, Eriksson U, Marsch S, Teracciano L, Krähenbühl
S. Fulminant liver failure associated with clarithromycin. Ann
Giannattasio A, D'Ambrosi M, Volpicelli M, Iorio R. Steroid therapy
for a case of severe drug-induced cholestasis. Ann Pharmacother
2006; 40: 1196-9.
Caramaschi P, Mahamid H, Bambara LM, Biasi D. Liver impairment
after concomitant administration of bosentan and clarithromycin in
systemic sclerosis. Joint Bone Spine 2010; 77: 81-2.
Hydzik P, Gawlikowski T, Groszek B. [Drug-induced erythrodermia
complicated by multiorgan failure--case report]. Przegl Lek 2011;
68: 503-5. Polish.
Maggi P, Solarino B, Cassano P, Tattoli L, Leone A, Maselli E,
Angarano G. Fatal fulminant hepatitis following administration of
clarithromycin in a patient chronically treated with antipsycotic
drugs. Immunopharmacol Immunotoxicol. 2013; 35: 191-4.
CLINDAMYCIN
Elmore MF, Rink LD, Rissing JP. Clindamycin, endocarditis,
hepatotoxicity. Ann Intern Med 1973; 78: 779-80.
Craig JA. Jaundice in acute pustular psoriasis. Br Med J 1974; 3: 43.
Elmore M, Rissing JP, Rink L, Brooks GF. Clindamycin-associated
hepatotoxicity. Am J Med 1974; 57: 627-30.
Altraif I, Lilly L, Wanless IR, Heathcote J. Cholestatic liver disease
with ductopenia (vanishing bile duct syndrome) after administration
of clindamycin and trimethoprim-sulfamethoxazole. Am J
De Valle MB, Av Klinteberg V, Alem N, Olsson R, Björnsson E. Druginduced liver injury in a Swedish University hospital out-patient
hepatology clinic. Aliment Pharmacol Ther 2006; 24: 1187-95.
Aygun C, Kocaman O, Gurbuz Y, Senturk O, Hulagu S. Clindamycininduced acute cholestatic hepatitis. World J Gastroenterol 2007; 13:
5408-10.
pii: S0016-5085(15)00311-X.
Flores Sahagun JE, Ortiz Soto JA, Mendez T, Cardenas Ochoa EC,
Hernandez Flores G. [Stevens Johsnon Syndrome and clindamycinor chlorpheniramine-induced intrahepatic cholestatis]. Dermatology
Online J 2009; 15: 12.
Bawany MZ, Bhutto B, Youssef WI, Nawras A, Sodeman T. Acute
Liver Failure: An Uncommon Complication of Commonly Used
Medication. Am J Ther 2011; 20: 566-8.
Miller Quidley A, Bookstaver PB, Gainey AB, Gainey MD. Fatal
clindamycin-induced drug rash with eosinophilia and systemic
symptoms (DRESS) syndrome. Pharmacotherapy 2012; 32: e38792.
CLOPIDOGREL
Willens HJ. Clopidogrel-induced mixed hepatocellular and cholestatic
liver injury. Am J Ther 2000; 7: 317-8.
Beltran-Robles M, Marquez Saavedra E, Sanchez-MuñD, RomeroGomez M. Hepatotoxicity induced by clopidogrel. J Hepatol 2004;
40: 560-2.
Chau TN, Yim KF, Mok NS, Chan WK, Leung VK, Leung MF, Lai ST.
Clopidogrel-induced hepatotoxicity after percutaneous coronary
stenting. Hong Kong Med J 2005; 11: 414-6.
Höllmüller I, Stadlmann S, Graziadei I, Vogel W. Clinicohistopathological characteristics of clopidogrel-induced hepatic
injury: case report and review of literature. Eur J Gastroenterol
Hepatol 2006; 18: 931-4.
Wiper A, Schmitt M, Roberts DH.Clopidogrel-induced hepatotoxicity.
J Postgrad Med. 2008 Apr-Jun;54(2):152.
Blombery PA, Russell PA, Daffy JR. An unusual case of recurrent
fever, jaundice and right upper quadrant pain. Med J Aust 2009;
191: 396-7.
Goyal RK, Srivastava D, Lessnau KD. Clopidogrel-induced
hepatocellular injury and cholestatic jaundice in an elderly patient:
case report and review of the literature. Pharmacotherapy 2009;
29: 608-12.
Kastalli S, El Aïdli S, Zaïem A, ben Abdallah H, Daghfous R. Fatal
liver injury associated with clopidogrel. Fundam Clin Pharmacol
2010; 24: 433-5.
Durán Quintana JA, Jiménez Sáenz M, Montero AR, Gutiérrez MH.
[Clopidogrel probably induced hepatic toxicity]. Med Clin(Barc)
2002; 119: 37. Spanish.
Ramos Ramos JC, Sanz Moreno J, Calvo Carrasco L, García Díaz Jde
D. [Clopidogrel-induced hepatotoxicity]. Med Clin(Barc) 2003; 120:
156-7. Spanish.
Ng JA, Goldberg N, Tafreshi MJ. Clopidogrel-induced hepatotoxicity
and fever. Pharmacotherapy 2006; 26: 1023-6.
López-Vicente J, Garfia C, López-Medrano F, Yela C. [Hepatic
toxicity and clopidogrel-induced systemic inflammatory response
syndrome]. Rev Esp Cardiol 2007; 60: 323-4. Spanish.
Pisapia R, Abdeddaim A, Mariano A, Rianda A, Vincenzi L, Taibi C,
Baiocchini A, et al. Acute Hepatitis Associated With Clopidogrel: A
Case Report and Review of the Literature. Am J Ther 2013 Jul 17.
CLOXACILLIN
Enat R, Pollack S, Ben-Arieh Y, Livni E, Barzilai D. Cholestatic
jaundice caused by cloxacillin: macrophage inhibition factor test in
preventing rechallenge with hepatotoxic drugs. Br Med J 1980; 280:
982-3.
Williams CN, Malatjalian DA. Severe penicillin-induced cholestasis in
a 91-year-old woman. Dig Dis Sci 1981; 26: 470-3.
Lobatto S, Dijkmans BA, Mattie H, Van Hooff JP. Flucloxacillinassociated liver damage. Neth J Med. 1982; 25: 47-8.
Aderka D, Livni E, Salamon F, Weinberger A, Pinkhas J. Use of
macrophage inhibition factor and mast-cell degranulation tests for
diagnosis of cloxacillin-induced cholestasis. Am J Gastroenterol
1986; 81: 1084-6.
Konikoff F, Alcalay J, Halevy J. Cloxacillin-induced cholestatic
jaundice. Am J Gastroenterol 1986; 81: 1082-3.
Pascual J, Orofino L, Marcén R, Quereda C, Ortuño J. Cloxacillininduced cholestasis in a renal allograft patient with chronic
hepatitis. Am J Gastroenterol 1990; 85: 335-6.
Hepatol 1992; 15: 154-61.
Barrio J, Castiella A, Cosme A, López P, Fernández J, Arenas JI.
[Hepatotoxicity caused by cloxacillin]. Rev Esp Enferm Dig. 1997
Jul;89(7):559-60. Spanish.
CLOZAPINE
Brodowski L, Matusewicz W, Urbańska-Ryś H, Krykowski E. [Acute
bone marrow and liver damage during treatment with clozapine]
[Article in Polish] Pol Tyg Lek 1984; 39: 721-2.
Schmidt G, Borsch G, Muller K-M, Ricken D. [Clozapine-induced
cholestatic liver injury: a case report]. Dtsch med Wschr 1987; 112:
844-6.
Dorta G, Siebenmann R, Frohli P, Freytag P, Koelz HR. Clozapininduzierter cholestatistcher Ikterus: Ein Fallbericht. Z Gastroenterol
1989; 27: 388-90
Kellner M, Wiedemann K, Krieg JC, Berg PA. Toxic hepatitis by
clozapine treatment. Am J Psychiatry 1993; 150: 985-6.
Eggert AE, Crismon ML, Dorson PG, Taylor RL. Clozapine
rechallenge after marked liver enzyme elevation. J Clin
Psychopharmacol 1994; 14: 425-6.
Hovens JE, Vogtländer LM, Verhoeve HA, Thunnissen PL. [Liver cell
necrosis during administration of clozapine]. Ned Tijdschr Geneeskd
1994; 138: 363-5.
Thatcher GW, Cates M, Bair B. Clozapine-induced toxic hepatitis.
Am J Psychiatry 1995; 152: 296-7.
Worrall R, Wilson A, Gullen M. Dystonia and drug-induced hepatitis
in a patient treated with clozapine. Am J Psychiatry 1995; 152:
647-8.
MacFarlane B, Davies S, Mannan K, Sarsam R, Pariente D, Dooley J.
Fatal acute fulminant liver failure due to clozapine: a case report
and review of clozapine-induced hepatotoxicity. Gastroenterology
1997; 112: 1707-9.
Markowitz JS, Grinberg R, Jackson C. Marked liver enzyme
elevations with clozapine. J Clin Psychopharmacol 1997; 17: 70-1.
Wirshing WC, Ames D, Bisheff S, Pierre JM, Mendoza A, Sun A.
Hepatic encephalopathy associated with combined clozapine and
divalproex sodium treatment. J Clin Psychopharmacol 1997; 17:
120-1.
Thompson J, Chengappa KNR, Good CB, Baker RW, Kiewe RP,
Bezner J, Schooler NR. Hepatitis, hyperglycemia, pleural effusion,
eosinophilia, hematuria and proteinuria occurring early in clozapine
treatment. Int Clin Psychopharmacol 1998; 13: 95-8.
Jang SJ, Yi HT, Paek HJ, Lee SY. Clozapine-induced acute hepatitis.
J Korean Neuropsychiatr Assoc 1999; 38: 227-33. Korean.
Panagiotis B. Grand mal seizures with liver toxicity in a case of
clozapine treatment. J Neuropsychiatry Clin Neurosci 1999; 11:
117-8.
Larsen JT, Clemensen SV, Klitgaard NA, Nielsen B, Brøsen K.
[Clozapine-induced toxic hepatitis]. Ugeskr Laeger 2001; 163:
2013-4.
Bell C, Delisle M. [Non-alcoholic liver steatorrhea secondary to
clozapine]. Can J Psychiatry. 2004; 49: 575-6.
Erdogan A, Kocabasoglu N, Yalug I, Ozbay G, Senturk H.
Management of marked liver enzyme increase during clozapine
treatment: a case report and review of the literature. Int J
Psychiatry Med 2004; 34: 83-9.
Fong SY, Au Yeung KL, Tosh JM, Wing YK. Clozapine-induced toxic
hepatitis with skin rash. J Psychopharmacol 2005; 19: 107.
Freund N. [Psychiatric patient with elevated liver values].
Praxis(Bern 1994) 2006; 95: 549-50.
Luo D, McColl P, Walmsley R. Acute onset of ascites with clozapineinduced hepatitis. Intern Med J 2007; 37: 204-5.
Keane S, Lane A, Larkin T, Clarke M. Management of clozapinerelated hepatotoxicity. J Clin Psychopharmacol 2009; 29: 606-7.
Chang A, Krygier DS, Chatur N, Yoshida EM. Clozapine-induced fatal
fulminant hepatic failure: a case report. Can J Gastroenterol 2009;
23: 376-8.
Chaplin AC, Curley MA, Wanless IR. Re: Recent case report of
clozapine-induced acute hepatic failure. Can J Gastroenterol
2010; 24: 739-40; author reply 741.
Gómez Espín R, Sánchez Quiles I, Hallal H, Plaza J. [Acute
hepatocellular lesion after successive exposure to clozapine and
olanzapine in a patient with chronic hepatitis C infection].
Brown CA, Telio S, Warnock CA, Wong AH. Clozapine toxicity and
hepatitis. J Clin Psychopharmacol 2013; 33: 570-1.
Tucker P. Liver toxicity with clozapine. Aust N Z J Psychiatry 2013;
47: 975-6.
CYCLOPHOSFAMIDE
Aubrey DA. Massive hepatic necrosis after cyclophosphamide.
BrMed J 1970; 16: 588.
Walters D, Robinson RG, Dick-Smith JB, Corrigan AB, Webb J. Poor
response in two cases of juvenile rheumatoid arthritis to treatment
with cyclophosphamide. Med J Aust 1972; 2: 1070.
Gravanis MB, Majmudar BN. Clinicopathologic conference: a case of
multiple myeloma followed up for 15 years. South Med J 1976; 69:
233-8.
Jick H, Walker AM, Porter J. Drug-induced liver disease. J Clin
Pharmacol 1981; 21: 359-64.
Bacon AM, Rosenberg SA. Cyclophosphamide hepatotoxicity in a
patient with systemic lupus erythematosus. Ann Intern Med 1982;
97: 62-3.
Goldberg JW, Lidsky MD. Cyclophosphamide-associated
hepatotoxicity. South Med J. 1985; 78: 222-3.
Shaunak S, Munro JM, Weinbren K, Walport MJ, Cox TM.
Cyclophosphamide induced liver necrosis: A possible interaction
with azathioprine. Q J Med 1988; 67: 309-17.
Arai N, Kaneko H, Umeda M, Tsukahara T, Shirai T. [Non-Hodgkin's
lymphoma in an elderly patient complicated by cyclophosphamideinduced allergic hepatic dysfunction]. Nippon Ronen Igakkai Zasshi
1992; 29: 681-5. Japanese.
Cleland BD, Pokorny CS. Cyclophosphamide related hepatotoxicity.
Aust N Z J Med 1993; 23: 408.
Snyder LS, Heigh RI, Anderson ML. Cyclophosphamide induced
hepatotoxicity in a patient with Wegener's granulomatosis. Mayo
Clin Proc 1993; 68: 1203-4.
Du LT, Rigaud D, Papo T, Godeau P. Cyclophosphamide-induced
hepatitis in Wegener's granulomatosis. Mayo Clin Proc 1994; 69:
912-3.
Modzelewski JR Jr, Daeschner C, Joshi VV, Mullick FG, Ishak KG.
Veno-occlusive disease of the liver induced by low-dose
cyclophosphamide. Mod Pathol 1994; 7: 967-72.
Gustafsson LL, Eriksson LS, Dahl ML, Eleborg L, Ericzon BG, Nyberg
AN. Cyclophosphamide-induced acute liver failure requiring
transplantation in a patient with genetically deficient debrisoquine
metabolism: a causal relationship? J Intern Med 1996; 240: 311-4.
Mok CC, Wong WM, Shek TW, Ho CT-K, Lau C-S, Lai C-L.
Cumulative hepatotoxicity induced by continuous low-dose
cyclophosphamide therapy. Am J Gastroenterol 2000; 95: 845-6.
Rosenthal AK, Klausmeier M, Cronin ME, McLaughlin JK. Hepatic
angiosarcoma occurring after cyclophosphamide therapy: case
report and review of the literature. Am J Clin Oncol 2000; 23: 5813.
Muratori L, Ferrari R, Muratori P, Granito A, Bianchi FB. Acute icteric
hepatitis induced by a short course of low-dose cyclophosphamide
in a patient with lupus nephritis. Dig Dis Sci 2005; 50: 2364-5.
Akay H, Akay T, Secilmis S, Kocak Z, Donderici O. Hepatotoxicity
after low-dose cyclophosphamide therapy. South Med J 2006; 99:
1399-400.
pii: S0016-5085(15)00311-X.
Patel A, Patel A, Patel S, Jalandhara P, Thakor P. Cyclophosphamide
therapy in granulomatous hepatitis: cure or culprit? Am J Ther
2009; 16: 367-70.
Martínez-Gabarrón M, Enríquez R, Sirvent AE, García-Sepulcre M,
Millán I, Amorós F. Hepatotoxicity following cyclophosphamide
treatment in a patient with MPO-ANCA vasculitis. Nefrologia 2011;
31: 496-8.
2013; 144: 1419-25.
Subramaniam SR, Cader RA, Mohd R, Yen KW, Ghafor HA. Lowdose cyclophosphamide-induced acute hepatotoxicity. Am J Case
Rep 2013; 14: 345-9.
CYPROTERONE
Meijers WH, Willemse PH, Sleijfer DT, Mulder NH, Grond J.
Hepatocellular damage by cyproterone acetate. Eur J Cancer Clin
Oncol. 1986 Sep;22(9):1121-2.
Lévesque H, Trivalle C, Manchon ND, Vinel JP, Moore N, Hémet J,
Courtois H, Bercoff E, Bourreille J.Fulminant hepatitis due to
cyproterone acetate. Lancet. 1989 Jan 28;1(8631):215-6.
Dore B, Orget J, Irani J, Aubert J. [Hepatitis after treatment with
cyproterone acetate. Apropos of a case]. J Urol (Paris).
1990;96(3):169-71. French.
Blake JC, Sawyerr AM, Dooley JS, Scheuer PJ, McIntyre N. Severe
hepatitis caused by cyproterone acetate. Gut. 1990 May;31(5):5567.
Parys BT, Hamid S, Thomson RG. Severe hepatocellular dysfunction
following cyproterone acetate therapy. Br J Urol. 1991
Mar;67(3):312-3. N=3
Antoni M, Bourlière M, Toullec J, Maillot A, Botta-Fridlund D,
Gauthier A. [Fatal subfulminant hepatitis caused by cyproterone
acetate]. Gastroenterol Clin Biol. 1991;15(10):772-3. French.
Hassler P, Duchêne R. [Hepatotoxicity of cyproterone acetate].
Rev Med Interne. 1992 May-Jun;13(3):245. French.
Drakos PE, Gez E, Catane R. Hepatitis due to cyproterone acetate.
Eur J Cancer. 1992;28A(11):1931-2.
Roila F, Crinò L, Carloni G, Natalini G. Cyproterone acetate:
hepatotoxicity and prostatic cancer treatment. Ann Oncol. 1993
Sep;4(8):701.
Bressollette L, Dubois A, Carlhant D, Morand C, Mottier D, Riche C.
[Fatal hepatitis caused by cyproterone acetate].
Therapie. 1994 Mar-Apr;49(2):153. French.
Pinganaud G, Chaslerie A, Bourdel Marchasson I, Decamps A,
Manciet G, Emeriau JP. Cyproterone-induced hepatotoxicity.
Ann Pharmacother. 1995 Jun;29(6):634.
Hirsch D, Kovatz S, Bernheim J, Shenkman L. Fatal fulminant
hepatitis from cyproterone acetate. Isr J Med Sci. 1994
Mar;30(3):238-40.
Castellani P, Bernardini D, Renou C, Zamora C, Portal I, Gauthier A,
et al. Fatal to sub-fulminant hepatitis caused by cyproterone
acetate. A new case. Gastroenterol Clin Biol 1996; 20: 915-916.
Murphy BJ, Collins BJ. Severe hepatitis and liver failure induced by
cyproterone acetate.Aust N Z J Med. 1996 Oct;26(5):724.
Ruiz-Rebollo ML, Polo F, Palenzuela R, Moretó M.[Severe acute
hepatitis due to cyproterone]. Gastroenterol Hepatol. 1997 AugSep;20(7):385. Review. Spanish.
Lombardi A, Ferrazza P, Castaldi F, Covotta L, Tesoriere A, Urbano
V, Midiri G. [Acute hepatic necrosis in a patient treated with
cyproterone acetate]. G Chir. 1998 Apr;19(4):161-3. Italian.
Friedman G1, Lamoureux E, Sherker AH. Fatal fulminant hepatic
failure due to cyproterone acetate. Dig Dis Sci. 1999
Jul;44(7):1362-3.
Giordano N1, Nardi P, Santacroce C, Geraci S, Gennari C. Acute
hepatitis induced by cyproterone acetate. Ann Pharmacother. 2001
Sep;35(9):1053-5.
Manolakopoulos S, Bethanis S, Armonis A, Economou M, Avgerinos
A, Tzourmakliotis D. Toxic hepatitis after sequential administration
of flutamide and cyproterone acetate. Dig Dis Sci. 2004
Mar;49(3):462-5.
Savidou I, Deutsch M, Soultati AS, Koudouras D, Kafiri G, Dourakis
SP.Hepatotoxicity induced by cyproterone acetate: a report of three
cases. World J Gastroenterol. 2006 Dec 14;12(46):7551-5.
Miquel M, Soler A, Vaqué A, Ojanguren I, Costa J, Planas
R.Suspected cross-hepatotoxicity of flutamide and cyproterone
acetate. Liver Int. 2007 Oct;27(8):1144-7.
Vodička M, Sálek T, Röderová E, Cerný D. [Hepatotoxicity induced
by cyproteron acetate in the prostate carcinoma treatment - a case
report]. Klin Onkol. 2013;26(1):47-8.
Abenavoli L, Milic N, Beaugrand M. Severe hepatitis induced by
cyproterone acetate: role of corticosteroids. A case report.
Ann Hepatol. 2013 Jan-Feb;12(1):152-5.
Kim JH, Yoo BW, Yang WJ. Hepatic failure induced by cyproterone
acetate: A case report and literature review.
Can Urol Assoc J. 2014 May;8(5-6):E458-61
DACARBAZINE
Frosch PJ, Czarnetzki BM, Macher E, Grundmann E, Gottschalk I.
Hepatic failure in a patient treated with dacarbazine (DTIC) for
malignant melanoma. J Cancer Res Clin Oncol 1979; 95: 281-6.
Houghton AN, Shafi N, Rickles FR. Acute hepatic vein thrombosis
occurring during therapy for Hodgkin's disease: a case report.
Cancer 1979; 44: 2324-9.
Asbury RF, Rosenthal SN, Descalzi ME, Ratcliffe RL, Arseneau JC.
Hepatic veno-occlusive disease due to DTIC. Cancer 1980; 45:
2670-4.
Balda BR, Bassermann R. DTIC therapie und Budd-Chiari-Sydrom.
Munch Med Wschr 1980; 122: 792-4.
Runne U, Doepfmer K, Antz H, Groth W, Feaux de Lacrois W. BuddChiari-Syndrom unter Dacarbazin. Dtsch Med Wochenschr 1980;
105: 230-3.
Voigt H, Caselitz J, Jänner M. [Veno-occlusive syndrome with acute
liver dystrophy following dacarbazine therapy of malignant
melanoma]. Klin Wochenschr 1981; 59: 229-36. German.
Czarnetzki BM, Macher E. DTIC(dacarbazine)-induced hepatic
damage. Possible pathogenesis and prevention. Arch Dermatol Res
1981; 270: 375-6.
Greenstone MA, Dowd PM, Mikhailidis DP, Scheuer PJ. Hepatic
vascular lesions associated with dacarbazine treatment. Br Med
J(Clin Res Ed) 1981; 282: 1744-5.
Doering CH, Pickartz H, Orfanos CE, Altenahr E. [Dacarbazine in
malignant melanoma. Rare, severe side-effect: Budd-Chiarisyndrome]. Z Hautkr 1982; 57: 971-80. German.
Swenson-Beck H, Trettel WH. Budd-Chiari-Syndrom bei DTICtherapie. Hautarzt 1982; 33: 30-1.
Feaux de Lacroix W, Runne U, Hauk H, Doepfmer K, Groth W,
Wacker D. Acute liver dystrophy with thrombosis of hepatic veins: a
fatal complication of dacarbazine treatment. Cancer Treat Rep
1983; 67: 779-84.
Dancygier H, Runne U, Leuschner U, Milbradt R, Classen M.
Dacarbazine (DTIC)-induced human liver damage: light and
electron-microscopic findings. Hepatogastroenterology 1983; 30:
93-5.
Sotaniemi EA, Sutinen S, Arranto AJ, Sutinen S, Sotaniemi KA,
Lehtola J, Pelkonen RO. Liver damage in nurses handling cytostatic
agents. Acta Med Scand 1983; 214: 181-9.
Erichsen C, Jönsson PE. Veno-occlusive liver disease after
dacarbazine therapy(DTIC) for melanoma. J Surg Oncol 1984; 27:
268-70.
Leyh F, Winzer M, Weber M, Hypa F. Budd-Chiari syndrome
following dacarbazine therapy of malignant melanoma--an
avoidable complication? Z Hautkr 1985; 60: 961-72.
Paschke R, Heine M. Pathophysiological aspects of dacarbazineinduced human liver damage. Hepatogastroenterology 1985; 32:
273-5.
Quinio P, Bouche O, Lambolais C, Savry C, Cartier H, Egreteau JP.
Fatal hepatic toxicity of DTIC: a new case. Intens Care Med 1997;
23: 1099-1102.
Herishanu Y, Lishner M, Kitay-Cohen Y. The role of glucocorticoids
in the treatment of fulminant hepatitis induced by dacarbazine.
Anticancer Drugs 2002; 13: 177-9.
Bessone F, et al. Cytroperone acetate induces a broad spectrum of
acute liver damage including corticosteroid-responsive hepatitis:
report of 22 cases. In press.
DICLOXACILLIN
Kleinman MS, Presberg JE. Cholestatic hepatitis after dicloxacillinsodium therapy. J Clin Gastroenterol 1986; 8: 77-8
Saab S, Venkataramani A, Yao F.Possible granulomatous hepatitis
after dicloxacillin therapy. J Clin Gastroenterol. 1996
Mar;22(2):163-4.
Hepatol 1992; 15: 154-61.
Siegmund JB, Tarshis AM. Prolonged jaundice after dicloxacillin
therapy. Am J Gastroenterol 1993; 88: 1299-300.
2013; 144: 1419-25.
DOXORUBICIN
Rodriguez V, Bodey GP, McCredie KB, Freireich EJ, Minow RA, Casey
JH, Luna M. Combination 6-mercaptopurine-adriamycin in refractory
adult acute leukemia. Clin Pharmacol Ther 1975; 18: 462-6.
Kun LE, Camitta BM. Hepatopathy following irradiation and
adriamycin. Cancer 1978; 42: 81-4.
Avilés A, Herrera J, Ramos E, Ambriz R, Aguirre J, Pizzuto J. Hepatic
injury during doxorubicin therapy. Arch Pathol Lab Med 1984; 108:
912-3.
Patakfalvi A, Gelencsér E, Sípos J. Drug hepatitis of cholestatic type
in association with a FAC-regimen for breast cancer. Acta Med Hung
1987; 44: 377-85.
DULOXETINE
Hanje AJ, Pell LJ, Votolato NA, Frankel WL, Kirkpatrick RB. Case
report: fulminant hepatic failure involving duloxetine hydrochloride.
Clin Gastroenterol Hepatol 2006; 4: 912-7.
Vuppalanchi R, Hayashi PH, Chalasani N, Fontana RJ, Bonkovsky H,
Saxena R, Kleiner D, et al; Drug-Induced Liver Injury Network
(DILIN). Duloxetine hepatotoxicity: a case-series from the druginduced liver injury network. Aliment Pharmacol Ther 2010; 32:
1174-83.
Park YM, Lee BH, Lee HJ, Kang SG. Cholestatic jaundice induced by
duloxetine in a patient with major depressive disorder. Psychiatry
Investig 2010; 7: 228-30.
Kang SG, Park YM, Lee HJ, Yoon B. Duloxetine-induced liver injury
in patients with major depressive disorder. Psychiatry Investig
2011; 8: 269-71.
Gimenez C, Guce G, Lingisetty C, Bernhardt L. Severe INR elevation
related to duloxetine use: a case report. Psychosomatics 2011; 52:
583-5.
ENALAPRIL/ENALAPRILAT
Adriansson M, Björnsson S.[Treatment with enalapril causing
leukopenia with septicemia and affected liver]. Lakartidningen.
1987 Apr 8;84(15):1270. Swedish.
Martin T, Taupignon A, Graf E, Perrin D.[Pancreatitis and hepatitis in
a patient treated with enalapril maleate. A case report].
Therapie. 1989 Nov-Dec;44(6):449-50. French.
Rosellini SR, Costa PL, Gaudio M, Saragoni A, Miglio F.
Hepatic injury related to enalapril. Gastroenterology. 1989
Sep;97(3):810.
Todd P, Levison D, Farthing MJ.Enalapril-related cholestatic
jaundice. J R Soc Med. 1990 Apr;83(4):271-2.
Kitai E, Sandiuk A, Zalewski S.Enalapril-induced immunologic
impairment of hepatic function. J Fam Pract. 1991 Sep;33(3):3012.
Hagley MT, Benak RL, Hulisz DT. Suspected cross-reactivity of
enalapril- and captopril-induced hepatotoxicity. Ann Pharmacother.
1992 Jun;26(6):780-1.
Valle R, Carrascosa M, Cillero L, Perez-Castrillon JL.
Enalapril-induced hepatotoxicity.Ann Pharmacother. 1993
Nov;27(11):1405.
Hürlimann R, Binek J, Oehlschlegel C, Hammer B.[Enalapril
(Reniten)-associated toxic hepatitis].Schweiz Med Wochenschr.
1994 Jul 23;124(29):1276-80. German.
Quílez C, Palazón JM, Chuliá T, Córdoba YC.
[Hepatoxicity by enalapril]. Gastroenterol Hepatol. 1999
Feb;22(2):113-4. Spanish.
Jeserich M, Ihling C, Allgaier HP, Berg PA, Heilmann C.
Acute liver failure due to enalapril. Herz. 2000 Nov;25(7):689-93.
González de la Puente MA, Calderón E, Espinosa R, Rincón M, Varela
JM. Fatal hepatotoxicity associated with enalapril.
Ann Pharmacother. 2001 Nov;35(11):1492.
Muela Molinero A, Linares Torres P, Domínguez Carbajo AB, Olcoz
Goñi JL. [Enalapril induced cholestasic hepatitis].
An Med Interna. 2002 Sep;19(9):492-3. Spanish.
Baş V, Erkan T, Calişkan S, Sever L, Kasapçopur O, Ozbay G, ArIsoy
N.Toxic hepatitis due to enalapril in childhood.
Pediatr Int. 2003 Dec;45(6):755-7. No abstract available.
Macías FM, Campos FR, Salguero TP, Soria PT, Carrasco FG, Martín
JM. Ductopenic hepatitis related to Enalapril.
J Hepatol. 2003 Dec;39(6):1091-2.
Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J.
[Epub ahead of print].
da Silva GH, Alves AV, Duques P, Sevá-Pereira T, Soares EC,
Escanhoela CA. Acute hepatotoxicity caused by enalapril: a case
report. J Gastrointestin Liver Dis. 2010 Jun;19(2):187-90.
Björnsson E, Olsson R. Outcome and prognostic markers in severe
drug-induced liver disease. Hepatology 2005; 42: 481-489.
ENFLURANE
Van der Reis L, Askin SJ, Frecker GN, Fitzgerald WJ. Letter: Hepatic
necrosis after enflurane anesthesia. JAMA 1974; 227: 76.
Denlinger JK, Lecky JH, Nahrwold ML. Hepatocellular dysfunction
without jaundice after enflurane anesthesia. Anesthesiology 1974;
41: 86-7.
Douglas HJ, Eger EI 2nd, Biava CG, Renzi C. Hepatic necrosis
associated with viral infection after enflurane anesthesia. N Engl J
Med 1977; 296: 553-5.
Ona FV, Patanella H, Ayub A. Hepatitis associated with enflurane
anesthesia. Anesth Analg 1980; 59: 146-9.
Lewis JH, Zimmerman HJ, Ishak KG, Mullick FG. Enflurane
hepatotoxicity. A clinicopathologic study of 24 cases. Ann Intern
Med 1983; 98: 984-92.
Sigurdsson J, Hreidarsson AB, Thjodleifsson B. Enflurane hepatitis.
A report of a case with a previous history of halothane hepatitis.
Acta Anaesthesiol Scand 1985; 29: 495-6.
ETHANERCEPT
DE, Serrano J, Rochon J, Fontana RJ, Bonacini M.Liver injury from
tumor necrosis factor-α antagonists: analysis of thirty-four
cases.Clin Gastroenterol Hepatol. 2013 May;11(5):558-564.e3.
Ethanercept=4
van Denderen JC, Blom GJ, van der Horst-Bruinsma IE, Dijkmans
BA, Nurmohamed MT. Elevated liver enzymes in patients with
ankylosing spondylitis treated with etanercept. Clin Rheumatol.
2012 Dec;31(12):1677-82.
Titos Arcos JC, Hallal H, Robles M, Andrade RJ. Recurrent
hepatotoxicity associated with etanercept and adalimumab but not
with infliximab in a patient with rheumatoid arthritis. Rev Esp
Enferm Dig. 2012 May;104(5):282-4.
Iwamoto M, Minota S.Successful treatment with very lowdose etanercept in a patient with etanerceptinduced liver dysfunction. Rheumatol Int. 2011 Apr;31(4):561-2.
Rodríguez Gil FJ, Martínez Crespo JJ, García Belmonte D, Nicolás de
Prado I, de Prado Serrano R.[Jaundice in a patient treated with
etanercept]. Gastroenterol Hepatol. 2009 Oct;32(8):584-5.
Harada K, Akai Y, Koyama S, Ikenaka Y, Saito Y. A case of
autoimmune hepatitis exacerbated by the administration of
etanercept in the patient with rheumatoid arthritis. Clin Rheumatol.
2008 Aug;27(8):1063-6.
Fathalla BM, Goldsmith DP, Pascasio JM, Baldridge A. Development
of autoimmune hepatitis in a child with systemic-onset juvenile
idiopathic arthritis during therapy with etanercept. J Clin Rheumatol
2008; 14: 297-8.
Farah M, Al Rashidi A, Owen DA, Yoshida EM, Reid
GD.Granulomatous hepatitis associated with etanercept therapy. J
Rheumatol. 2008 Feb;35(2):349-51
Leak AM, Rincon-Aznar B. Hepatotoxicity associated
with etanercept in psoriatic arthritis.J Rheumatol. 2008
Nov;35(11):2286-7. 4 patients
R, Ludviksson BR, Gudbjörnsson B, Olafsson O. The risk of druginduced liver injury from Tumor Necrosis Factor (TNF)-alphaantagonists. Clin Gastroenterol Hepatol. 2014; 14: S1542-3565.
ETHIONAMIDE
Moulding TS Jr, Goldstein S. Hepatotoxicity due to ethionamide. Am
Rev Respir Dis 1962; 86: 252-5.
Phillips S, Tashman H. Ethionamide jaundice. Am Rev Respir Dis
1963; 87: 896-8.
Lees AW. Jaundice due to ethionamide. Br J Dis Chest 1963; 57:
158-61.
ETHIONAMIDE AND HEPATOTOXICITY: A CLINICAL STUDY.
EL-KHOURY SA, DUNMORE LA Jr. Med Ann Dist Columbia. 1964
Jan;33:15-7.
Conn HO, Binder HJ, Orr HD. Ethionamide-induced hepatitis. A
review with a report of an additional case. Am Rev Respir Dis 1964;
90: 542-52.
Nagasawa J, Mikami R. The side effects of ethionamide with
emphasis on its hepatotoxicity. Bull Int Union Tuberc 1964; 35:
139-41.
De Voogd A. [Development of a benign catarrhal jaundice in a child
subjected to ethionamide treatment]. Rev Tuberc Pneumol(Paris)
1964; 28: 357-60. French.
Gupta DK, Mital OP, Agarwala MC.Hepatic injury due to ethionamide
(1314-TH) and prothionamide (1321-TH). J Assoc Physicians India.
1975 Feb;23(2):147-51.
See A, Hervio P, Bouvry M. [The hepatotoxicity of ethionamide
remains a topical subject. Apropos of a case of acute hepatitis]. Ann
Gastroenterol Hepatol(Paris) 1986; 22: 129-30. French.
FELBAMATE
O'Neil MG, Perdun CS, Wilson MB, McGown ST, Patel S. Felbamateassociated fatal acute hepatic necrosis. Neurology 1996; 46: 14579.
Pirmohamed M, Leeder SJ. Anticonvulsant agents. In, Kaplowitz N,
DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam:
Elsevier, 2013: pp 423-41.
Pellock JM. Felbamate in epilepsy therapy: evaluating the risks.
Drug Saf 1999; 21: 225-39.
FENOFIBRATE
Aron E, Metman EH, Bougnoux P. [Hepatitis due to procetofene? 1
case]. Nouv Presse Med 1979; 8: 783. French.
Couzigou P, Boutillier P, Boisseau C, Faucher P, De Mascarel A,
Amouretti M, Beraud C, et al. [Drug-induced hepatitis due to
fenofibrate] Therapie 1980; 35: 403.
Vachon JM. [Hepatitis caused by procetofen]. Nouv Presse Med
1980; 9: 2740. French.
Massen H, Furet Y. [Hepatitis caused by fenofibrate] Cah
Anesthesiol 1986; 34: 249-50.
Rigal J, Furet Y, Autret E, Breteau M. [Severe mixed hepatitis
caused by fenofibrate? A review of the literature apropos of a case]
Rev Med Interne 1989; 10: 65-7.
Bravo ML, Azagra R, Aguyé A, Freixas M. [Acute hepatitis: an
adverse reaction to fenofibrate treatment] Aten Primaria 1992; 10:
697-8.
Lelouch S, Pelletier G, Sinico M, Ducreux M, Etienne JP.
[Fenofibrate-induced acute hepatitis with pseudo-cholangitis]
Chatrenet P, Regimbeau C, Ramain JP, Penot J, Bruandet P.
[Chronic active cirrhogenic hepatitis induced by fenofibrate]
Bernard PH, Lamouliatte H, Le Bail B, Bioulac-Sage P, Quinton A,
Balabaud C. [Chronic active hepatitis associated with antinuclear
antibodies induced by fenofibrate] Gastroenterol Clin Biol 1994; 18:
1048-9.
Lepicard A, Mallat A, Zafrani ES, Dhumeaux D. Atteinte chronique
des canaux biliares interlobulaires induite par le fenofibrate.
Rouhier ML, Rifflet H, Rifflet I, Oberti F, Vuillemin E, Chevailler A,
Calès P. [Painful acute liver involvement related to ingestion of
fenofibrate] Gastroenterol Clin Biol 1996; 20: 1137-8.
Ganne-Carrié N, de Leusse A, Guettier C, Castera L, Levecq H,
Bertrand HJ, Plumet Y, et al. [Autoimmune hepatitis induced by
fibrates] Gastroenterol Clin Biol 1998; 22: 525-9.
Fartoux-Heymann L, Narcy-Lambare B, Labayle D, Fischer D. [Acute
hepatitis and drug dermatitis due to fenofibrate(Secalip)] Ann Med
Interne (Paris) 2001; 152: 353-4.
Punthakee Z, Scully LJ, Cuindi MM, Ooi TC. Liver fibrosis attributed
249-54
Pichon N, Vincensini JF, Rozière A, Labrousse F, Sautereau D,
Pillegand B. [Acute cytolytic and cholestatic hepatitis induced by
fenofibrate] Gastroenterol Clin Biol 2003; 27: 947-9.
Ho CY, Kuo TH, Chen TS, Tsay SH, Chang FY, Lee SD. Fenofibrateinduced acute cholestatic hepatitis. J Chin Med Assoc 2004; 67:
245-7.
Ahmed F, Petrovic L, Rosen E, Gonzalez R, Jacobson IM.
Fenofibrate-induced cirrhosis. Dig Dis Sci 2005; 50: 312-3.
Dohmen K, Wen CY, Nagaoka S, Yano K, Abiru S, Ueki T, Komori A,
et al. Fenofibrate-induced liver injury. World J Gastroenterol 2005;
11: 7702-3.
Lucena MI, Andrade RJ, Vicioso L, Gonzalez FJ, Pachkoria K, GarciaMunoz B. Prolonged cholestasis after raloxifene and fenofibrate
interaction: a case report. World J Gastroenterol 2006; 12: 5244-6.
Andrade RJ, Lucena MI, Kaplowitz N, García-Muņoz B, Borraz Y,
Tudesq N, Bentournes M. [Hepatitis induced by fibrates] Ann Biol
Clin(Paris) 2006; 64: 515-6. French.
pii: S0016-5085(15)00311-X.
Hajdu D, Aiglová K, Vinklerová I, Urbánek K. Acute cholestatic
hepatitis induced by fenofibrate. J Clin Pharm Ther 2009; 34: 599602.
FLUCONAZOLE
Franklin IM, Elias E, Hirsch C. Fluconazole-induced jaundice. Lancet
1989; 336: 565.
Wells C, Lever AM. Dose-dependent fluconazole hepatotoxicity
proven on biopsy and rechallenge. J Infect 1992; 24: 111-2.
Gearhart M. Worsening of liver function with fluconazole and review
of azole antifungal hepatotoxicity. Ann Pharmacother 1994; 28:
1177-81.
Trujillo MA, Galgiani JN, Sampliner RE. Evaluation of hepatic injury
arising during fluconazole therapy. Arch Intern Med 1994; 154:
102-4.
Jacobson MA, Hanks DK, Ferrell LD. Fatal acute hepatic necrosis due
to fluconazole. Am J Med 1994; 96: 188-90
Guillaume MP, De Prez C, Cogan E. Subacute mitochondrial liver
disease in a patient with AIDS: possible relationship to prolonged
fluconazole administration. Am J Gastroenterol 1996; 91: 165-8.
Bronstein JA, Gros P, Hernandez E, Larroque P, Molinié C. Fatal
acute hepatic necrosis due to dose-dependent fluconazole
hepatotoxicity. Clin Infect Dis 1997; 25: 1266-7.
Schöttker B, Dösch A, Kraemer D. Severe hepatotoxicity after
application of desloratadine and fluconazole. Acta Haematol 2003;
110: 43-44.
Su FW, Perumalswami P, Grammer LC. Acute hepatitis and rash to
fluconazole. Allergy 2003; 58: 1215-6.
Linnebur SA, Parnes BL. Pulmonary and hepatic toxicity due to
nitrofurantoin and fluconazole treatment. Ann Pharmacother 2004;
38: 612-6.
Björnsson E, Davidsdottir L. The long-term follow-up after
idiosyncratic drug-induced liver injury with jaundice. J Hepatol
2009; 50: 511-7.
Kao WY, Su CW, Huang YS, Chou YC, Chen YC, Chung WH, Hou MC,
et al. Risk of oral anti-fungal agent-induced liver injury in
Taiwanese. Br J Clin Pharmacol 2014; 77: 180-9.
FLUVASTATIN
Gascon A, Zabala S, Iglesuas E. Acute cholestasis during long-term
treatment with fluvastatin in a nephrotic patient. Nephrol Dial
Transplant 1999; 14: 1038.
Hartleb M, Biernat L, Kochel A. Drug-induced liver damage – a
three-year study of patients from one gastroenterological
department. Med Sci Monit 2002; 8: CR292-6.
Castiella A, Fernanzez J, Zapata E. Autoimmune hepatitis after
treatment with fluvastatin. Liver Int 2007; 27: 592.
Akoglu H, Yilmaz K, Kirkpantur A, Arici M, Altun B, Turgan C.
Combined organ failure with combination antihyperlipidemic
treatment: a case of hepatic injury and acute renal failure. Ann
pii: S0016-5085(15)00311-X.
Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury
associated with statins. Semin Liver Dis 2009; 29: 412-22.
Hepatol 2012; 56:374-80.
GLIBENCLAMIDE/GLYBURIDE
Clarke BF, Campbell IW, Ewing DJ, Beveridge GW, MacDonald MK.
Generalized hypersensitivity reaction and visceral arteritis with fatal
outcome during glibenclamide therapy. Diabetes 1974; 23: 739-42.
Ingelmo M, Vivancos J, Bruguera M, Sierra J, Balcells A.
[Hypersensitivity vasculitis and granulomatous hepatitis induced
by glybenclamide: a case report]. Med Clin (Barcelona) 1980; 75:
306-8.
Wongpaitoon V, Russell RF, Mills PR, Patrick RS. Intrahepatic
cholestasis and cutaneous bullae associated with glibenclamide
therapy. Postgrad Med J 1981; 57: 244
Goodman RC, Dean PJ, Radparvar A, Kitabchi AE. Glyburide-induced
hepatitis. Ann Intern Med 1987; 106: 837-9.
Meadow P, Tullio CJ. Glyburide-induced hepatitis. Clin Pharm 1989;
8: 470.
van Basten JP, van Hoek B, Zeijen R, Stockbrügger R. Glyburideinduced cholestatic hepatitis and liver failure. Case-report and
review of the literature. Neth J Med 1992; 40: 305-7
Saw D, Pitman E, Maung M, Savasatit P, Wasserman D, Yeung CK.
Granulomatous hepatitis associated with glyburide. Dig Dis Sci
1996; 41: 322-5.
Pérez-Roldán F, Aguirre A, Bañares R, Casado M, González-Asanza
C, Alvarez E, Clemente G. [Cholestatic hepatitis caused by
glybenclamide in a patient with hepatitis C virus]. Rev Esp Enf
Digest 1995; 87: 174-6.
Krivoy N, Zaher A, Yaacov B, Alroy G. Fatal toxic intrahepatic
cholestasis secondary to glibenclamide. Diabetes Care 1996; 19:
385-6.
Petrogiannopoulos C, Zacharof A. Glibenclamide and liver disease.
Diabetes Care 1997; 20: 1215.
Tholakanahalli VN, Potti A, Heyworth MF. Glibenclamide-induced
cholestasis. West J Med 1998; 168: 274-7.
pii: S0016-5085(15)00311-X.
HALOPERIDOL
Zimmerman HJ. Neuroleptic drugs. In, Zimmerman HJ.
Hepatotoxicity: the adverse effects of drugs and other chemicals on
the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 483-91.
Fuller CM, Yassinger S, Donlon P, Imperato TJ, Ruebner B.
Haloperidol-induced liver disease. West J Med 1977; 127: 515-8.
Dincsoy HP, Saelinger DA. Haloperidol-induced chronic cholestatic
liver disease. Gastroenterol 1982; 83: 694-700.
HEPARINS
Sonnenblick M, Oren A, Jacobsonn W. Hyper-transaminasemia with
heparin therapy. Br Med J. 1975 Jul 12;3(5975):77.
Olsson R, Korsan-Bengtsen BM, Korsan-Bengtsen K, Lennartsson J,
Waldenström J. Serum aminotransferases after low-dose heparin
treatment. Short communication. Acta Med Scand.
1978;204(3):229-30.
Olsson R, Leonhardt T.Cholestatic liver reaction during heparin
therapy. J Intern Med. 1991 May;229(5):471-3.
Pipek R, Avizohar O, Levy Y.Transient hepatic dysfunction in two
brothers receiving heparin and streptokinase: a genetic
predisposition? Int J Cardiol. 1994 Oct;46(3):299-301. N=2
Tison T, Dazzi F, Vianello F, Radossi P, Girolami A. Marked but
transitory elevation of hepatic transaminases after subcutaneous
calcium heparin administration. Acta Haematol. 1994;92(1):54.
Manfredini R, Boari B, Regoli F, Gallerani M. Cholestatic liver
reaction and heparin therapy. Arch Intern Med. 2000 Nov
13;160(20):3166.
Barreiro López B, Canet JJ, Ochoa de Echaguen Aguilar A.
[Liver toxicity from heparin]. An Med Interna. 2000 Mar;17(3):164.
Spanish. N=1
AL-Mekhaizeem KA, Sherker AH. Heparin-induced hepatotoxicity.
Can J Gastroenterol. 2001 Aug;15(8):527-30.
Meier Y, Cavallaro M, Roos M, Pauli-Magnus C, Folkers G, Meier PJ,
Fattinger K.Incidence of drug-induced liver injury in medical
inpatients. Eur J Clin Pharmacol. 2005 Apr;61(2):135-43.
Pannicke N, Pollok JM, Kluge S, Petzoldt M.Heparin-induced
thrombocytopenia associated with acute liver graft failure. BMJ Case
Rep. 2012 Nov 27;2012.
IMATINIB
Lin NU, Sarantopoulos S, Stone JR, Galinsky I, Stone RM, Deangelo
DJ, Soiffer RJ. Fatal hepatic necrosis following imatinib mesylate
therapy. Blood 2003; 102: 3455-6.
James C, Trouette H, Marit G, Cony-Makhoul P, Mahon FX.
Histological features of acute hepatitis after imatinib mesylate
treatment. Leukemia 2003; 17: 978-9.
Rocca P, El Jastimi S, Troncy J, Scoazec JY, Boucher A, Vial T, Trepo
C, et al. [Imatinib mesylate-induced acute cytolytic hepatitis].
Kikuchi S, Muroi K, Takahashi S, Kawano-Yamamoto C, Takatoku M,
Miyazato A, Nagai T, et al. Severe hepatitis and complete molecular
response caused by Imatinib mesylate: possible association of its
serum concentration and clinical outcomes. Leuk Lymphoma 2004;
45: 2349-51.
Ikuta K, Torimoto Y, Jimbo J, Inamura J, Shindo M, Sato K,
Tokusashi Y, et al. Severe hepatic injury caused by imatinib
mesylate administered for the treatment of chronic myeloid
leukemia and the efficacy of prednisolone for its management. Int J
Hematol 2005; 82: 343-6.
Ayoub WS, Geller SA, Tran T, Martin P, Vierling JM, Poordad FF.
Imatinib(Gleevec)-induced hepatotoxicity. J Clin Gastroenterol
2005; 39: 75-7.
Ferrero D, Pogliani EM, Rege-Cambrin G, Fava C, Mattioli G,
Dellacasa C, Campa E, et al. Corticosteroids can reverse severe
imatinib-induced hepatotoxicity. Haematologica 2006; 91(6 Suppl):
ECR27.
Pariente A, Etcharry F, Cales V, Laborde Y, Ferrari S, Biour M.
Imatinib mesylate-induced acute hepatitis in a patient treated for
gastrointestinal stromal tumour. Eur J Gastroenterol Hepatol 2006;
18: 785-7
Dhalluin-Venier V, Besson C, Dimet S, Thirot-Bibault A, Tchernia G,
Buffet C. Imatinib mesylate-induced acute hepatitis with
autoimmune features. Eur J Gastroenterol Hepatol 2006; 18: 12357.
Cross TJ, Bagot C, Portmann B, Wendon J, Gillett D. Imatinib
mesylate as a cause of acute liver failure. Am J Hematol 2006; 81:
189-92.
Ikeda K, Shiga Y, Takahashi A, Kai T, Kimura H, Takeyama K, Noji
H, et al. Fatal hepatitis B virus reactivation in a chronic myeloid
leukemia patient during imatinib mesylate treatment. Leuk
Lymphoma 2006; 47: 155-7.
Mindikoglu AL, Regev A, Bejarano PA, Martinez EJ, Jeffers LJ, Schiff
ER. Imatinib mesylate(gleevec) hepatotoxicity. Dig Dis Sci 2007;
52: 598-601.
Ridruejo E, Cacchione R, Villamil AG, Marciano S, Gadano AC,
Mandó. Imatinib-induced fatal acute liver failure. World J
Gastroenterol 2007; 13: 6608-111.
Kong JH, Yoo SH, Lee KE, Nam SH, Kwon JM, Lee SM, Chang HJ, et
al. Early imatinib-mesylate-induced hepatotoxicity in chronic
myelogenous leukaemia. Acta Haematol 2007; 118: 205-8.
Fuster F, Medina L, Vallansot R, Granell M, Bruguera M. [Imatinibinduced toxic hepatitis: description of two cases and review of the
literature]. Gastroenterol Hepatol 2007; 30: 525-30
Al Sobhi E, Zahrani Z, Zevallos E, Zuraiki A. Imatinib-induced
immune hepatitis: case report and literature review. Hematology
2007; 12: 49-53.
Lakhani S, Davidson L, Priebat DA, Sherker AH. Reactivation of
chronic hepatitis B Infection related to imatinib mesylate therapy.
Hepatol Int 2008; 2: 498-9.
Thia TJ, Tan HH, Chuah TH, Chow WC, Lui HF. Imatinib mesylaterelated fatal acute hepatic failure in a patient with chronic myeloid
leukaemia and chronic hepatitis B infection. Singapore Med J 2008;
49(3): e86-9.
Al-Kali A, Farooq S, Tfayli A. Tumor lysis syndrome after starting
treatment with Gleevec in a patient with chronic myelogenous
leukemia. J Clin Pharm Ther 2009; 34: 607-10.
Aliberti S, Grignani G, Allione P, Fizzotti M, Galatola G, Pisacane A,
Aglietta M. An acute hepatitis resembling autoimmune hepatitis
occurring during imatinib therapy in a gastrointestinal stromal
tumor patient. Am J Clin Oncol 2009; 32: 640-1.
Perini GF, Santos FP, Funke V, Ruiz J, Neto BH, Hamerschlak N.
Nilotinib post-liver transplantation for acute hepatic failure related
to imatinib. Leuk Res 2009; 33:
Tonyali O, Coskun U, Yildiz R, Karakan T, Demirci U, Akyurek N,
Benekli M, et al. Imatinib mesylate-induced acute liver failure in a
patient with gastrointestinal stromal tumors. Med Oncol 2010; 27:
768-73
Bilgi N, Bell K, Ananthakrishnan AN, Atallah E. Imatinib and Panax
ginseng: a potential interaction resulting in liver toxicity. Ann
Spataro V. Nilotinib in a patient with postnecrotic liver cirrhosis
related to imatinib. J Clin Oncol 2011; 29: e50-2.
Gupta S, Bhatt VR, Varma S. Recurrent imatinib-induced
hepatotoxicity in a chronic myeloid leukaemia patient successfully
managed with prednisone. BMJ Case Rep 2011; 2011.
Martínez Pascual C, Valdés Mas M, de la Peña Moral JM, Miras López
M. [Fulminating hepatitis for imatinib in a patient with chronic
myeloid leukaemia]. Med Clin (Barc) 2011; 137: 329-30. Spanish.
García-Valdés M, Miras López M, Garrido Corro B, De La Rubia Nieto
A. [Survival following liver transplant due to imatinib-induced acute
liver failure: a case study]. Farm Hosp 2012; 36: 50-1. Spanish.
Wang YD, Cui GH, Li M, Gowrea B, Xia J, Hu Y. Hepatitis B virus
reactivation in a chronic myeloid leukemia patient treated with
imatinib mesylate. Chin Med J (Engl) 2012; 125: 2636-7.
Yachoui R. Early onset imatinib mesylate-induced hepatotoxicity in
a patient with gastrointestinal stromal tumors. Am J Ther 2013 Apr
5. [Epub ahead of print]
2013; 144: 1419-25.
pii: S0016-5085(15)00311-X.
IMIPRAMINE
Lund MA. [Jaundice during therapy with imipramine] Ikterus unter
behandling med imipramine. Ugeskr Laeg 1962; 124: 800-2.
Miller M. Neuropathy, agranulocytosis and hepatotoxicity following
imipramine therapy. Am J Psychiatry 1963; 20: 185-6. Not in
Hoaken PSC. Jaundice during imipramine treatment. Can Med Assoc
J 1964; 90: 1367.
Strothers G. Jaundice and its relation to therapeutic agents. Lancet
1965; 1: 434.
Powell WJ, Koch-Weser J, Williams RA. Lethal hepatic necrosis after
therapy with imipramine and desipramine. JAMA 1968; 206: 642-5.
Short MH, Burns JM, Harris ME. Cholestatic jaundice during
imipramine therapy. JAMA 1968; 206: 1791-2.
Karkalas Y, Lal H. Jaundice following therapy with imipramine and
cyproheptadine. Clin Toxicol 1971; 4: 47-53.
Weaver GA, Pavlinac D, Davis JS. Hepatic sensitivity to imipramine.
Am J Dig Dis 1977; 22: 551-3.
Bui HD, Chaney RH. Transient hepatitis due to low dose neuroleptic
medication. Am J Gastroenterol 1989; 84: 578-79.
Horst DA, Grace ND, LeCompte PM. Prolonged cholestasis and
progressive hepatic fibrosis following imipramine therapy.
Moskovitz R, DeVane CL, Harris R, Stewart RB. Toxic hepatitis and
single daily dosage imipramine therapy. J Clin Psychiatry 1982; 43:
165-6.
Schaefer MS, Edmunds RS, Markin RP, Wood RP, Pillen TJ, Shaw
BW. Hepatic failure associated with imipramine therapy.
Remy AL, Larrey D, Pageaux GP, Desprez D, Ramos J, Michel H.
Cross hepatotoxicity between tricyclic antidpressants and
phenothiazines. Eur J Gastroenterol 1995; 7: 373-6.
Ilan Y, Samuel D, Teynes M, Tur-Kaspa R. Hepatitis failure
associated with imipramine therapy. Pharmacopsychiatry 1996; 29:
79-80.
pii: S0016-5085(15)00311-X.
INTERFERON ALFA
Vento S, Di Perri G, Garofano T, Cosco L, Concia E, Ferraro T,
Bassetti D. Hazards of interferon therapy for HBV-seronegative
chronic hepatitis. Lancet 1989; 2: 926.
Silva MO, Reddy KR, Jeffers LJ, Hill M, Schiff ER. Interferon-induced
chronic active hepatitis? Gastroenterology 1991; 101: 840-2.
Ruiz-Moreno M, Rua MJ, Carreno V, Quiroga JA, Manns M, Meyer
zum Buschenfelde KH. Autoimmune chronic hepatitis type 2
manifested during interferon therapy. J Hepatol 1991; 12: 265-6.
Marcellin P, Colin F-F, Boyer N, Bernuau J, Degott C, Hirschauer C,
Benhamou J-P. Fatal exacerbation of chronic hepatitis B induced by
recombinant alpha-interferon. Lancet 1991; 338: 828.
Durand JM, Kaplanski G, Portal I, Scheiner C, Berland Y,
Soubeyrand J. Liver failure due to recombinant alpha interferon.
Lancet 1991; 338: 1268-9.
Wandl UB, Kloke O, Niederle N. Liver failure due to recombinant
alpha interferon for chronic myelogenous leukaemia. Lancet 1992;
339: 123-4.
Shindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerbation of liver
disease during interferon alfa therapy for chronic hepatitis C.
Gastroenterology 1992; 102(4 Pt 1): 1406-8.
Papo T, Marcellin P, Bernuau J, Durand F, Poynard T, Benhamou JP.
Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann
Intern Med. 1992; 116: 51-3.
Lindahl K, Weiland O, Schvarcz R. [Report of a case: hepatic failure
after treatment with interferon]. Lakartidningen. 1993; 90: 3075-6.
Swedish
van der Watt M, Lemmer E, Robson SC. Exacerbation of liver
disease during interferon-alpha therapy for chronic hepatitis C. S
Afr Med J 1994; 84(8 Pt 1): 509.
D'Amico E, Paroli M, Fratelli V, Palazzi C, Barnaba V, Callea F,
Consoli G. Primary biliary cirrhosis induced by interferon-. therapy
for hepatitis C virus infection. Dig Dis Sci 1995; 40: 2113-6.
Propst A, Propst T, Dietze O, Kathrein H, Judmeier G, Vogel W.
Development of granulomatous hepatitis during treatment with
interferon-alpha 2b. Dig Dis Sci 1995; 40: 2117-8.
Maeda T, Onishi S, Muira T, Iwamura S, Tomita A, Saibara T,
Yamamoto Y. Exacerbation of primary biliary cirrhosis during
interferon-alfa2b therapy for chronic active hepatitis C. Dig Dis Sci
1996; 40: 1226-30.
Hirashima N, Mizokami M, Orito E, Koide T, Itazu I, Kumada K,
Sakakibara K, et al. Case report: development of hepatocellular
carcinoma in a patient with chronic hepatitis C infection after a
complete and sustained response to interferon-alpha. J
Veerabagu MP, Finkelstein SD, Rabinovitz M. Granulomatous
hepatitis in a patient with chronic hepatitis C treated with
interferon-alpha. Dig Dis Sci 1997; 42: 1445-8.
1996; 40: 1226-30.
Veerabagu MP, Finkelstein SD, Rabinovitz M. Granulomatous
hepatitis in a patient with chronic hepatitis C treated with
interferon-alpha. Dig Dis Sci 1997; 42: 1445-8.
Ryan BM, McDonald GS, Pilkington R, Kelleher D. The development
of hepatic granulomas following interferon-alpha2b therapy for
chronic hepatitis C infection. Eur J Gastroenterol Hepatol 1998; 10:
349-51.
Lock G, Reng CM, Graeb C, Anthuber M, Wiedmann KH. Interferoninduced hepatic failure in a patient with hepatitis C. Am J
Kraus I, Vitezic D. Acute hepatitis induced by alpha-interferon in a
patient with chronic hepatitis C. Can J Gastroenterol 2001; 15: 3335.
IRINOTECAN
Ohtsu T, Sasaki Y, Igarashi T, Murayama T, Kobayashi Y, Tobinai K.
Unexpected hepatotoxicities in patients with non-Hodgkin's
lymphoma treated with irinotecan(CPT-11) and etoposide. Jpn J Clin
Oncol 1998; 28: 502-6.
Ong SY, Clarke SJ, Bishop J, Dodds HM, Rivory LP. Toxicity of
irinotecan(CPT-11) and hepato-renal dysfunction. Anticancer Drugs
2001; 12: 619-25.
Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG,
Strasberg SM. Effect of steatohepatitis associated with irinotecan or
oxaliplatin pretreatment on resectability of hepatic colorectal
metastases. J Am Coll Surg 2005; 200: 845-53.
Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong
HQ, et al. Chemotherapy regimen predicts steatohepatitis and an
increase in 90-day mortality after surgery for hepatic colorectal
metastases. J Clin Oncol 2006; 24: 2065-72.
Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA.
Preoperative chemotherapy for colorectal liver metastases: impact
on hepatic histology and postoperative outcome. J Gastrointest Surg
2007; 11: 860-8.
Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, Brunetti
IM, et al. Long-term outcome of initially unresectable metastatic
colorectal cancer patients treated with 5-fluorouracil/ leucovorin,
oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery
of metastases. Ann Surg 2009; 249: 420-5.
Lu QY, Zhao AL, Deng W, Li ZW, Shen L. Hepatic histopathology
and postoperative outcome after preoperative chemotherapy for
Chinese patients with colorectal liver metastases. World J
Gastrointest Surg 2013; 5: 30-6.
ISOFLURANE
McLaughlin DF, Eger EI 2nd. Repeated isoflurane anesthesia in a
patient with hepatic dysfunction. Anesth Analg 1984; 63: 775-8.
Fisher NA, Iwata RT, Eger EI 2nd, Smuckler EA. Hepatic necrosis
associated with herpes virus after isoflurane anesthesia. Anesth
Analg 1985; 64: 1131-3.
Grégoire S, Smiley RK. Acute hepatitis in a patient with mild factor
IX deficiency after anesthesia with isoflurane. CMAJ 1986; 135:
645-6.
Carrigan TW, Straughen WJ. A report of hepatic necrosis and death
following isoflurane anesthesia. Anesthesiology 1987; 67: 581-3.
Brunt EM, White H, Marsh JW, Holtmann B, Peters MG. Fulminant
hepatic failure after repeated exposure to isoflurane anesthesia: a
case report. Hepatology 1991; 13: 1017-21.
Gunza JT, Pashayan AG. Postoperative elevation of serum
transaminases following isoflurane anesthesia. J Clin Anesth 1992;
4: 336-41.
Scheider DM, Klygis LM, Tsang TK, Caughron MC. Hepatic
dysfunction after repeated isoflurane administration. J Clin
Slayter KL, Sketris IS, Gulanikar A. Halothane hepatitis in a renal
transplant patient previously exposed to isoflurane. Ann
Pharmacother 1993; 27: 101.
Gunaratnam NT, Benson J, Gandolfi AJ, Chen M. Suspected
isoflurane hepatitis in an obese patient with a history of halothane
hepatitis. Anesthesiology 1995; 83: 1361-4.
Gelven PL, Cina SJ, Lee JD, Nichols CA. Massive hepatic necrosis
and death following repeated isoflurane exposure: case report and
review of the literature. Am J Forensic Med Pathol 1996; 17: 61-4.
Sinha A, Clatch RJ, Stuck G, Blumenthal SA, Patel SA. Isoflurane
hepatotoxicity: a case report and review of the literature. Am J
Weitz J, Kienle P, Böhrer H, Hofmann W, Theilmann L, Otto G. Fatal
hepatic necrosis after isoflurane anaesthesia. Anaesthesia 1997;
52: 892-5
Hasan F. Isoflurane hepatotoxicity in a patient with a previous
history of halothane-induced hepatitis. Hepatogastroenterology
1998; 45: 518-22.
Meldrum DJ, Griffiths R, Kenna JG. Gallstones and isoflurane
hepatitis. Anaesthesia 1998; 53: 905-9.
Turner GB, O'Rourke D, Scott GO, Beringer TR. Fatal hepatotoxicity
after re-exposure to isoflurane: a case report and review of the
literature. Eur J Gastroenterol Hepatol 2000; 12: 955-9.
Martin JL, Keegan MT, Vasdev GM, Nyberg SL, Bourdi M, Pohl LR,
Plevak DJ. Fatal hepatitis associated with isoflurane exposure and
CYP2A6 autoantibodies. Anesthesiology 2001; 95: 551-3.
Malnick SD, Mahlab K, Borchardt J, Sokolowski N, Attali M. Acute
cholestatic hepatitis after exposure to isoflurane. Ann Pharmacother
2002; 36: 261-3.
Njoku DB, Shrestha S, Soloway R, Duray PR, Tsokos M, Abu-Asab
MS, Pohl LR, West AB. Subcellular localization of trifluoroacetylated
liver proteins in association with hepatitis following isoflurane.
Anesthesiology 2002; 96: 757-61.
Ihtiyar E, Algin C, Haciolu A, Isiksoy S. Fatal isoflurane
hepatotoxicity without re-exposure. Indian J Gastroenterol 2006;
25: 41-2.
Côté G, Bouchard S. Hepatotoxicity after desflurane anesthesia in a
15 month old child with Mobius syndrome after previous exposure
to isoflurane. Anesthesiology 2007; 107: 843-5.
Peiris LJ, Agrawal A, Morris JE, Basnyat PS. Isoflurane hepatitis-
induced liver failure: a case report. J Clin Anesth 2012; 24: 477-9.
pii: S0016-5085(15)00311-X.
ITRACONAZOLE
Lavrijsen AP, Balmus KJ, Nugteren-Huying WM, Roldaan AC, van't
Wout JW, Stricker BH. Hepatic injury associated with itraconazole.
Lancet 1992; 340: 251-2.
Hann SK, Kim JB, Im S, Han KH, Park YK. Itraconazole-induced
acute hepatitis. Br J Dermatol 1993; 129: 500-1.
Gallardo-Quesada S, Luelmo-Aguilar J, Guanyabens-Calvet C.
Hepatotoxicity associated with itraconazole. Int J Derm 1995; 34:
589.
Talwalkar JA, Soetikno RE, Carr-Locke DL, Berg CL. Severe
cholestasis related to itraconazole for the treatment of
onychomycosis. Am J Gastroenterol 1999; 94: 3632-3.
Adriaenssens B, Roskams T, Steger P, Van Steenbergen W.
Hepatotoxicity related to itraconazole: report of three cases. Acta
Clin Belg 2001; 56: 364-9.
Wolf R, Wolf D, Kuperman S. Focal nodular hyperplasia of the liver
after itraconazole treatment. J Clin Gastroenterol 2001; 33: 418-20.
Legras A, Bergemer-Fouquet AM, Jonville-Bera AP. Fatal hepatitis
with leflunomide and itraconazole. Am J Med 2002; 113: 352-3.
Jiménez-Sáenz M, Villar-Rodríguez JL, del Carmen MartínezSánchez M, Rebllo-Bernardez J, Carmona-Soria I, Herrerias-Esteban
JM, Herrerias-Gutierrez JM. Itraconazole-induced acute hepatitis in
an agricultural worker: susceptibility or drug interaction? J Clin
Tuccori M, Bresci F, Guidi B, Blandizzi C, Del Tacca M, Di Paolo M.
Fatal hepatitis after long-term pulse itraconazole treatment for
onychomycosis. Ann Pharmacother 2008; 42: 1112-7.
Yoshikado T, Takada T, Yamamoto T, Yamaji H, Ito K, Santa T,
Yokota H, et al. Itraconazole-induced cholestasis: involvement of
the inhibition of bile canalicular phospholipid translocator
MDR3/ABCB4. Mol Pharmacol 2011; 79: 241-50.
Lou HY, Fang CL, Fang SU, Tiong C, Cheng YC, Chang CC. Hepatic
failure related to itraconazole use successfully treated by
corticosteroids. Hepat Mon 2011; 11: 843-6.
KETAMINE
Wong SW, Lee KF, Wong J, Ng WW, Cheung YS, Lai PB. Dilated
common bile ducts mimicking choledochal cysts in ketamine
abusers. Hong Kong Med J 2009; 15: 53-6.
Lo RS, Krishnamoorthy R, Freeman JG, Austin AS. Cholestasis and
biliary dilatation associated with chronic ketamine abuse: a case
series. Singapore Med J 2011; 52: e52-5.
Seto WK, Ng M, Chan P, Ng IO, Cheung SC, Hung IF, Yuen MF, Lai
CL. Ketamine-induced cholangiopathy: a case report. Am J
Noppers IM, Niesters M, Aarts LP, Bauer MC, Drewes AM, Dahan A,
Sarton EY. Drug-induced liver injury following a repeated course of
ketamine treatment for chronic pain in CRPS type 1 patients: a
report of 3 cases. Pain 2011; 152: 2173-8.
Turkish A, Luo JJ, Lekfowitch JH. Ketamine abuse, biliary tract
disease and secondary sclerosing cholangitis. Hepatology 2013; 58:
825-7.
Zhou J, Shaw SG, Gilleece Y. Dilated common bile duct and
deranged liver function tests associated with ketamine use in two
HIV-positive MSM. Int J STD AIDS 2013; 24: 667-9.
Gutkin E, Hussain SA, Kim SH.Ketamine-induced biliary dilatation:
from Hong Kong to New York. J Addict Med. 2012 Mar;6(1):89-91.
pii: S0016-5085(15)00311-X.
LAMOTRIGINE
Chattergoon DS, McGuigan MA, Koren G, Hwang P, Ito S.
Multiorgan dysfunction and disseminated intravascular coagulation
in children receiving lamotrigine and valproic acid. Neurology 1997;
49: 1442-4.
Jones D, Chhiap V, Resor S, Appel G, Grossman ME. Phenytoin-like
hypersensitivity associated with lamotrigine. J Am Acad Dermatol
1997; 36 (6 Pt 1):1016-8.
Gómez Caturla A, Arteta Jiménez M, Fernández Planelles C, Portillo
J. [Acute hepatitis associated with lamotrigine administration]. Med
Clin (Barc) 1998; 111: 675-6. Spanish.
Arnon R, DeVivo D, Defelice AR, Kazlow PG. Acute hepatic failure in
a child treated with lamotrigine. Pediatr Neurol 2000; 18: 251–2.
Fayad M, Choueiri R, Mikati M. Potential hepatotoxicity of
lamotrigine. Pediatr Neurol 2000; 22: 49–52.
Sauve G, Bresson-Hadni S, Prost P, Le Calvez S, Becker M-C,
Galmiche J, Carbillet J-P, Miguet J-P. Acute hepatitis after
lamotrigine administration. Dig Dis Sci 2000; 45:1874–7.
Overstreet K, Costaanza C, Behling C, Hassanin T, Masliah E. Fatal
progressive hepatic necrosis associated with lamotrigine treatment:
a case report and literature review. Dig Dis Sci 2002; 47: 1921-5.
Bin-Nakhi HA, Sadeq S, Pinto RG, Habeeb Y. Anticonvulsant
hypersensitivity syndrome: report of 2 cases from Kuwait. Med
Princ Pract 2003; 12: 197-9.
Petkov T, Pehlivanov G, Grozdev I, Kavaklieva S, Tsankov N. Toxic
epidermal necrolysis as a dermatological manifestation of drug
hypersensitivity syndrome. Eur J Dermatol 2007; 17: 422-7.
Gerstner T, Bauer MO, Longin E, Bell N, Koenig SA. Reversible
hepatotoxicity, pancreatitis, coagulation disorder and simultaneous
bone marrow suppression with valproate in a 2-year-old girl.
Seizure 2007; 16: 554-6
Moeller KE, Wei L, Jewell AD, Carver LA. Acute hepatotoxicity
associated with lamotrigine. Am J Psychiatry 2008; 165: 539-40.
Delima SI, Walsh LE, Golomb MR. Simultaneous toxicities in a child
on multiple anticonvulsants. J Child Neurol. 2008; 23: 1054-7.
Su-Yin AN, Tai WW, Olson KR. Lamotrigine-associated reversible
severe hepatitis: a case report. J Med Toxicol 2008; 4: 258-60.
Aouam K, Ben Romdhane F, Loussaief C, Salem R, Toumi A,
Belhadjali H, Chaabane A, et al. Hypersensitivity syndrome induced
by anticonvulsants: possible cross-reactivity between
carbamazepine and lamotrigine. J Clin Pharmacol 2009; 49: 148891.
Amante MF, Filippini AV, Cejas N, Lendoire J, Imventarza O, Parisi
C. Dress syndrome and fulminant hepatic failure induced by
lamotrigine. Ann Hepatol 2009; 8: 75-7.
Ouellet G, Tremblay L, Marleau D. Fulminant hepatitis induced by
lamotrigine. South Med J 2009; 102: 82-4.
Bakker CV, Hegt VN, Praag MC. Lamotrigine hypersensitivity
syndrome and spiking Fever. Indian J Dermatol 2012; 57:
Bhayana H, Appasani S, Thapa BR, Das A, Singh K. Lamotrigineinduced vanishing bile duct syndrome in a child. J Pediatr
Gastroenterol Nutr 2012; 55: e147-8.
pii: S0016-5085(15)00311-X.
LEFLUNOMIDE
Sevilla-Mantilla C, Ortega L, Agúndez JA, Fernández-Gutiérrez B,
Ladero JM, Díaz-Rubio M. Leflunomide-induced acute hepatitis. Dig
Liver Dis 2004; 36: 82-4.
Vaish AK, Tripathi AK, Gupta LK, Jain N, Agarwal A, Verma SK. An
unusual case of DRESS syndrome due to leflunomide. BMJ Case Rep
2011; 2011.
Goldberg D, et al. Incidence of Drug-Induced Acute Liver Failure: A
Population-Based Study for Gastroenterology. submitted to
Gastroenterology, 1 case= transplanted
pii: S0016-5085(15)00311-X.
LEVOFLOXACIN/ OFLOXACIN
Hautekeete ML, Kockx MM, Naegels S, Holvoet JK, Hubens H,
Kloppel G. Cholestatic hepatitis related to quinolones: a report of
two cases. J Hepatol 1995; 23: 759-60.
Jones SF, Smith RH. Quinolones may induce hepatitis. BMJ 1997;
314: 869.
González Carro P, Huidobro ML, Zabala AP, Vicente EM. Fatal
subfulminant hepatic failure with ofloxacin. Am J Gastroenterol
2000; 95: 1606.
Spahr L, Rubbia-Brandt L, Marinescu O, Armenian B, Hadengue A.
Acute fatal hepatitis related to levofloxacin. J Hepatol 2001; 35:
308-9.
Karim A, Ahmed S, Rossoff LJ, Siddiqui RK, Steinberg HN. Possible
levofloxacin-induced acute hepatocellular injury in a patient with
chronic obstructive lung disease. Clin Infect Dis 2001; 33: 2088-90.
Digwood-Lettieri S, Reilly KJ, Haith LR Jr, Patton ML, Guilday RJ,
Cawley MJ, Ackerman BH. Levofloxacin-induced toxic epidermal
necrolysis in an elderly patient. Pharmacotherapy 2002; 22: 78993.
Heluwaert F, Roblin X, Duffournet V, Capony P, Martin D, Roblin X.
[Hepatitis related to amoxicillin or levofloxacin: a case report]. Rev
Med Interne 2003; 24: 841-3. French.
Schwalm JD, Lee CH. Acute hepatitis associated with oral
levofloxacin therapy in a hemodialysis patient. CMAJ 2003; 168:
847-8.
Coban S, Ceydilek B, Ekiz F, Erden E, Soykan I. Levofloxacininduced acute fulminant hepatic failure in a patient with chronic
hepatitis B infection. Ann Pharmacother 2005; 39: 1737-40.
Carrascosa MF, Lucena MI, Andrade RJ, Caviedes JRS, et al. Fatal
acute hepatitis after sequential treatment with levofloxacin,
doxycycline, and naproxen in a patient presenting with acute
Mycoplasma pneumoniae infection. Clin Ther 2009; 31: 1014-19.
Figueira-Coelho J, Pereira O, Picado B, Mendonça P, Neves-Costa J,
Neta J. Acute hepatitis associated with the use of levofloxacin. Clin
Ther 2010; 32: 1733-7.
García-Aparicio J, Herrero-Herrero JI. [Toxic hepatitis following
sequential treatment with cotrimoxazol, levofloxacin, doxycycline
and sertraline in a patient with a respiratory infection]. Farm Hosp
2010; 34: 152-4. Spanish.
Titos-Arcos JC, Hallal H, Robles M, Andrade RJ. [Acute cholestatic
hepatitis associated with levofloxacin.]. Gastroenterol
Coelho J, Gonçalves C, Leitão S, Marques Dos Santos R, Nascimento
Costa J. [Levofloxacin hepatotoxicity. Higher risk in diabetics?].
Acta Med Port 2011; 24 Suppl 3: 729-34. Portuguese.
pii: S0016-5085(15)00311-X.
LISINOPRIL
Larrey D, Babany G, Bernuau J, Andrieux J, DeGott C, Pessayre D,
Benhamou J-P. Fulminant hepatitis after lisinopril administration.
Gastroenterology 1990; 99: 1832-3.]
Droste HT, de Vries RA.Chronic hepatitis caused by lisinopril.
Neth J Med. 1995 Feb;46(2):95-8.
Zalawadiya SK, Sethi S, Loe S, Kumar S, Tchokonte R, Shi D, Adam
AK, May EJ.Unique case of presumed lisinopril-induced
hepatotoxicity. Am J Health Syst Pharm. 2010 Aug 15;67(16):13546
Lindgren A, Olsson R.[Liver damage following antihypertensive
therapy. A case report of hepatitis induced by lisinopril and a
review]. Lakartidningen. 1993 Apr 21;90(16):1557-8. 1 case+ 4
cases possible to SADRAC.
pii: S0016-5085(15)00311-X.
LOVASTATIN
McQueen MJ. Cholestatic jaundice associated with lovastatin
(Mevacor) therapy. Can Med Assoc J 1990; 142: 841-2.
Geddes JA. Cholestatic jaundice associated with lovastatin(Mevacor)
therapy. Can Med Assoc J 1990; 143: 13-14.
Spreckelsen U, Kirchoff R, Haake H. [Cholestatic jaundice during
lovastatin medication](German). Dtsch Med Wochenschr 1991; 116:
739-40.
Raveh D, Arnon R, Israeli A, Eisenberg S. Lovastatin-induced
hepatitis. Isr J Med Sci. 1992; 28: 101-2.
Grimbert S, Pessayre D, Degott C, Benhamou JP. Acute hepatitis
induced by HMG-CoA reductase inhibitor, lovastatin. Dig Dis Sci.
1994; 39: 2032-3.
Huchzermeyer H, Munzenmaier R. [Lovastatin-induced acute
cholestatic hepatitis] [German]. Dtsch Med Wochenschr.
1995;120:252-6. German.
Gavilán Carrasco JC, Bermúdez Recio F, Salgado Ordóñez F,
González Santos P. [Hepatitis due to lovastatin] Med Clin(Barc)
1996; 107: 557-8.
Bruguera M, Joya P, Rodés J. [Hepatitis associated with treatment
with lovastatin. Presentation of 2 cases] Gastroenterol Hepatol.
1998; 21: 127-8.
pii: S0016-5085(15)00311-X.
MELPHALAN
Mocellin S, Pilati P, Da Pian P, Forlin M, Corazzina S, Rossi CR,
Innocente F, et al. Correlation between melphalan pharmacokinetics
and hepatic toxicity following hyperthermic isolated liver perfusion
for unresectable metastatic disease. Ann Surg Oncol 2007; 14: 8029.
METFORMIN
Cubukcu A, Yilmaz MT, Satman I, Buyukdevrim AS. Metformin
kullanimina bagli bir akut hepatiti vakasi (metformin-induced
hepatitis). Tip Fak Mecm 1991; 54: 447-52. [Turkish]. [Not in
Babich MM, Pike I, Shiffman ML. Metformin-induced acute hepatitis.
Am J Med 1998; 104: 490-2.
Lin KD, Lin JD, Juang JH. Metformin-induced hemolysis with
jaundice. N Engl J Med 1998; 339: 1860-1.
Swislocki AL, Noth R. Case report. Pseudohepatotoxicity of
metformin. Diabetes Care 1998; 21: 677-8.
Crespo Valadés E, Ortega Gómez A, Alvarado Izquierdo MI, Magro
Ledesma D. [Hepatotoxic reaction associated with metformin and
chlorpropamide treatment] Rev Clin Esp 1999; 199: 118-9.
Spanish.
Chaudhry MU, Simmons DL. Case of the month. Hepatic and renal
failure in a patient taking troglitazone and metformin. J Ark Med
Soc 2001; 98: 16-9.
Desilets DJ, Shorr AF, Moran KA, Holtzmuller KC. Cholestatic
jaundice associated with the use of metformin. Am J Gastroenterol
2001; 96: 2257-8.
Nammour FE, Fayad NF, Peikin SR. Metformin-induced cholestatic
hepatitis. Endocr Pract 2003; 9: 307-9.
Deutsch M, Kountouras D, Dourakis SP. Metformin hepatotoxicity.
Ann Intern Med 2004; 140: W25
Barquero Romero J, Pérez Miranda M. [Metformin-induced
cholestatic hepatitis] Gastroenterol Hepatol 2005; 28: 257-8.
Spanish.
Kutoh E. Possible metformin-induced hepatotoxicity. Am J Geriatr
de la Poza Gómez G, Rivero Fernández M, Vázquez Romero M,
Angueira Lapeña T, Arranz de la Mata G, Boixeda de Miquel D.
[Constitutional syndrome associated to metformin induced
hepatotoxicity]. Gastroenterol Hepatol 2008; 31: 643-5. Spanish.
Olivera-González S, de Escalante-Yangüela B, Velilla-Soriano C,
Amores-Arriaga B, Martín-Fortea P, Navarro-Aguilar ME.
[Metformin-associated hepatotoxicity.]. Med Intensiva 2010; 34:
483-7. Spanish.
Cone CJ, Bachyrycz AM, Murata GH. Hepatotoxicity associated with
metformin therapy in treatment of type 2 diabetes mellitus with
nonalcoholic fatty liver disease. Ann Pharmacother 2010; 44: 16559.
Miralles-Linares F, Puerta-Fernandez S, Bernal-Lopez MR, Tinahones
FJ, Andrade RJ, Gomez-Huelgas R. Metformin-induced
hepatotoxicity. Diabetes Care 2012; 35 (3): e21.
Zheng L. Metformin as a rare cause of drug-induced liver injury, a
case report and literature review. Am J Ther 2013 Nov 20. [Epub
ahead of print]
Saadi T, Waterman M, Yassin H, Baruch Y. Metformin-induced
mixed hepatocellular and cholestatic hepatic injury: case report and
literature review. Int J Gen Med 2013; 6: 703-6.
Hashmi T. Probable hepatotoxicity associated with the use of
metformin in type 2 diabetes. BMJ Case Rep. 2011 Sep 13;2011.
METHIMAZOLE
Specht NW, Boehme EJ. Death due to agranulocytosis induced by
methimazole therapy. JAMA 1952; 149: 1010-1. Not in
Rosenbaum H, Reveno WS. Agranulocytosis and toxic hepatitis from
methimazole. JAMA 1953; 152: 27.
Shipp JC. Jaundice during methimazole (‘Tapazole’) administration.
Ann Intern Med 1955; 42: 701-6.
Tennenbaum JI, Dreskin OH. Toxic hepatitis during treatment with
methimazole (Tapazole). Report of a case with apparent recovery.
Ohio Med J 1962; 58: 306-7.
Martinez-Lopez JI, Greenberg SE, Kling RR. Drug-induced hepatic
injury during methimazole therapy. Gastroenterology 1962; 43: 847.
Schmidt G, Boerach G, Mueller KM, Wegener M. Methimazole
associated cholestatic liver injury: case report and brief literature
review. Hepato-gastroenterol 1986; 33: 244-6.
Baker B, Shapiro B, Fig LM, Woodbury D, Sisson JC, Beierwaltes
WH. Unusual complications of antithyroid drug therapy: four case
reports and review of literature. Thyroidology 1989; 1: 17-26.
Kang H, Choi JD, Jung IG, Kim DW, Kim TB, Shin HK, et al. A case
of methimazole-induced acute hepatic failure in a patient with
chronic hepatitis B carrier. Korean J Intern Med 1990; 5: 69-73.
Di Gregorio C, Ghini F, Rivasi F. Granulomatous hepatitis in a
patient receiving methimazole. Ital J Gastroenterol 1990; 22: 75-7.
Findor J, Bruch Igartúa E, Sorda J, Jury R. [Jaundice caused by
methimazole]. Acta Gastroenterol Latinoam 1991; 21: 115-9.
Spanish.
Mamianetti A, Muñoz A, Ronchetti RD, Maccione E, Poggi U,
Mugnolo R, et al. [Acquired sideroblastic anemia and cholestasis in
a hyperthyroid patient treated with methimazole and atenolol].
Medicina (B Aires) 1995; 55: 693-6. Spanish
Arab DM, Malatjalian DA, Rittmaster RS. Severe cholestatic jaundice
in uncomplicated hyperthyroidism treated with methimazole. J Clin
Endocrinol Metab 1995; 80: 1083-5.
Schwab GP, Wetscher GJ, Vogl W, Redmond E. Methimazoleinduced cholestatic liver injury, mimicking sclerosing cholangitis.
Langenbecks Arch Chir 1996; 381: 225-7.
Hung YT, Yu WK, Chow E. Delayed cholestatic hepatitis due to
methimazole. Hong Kong Med J 1999; 5: 200-1.
Woeber KA. Methimazole-induced hepatotoxicity. Endocr Pract
2002; 8: 222-4.
Mikhail NE. Methimazole-induced cholestatic jaundice. South Med J
2004; 97: 178-82.
Casallo Blanco S, Valero MA, Marcos Sánchez F, de Matías Salces L,
Blanco González JJ, Martín Barranco MJ. [Methimazole and
propylthiouracil induced acute toxic hepatitis]. Gastroenterol
Ramos-Bonner LS, Goldberg TH, Moyer S, Anastasopoulou C.
Methimazole-induced cholestatic jaundice in an elderly hyperthyroid
patient. Am J Geriatr Pharmacother 2007; 5: 236-40.
Gallelli L, Staltari O, Palleria C, De Sarro G, Ferraro M.
Hepatotoxicity induced by methimazole in a previously healthy
patient. Curr Drug Saf 2009; 4: 204-6.
Zhang M, Zhou H, He R, Di F, Yang L, Yang T. Steroids for the
treatment of methimazole-induced severe cholestatic jaundice in a
74-year-old woman with type 2 diabetes. Endocrine 2010; 37: 2413.
Livadas S, Xyrafis X, Economou F, Boutzios G, Christou M, Zerva A,
Karachalios A, Palioura H, Palimeri S, Diamanti-Kandarakis E. Liver
failure due to antithyroid drugs: report of a case and literature
review. Endocrine 2010; 38: 24-8.
Shen C, Zhao CY, Liu F, Wang YD, Yu J. Acute-on-chronic liver
failure due to thiamazole in a patient with hyperthyroidism and
trilogy of Fallot: case report. BMC Gastroenterol 2010; 10: 93.
Alvarez MP, Cano RL, Fernández CP, Méndez LF, García RG. [Acute
toxic hepatitis induced by methimazole: two cases]. Endocrinol Nutr
2010; 57: 451-3. Spanish.
Yang J, Zhong J, Zhou LZ, Hong T, Xiao XH, Wen GB. Sudden onset
agranulocytosis and hepatotoxicity after taking methimazole. Intern
Med 2012; 51: 2189-92.
López-P Rdel P, Forero JD, Sierra F.[Methimazole-induced
cholestatic jaundice in a hyperthyroid patient]. Acta Gastroenterol
Latinoam. 2014 Mar;44(1):52-8. Spanish.
MOXIFLOXACIN
Soto S, López-Rosés L, Avila S, et al. Moxifloxacin-induced acute
liver injury. Am J Gastroenterol 2002; 97: 1853-4.
Nori S, Bebesio C, Brashear R, Travers JB. Moxifloxacin-associated
drug hypersensitivity syndrome with toxic epidermal necrolysis and
fulminant hepatitis failure. Arch Dermatol 2004; 140: 1537-8.
Franco Hidalgo S, Prieto de Paula JM, García Lorenzo R, Salado
Valdivieso I. [Moxifloxacin and hepatic toxicity]. Gastroenterol
Verma R, Dhamija R, Batts DH, Ross SC, Loehrke ME. Moxifloxacin
induced fatal hepatotoxicity in a 72-year-old man: a case report.
Cases J. 2009 Jul 20;2:8063. doi: 10.4076/1757-1626-2-8063.
Puerto Alonso JL, Díaz Souza P, Chamorro Mohedano J, Rojas Martín
E. [Fatal acute hepatitis and cholestasis associated with liver
disease]. Med Clin (Barc) 2010; 134: 375-6. Spanish.
Orman ES, Conjeevaram HS, Vuppalanchi R, Freston JW, Rochon J,
Kleiner DE, Hayashi PH; DILIN Research Group. Clinical and
histopathologic features of fluoroquinolone-induced liver injury. Clin
pii: S0016-5085(15)00311-X.
NAPROXEN
Bass BH. Letter: Jaundice associated with naproxen. Lancet 1974;
1: 998.
Law IP, Knight H. Jaundice associated with naproxen. N Engl J Med
1976; 295: 1201. PubMed Citation (54 year old woman developed
jaundice [bilirubin 2.5 mg/dL; AST 1000 U/L, Alk P 400 U/L] 1 week
after starting naproxen, resolving within 4 weeks).
Krogsgaard K, Hardt F, Malchow-Møller A. [Liver involvement after
treatment with naproxen] Ugeskr Laeger 1980; 142: 450-1. Danish.
Victorino RM, Silveira JC, Baptista A, de Moura MC. Jaundice
associated with naproxen. Postgrad Med J 1980; 56: 368-70.
Giarelli L, Falconieri G, Delendi M. Fulminant hepatitis following
naproxen administration. Hum Pathol 1986; 17: 1079. Erratum in:
Hum Pathol 1987; 18: 205.
Grattan CEH. Pustular reaction to naproxen with cholestatic
jaundice. Dermatologica 1989; 179: 57-8.
Reeve PA, Moshiri M, Bell GD. Pulmonary oedema, jaundice and
renal impairment with naproxen. Br J Rheumatol 1987; 26: 70-1.
Andrejak M, Davion T, Gineston JL, Capron JP. Cross hepatotoxicity
between non-steroidal anti-inflammatory drugs. Br Med J 1987;
295: 180-1.
F D’Amore F, Agostino A, Santoro A. Colesasi da famaci: contributo
clinico. Minerva Gastroenterol Dietol 1996; 42: 215-9.
Demirag MD, Ozenirler S, Goker B, Poyraz A, Haznedaroglu S,
Ozturk MA. Idiosyncratic toxic hepatitis secondary to single dose of
naproxen. Acta Gastroenterol Belg 2007; 70: 247-8.
Ting TV, Hashkes PJ. Methotrexate/naproxen-associated severe
hepatitis in a child with juvenile idiopathic arthritis. Clin Exp
Rheumatol 2007; 25: 928-9.
Carrascosa MF, Lucena MI, Andrade RJ, Caviedes JR, LavÃn AC,
Mones JC, Rivero AP, et al. Fatal acute hepatitis after sequential
treatment with levofloxacin, doxycycline, and naproxen in a patient
presenting with acute Mycoplasma pneumoniae infection. Clin Ther
2009; 31: 1014-9.
Ali S, Pimentel JD, Ma C. Naproxen-induced liver injury.
Hepatobiliary Pancreat Dis Int. 2011; 10: 552-6.
NIFEDIPINE
Rotmensch HH, Roth A, Liron M, Rubinstein A, Gefel A, Livni E.
Lymphocyte sensitization in nifedipine-induced hepatitis. Br Med J
1980; 281; 976-7.
Davidson AR. Lymphocyte sensitization to nifedipine-induced
hepatitis. Br Med J 1980; 281: 1354.
Abramson M, Littlejohn GO. Hepatic reactions to nifedipine. Med J
Aust 1985; 142: 47-8.
Welch HG, Lazar B, Gresser J, McMahon BJ. Nifedipine-induced
hepatitis. Alaska Med 1986; 28:11-2.
Kiire CF, Rutherford D. Nifedipine-associated jaundice: a second
case. East Afr Med J 1986; 63: 560-1.
Richter WO, Schwandt P. Serious side effects of nifedipine. Arch
Intern Med 1987; 147: 1852.
Shaw DR, Misan GM, Johnson RD. Nifedipine hepatitis. Aust N Z J
Med 1987; 17: 447-8. Biour M, Grange JD, Barbare JC, et al. [Hepatic involvement due to
nifedipine. Description of a case and review of the literature]
Therapie 1987; 42: 301-3 [French]. Babany G, Uzzan F, Larrey D, et al. Alcohol-like liver lesions induced
by nifedipine. J Hepatol 1989; 9: 252-5.
Sawaya GF, Robertson PA. Hepatotoxicity with the administration of
nifedipine for treatment of preterm labor. Am J Obstet Gynecol
1992; 167: 512-3.
Basile C, Mascia E. Dihydropyridine calcium channel blockers: a rare
and reversible cause of hepatotoxicity with cholestasis in a CAPD
patient. Nephrol Dial Transplant 1999; 14: 2776-7.
OLANZAPINE
Raz A, Bergman R, Eilam O, Yungerman T, Hayek T. A case report
of olanzapine-induced hypersensitivity syndrome. Am J Med Sci
2001; 321: 156-8.
Kolpe M, Ravasia S. Effect of olanzapine on the liver transaminases.
Can J Psychiatry. 2003; 48: 210.
Tchernichovsky E, Sirota P. Hepatotoxicity, leucopenia and
neutropenia associated with olanzapine therapy. Int J Psychiatry
Clin Pract 2004; 8: 173-7.
Ozcanli T, Erdogan A, Ozdemir S, Onen B, Ozmen M, Doksat K,
Sonsuz A. Severe liver enzyme elevations after three years of
olanzapine treatment: a case report and review of olanzapine
associated hepatotoxicity. Prog Neuropsychopharmacol Biol
Psychiatry 2006; 30: 1163-6.
Lui SY, Tso S, Lam M, Cheung EF. Possible olanzapine-induced
hepatotoxicity in a young Chinese patient. Hong Kong Med J 2009;
15: 394-6.
Gómez Espín R, Sánchez Quiles I, Hallal H, Plaza J. [Acute
hepatocellular lesion after successive exposure to clozapine and
olanzapine in a patient with chronic hepatitis C infection].
Manceaux P, Constant E, Zdanowicz N, Jacques D, Reynaert C.
Management of marked liver enzyme increase during olanzapine
treatment: a case report and review of the literature. Psychiatr
Danub 2011; 23 Suppl 1: S15-7.
Domínguez-Jiménez JL, Puente-Gutiérrez JJ, Pelado-García EM,
Cuesta-Cubillas D, García-Moreno AM. Liver toxicity due to
olanzapine. Rev Esp Enferm Dig 2012; 104: 617-618.
pii: S0016-5085(15)00311-X.
OMEPRAZOLE/ESOMEPRAZOLE
Jochem V, Kirkpatrick R, Greenson J, Brogan M, Sturgis T, CookGlenn C. Fulminant hepatic failure related to omeprazole. Am J
Navarro JF, Gallego E, Aviles J. Recurrent severe acute hepatitis and
omeprazole. Ann Intern Med 1997; 127: 1135-6.
Christe C, Stoller R, Vogt N. Omeprazole-induced hepatotoxicity? A
case report. Pharmacoepidemiol Drug Saf 1998; 7 Suppl 1: S41-4.
Koury SI, Stone CK, La Charité DD. Omeprazole and the
development of acute hepatitis. Eur J Emerg Med 1998; 5: 467-9.
Koury SI, Stone CK, La Charité DD. Acute hepatitis induced by
omeprazole. Am J Emerg Med 1998; 16: 550-1.
Romero-Gómez M, Otero MA, Suárez-García E, García Díaz E,
Fobelo MJ, Castro-Fernández M. Acute hepatitis related to
omeprazole. Am J Gastroenterol 1999; 94: 1119-20.
El-Matary W, Dalzell M. Omeprazole-induced hepatitis. Pediatr
Emerg Care 2005; 21: 529-30.
Darabi K. Proton-pump-inhibitor-induced hepatitis.
South Med J. 2005 Aug;98(8):844-5.
Capitain O, Lortholary A, Abadie-Lacourtoisie S. [Cytolytic hepatitis
and esomeprazole during chemotherapy]. Presse Med 2005; 34:
1235-6. French.
Sánchez Garrido A. [Omeprazole-induced acute cholestatic
hepatitis]. Gastroenterol Hepatol 2007; 30: 54. Spanish.
Domínguez-Leñero V, Barrera-Ledesma M, Romero-Alonso M,
Garrido Martínez MT. [Stevens-Johnson syndrome and toxic
hepatitis due to esomeprazole]. Farm Hosp 2009; 33: 118-9.
Spanish.
Zaccardi F, Pitocco D, Martini F, Caputo S, Miele L, Grieco A,
Ghirlanda G. A case of esomeprazole-induced transient diabetes and
hepatitis: the role of liver inflammation in the pathogenesis of
insulin resistance. Acta Diabetol. 2014 Feb;51(1):151-3.
pii: S0016-5085(15)00311-X.
OXACILLIN
Freedman MA. Oxacillin—apparent hematologic and hepatic toxicity.
Rocky Mt Med J 1965; 62: 34-6.
Pas AT, Quinn EL. Cholestatic hepatitis following the administration
of sodium oxacillin. JAMA 1965; 191: 674-5.
Dismukes WE. Oxacillin-induced hepatic dysfunction. JAMA 1973;
226: 861-3.
Klein I, Tobias H. Oxacillin-associated hepatitis. Am J Gastroenterol
1976; 65: 546.
Olans RN, Weiner LB. Reversible oxacillin hepatotoxicity. J Pediatr
1976; 89: 835-8.
Bruckstein AH, Attia AA. Oxacillin hepatitis. Two patients with liver
biopsy, and review of the literature. Am J Med 1978; 64: 519-22.
Goldstein LI, Granoff M, Waisman J. Hepatic injury due to oxacillin
administration. Am J Gastroenterol 1978; 70: 171-4.
Onorato IM, Axelrod JL. Hepatitis from intravenous high-dose
oxacillin therapy: findings in an adult inpatient population. Ann
Intern Med 1978; 89: 497-500.
Taylor C, Corrigan K, Steen S, Craig C. Oxacillin and hepatitis. Ann
Intern Med 1979; 90: 857-8.
Pollock AA, Berger SA, Simberkoff MS, Rahal JJ Jr. Hepatitis
associated with high-dose oxacillin therapy. Arch Intern Med 1978;
138: 915-7.
Halloran TJ, Clague MD. Hepatitis associated with high-dose
oxacillin therapy. Arch Intern Med 1979; 139: 376-7.
Al-Homaidhi H, Abdel-Haq NM, El-Baba M, Asmar BI. Severe
hepatitis associated with oxacillin therapy. South Med J 2002; 95:
650-2.
Lee CY, Chen PY, Huang FL, Chi CS. Reversible oxacillin-associated
hepatitis in a 9-month old boy. J Ped Child Health 2008; 44: 1468.
pii: S0016-5085(15)00311-X.
PAROXETINE
Helmchen C, Boerner RJ, Meyendorf R, Hegerl U. Reversible
hepatotoxicity of paroxetine in a patient with major depression.
Pharmacopsychiatry 1996; 29: 223-6.
Benbow SJ, Gill G. Paroxetine and hepatotoxicity. Br Med J 1997;
314: 1387
de Man RA. [Severe hepatitis attributed to paroxetine (Seroxat)].
Ned Tijdschr Geneeskund 1997; 141: 540-2.
Cadranel JF, DiMartino V, Cazier A, Pras V, Bachmeyer C, Olympio
P, Gonzenbach A, et al. Atrium and paroxetine-related severe
hepatitis. J Clin Gastroenterol 1999; 28: 52-5.
Odeh M, Misselevech I, Boss JH, Oliven A. Severe hepatotoxicity
with jaundice associated with paroxetine. Am J Gastroenterol 2001;
96: 2494-6. PubMed Citation
Azaz-Livshits T, Hershko A, Ben-Chetrit E. Paroxetine associated
hepatotoxicity: a report of 3 cases and a review of the literature.
Pharmacopsychiatry 2002; 35: 112-5.
Colakoglu O, Tankurt E, Unsal B, Ugur F, Kupelioglu A, Buyrac Z,
Akpinar Z. Toxic hepatitis associated with paroxetine. Int J Clin
Pract 2005; 59: 861-2.
Guzmán Ruiz O, Ramírez Martín del Campo M, Fernandez López I,
Romero Gómez M. [Hepatotoxicity induced by paroxetine]. Med
Clin(Barc) 2005; 124: 399. Spanish.
Pompili M, Tittoto P, Mascianà R, Gasbarrini G, Rapaccini GL. Acute
hepatitis associated with use of paroxetine. Intern Emerg Med
2008; 3: 275-7.
PEGINTERFERON
Vento S, Di Perri G, Garofano T, Cosco L, Concia E, Ferraro T,
Bassetti D. Hazards of interferon therapy for HBV-seronegative
chronic hepatitis. Lancet 1989; 2: 926.
Silva MO, Reddy KR, Jeffers LJ, Hill M, Schiff ER. Interferon-induced
chronic active hepatitis? Gastroenterology 1991; 101: 840-2.
Ruiz-Moreno M, Rua MJ, Carreno V, Quiroga JA, Manns M, Meyer
zum Buschenfelde KH. Autoimmune chronic hepatitis type 2
manifested during interferon therapy. J Hepatol 1991; 12: 265-6.
Marcellin P, Colin F-F, Boyer N, Bernuau J, Degott C, Hirschauer C,
Benhamou J-P. Fatal exacerbation of chronic hepatitis B induced by
recombinant alpha-interferon. Lancet 1991; 338: 828
Durand JM, Kaplanski G, Portal I, Scheiner C, Berland Y,
Soubeyrand J. Liver failure due to recombinant alpha interferon.
Lancet 1991; 338: 1268-9
Wandl UB, Kloke O, Niederle N. Liver failure due to recombinant
alpha interferon for chronic myelogenous leukaemia. Lancet 1992;
339: 123-4.
Shindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerbation of liver
disease during interferon alfa therapy for chronic hepatitis C.
Gastroenterology 1992; 102(4 Pt 1): 1406-8.
Papo T, Marcellin P, Bernuau J, Durand F, Poynard T, Benhamou JP.
Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann
Intern Med. 1992; 116: 51-3
Lindahl K, Weiland O, Schvarcz R. [Report of a case: hepatic failure
after treatment with interferon]. Lakartidningen. 1993; 90: 3075-6.
Swedish.
van der Watt M, Lemmer E, Robson SC. Exacerbation of liver
disease during interferon-alpha therapy for chronic hepatitis C. S
Afr Med J 1994; 84(8 Pt 1): 509.
D'Amico E, Paroli M, Fratelli V, Palazzi C, Barnaba V, Callea F,
Consoli G. Primary biliary cirrhosis induced by interferon-. therapy
for hepatitis C virus infection. Dig Dis Sci 1995; 40: 2113-6.
Propst A, Propst T, Dietze O, Kathrein H, Judmeier G, Vogel W.
Development of granulomatous hepatitis during treatment with
interferon-alpha 2b. Dig Dis Sci 1995; 40: 2117-8.
1996; 40: 1226-30.
Ryan BM, McDonald GS, Pilkington R, Kelleher D. The development
of hepatic granulomas following interferon-alpha2b therapy for
chronic hepatitis C infection. Eur J Gastroenterol Hepatol 1998; 10:
349-51.
Crosignani A, Invernizzi P, Ferrari R, Manzin A, Bruno S, Zuin M,
Bianchi FB, et al. Exacerbation of chronic hepatitis D during
interferon alpha administration. Ital J Gastroenterol Hepatol 1999;
31: 66-9.
Lock G, Reng CM, Graeb C, Anthuber M, Wiedmann KH. Interferoninduced hepatic failure in a patient with hepatitis C. Am J
Kraus I, Vitezic D. Acute hepatitis induced by alpha-interferon in a
patient with chronic hepatitis C. Can J Gastroenterol 2001; 15: 3335.
Kontorinis N, Agarwal K, Elhajj N, Fiel MI, Schiano TD. Pegylated
interferon-induced immune-mediated hepatitis post-liver
transplantation. Liver Transpl. 2006; 12: 827-30
Kogure T, Ueno Y, Fukushima K, Nagasaki F, Inoue J, Kakazu E,
Matsuda Y, et al. Fulminant hepatic failure in a case of autoimmune
hepatitis in hepatitis C during peg-interferon-alpha 2b plus ribavirin
treatment. World J Gastroenterol 2007; 13: 4394-7.
Coriat R, Podevin P. Fulminant autoimmune hepatitis after
successful interferon treatment in an HIV-HCV co-infected patient.
Int J STD AIDS 2008; 19: 208-10.
PENICILLAMIN
Rau R, Weber S, Böni A. [Allergic-toxic liver damage due to Dpenicillamine]. Schweiz Med Wochenschr 1972; 102: 1226-8.
German.
Siegmund H. [Intrahepatic cholestasis after therapy with dpenicillamine and indomethacin]. Med Welt 1976; 27: 172-4.
German.
Sacher M, Thaler H. Toxic hepatitis after therapeutic doses of
benorylate and D-penicillamine. Lancet 1977; 1: 481-2.
Barzilai D, Dickstein G, Enat R, Bassan H, Lichtig C, Gellei B. Case
report: cholestatic jaundice caused by D-penicillamine. Ann Rheum
Dis 1978; 37: 98-100.
McLeod BD, Kinsella TD. Cholestasis associated with D-penicillamine
for rheumatoid arthritis. Can Med Assoc J 1979; 120: 965-6.
Crickx L, Leger JM, Auquier L. [Granulomatous hepatitis and
parotiditis induced by d-penicillamine in a case of rheumatoid
arthritis]. Nouv Presse Med 1979; 8: 212. French. i
Rosenbaum J, Katz WA, Schumacher HR. Hepatotoxicity associated
with use of D-penicillamine in rheumatoid arthritis. Ann Rheum Dis
1980; 39: 152
Seibold JR, Lynch CJ, Medsger TA. Cholestasis associated with Dpenicillamine therapy: case report and review of the literature.
Jensen OH. [Penicillamine induced liver involvement]. Ugeskr
Laeger 1981; 143: 3471-2. Danish.
Multz CV. Cholestatic hepatitis caused by penicillamine. JAMA 1981;
246: 674-5.
Job-Deslandre C, Delrieu F, Rondier J, Guedri M, Delbarre F.
Hepatitie cholestatique et anticorps anti-DNA induits par la dpenicillamine. Nouv Presse Med 1982; 11: 2356-7.
Grauer JL, Fonteille J, Zarski JP, Gintz B, Phelip X, Cabanel G.
[Erythema nodosum and cholestatic hepatitis during treatment with
D-penicillamine]. Presse Med 1983; 12:1997. French.
Gefel D, Hrats N, Lijovetsky G, Eliakim M. Cholestatic jaundice
associated with d-penicillamine therapy. Scand J Rheumatol 1985;
14: 303-6.
Devogelaer JP, Huaux JP, Coche E, Rahier J, Nagant de
Deuxchaisnes C. A case of cholestatic hepatitis associated with Dpenicillamine therapy for rheumatoid arthritis. Int J Clin Pharmacol
Res 1985; 5: 35-8.
Kumar A, Bhat A, Gupta DK, Goel A, Malaviya AN. D-penicillamineinduced acute hypersensitivity pneumonitis and cholestatic hepatitis
in a patient with rheumatoid arthritis. Clin Exp Rheumatol 1985; 3:
337-9.
Choudhuri G, Tandon RK. D-penicillamine induced cholestatic
jaundice. J Assoc Phys India 1986; 34: 299-300.
Roux H, Bonnefoy-Cudraz M, Antipoff GM. [Liver complications
caused by D-penicillamine. Apropos of a case]. Rev Rhum Mal
Osteoartic 1986; 53: 21-3. French.
Berbis P, Fabre JF, Privat Y. [Cholestatic hepatitis: a rare
complication of the treatment with D. penicillamine]. Ann Dermatol
Venereol 1987; 114: 377-9. French.
Guerrero Navarro L, Molina Lorente E, Mur Villacampa M, Revillo
Pinilla P. [Cholestatic hepatitis caused by D-penicillamine]. Rev Esp
Enferm Apar Dig 1988; 73: 221. Spanish.
Fishel B, Tishler M, Caspi D, Yaron M. Fatal aplastic anaemia and
liver toxicity caused by d-penicillamine treatment of rheumatoid
arthritis. Ann Rheum Dis 1989; 48: 609-10.
Jacobs JW, Van der Weide FR, Kruijsen MW. Fatal cholestatic
hepatitis caused by D-penicillamine. Br J Rheumatol 1994; 33: 7703.
PHENOBARBITAL/PENTOBARBITAL
Birch CA. Jaundice due to phenobarbital. Lancet 1936; i: 478-9.
Welton DG. Exfoliative dermatitis and hepatitis due to
phenobarbital. JAMA 1950; 143: 232-4.
McGeachy TE, Bloomer WE. The phenobarbital sensitivity syndrome.
Am J Med 1953; 14: 600-4.
Pagliaro L, Campesi G, Aguglia F. Barbiturate jaundice. Report of a
case due to a barbital-containing drug, with positive rechallenge to
phenobarbital. Gastroenterology 1969; 56: 938-43.
Weisburst M, Self T, Peace R, Cooper J. Jaundice and rash
associated with the use of phenobarbital and hydrochlorothiazide.
South Med J 1976; 69: 126-7.
Evans WE, Self TH, Weisburst MR. Phenobarbital-induced hepatic
dysfunction. Drug Intell Clin Pharm 1976; 10: 439-43.
Thirunavukkaram S, Merk P, Fitzgerald JF. Near-fatal phenobarbital
hepatotoxicity in an 8 year old male. Gastroenterology 1979; 76:
1261.
Shapiro PA, Antonioli DA, Peppercorn MA. Barbiturate-induced
submassive hepatic necrosis. Am J Gastroenterol 1980; 74: 270-3.
Jacobi G, Thorbeck R, Ritz A, Janssen W, Schmidts HL. Fatal
hepatotoxicity in child on phenobarbitone and sodium valproate.
Lancet 1980; 1: 712-3.
Spielberg SP, Gordeon GB, Blake DA, Goldstein DA, Herlong HF.
Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl
J Med 1981; 305: 722-7.
Lane T, Peterson EA. Hepatitis as a manifestation of phenobarbital
hypersensitivity. South Med J 1984; 77: 94.
Knutsen AP, Anderson J, Satayaviboon S, Slavin RG. Immunologic
aspects of phenobarbital hypersensitivity. J Pediatr 1984; 105: 55863.
Kahn HD, Faguet GB, Agee JF, Middleton HM. Drug-induced liver
injury. In vitro demonstration of hypersensitivity to both phenytoin
and phenobarbital. Arch Intern Med 1984; 144; 1677-9.
Palomeque A, Doménech P, Martínez-Gutiérrez A, Lequerica P.
[Severe hypersensitivity to phenobarbital with erythema
multiforme, cholestatic hepatitis and aplastic anemia] An Esp
Pediatr 1986; 24: 328-30. Spanish.
Roberts EA, Spielberg SP, Goldbach M, Phillips MJ. Phenobarbital
hepatotoxicity in an 8-month-old infant. J Hepatol 1990; 10: 235-9.
Di Martino V, Mallat A, Duvoux C, Zafrani ES, Dhumeaux D. [Severe
hepatitis caused by phenobarbital] Gastroenterol Clin Biol 1994; 18:
904-5.
Lachgar T, Touil Y. [The drug hypersensitivity syndrome or DRESS
syndrome to phenobarbital] Allerg Immunol (Paris) 2001; 33: 1735.
Turner RB, Kim CC, Streams BN, Culpepper K, Haynes HA.
Anticonvulsant hypersensitivity syndrome associated with Bellamine
S, a therapy for menopausal symptoms. J Am Acad Dermatol 2004;
50(5 Suppl): S86-9.
Autret-Leca E, Norbert K, Bensouda-Grimaldi L, Jonville-Béra AP,
Saliba E, Bentata J, Barthez-Carpentier MA. [DRESS syndrome, a
drug reaction which remains bad known from paediatricians] Arch
Pediatr 2007; 14: 1439-41.
Di Mizio G, Gambardella A, Labate A, Perna A, Ricci P, Quattrone A.
Hepatonecrosis and cholangitis related to long-term phenobarbital
therapy: an autopsy report of two patients. Seizure 2007; 16: 6536.
PIROXICAM
Zarski JP, Aubert H, Dentant L, Rachail M. [Hepatitis due to nonsteroidal anti-inflammatory agents: a new involved molecule,
piroxicam(Feldène) ?] Gastroenterol Clin Biol 1984; 8: 980-1.
French.
Hartmann H, Fischer G, Janning G. Prolonged cholestatic jaundice
and leukopenia associated with piroxicam Z Gastroenterol 1984;
22: 343-5.
Coscojuela C, Charro L, Guallar A, Ferrer-Dufoll MA, Carapeto FJ.
[Toxic epidermal necrolysis(Lyell's syndrome) caused by piroxicam,
with fatal outcome from disseminated aspergillosis]. Med Cutan
Ibero Lat Am 1985; 13: 291-300. Spanish.
Lee SM, O'Brien CJ, Williams R, Whitaker S, Gould SR. Subacute
hepatic necrosis induced by piroxicam. Br Med J(Clin Res Ed) 1986;
293: 540-1.
Haye OL. Piroxicam and pancreatitis. Ann Intern Med 1986; 104:
895.
Bismuth H, Samuel D, Gugenheim J, Castaing D, Bernuau J, Rueff
B, et al. Emergency liver transplantation for fulminant hepatitis. Ann
Intern Med 1987; 107: 337-41.
Caballeria E, Masso RM, Arago JV, Sanchis A. Piroxicam
Planas R, De Leon R, Quer JC, Barranco C, Bruguera M, Gassull MA.
Fatal submassive necrosis of the liver associated with piroxicam.
Hepps KS, Maliha GM, Estrada R, Goodgame RW. Severe cholestatic
jaundice associated with piroxicam. Gastroenterology 1991; 101:
1737-40.
Sherman KE, Jones C. Hepatotoxicity associated with piroxicam use.
Paterson D, Kerlin P, Walker N, Lynch S, Strong R. Piroxicam
induced submassive necrosis of the liver. Gut 1992; 33: 1436-8.
PROPAFENON
Schuff-Werner P, Kaiser D. [Cholestatic hepatitis following
antiarrhythmic propafenone therapy]. Dtsch Med Wochenschr 1980;
105: 137-8.
Konz KH, Berg PA, Seipel L. [Cholestasis after antiarrhythmic
therapy with propafenone]. Dtsch Med Wochenschr 1984; 109:
1525-7. German
Spinler SA, Elder CA, Kindwall KE. Propafenone-induced liver injury.
Ann Pharmacother 1992; 26: 926-8.
Mondardini A, Pasquino P, Bernardi P, Aluffi E, Tartaglino B,
Mazzucco G, Bonino F, et al. Propafenone-induced liver injury:
report of a case and review of the literature. Gastroenterology
1993; 104: 1524-6.
Elizalde JI, Batallier R, Bruix J, Rodes J. [Hepatotixicity of
propafenone]. Gastroenterol Hepatol 1994; 17: 382-3. Not in
Arinzon Z, Fridman R. [Liver function test impairment induced by
propafenone in a 73 year old woman]. Harefuah 2001; 140: 10103, 1119. Hebrew.
La Brocca A. [Hepatic toxicity of propafenone: a case description].
Ann Ital Med Int 2002; 17: 261-4. Italian.
Grieco A, Forgione A, Giorgi A, Miele L, Gasbarrini G. Propafenonerelated cholestatic hepatitis in an elderly patient. Ital Heart J 2002;
3: 431-4.
Cocozzella D, Curciarello J, Corallini O, Olivera A, Alburquerque MM,
Fraquelli E, Zamagna L, et al. Propafenone hepatotoxicity: report of
two new cases. Dig Dis Sci 2003; 48: 354-7.
Marrtín EP, Cervantes JL, Yangüela J. [Propafenone hepatotoxicity].
Rev Esp Enferm Dig 2004; 96: 734-5. Spanish.
QUININE
Katz B, Weetch M, Chopra S. Quinine-induced granulomatous
hepatitis. Br Med J 1983; 286: 264-5.
Mathur S, Dooley J, Scheuer PJ. Quinine induced granulomatous
hepatitis and vasculitis. BMJ 1990; 300: 613.
Punukollu RC, Kumar S, Mullen KD. Quinine hepatotoxicity: an
under recognized or rare phenomenon? Arch Intern Med 1990; 150:
1112-3.
Perez JA, Stryker J, Arsura EL, Hewitt JM. Probable quinine-induced
hepatotoxicity. West J Med 1994; 160: 59-60.
Horney E, Lagerstedt C, Wadenvik H. [Quinine induced
thrombocytopenia and granulomatous hepatitis]. Lakartidningen
1996; 93: 361-4. Swedish.
Hou M, Horney E, Stockelberg D, Jacobsson S, Kutti J, Wadenvik H.
Multiple quinine-dependent antibodies in a patient with episodic
thrombocytopenia, neutropenia, lymphocytopenia, and
granulomatous hepatitis. Blood 1997; 90: 4806-11.
Farver DK, Lavin MN. Quinine-induced hepatotoxicity. Ann
Pharmacother 1999: 33: 32-4.
Howard MA, Hibbard AB, Terrell DR, Medina PJ, Vesely SK, George
JN. Quinine allergy causing acute severe systemic illness: report of
4 patients manifesting multiple hematologic, renal, and hepatic
abnormalities. Proc(Bayl Univ Med Cent) 2003; 16: 21-6.
Schlegel A. Factitious granulomatous hepatitis? Am J Med 2004;
116: 500-1..
RANITIDINE
Cleator IG. Adverse effects of ranitidine therapy. Can Med Assoc J
1983; 129: 405.
Proctor JD. Hepatitis associated with ranitidine. JAMA 1984; 251:
1554.
Lauritsen K, Havelund T, Rask-Madsen J. Ranitidine and
hepatotoxicity. Lancet 1984; 2: 1471
Bredfeldt JE, von Huene C. Ranitidine, acetaminophen, and
hepatotoxicity. Ann Intern Med 1984; 101: 719.
Souza Lima MA. Hepatitis associated with ranitidine. Ann Intern Med
1984; 101: 207-8.
Karachalios GN. Ranitidine and hepatitis. Ann Intern Med 1985;
103: 634-5.
Ramrakhiani S, Brunt EM, Bacon BR. Possible cholestatic injury from
ranitidine with a review of the literature. Am J Gastroenterol 1998;
93: 822-6.
Luparini RL, Rotundo A, Mattace R, Marigliano V. [Possibly
ranitidine-induced autoimmune hepatitis]. Ann Ital Med Int 2000;
15: 214-7. Italian.
Kantarçeken B, Cetinkaya A, Bülbüloglu E, Yerhan H, Uçar MA.
Severe liver enzyme elevation due to single-dose ranitidine in a
pregnant woman. Turk J Gastroenterol 2006; 17: 242-3.
Desaint B, Alperine M, Legendre C, Florent C, Lévy VG. [Hepatitis
caused by ranitidine]. Gastroenterol Clin Biol 1985; 9: 746-7.
French.
Cherqui B, Desaint B, Legendre C, Lévy VG. [Fatal hepatitis in a
female patient treated with ranitidine]. Gastroenterol Clin Biol
1989; 13: 952-3. French
pii: S0016-5085(15)00311-X.
RIVAROXABAN
Liakoni E, Rätz Bravo AE, Terracciano L, Heim M, Krähenbühl S.
Symptomatic hepatocellular liver injury with hyperbilirubinemia in
two patients treated with rivaroxaban. JAMA Intern Med. 2014
Oct;174(10):1683-6.
Severe Drug-Induced Skin and Liver Injury from Rivaroxaban.
Barrett P, Vuppalanchi R, Masuoka H, Chalasani N.
Dig Dis Sci. 2015 Jan 6. [Epub ahead of print]
Russmann S, Niedrig DF, Budmiger M, Schmidt C, Stieger B4,
Hürlimann S5, Kullak-Ublick GA. Rivaroxaban postmarketing risk of
liver injury. J Hepatol. 2014 Aug;61(2):293-300.
ROSUVASTATIN
Wolters LMM, Van Buuren HR. Rosuvastatin-associated hepatitis
with autoimmune features(letter). Eur J Gastroenterol Hepatol
2005; 17: 589-90.
Merz T, Fuller SH. Elevated serum transaminase levels resulting
from concomitant use of rosuvastatin and amiodarone. Am J Health
Syst Pharm 2007; 64: 1818-21.
Famularo G, Miele L, Minisola G, Grieco A. Liver toxicity of
rosuvastatin therapy. World J Gastroenterol 2007; 13: 1286-8.
Oteri A, Catania MA, Russo A, Salvo F, Giacci L, Caputi AP, Polimeni
G. Reversible acute hepatitis induced by rosuvastatin. South Med J
2008; 101: 768.
Hepatol 2012; 56:374-80.
pii: S0016-5085(15)00311-X.
SERTRALINE
Menon RR, Howard R. Sertraline and liver toxicity in the elderly. Int
J Geriatr Psychiatry 1994; 9: 332-4.
Hautekeete ML, Colle I, van Vlierberghe H, Elewaut A. Symptomatic
liver injury probably related to sertraline. Gastroenterol Clin Biol
1998; 22: 364-5.
Kim KY, Hwang W, Narendran R. Acute liver damage possibly
related to sertraline and venlafaxine ingestion. Ann Pharmacother
1999; 33: 381-2.
Verrico MM, Nace DA, Towers AL. Fulminant chemical hepatitis
possibly associated with donepezil and sertraline therapy. J Am
Geriatr Soc 2000; 48: 1659-63.
Fartoux-Heymann L, Hézode C, Zafrani ES, Dhumeaux D, Mallat A.
Acute fatal hepatitis related to sertraline. J Hepatol 2001; 35: 6834.
Galán Navarro JL. [Acute cholestatic hepatitis probably caused by
sertraline]. Rev Esp Enferm Dig. 2001; 93: 822
Persky S, Reinus JF. Sertraline hepatotoxicity: a case report and
review of the literature on selective serotonin reuptake inhibitor
hepatotoxicity. Dig Dis Sci 2003; 48: 939-44.
Solomons K, Gooch S, Wong A. Toxicity with selective serotonin
reuptake inhibitors. Am J Psychiatry 2005; 162: 1225.
Collados Arroyo V, Plaza Aniorte J, Hallal H, Perez Cuadradob E.
[Hepatotoxicity associated with sertraline]. Farm Hosp 2008; 32:
60-1.
pii: S0016-5085(15)00311-X.
Tabak F, Gunduz F, Tahan V, Tabak O, Ozaras R. Sertraline
hepatotoxicity: report of a case and review of the literature. Dig Dis
Sci. 2009; 54: 1589-91.
Collados V, Hallal H, Andrade RJ. Sertraline hepatotoxicity: report of
a case and review of the literature. Dig Dis Sci 2010; 55: 1806-7.
Suen CF, Boyapati R, Simpson I, Dev A. Acute liver injury
secondary to sertraline. BMJ Case Rep 2013; 2013. pii:
bcr2013201022.
SEVOFLURANE
Ogawa M, Doi K, Mitsufuji T, Satoh K, Takatori T. [Drug induced
hepatitis following sevoflurane anesthesia in a child] Masui 1991;
40: 1542-5. Japanese.
Shichinohe Y, Masuda Y, Takahashi H, Kotaki M, Omote T,
Shichinohe M, Namiki A. [A case of postoperative hepatic injury
after sevoflurane anesthesia] Masui 1992; 41: 1802-5. Japanese.
Watanabe K, Hatakenaka S, Ikemune K, Chigyo Y, Kubozono T, Arai
T. [A case of suspected liver dysfunction induced by sevoflurane
anesthesia] Masui 1993; 42: 902-5. Japanese.
Ohmori H, Seki S, Kanaya N, et al. A case report of postoperative
liver dysfunction following sevoflurane anesthesia after isoflurane
anesthesia. J Jpn Soc Clin Anesth 1994; 14: 68-71.
Bruun LS, Elkjaer S, Bitsch-Larsen D, Andersen O. Hepatic failure in
a child after acetaminophen and sevoflurane exposure. Anesth
Analg 2001; 92: 1446-8.
Reich A, Everding AS, Bulla M, Brinkmann OA, Van Aken H.
Hepatitis after sevoflurane exposure in an infant suffering from
primary hyperoxaluria type 1. Anesth Analg 2004; 99: 370-2, table
of contents.
Jang Y, Kim I. Severe hepatotoxicity after sevoflurane anesthesia in
a child with mild renal dysfunction. Paediatr Anaesth 2005; 15:
1140-4.
Turillazzi E, D'Errico S, Neri M, Riezzo I, Fineschi V. A fatal case of
fulminant hepatic necrosis following sevoflurane anesthesia. Toxicol
Pathol 2007; 35: 840-5.
Alotaibi WM. Severe hepatic dysfunction after sevoflurane exposure.
Saudi Med J 2008; 29: 1344-6.
Fernández-Meré LA, Muñoz González F, Sopena Zubiria LA, Alvarez
Blanco M. [Sevoflurane and liver dysfunction]. Rev Esp Anestesiol
Reanim 2008; 55 :184-5. Spanish.
pii: S0016-5085(15)00311-X.
Zizek D, Ribnikar M, Zizek B, Ferlan-Marolt V. Fatal subacute liver
failure after repeated administration of sevoflurane anaesthesia. Eur
J Gastroenterol Hepatol 2010; 22: 112-5.
Singhal S, Gray T, Guzman G, Verma A, Anand K. Sevoflurane
hepatotoxicity: a case report of sevoflurane hepatic necrosis and
review of the literature. Am J Ther 2010; 17: 219-22.
Nicoll A, Moore D, Njoku D, Hockey B. Repeated exposure to
modern volatile anaesthetics may cause chronic hepatitis as well
as acute liver injury. BMJ Case Rep 2012; 2012.
Masin-Spasovska J, Dimitrovski K, Stavridis S, Stankov O, Dohcev
S, Saidi S, Jakovski K, et al. Acute fulminant hepatatis in kidney
transplant recipient after repeated sevoflurane anesthesia--a case
report and literature review. Curr Drug Saf 2013; 8: 141-4.
Gudnason HO, Björnsson HK, Gardarsdottir M, Thorisson HM,
Olafsson S, Bergmann OM, Björnsson ES. Secondary sclerosing
cholangitis in patients with drug-induced liver injury. Dig Liv Dis
2015.
STAVUDINE
Lenzo NP. Garas BA, French MA. Hepatic steatosis and lactic
acidosis associated with stavudine treatment in an HIV patient: a
case report. AIDS 1997; 11: 1294-6.
Finkle HI. Hepatic mitochondrial toxicity from nucleoside analog
therapy. Arch Pathol Lab Med 1999; 123: 189.
Bleeker-Rovers C, Kadir S, van Leusen R, Richter C. Hepatic
steatosis and lactic acidosis caused by stavudine in an HIV-infected
patient. Neth J Med 2000; 57: 190-3.
ter Hofstede HJ, de Marie S, Foudraine NA, Danner SA, Brinkman K.
Clinical features and risk factors of lactic acidosis following longterm antiretroviral therapy: 4 fatal cases. Int J STD AIDS 2000; 11:
611-6.
Johri S, Alkhuja S, Siviglia G, Soni A. Steatosis-lactic acidosis
syndrome associated with stavudine and lamivudine therapy. AIDS
2000; 14: 1286.
Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC.
Hyperlactatemia and hepatic abnormalities in 10 human
immunodeficiency virus-infected patients receiving nucleoside
analogue combination regimens. Clin Infect Dis 2000; 31: 162-6.
Miller K, Cameron M, Wood L, Dalakas M, Kovacs J. Lactic acidosis
and hepatic steatosis associated with use of stavudine: report of
four cases. Ann Intern Med 2000; 133: 192-6.
Mokrzycki MH, Harris C, May H, Laut J, Palmisano J. Lactic acidosis
associated with stavudine administration: a report of five cases. Clin
Infect Dis 2000; 30: 198-200.
Carr A, Morey A, Mallon P, Williams D, Thorburn DR. Fatal portal
hypertension, liver failure, and mitochondrial dysfunction after HIV1 nucleoside analogue-induced hepatitis and lactic acidaemia.
Lancet 2001; 357: 1412-4.
Koch RO, Graziadel IW, Zangerle R, Romani N, Maier H, Vogel W.
Acute hepatic failure and lactic acidosis associated with
antiretroviral treatment for HIV. Wien Klin Wochenschr 2003; 115:
135-40.
Rivas P, Polo J, de Górgolas M, Fernández-Guerrero ML. Drug
Points: Fatal lactic acidosis associated with tenofovir. BMJ 2003,
327: 711.
Lichterfeld M, Fischer HP, Spengler U, Rockstroh JK. [Fatty liver and
increased serum lactate in a woman with HIV]. Dtsch Med
Wochenschr 2003; 128: 81-4.
Lapadula G, Izzo I, Costarelli S, Cologni G, Bercich L, Casari S,
Gambarotti M, et al. Dideoxynucleoside HIV reverse transcriptase
inhibitors and drug-related hepatotoxicity: a case report. J Med
Case Rep 2007; 1: 19.
Nelson M, Azwa A, Sokwala A, Harania RS, Stebbing J. Fanconi
syndrome and lactic acidosis associated with stavudine and
lamivudine therapy. AIDS 2008; 22: 1374-6.
Fielder J, Rambiki K. Occurrence of stavudine-induced lactic acidosis
in 3 members of an African family. J Int Assoc Physicians AIDS Care
(Chic) 2010; 9: 236-9.
TAMOXIFEN
Ward HW. Anti-oestrogen therapy for breast cancer: a trial of
tamoxifen at two dose levels. Br Med J 1973; 1: 13-4.
Agrawal BL, Zelkowitz L. Bone flare: hypercalcemia and jaundice
after tamoxifen therapy. Arch Intern Med 1981; 141: 1240.
Shah KA, Levin J, Rosen N, Greenwald E, Zumoff B. Allopurinol
hepatotoxicity potentiated by tamoxifen. N Y State J Med 1982; 82:
1745-6.
Loomus GN, Aneja P, Bota RA. A case of peliosis hepatis in
association with tamoxifen therapy. Am J Clin Pathol 1983; 80:
881-3.
Blackburn AM, Amiel SA, Millis RR, Rubens RD. Tamoxifen and liver
damage. Br Med J(Clin Res Ed) 1984; 289(6440): 288.
Ching CK, Smith PG, Long RG. Tamoxifen-associated hepatocellular
damage and agranulocytosis. Lancet 1992; 339: 940.
Maruyama S, Hirayama C, Abe J, Tanaka J, Matsui K. Chronic active
hepatitis and liver cirrhosis in association with combined
tamoxifen/tegafur adjuvant therapy. Dig Dis Sci 1995; 40: 2602-7.
Pratt DS, Knox TA, Erban J. Tamoxifen-induced steatohepatitis. Ann
Intern Med 1995; 123: 236.
Cortez-Pinto H, Baptista A, Camilo ME, de Costa EB, Valente A, de
Moura MC. Tamoxifen-associated steatohepatitis - report of three
cases. J Hepatol 1995; 23: 95-7.
Van Hoof M, Rahier J, Horsmans Y. Tamoxifen-induced
steatohepatitis. Ann Intern Med 1996; 124: 855-6.
Floren LC, Hebert MF, Venook AP, Jordan VC, Cisneros A, Somberg
KA. Tamoxifen in liver disease: potential exacerbation of hepatic
dysfunction. Ann Oncol 1998; 9: 1123-6.
Oien KA, Moffat D, Curry GW, Dickson J, Habeshaw T, Mills PR,
McSween RN. Cirrhosis with steatohepatitis after adjuvant
tamoxifen. Lancet 1999; 353: 36-7.
Saibara T, Onishi S, Ogawa Y, Yoshida S, Enzan H. Bezafibrate for
tamoxifen-induced non-alcoholic steatohepatitis. Lancet 1999; 353:
1802.
Dray X, Tainturier MH, De La Lande P, Marty O, Mallet L. [Cirrhosis
with non alcoholic steatohepatitis: role of tamoxifen]. Gastroenterol
Storen EC, Hay JE, Kaur J, Zahasky K, Hartmann L. Tamoxifeninduced submassive hepatic necrosis. Cancer J 2000; 6: 58-60.
Cai Q, Bensen M, Greene R, Kirchner J. Tamoxifen-induced transient
multifocal hepatic fatty infiltration. Am J Gastroenterol 2000; 95:
277-9.
Kotiloglu G, Aki ZS, Ozyilkan O, Kutlay L. Tamoxifen-induced
cirrhotic process. Breast J 2001; 7: 442-3
Lasso De La Vega MC, Zapater P, Such J, Sola-Vera J, Payá A,
Horga JF, Pérez-Mateo M. [Toxic hepatitis associated with tamoxifen
use. A case report and literature review]. Gastroenterol Hepatol
2002; 25: 247-50. Spanish.
Kanda T, Yokosuka O, Chiba T, Kojima H, Fukai K, Imazeki F,
Saisho H. [A case of steatohepatitis associated with tamoxifen].
Nippon Shokakibyo Gakkai Zasshi 2002; 99: 1119-21.
Rabaglio M, Ruepp B; Soft/Text/Perche Steering Committee. Death
due to liver failure during endocrine therapy for premenopausal
breast cancer. Acta Oncol 2010; 49: 874-6.
pii: S0016-5085(15)00311-X.
TERBINAFINE
Lowe G, Green C, Jennings P. Hepatitis associated with terbinafine
treatment. BMJ 1993; 306: 248.
van ‘t Wout JW, Herrmann WA, de Vries RA, Stricker BHC.
Terbinafine-associated hepatic injury. J Hepatology 1994; 21: 11157.
Ihre-Lundgren C, Frisell J, Bergman U. [A patient treated with
terbinafine. Intrahepatic biliary stasis is a severe adverse effect].
Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC.
Terbinafine-induced cholestatic liver disease. J Hepatol 1996; 24:
753-6.
Boldewijn OY, Ottervanger JP, Mostart CM, Janssens AR, Calame J,
Jonkers GJ. [Hepatitis attributed to the use of terbinafine]. Ned
Vantaux P, Grasset D, Nougue J, Lagier E, Seigneuric C. [Acute
hepatitis related to the ingestion of terbinafine]. Gastroenterol Clin
Biol 1996; 20: 402-3. French.
Dwyer CM, White MI, Sinclair TS. Cholestatic jaundice due to
terbinafine. Br J Dermatol 1997; 136: 976-7.
Mallat A, Zafrani ES, Metreau JM, Dhumeaux D. Terbinafine-induced
prolonged cholestasis with reduction of interlobular bile ducts. Dig
Dis Sci 1997; 42: 1486-8.
Shiloah E, Horowiz M, Zecler E. [Terbinafine-induced cholestatic
liver injury]. Harefuah 1997; 133: 11-2, 80-1. Hebrew.
Tejada García M, Llvona Hevia AM, Martín Arias L, García-Pando AC.
[Terbinafine and cholestatic hepatitis]. Med Clin(Barc) 1997; 109:
356. Spanish.
Vivas S, Rodríguez M, Palacio MA, Cadenas F, Lomo J, Rodrigo L.
[Acute hepatitis associated with terbinafine]. Gastroenterol Hepatol
1997; 20: 456-8. Spanish.
Fernandes NF, Geller SA, Fong TL. Terbinafine hepatotoxicity: case
report and review of the literature. Am J Gastroenterol 1998; 93:
459-60.
Gupta AK, del Rosso JQ, Lynde CW, Brown GH, Shear NH. Hepatitis
associated with terbinafine therapy: three case reports and a review
of the literature. Clin Exp Dermatol 1998; 23: 64-7.
Agarwal K, Manas DM, Hudson M. Terbinafine and fulminant hepatic
failure. N Engl J Med 1999; 340: 1292-3.
Chambers WM, Millar A, Jain S, Burroughs AK. Terbinafine-induced
hepatic dysfunction. Eur J Gastroenterol Hepatol 2001; 13: 1115-8.
Conjeevaram G, Vongthavaravat V, Sumner R, Koff RS. Terbinafineinduced hepatitis and pancytopenia. Dig Dis Sci 2001; 46: 1714-6.
Johnstone D, Berger C, Fleckman P. Acute fulminant hepatitis after
treatment with rabeprazole and terbinafine. Arch Intern Med 2001;
161: 1677-8.
Anania FA, Rabin L. Terbinafine hepatotoxicity resulting in chronic
biliary ductopenia and portal fibrosis. Am J Med 2002; 112: 741-2.
Walter RB, Lukaschek J, Renner EL, Müllhaupt B, Bachli EB. Fatal
hepatic veno-occlusive disease associated with terbinafine in a liver
transplant recipient. J Hepatol 2003; 38: 373-4.
Zapata Garrido AJ, Romo AC, Padilla FB. Terbinafine hepatotoxicity.
A case report and review of the literature. Ann Hepatol 2003; 2: 4751.
Ajit C, Suvannasankha A, Zaeri N, Munoz SJ. Terbinafine-associated
hepatotoxicity. Am J Med Sci 2003; 325: 292-5.
Burstein Z, Vildosola H, Lozano Z, Verona R, Vargas G. Colestasic
toxic hepatitis caused by terbinafine: case report. Rev Gastroenterol
Peru 2004; 24: 357-62. Spanish.
Perveze Z, Johnson MW, Rubin RA, Sellers M, Zayas C, Jones JL,
Cross R, et al. Terbinafine-induced hepatic failure requiring liver
transplantation. Liver Transpl 2007; 13: 162-4.
Gendre G, Buclin T, Morard I, Fontannaz J, Berney JL. [Terbinafine
induced hepatitis with persistent cholestasis]. Rev Med Suisse 2008;
4: 736-9. French.
THIABENDAZOLE
Jalota R, Freston JW. Severe intrahepatic cholestasis due to
thiabendazole. Am J Trop Med Hyg 1974; 23: 676-8.
Feregrino Goyos M, Lifshitz Guinzberg A, Hernández Berumen A,
Ramírez Degollado J, Cervantes LF. [Intrahepatic cholestasis by
thiabendazole treated with phenobarbital]. Prensa Med Mex 1976;
41: 167-71. Spanish.
Fink AI, MacKay CJ, Cutler SS. Sicca complex and cholestatic
jaundice in two members of a family caused by thiabendazole.
Trans Am Ophthalmol Soc 1978; 76: 108-15.
Fink AI, MacKay CJ, Cutler SS. Sicca complex and cholangiostatic
jaundice in two members of a family probably caused by
thiabendazole. Ophthalmology 1979; 86: 1892-6.
Rex D, Lumeng L, Eble J, Rex L. Intrahepatic cholestasis and sicca
complex after thiabendazole. Report of a case and review of the
literature. Gastroenterology 1983; 85: 718-21.
Manivel JC, Bloomer JR, Snover DC. Progressive bile duct injury
after thiabendazole administration. Gastroenterology 1987; 93:
245-9.
Davidson RN, Weir WR, Kaye GL, McIntyre N. Intrahepatic
cholestasis after thiabendazole. Trans R Soc Trop Med Hyg 1988;
82: 620.
Roy MA, Nugent FW, Aretz HT. Micronodular cirrhosis after
thiabendazole. Dig Dis Sci 1989; 34: 938-41.
Bion E, Pariente EA, Maitre F. Severe cholestasis and sicca
syndrome after thiabendazole. J Hepatol 1995; 23: 762-3.
Skandrani K, Richardet JP, Duvoux C, Cherqui D, Zafrani ES,
Dhumeaux D. [Hepatic transplantation for severe ductopenia related
to ingestion of thiabendazole]. Gastroenterol Clin Biol 1997; 21:
623-5. French.
Eland IA, Kerkhof SC, Overbosch D, Wismans PJ, Stricker BH.
[Cholestatic hepatitis ascribed to the use of thiabendazole]. Ned
Groh M, Blanche P, Calmus Y, Guillevin L. Thiabendazole-induced
acute liver failure requiring transplantation and subsequent
diagnosis of polyarteritis nodosa. Clin Exp Rheumatol 2012; 30 (1
Suppl 70): S107-9.
THIORIDAZINE
Block SL. Jaundice following thioridazine administration. Am J
Psychol 1962; 119: 77.
Winkelmayer R. Subicterus following the administration of
thioridazine and chlordiazepoxide. Del Med J 1966; 38: 334-6.
Reinhart MJ, Benson RM, Kwass SK, Storey WF. Suggestive
evidence of hepatotoxicity concomitant with thioridazine
hydrochloride use. JAMA 1966; 197: 767-9.
Walker CO, Combes B. Biliary cirrhosis induced by chlorpromazine.
Barancik M, Brandborg LL, Albion MJ. Thioridazine-induced
cholestasis. JAMA 1967; 200: 69-70.
Kane FJ Jr, Moore LP. Hepatotoxicity occurring with thioridazine
therapy. South Med J 1971; 64: 573.
Kane FJ Jr, Moore LP. Hepatotoxicity occurring with thioridazine
therapy. South Med J 1971; 64: 573.
Weiden PL, Buckner CD. Thioridazine toxicity. Agranulocytosis and
hepatitis with encephalopathy. JAMA 1973; 224: 518-20.
Kristensen O. [Icterus induced by thioridazine(Melleril). Report of 1
case]. Tidsskr Nor Laegeforen 1975; 95: 1910-1. Norwegian.
Urberg M. Thioridazine-induced non-icteric hepatotoxicity. Report of
a case. J Fam Pract 1990; 30: 342-3.
VENLAFAXIN/DESVENLAFAXIN
Horsmans Y, De Clercq M, Sernpoux C. Venlafaxine-associated
Cardona X, Avila A, Castellanos P. Venlafaxine-associated hepatitis.
Ann Intern Med 1999; 130: 944.
Carvajal García-Pando A, García del Pozo J, Sánchez AS, Velasco
MA, Rueda de Castro AM, Lucena MI. Hepatotoxicity associated with
the new antidepressants. J Clin Psychiatry 2002; 63: 135-7.
Maroy B. Hepatite aigue cytolytique apres devenlafaxine. [Acute
cytolytic hepatitis after venlafaxine therapy]. Gastroenterol Clin Biol
2002; 26: 804. French.
Phillips BB, Digmann RR, Beck MG. Hepatitis associated with lowdose venlafaxine for postmenopausal vasomotor symptoms.
AnnPharmacother 2006; 40: 323-7.
Yildirim B, Tuncer C, Ergun M, Unal S. Venlafaxine-induced
hepatotoxicity in a patient with ulcerative colitis. Ann Hepatol 2009;
8: 271-2.
Arroyo VC, Hallal H, Agudo JL, Aniorte JP. [Venlafaxine-induced
cholestatic hepatitis]. Gastroenterol Hepatol 2009; 32: 382-3.
Spanish.
liver injury in the generalpopulation of Iceland. Gastroenterology
2013; 144: 1419-25.
VORICONAZOLE
Porte L, Khatibi S, Hajj LE, Cassaing S, Berry A, Massip P, Linas MD,
et al. Scedosporium apiospermum mycetoma with bone
involvement successfully treated with voriconazole. Trans R Soc
Trop Med Hyg 2006; 100: 891-4.
Foo H, Gottlieb T. Lack of cross-hepatotoxicity between voriconazole
and posaconazole. Clin Infect Dis 2007; 45: 803-5.
Belaiche S, Roustit M, Bedouch P, Quetant S, Saint-Raymond C,
Pison C. Management of voriconazole hepatotoxicity in a lung
transplant patient. Transpl Infect Dis 2011 ; 13: 309-11.
Solís-Muñoz P, López JC, Bernal W, Willars C, Verma A, Heneghan
MA, Wendon J, Auzinger G. Voriconazole hepatotoxicity in severe
liver dysfunction. J Infect. 2013 Jan;66(1):80-6.
ZIDOVUDINE
Melamed AJ, Muller RJ, Gold JW, Campbell SW, Kleinberg MI,
Armstrong D. Possible zidovudine-induced hepatotoxicity. JAMA
1987; 258: 2063.
Dubin G, Braffman MN. Zidovudine-induced hepatotoxicity. Ann
Intern Med 1989; 110: 85.
Jolliet P, Widman JJ. Reye’s syndrome in adult with AIDS. Lancet
1990; 335: 1457.
Wassef M, Keiser P. Hypersensitivity to zidovudine: report of a case
of anaphylaxis and review of the literature. Clin Infect Dis 1995; 20:
1387-9.
Hochster H, Dieterich D, Bozzette S, Reichman RC, Connor JD,
Liebes L, Sonke RL, et al. Toxicity of combined ganciclovir and
zidovudine for cytomegalovirus disease associated with AIDS. An
AIDS Clinical Trials Group Study. Ann Intern Med 1990; 113: 111-7.
Henry K, Acosta EP, Jochimsen E. Hepatotoxicity and rash
associated with zidovudine and zalcitabine chemoprophylaxis. Ann
Intern Med 1996; 124: 855.
Charton-Bain MC, Flamant M, Aubertin JM, Belair MF, Gilquin J,
Kazatchkine M, Bruneval P. [Lactic acidosis and hepatic
mitochondrial changes during a treatment with zidovudine].
Sundar K, Suarez M, Banagon P, Shapiro J. Zidovudine-induced
fatal lactic acidosis and hepatic failure in patients with acquired
immunodeficiency syndrome: report of two patients and review of
the literature. Crit Care Med 1997; 25: 1425-39.
Chariot P, Drogou I, de Lacroix-Szmania I, Eliezer-Vanerot M,
Chazaud B, Lombès A, Schaeffer A, et al. Zidovudine-induced
mitochondrial disorder with massive liver steatosis, myopathy, lactic
acidosis, and mitochondrial DNA depletion. J Hepatol 1999; 30:
156-60.
Hill JB, Sheffield JS, Zeeman GG, Wendel GD Jr. Hepatotoxicity with
antiretroviral treatment of pregnant women. Obstet Gynecol 2001;
98: 909-11.
Church JA, Mitchell WG, Gonzalez-Gomez I, Christensen J, Vu TH,
Dimauro S, Boles RG. Mitochondrial DNA depletion, near-fatal
metabolic acidosis, and liver failure in an HIV-infected child treated
with combination antiretroviral therapy. J Pediatr 2001; 138: 74851.
ABACAVIR
Giola M, Basilico C, Grossi P. Fatal lactic acidosis associated with
tenofovir and abacavir. Int J Infect Dis 2005; 9: 228-9.
Soni S, Churchill DR, Gilleece Y. Abacavir-induced hepatotoxicity: a
report of two cases. AIDS 2008; 22: 2557-8.
Di Filippo E, Ripamonti D, Rizzi M. Abacavir-induced liver toxicity in
an HIV-infected patient. AIDS 2014; 28: 613.
Di Filippo E, Ripamonti D, Rizzi M. Abacavir-induced liver toxicity in
an HIV-infected patient. AIDS. 2014 Feb 20;28(4):613. prob
ACEBUTOLOL
Tanner LA, Bosco LA, Zimmerman HJ. Ann Intern Med. Hepatic
toxicity after acebutolol therapy. Ann Intern Med. 1989;111: 533-4.
ACITRETININ
Leithead JA, Simpson KJ, MacGilchrist AJ. Fulminant hepatic failure
following overdose of the vitamin A metabolite acitretin.
Eur J Gastroenterol Hepatol. 2009 Feb;21(2):230-2. prob
Kreiss C, Amin S, Nalesnik MA, Chopra K, Shakil AO. Severe
cholestatic hepatitis in a patient taking acitretin. Am J
Gastroenterol. 2002 Mar;97(3):775-7.prob
Coschieri M, Philippon A, Quinsat D, Dor JF, Chichmanian RM.
[Acute hepatic involvement during ingestion of acitretin].
Gastroenterol Clin Biol. 1993;17(10):769-70. French. poss
ADALIMUMAB
Massarotti M, Marasini B. Successful treatment with etanercept of a
patient with psoriatic arthritis after adalimumab-related
hepatotoxicity. Int J Immunopathol Pharmacol. 2009 AprJun;22(2):547-9.
Adar T, Mizrahi M, Pappo O, Scheiman-Elazary A, Shibolet O.
Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol.
2010 Jan;44(1):e20-2.
Féau S, Causse X, Corondan A, Michenet P, Autret-Leca E.[Acute
drug-induced hepatitis during adalimumab and ibuprofen
treatment].Gastroenterol Clin Biol. 2010 Aug-Sep;34(6-7):420-2.
Hagel S, Bruns T, Theis B, Herrmann A, Stallmach A. Subacute liver
failure induced by adalimumab. Int J Clin Pharmacol Ther. 2011
Jan;49(1):38-40.
Grasland A, Sterpu R, Boussoukaya S, Mahe I. Autoimmune
hepatitis induced by adalimumab with successful switch to
abatacept. Eur J Clin Pharmacol. 2012 May;68(5):895-8
Titos Arcos JC, Hallal H, Robles M, Andrade RJ. Recurrent
hepatotoxicity associated with etanercept and adalimumab but not
with infliximab in a patient with rheumatoid arthritis. Rev Esp
Enferm Dig. 2012 May;104(5):282-4
Perdan-Pirkmajer K, Hočevar A, Rotar Ž, Žibert J, Marolt VF, Gučev
F, Tomšič M. Tumour necrosis factor-alpha inhibitor-induced hepatic
injury in patients with rheumatoid arthritis: two case reports and an
analysis of the laboratory data from the Slovenian national
biologicals registry. Rheumatol Int. 2013 Nov;33(11):2885-8,
1=case
DE, Serrano J, Rochon J, Fontana RJ, Bonacini M; US Drug-Induced
Liver Injury Network. Liver injury from tumor necrosis factor-α
antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol
2013; 11: 558-564.
Latus J, Klein R, Koetter I, Schwab M, Fritz P, Kimmel M, Alscher
MD, Braun N.Cholestatic liver disease after rituximab and
adalimumab and the possible role of cross-reacting antibodies to
Fab 2 fragments. PLoS One. 2013 Nov 11;8(11):e78856
R, Ludviksson BR, Gudbjörnsson B, Olafsson O. The risk of druginduced liver injury from Tumor Necrosis Factor (TNF)-alphaantagonists. Clin Gastroenterol Hepatol. 2014.
ALBENDAZOLE
Choudhuri G, Prasad RN. Jaundice due to albendazole. Indian J
Choi GY, Yang HW, Cho SH, Kang DW, Go H, Lee WC, Lee YJ, et al.
Acute drug-induced hepatitis caused by albendazole. J Korean Med
Sci 2008; 23: 903-5.
Mikić D, Jevtić M, Arsić-Komljenović G, Ristanović E, Stanković N,
Sjenicić G, Janićijević-Hudomal S. [Impossibility of the treatment of
inoperable liver multicystic echinococcosis due to adverse reactions
to antihelminitics]. Vojnosanit Pregl 2009; 66: 833-9.
Amoruso C, Fuoti M, Miceli V, Zito E, Celano MR, De Giorgi A,
Nebbia G. [Acute hepatitis as a side effect of albendazole: a
pediatric case]. Pediatr Med Chir 2009; 31: 176-8. Italian.
Marin Zuluaga JI, Marin Castro AE, Perez Cadavid JC, Restrepo
Gutierrez JC. Albendazole-induced granulomatous hepatitis: a case
report. J Med Case Rep 2013; 7: 201.
Gözüküçük R. Albendazole-induced toxic hepatitis: A case report.
Turk J Gastroenterol 2013; 24: 82-3.
Sıvgın S, Eser B, Kaynar L, Kurnaz F, Sıvgın H, Yazar S, Cetin M, et
al. Encephalitozoon intestinalis: a rare cause of diarrhea in an
allogeneic hematopoietic stem cell transplantation (HSCT) recipient
complicated by albendazole-related hepatotoxicity. Turk J Haematol
2013; 30: 204-8.
Shah C, Mahapatra A, Shukla A, Bhatia S. Recurrent acute hepatitis
caused by albendazole. Trop Gastroenterol 2013; 34: 38-9.
Ben Fredj N, Chaabane A, Chadly Z, Ben Fadhel N, Boughattas NA,
Aouam K. Albendazole-induced associated acute hepatitis and
bicytopenia. Scand J Infect Dis. 2014 Feb;46(2):149-51. prob
Nandi M, Sarkar S. Albendazole-induced recurrent hepatitis.
Indian Pediatr. 2013 Nov 8;50(11):1064. No abstract available.
prob
ALFUZOSIN
Titos-Arcos JC, Hallal H, Andrade RJ, López Martín A.[Recurrent
hepatocellular lesion due to alfuzosin].Gastroenterol Hepatol. 2011
Feb;34(2):125-7. Spanish. No abstract available.
Kim SY, Kim BH, Dong SH, Kim HJ, Chang YW, Chang R, Kim YW.
Alfuzosin-induced acute liver injury. Korean J Hepatol. 2007
Sep;13(3):414-8.
Yolcu OF, Köklü S, Köksal AS, Yüksel O, Beyazit Y, Basar
O.Alfuzosin-induced acute hepatitis in a patient with chronic liver
disease.Ann Pharmacother. 2004 Sep;38(9):1443-5.
Zabala S, Thomson C, Valdearcos S, Gascón A, Pina MA. Alfuzosininduced hepatotoxicity. J Clin Pharm Ther. 2000 Feb;25(1):73-4.
AMLODIPINE
Basile C, Mascia E. Dihydropyridine calcium channel blockers: a rare
and reversible cause of hepatotoxicity with cholestasis in a CAPD
patient. Nephrol Dial Transplant 1999; 14: 2776-7.
Lafuente NG. Calcium channel blockers and hepatotoxicity. Am J
Gastroenterol 2000; 95: 2145.
Khemissa-Akouz F, Ouguergouz F, Sulem P, Tkoub el M, Vaucher E.
Amlodipine-induced acute hepatitis. Gastroenterol Clin Biol 2002;
26: 637-8.
Lopez Vivancos J, Bara Olivan B, Muniz Garcia R. [Toxic hepatitis
caused by amlodipine] Gastroenterol Hepatol 2002; 25: 112.
Spanish.
Zinsser P, Meyer-Wyss B, Rich P. Hepatotoxicity induced by
celecoxib and amlodipine. Swiss Med Wkly. 2004 Apr 3;134(1314):201. N
de Luis DA, Aller R, Moreira V.[Hepatic toxicity and amlodipine].
Med Clin (Barc). 1998 May 9;110(16):638-9. Spanish.
Amphetamine
Harvey JK, Todd CW, Howard JW. Fatality associated with
benzedrine ingestion; a case report. Del Med J 1949; 21: 111-5.
Ginsberg MD, Hertzmann M, Schmidt-Nowara WW. Amphetamine
intoxication with coagulopathy, hyperthermia and reversible renal
failure. Ann Intern Med 1970; 73: 81-5.
Jones AL, Jarvie DR, McDermid G, Proudfoot AT. Hepatocellular
damage following amphetamine intoxication. J Toxicol Clin Toxicol
1994; 32: 435-44.
Hood B, Nowicki MJ. Eosinophilic hepatitis in an adolescent during
lisdexamfetamine dimesylate treatment for ADHD. Pediatrics 2010;
125: e1510-3.
AMPHOTERICIN B
Gill J, Sprenger H, Ralph E, Sharpe M. Hepatotoxicity possibly
caused by amphotericin B. Ann Pharmacother 1999; 33: 683-5.
PubMed Citation]
Mohan U, Bush A. Amphotericin B-induced hepatorenal failure in
cystic fibrosis. Ped Pulmonol 2002; 33: 497-500.
Miller M. Reversible hepatotoxicity related to amphotericin B. Can
Med Assoc J 1984; 131: 1245-7.
Campo C, Antón E, Morata C, Lacruz J. [Amphotericin B associated
with severe liver toxicity]. Rev Clin Esp 1999; 199: 49.
Michot JM, Gubavu C, Fourn E, Maigne G, Teicher E, Angoulvant A,
Blanche S, et al. Very prolonged liposomal amphotericin B use
leading to a lysosomal storage disease. Int J Antimicrob Agents
2014 Apr 12. pii:
AMPICILLIN
McArthur JE, Dyment PG. Stevens-Johnson syndrome with hepatitis
following therapy with ampicillin and cephalexin. NZ Med J 1975;
81: 390-2.
Cavanzo FJ, Garcia CF, Botero RC. Chronic cholestasis, paucity of
bile ducts, red cell aplasia, and the Stevens-Johnson syndrome. An
ampicillin-associated case. Gastroenterology 1990; 99: 854-6.
Köklü S, Yüksel O, Filik L, Usküdar O, Altundag K, Altiparmak E.
Recurrent cholestasis due to ampicillin. Ann Pharmacother 2003;
37: 395-7.
Björnsson E, Davidsdottir L. The long-term follow-up after
idiosyncratic drug-induced liver injury with jaundice. J Hepatol
2009; 50: 511-7.
ANAKINRA
Diallo A, Mekinian A, Boukari L, Mouas H, Zamy M, Nahon P, Gérin
M, et al. [Severe hepatitis in a patient with adult-onset Still's
disease treated with anakinra]. Rev Med Interne 2013; 34:168-70.
Aly L, Iking-Konert C, Quaas A, Benten D. Subacute liver failure
following anakinra treatment for adult-onset Still disease. J
Rheumatol 2013; 40(10): 1775-7.
Canna S, Frankovich J, Higgins G, Narkewicz MR, Nash SR, Hollister
JR, Soep JB, Dragone LL. Acute hepatitis in three patients with
systemic juvenile idiopathic arthritis taking interleukin-1 receptor
antagonist. Pediatr Rheumatol Online J. 2009 Dec 22;7:21. n=3
ATOMEXITINE
Lim JR, Faught PR, Chalasani NP, Molleston JP. Severe liver injury
after initiating therapy with atomoxetine in two children. J Pediatr
2006; 148: 831-4.
Stojanovski SD, Casavant MJ, Mousa HM, Baker P, Nahata MC.
Atomoxetine-induced hepatitis in a child. Clin Toxicol (Phila) 2007;
45: 51-5.
Molleston JP, Fontana RJ, Lopez MJ, Kleiner DE, Gu J, Chalasani N:
Erdogan A, Ozcay F, Piskin E, Karaman MG, Bilezikci B, Calik M,
Tekin I, et al. Idiosyncratic liver failure probably associated with
atomoxetine: a case report. J Child Adolesc Pscyhopharmacol 2011;
21: 295-7.
BOSENTAN
Nagai Y, Okada E, Mihara S, Sato K, Ohi S, Ishikawa O.
Severe liver dysfunction due to bosentan in a patient with mixed
connective tissue disease. Eur J Dermatol. 2008 MarApr;18(2):190-1.
Mulchey K, Bshouty Z. An atypical presentation of liver enzyme
elevation resulting from bosentan use. Can Respir J. 2009 SepOct;16(5):e54-6.
Dwyer N, Jones G, Kilpatrick D.Severe hepatotoxicity in a patient on
bosentan upon addition of methotrexate: reversible with resumption
of methotrexate without bosentan. J Clin Rheumatol. 2009
Mar;15(2):88-9.
Eriksson C, Gustavsson A, Kronvall T, Tysk C.Hepatotoxicity by
bosentan in a patient with portopulmonary hypertension: a casereport and review of the literature. J Gastrointestin Liver Dis. 2011
Mar;20(1):77-80.
Don GW, Joseph F, Celermajer DS, Corte TJ. Ironic case of hepatic
dysfunction following the global withdrawal of sitaxentan. Intern
Med J. 2012 Dec;42(12):1351-4.
pii: S0016-5085(15)00311-X.
BUPROPION
Oslin DW, Duffy K. The rise of serum aminotransferases in a patient
treated with bupropion. J Clin Psychopharmacol. 1993; 13: 364-5.
Hu KQ, Tiyyagura L, Kanel G, Redeker AG. Acute hepatitis induced
by bupropion. Dig Dis Sci 2000; 45: 1872-3.
Alvaro D, Onetti-Muda A, Moscatelli R, Atili AF. Acute cholestatic
hepatitis induced by bupropion prescribed as pharmacological
support to stop smoking. A case report. Dig Liver Dis 2001; 33:
703-6.
Bagshaw SM, Cload B, Gilmour J, Leung ST, Bowen TJ. Druginduced rash with eosinophilia and systemic symptoms syndrome
with bupropion administration. Ann Allergy Asthma Immunol 2003;
90: 572-5.
Khoo A-L, Tham L-S, Lee K-H, Lim G-K. Acute liver failure with
concurrent bupropion and carbimazole therapy. Ann Pharmacother
2003; 37: 220-3.
pii: S0016-5085(15)00311-X.
Humayun F, Shehab TM, Tworek JA, Fontana RJ. A fatal case of
bupropion (Zyban) hepatotoxicity with autoimmune features: Case
report. J Med Case Reports 2007; 1: 88.
Alonso Rodríguez L, Barcina Pajares R, Fuentes Vigil J, Gutiérrez
González A, Rodríguez Pérez L. [Acute toxic hepatitis secondary to
a single dose of bupropion]. Gastroenterol Hepatol 2010; 33: 5479. Spanish.
CANDESARTAN
González-Jiménez D, Varela JM, Calderón E, Galindo J, González de
la Puente MA.
Candesartan and acute liver injury. Eur J Clin Pharmacol. 2000
Dec;56(9-10):769-70
Vallejo I, García Morillo S, Pamies E.[Acute hepatitis induced by
candesartan].Med Clin (Barc). 2000 Nov 25;115(18):719. Spanish.
Basile G, Villari D, Gangemi S, Ferrara T, Accetta MG, Nicita-Mauro
V. Candesartan cilexetil-induced severe hepatotoxicity. J Clin
Sturm N, Hilleret MN, Dreyfus T, Barnoud D, Leroy V, Zarski JP.
[Candesartan Cilexetil (Atacand) induced prolonged severe
cholestasis improved by extracorporeal albumin dialysis].
Gastroenterol Clin Biol. 2005 Dec;29(12):1299-301. French.
Jiménez-Sáenz M, Arroyo Q, Sanjuan M, Herrerías JM.
[Candesartan-induced cholestatic hepatitis: a case report].
Gastroenterol Hepatol. 2010 Jan;33(1):66-7.
CEPHALEXIN
Agrawal A, Rao M, Jasdanwala S, Mathur A, Eng M.Cephalexin
induced cholestatic jaundice. Case Rep Gastrointest Med.
2014;2014:260743.
Skoog SM, Smyrk TC, Talwalkar JA. Cephalexin induced cholestatic
hepatitis,” Journal of Clinical Gastroenterology J Clin Gastroenterol.
2004 Oct;38(9):833
Singla A, H. T. Hazem, and G. M. Hammoud, “Uncommon
cause of acute drug-induced liver injury following mammoplasty,”
Gastroenterology Research 2010; 3: 171–172.
Fung-Herrera CG, Mulvaney WP. Cephalexin nephrotoxicity.
Reversible nonoliguric acute renal failure and hepatotoxicity
associated with Cephalexin therapy. JAMA 1974; 229: 318-319.
CITALOPRAM
Milkiewicz P, Chilton AP, Hubscher SG, Elias E. Antidepressant
induced cholestasis: hepatocellular redistribution of multidrug
resistant protein (MRP2). Gut 2003; 52: 300-3.
Lopez-Torres E, Lucena MI, Seoane J, Verge C, Andrade RJ.
Hepatotoxicity related to citalopram. Am J Psychiatry 2004; 161:
923-4.
Neumann H, Csepregi A, Evert M, Malfertheiner P. Drug-induced
liver disease related to citalopram. J Clin Psychopharmacol 2008;
28: 254-5.
Merino MI, Carrero AA, García JF, Martínez JA. [Citalopram
hepatotoxicity]. Med Clin (Barc) 2011; 136: 270-1. Spanish.
CLOMIPHEN
Balasch J, Carmona F, Llach J, Arroyo V, Jové I, Vanrell JA.
Acute prerenal failure and liver dysfunction in a patient with severe
ovarian hyperstimulation syndrome. Hum Reprod. 1990
Apr;5(3):348-51.
Marsepoil T, Cordesse A, Varguy P, Dauptain G, Levesque P.
[Hepatic involvement in the course of ovarian hyperstimulation
syndrome]. Rev Fr Gynecol Obstet. 1992 Mar;87(3):148-9.
Wakim AN, Fox SD. Elevated liver function tests in a case of
moderate ovarian hyperstimulation syndrome. Hum Reprod. 1996
Mar;11(3):588-9.
Nawroth F, Heinrich J, Bruns U, Wood WG. Severe ovarian
hyperstimulation syndrome (OHSS) and icterus. Hum Reprod. 1996
Nov;11(11):2441-2.
Shimono J, Tsuji H, Azuma K, Hashiguchi M, Fujishima M. A rare
case of hepatic injury associated with ovarian hyperstimulation
syndrome. Am J Gastroenterol. 1998 Jan;93(1):123-4.
Obrzut B, Kuczyński W, Grygoruk C, Putowski L, Kluz S, Skret
A.Liver dysfunction in severe ovarian hyperstimulation syndrome.
Gynecol Endocrinol. 2005 Jul;21(1):45-9.
CYPROHEPTADINE
Freneaux E, Larrey D, Berson A, Pessayre D, Benhamou JP.
[Hepatitis caused by cyproheptadine (Periactine). A case and review
of the literature]. Gastroenterol Clin Biol. 1988 Jun-Jul;12(67):573-5. Review. French.
Larrey D, Geneve J, Pessayre D, Machayekhi JP, Degott C,
Benhamou JP. Prolonged cholestasis after cyproheptadine-induced
acute hepatitis. J Clin Gastroenterol. 1987 Feb;9(1):102-4.
Henry DA, Lowe JM, Donnelly T.Jaundice during cyproheptadine
treatment. Br Med J. 1978 Mar 25;1(6115):753
Karkalas Y, Lal H.Jaundice following therapy with imipramine and
cyproheptadine. Clin Toxicol. 1971 Mar;4(1):47-53.
CYTARABINE
George CB, Mansour RP, Redmond J 3rd, Gandara DR. Hepatic
dysfunction and jaundice following high-dose cytosine arabinoside.
Cancer 1984; 54: 2360-2.
Hashimoto M, Seekikawa I, Saito K, Horie S, Ishiyama T, Sugimoto
M, Wakabayashi Y, Hirose S. [Acute leukemia complicated by
hyperbilirubinemia due to high dose cytosine arabinoside therapy].
Rinsho Ketsueki 1989; 30: 262-5. Japanese.
Wysocki M, Nowaczyk-Michalak A, Pilecki O, Trybu. L, Balcar-Boro.
A. Jaundice following high-dose arabinoside cytosine in a child with
acute myelogenous leukemia. Acta Haematol Pol 1992; 23: 197-9.
Tanaka M, Kanamori H, Yamaji S, Mishima A, Fujita H, Fujisawa S,
Murata T, et al. Low-dose cytarabine-induced hepatic and renal
dysfunction in a patient with myelodysplastic syndrome. Anticancer
Drugs 1999; 10: 289-91.
DACTINOMYCIN
Mihevc-Srakar N, Petrić-Grabnar G. [Actinomycin D: toxic effects
with special reference to hepatic injury]. Bilt Hematol Transfuz
1979; 7: 85-90.
Green DM, Finklestein JZ, Norkool P, D'Angio GJ. Severe hepatic
toxicity after treatment with single-dose dactinomycin and
vincristine. A report of the National Wilms' Tumor Study. Cancer
1988; 62: 270-3.
DAPTOMYCIN
Abraham G, Finkelberg D, Spooner LM. Daptomycin-induced acute
renal and hepatic toxicity without rhabdomyolysis. Ann
Farruggia P, Macaluso A, Tropia S, Di Marco F, Russo D, Grigoli A,
Trizzino A, D'Angelo P. Hepatopathy-thrombocytopenia syndrome
(HTS) after actinomycin-D therapy: report of three cases and
review of the literature. Pediatr Hematol Oncol. 2011
Apr;28(3):237-43.
DESFLURANE
Tung D, Yoshida EM, Wang CS, Steinbrecher UP. Severe desflurane
hepatotoxicity after colon surgery in an elderly patient. Can J
Anaesth 2005; 52: 133-6.
Martin JL, Plevak DJ, Flannery KD, Charlton M, Poerucha JJ,
Humphreys CE, Derfus G, Pohl L. Hepatotoxicity after desflurane
anesthesia. Anesthesiology 1995; 83: 1125-9.
Berghaus TM, Baron A, Geier A, Lamerz R, Paumgartner G.
Hepatotoxicity following desflurane anesthesia. Hepatology 1999;
29: 613-4.
Côté G, Bouchard S. Hepatotoxicity after desflurane anesthesia in a
15 month old child with Mobius syndrome after previous exposure
to isoflurane. Anesthesiology 2007; 107: 843-5.
pii: S0016-5085(15)00311-X.
Chin MW, Njoku DB, MacQuillan G, Cheng WS, Kontorinis N.
Desflurane-induced acute liver failure. Med J Aust 2008; 189: 2934.
DIFLUNISAL
Geoffroy P, Carteret E, Salagnac V, Kalis B, Zeitoun P. [Hepatitis
caused by diflunisal (Dolobis). Apropos of a case]. Therapie. 1987;
42: 253. French.
Warren NS. Diflunisal-induced cholestatic jaundice. Br Med J 1978;
2: 736-7.
Cook DJ, Achong MR, Murphy FR. Three cases of diflunisal
hypersensitivity. Canad Med Assoc J 1988; 138: 1029-30.
Muller AF, Toghill PJ, Smith P. "Relapse of chronic active
hepatitis"not always what it seems. Postgrad Med J 1996; 72: 4312.
DILTIAZEM
Scolnick B, Brinberg D. Diltiazem and generalized
lymphadenopathy. Ann Intern Med 1985; 102: 558.
Sarachek NS, London RL, Matulewicz TJ. Diltiazem and
granulomatous hepatitis. Gastroenterology 1985; 88: 1260-2.
Shallcross H, Padley SP, Glynn MJ, Gibbs DD. Fatal renal and
hepatic toxicity after treatment with diltiazem. Br Med J 1987;
295:1236-7.
Toft E, Vyberg G, Therkelsen K. Diltiazem-induced granulomatous
hepatitis. Histopathology 1991; 18: 474-5.
Kanathur N, Mathai MG, Byrd RP Jr, Fields CL, Roy TM. Simvastatindiltiazem drug interaction resulting in rhabdomyolysis and hepatitis.
Tenn Med 2001; 94(9): 339-41.
DISOPYRAMIDE
Riccioni N, Bozzi L, Susini N, Roni P. Disopyramide-induced
intrahepatic cholestasis. Lancet 1977; 2: 1362-3.
Meinertz T, Langer KH, Kasper W, Just H. Disopyramide-induced
intrahepatic cholestasis. Lancet 1977; 2: 828-9.
Craxi A, Gatto G, Maringhini A, Orsini S, Pinzello G, Pagliaro L.
Disopyramide and cholestasis. Ann Intern Med 1980; 93: 150-1.
Edmonds ME, Hayler AM. A case of intra-hepatic cholestasis after
disopyramide therapy. Eur J Clin Pharmacol 1980; 18: 285-6.
Bakris GL, Cross PD, Hammarsten JE. Disopyramide-associated liver
dysfunction. Mayo Clin Proc 1983; 58: 265-7.
DOXYCYCLINE
Lienart F, Morissens M, Jacobs P, Ducobu J.Doxycycline and
hepatotoxicity. Acta Clin Belg. 1992;47(3):205-8.
Björnsson E, Lindberg J, Olsson R.Liver reactions to oral low-dose
tetracyclines. Scand J Gastroenterol. 1997 Apr;32(4):390-5.
Westermann GW, Böhm M, Bonsmann G, Rahn KH, Kisters K.
Chronic intoxication by doxycycline use for more than 12 years.
J Intern Med. 1999 Dec;246(6):591-2.
Chavant F, Lafay-Chebassier C, Beauchant M, Perault-Pochat MC.
[Doxycycline induced hepatitis]. Gastroenterol Clin Biol. 2008
Oct;32(10):825-7.
García-Aparicio J, Herrero-Herrero JI.[Toxic hepatitis following
sequential treatment with cotrimoxazol, levofloxacin, doxycycline
and sertraline in a patient with a respiratory infection].
Farm Hosp. 2010 May-Jun;34(3):152-4. Spanish.
Mailhol C, Tremeau-Martinage C, Paul C, Godel A, Lamant L,
Giordano-Labadie F.[Severe drug hypersensitivity reaction (DRESS
syndrome) to doxycycline]. Ann Dermatol Venereol. 2010
Jan;137(1):40-3.
pii: S0016-5085(15)00311-X.
DRONEDARONE
Joghetaei N, Weirich G, Huber W, Büchler P, Estner H. Acute liver
failure associated with dronedarone. Circ Arrhythm Electrophysiol
2011; 4: 592-3.
Del Pozo Ruiz JJ, Martín Sanz A, Alvarez Vicente G, Arenas Monzo C.
[Dronedarone-associated hepatotoxicity. A propos of a case]. Farm
Hosp 2012; 36: 545-7.
Jahn S, Zollner G, Lackner C, Stauber RE. Severe toxic hepatitis
associated with dronedarone. Curr Drug Saf 2013; 8: 201-2.
pii: S0016-5085(15)00311-X.
ERLOTINIB
Liu W, Makrauer FL, Qamar AA, Jänne PA, Odze RD. Fulminant
hepatic failure secondary to erlotinib. Clin Gastroenterol Hepatol
2007; 5: 917-20.
Saif MW. Erlotinib-induced acute hepatitis in a patient with
pancreatic cancer. Clin Adv Hematol Oncol 2008; 6: 191-199.
Pellegrinotti M, Fimognari FL, Franco A, Repetto L, Pastorelli R.
Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an
elderly man with lung cancer. Ann Pharmacother 2009; 43: 542-5.
Huang YS, An SJ, Chen ZH, Wu YL. Three cases of severe hepatic
impairment caused by erlotinib. Br J Clin Pharmacol 2009; 68: 4647.
Schacher-Kaufmann S, Pless M. Acute Fatal Liver Toxicity under
Erlotinib. Case Rep Oncol 2010; 3: 182-8.
Gunturu KS, Abu-Khalaf M, Saif MW. Hepatic failure and
hepatorenal syndrome secondary to erlotinib: a possible etiology of
complications in a patient with pancreatic cancer. JOP 2010; 11:
484-5.
Nakatomi K, Nakamura Y, Tetsuya I, Kohno S. Treatment with
gefitinib after erlotinib-induced liver injury: a case report. J Med
Case Reports 2011; 5: 593.
Lai YC, Lin PC, Lai JI, Hsu SY, Kuo LC, Chang SC, Wang WS.
Successful treatment of erlotinib-induced acute hepatitis and acute
interstitial pneumonitis with high-dose corticosteroid: a case report
and literature review. Int J Clin Pharmacol Ther 2011; 49: 461-6.
Kunimasa K, Yoshioka H, Iwasaku M, Nishiyama A, Korogi Y,
Masuda G, Takaiwa T, et al. Successful treatment of non-small cell
lung cancer with gefitinib after severe erlotinib-related
hepatotoxicity. Intern Med 2012; 51: 431-4.
ETODOLAC
Latrive JP, Combaux D, Crepin P, Brbara JC. Acute hepatitis
associated with etodolac therapy. Therapie 1992; 47: 82.
Mabee CL, Mabee SW, Baker PB, Kirkpatrick RB, Levine EJ.
Am J Gastroenterol. 1995 Apr;90(4):659-61.Fulminant hepatic
failure associated with etodolac use.
Sampaziotis F, Brais RJ, Griffiths WJ. A case of acute liver failure
due to etodolac. Br J Clin Pharmacol 2013; 75: 1156-7
pii: S0016-5085(15)00311-X.
ETOPOSIDE
Paschke R, Worst P, Brust J, Queisser W. [Hepatotoxicity with
etoposide-ifosfamide combination therapy]. Onkologie 1988; 11:
273-5. German.
Tran A, Housset C, Boboc B, Tourani JM, Carnot F, Berthelot P.
Etoposide(VP 16-213) induced hepatitis. Report of three cases
following standard-dose treatments. J Hepatol 1991; 12: 36-9.
EZETIMIBE
van Heyningen C. Drug-induced acute autoimmune hepatitis during
combination therapy with atorvastatin and ezetimibe. Ann Clin
Biochem 2005; 42: 402-4.
Stolk MF, Becx MC, Kuypers KC, Seldenrijk CA. Severe hepatic side
effects of ezetimibe. Clin Gastroenterol Hepatol 2006; 4: 908-11.
Tuteja S, Pyrsopoulos NT, Wolowich WR, Khanmoradi K, Levi DM,
Selvaggi G, Weisbaum G, et al. Simvastatin-ezetimibe-induced
hepatic failure necessitating liver transplantation. Pharmacotherapy
2008; 28: 1188-93.
Liu Q, Tobias H, Petrovic LM. Drug-induced liver injury associated
with ezetimibe therapy. Dig Dis Sci 2007; 52: 602-5.
Castellote J, Ariza J, Rota R, Girbau A, Xiol X. Serious drug-induced
liver disease secondary to ezetimibe. World J Gastroenterol 2008;
14: 5098-9.
pii: S0016-5085(15)00311-X.
FAMOTODINE
Ament PW, Roth JD, Fox CJ. Famotidine-induced mixed
hepatocellular jaundice. Ann Pharmacother 1994; 28: 40-2.
Hashimoto F, Davis RL, Egli D. Hepatitis following treatments with
famotidine and then cimetidine. Ann Pharmacother 1994; 28: 37-9.
Sohn JH, Sohn YW, Jeon YC, Han DS, Hahm JS, Choi HS, Park KN,
Kee CS. Three cases of hepatitis related to the use of famotidine
and ranitidine. Korean J Hepatol 1998; 4: 194-9.
Jiménez-Sáenz M, Argüelles-Arias F, Herrerías-Gutiérrez JM, DuránQuintana JA. Acute cholestatic hepatitis in a child treated with
famotidine. Am J Gastroenterol 2000; 95: 3665-6.
Gupta N, Patel C, Panda M. Hepatitis following famotidine: a case
report. Cases J 2009; 2: 89.
FLAVOCOXID
pii: S0016-5085(15)00311-X.
FLUOROURACIL
Vestfrid MA, Castelleto L, Giméz PO. [Diffuse liver necrosis in
treatment with 5-fluorouracil]. Rev Clin Esp 1972; 125: 549-50.
Luquel L, Ekherian JM, De Gramont A, Offenstadt G. [Anuria,
hepatocellular insufficiency and bone marrow aplasia after the
administration of streptozocin and fluorouracil]. Therapie 1988; 43:
125. French.
Brooks AJ, Begg EJ, Chapman BA, Fitzharris BM. Two cases of
severe liver injury possibly related to 5-fluorouracil and calcium
folinate. Intern Med J 2007; 37: 344-5.
FLUOXETINE
Mars F, Dumas de la Roque G, Goissen P. [Acute hepatitis during
treatment of fluoxetine]. Gastroenterol Clin Biol 1991; 15: 270-1.
French.
Bobichon R, Bernard G, Mion F. [Acute hepatitis during treatment
with fluoxetine]. Gastroenterol Clin Biol 1993; 17: 406-7. French.
Friedenberg FK, Rothstein KD. Hepatitis secondary to fluoxetine
treatment. Am J Psychiatry 1996; 153: 580.
Cosme A, Barrio J, Lobo C, Gil Y, Castiella A, Arenas JI. Acute
cholestasis by fluoxetine. Am J Gastroenterol 1996; 91: 2449-50.
Cai Q, Benson MA, Talbot TJ, Devadas G, Swanson HJ, Olson JL,
Kirchner JP. Acute hepatitis due to fluoxetine therapy. Mayo Clin
Proc 1999; 74: 692-4.
GABAPENTIN
Lasso-de-la-Vega MC, Zapater P, Such J, Pérez-Mateo M, Horga JF.
Gabapentin-associated hepatotoxicity. Am J Gastroenterol 2001;
96: 3460-2.
pii: S0016-5085(15)00311-X.
GEFITINIB
Takeda M, Okamoto I, Fukuoka M, Nakagawa K. Successful
treatment with erlotinib after gefitinib-related severe hepatotoxicity.
J Clin Oncol 2010; 28: e273-4.
Ku GY, Chopra A, de Lima Lopes G Jr. Successful treatment of two
lung cancer patients with erlotinib following gefitinib-induced
hepatotoxicity. Lung Cancer 2010; 70: 223-5.
Kijima T, Shimizu T, Nonen S, Furukawa M, Otani Y, Minami T,
Takahashi R, et al. Safe and successful treatment with erlotinib
after gefitinib-induced hepatotoxicity: difference in metabolism as a
possible mechanism. J Clin Oncol 2011; 29: e588-90.
GEMCITABINE
Coeman DC, Verbeken EK, Nackaerts KL, Demedts MG,
Vansteenkiste JF. A fatal case of cholestatic liver failure probably
related to gemcitabine. Ann Oncol 2000; 11: 1503.
Kagohashi K, Funayama Y, Satoh H, Sekizawa K. Fatal hepatic
failure due to gemcitabine and vinorelbine. Ann Oncol. 2003
Jun;14(6):960.
Saadati H, Peccerillo J, Kaley K, Schilsky ML, Saif MW. Gemcitabineinduced hepatitis in a pancreatic cancer patient receiving adjuvant
therapy following metastasectomy. JOP 2009; 10: 573-5.
Matsuda M, Watanabe G, Mine S, Hashimoto M. [Fatal liver failure
associated with gemcitabine hydrochloride therapy]. Gan To Kagaku
Ryoho 2008; 35: 157-9. Japanese.
Tanaka H, Takamori H, Eto S, Ozaki N, Akaboshi S, Nakahara O, Ida
S, et al. [Acute liver injury with hepatic encephalopathy associated
with gemcitabine administration for adjuvant chemotherapy in an
HBV carrier with pancreatic cancer]. Gan To Kagaku Ryoho 2010;
37: 1783-6. Japanese.
Stellman A, Loke MM, Mann S.Acute liver failure secondary to
gemcitabine. BMJ Case Rep. 2010 Apr 22;2010.
GEMFIBROZIL
Bustamante Balén M, Plumé Gimeno G, Bau González I, Berenguer
Lapuerta J. Acute hepatitis caused by gemfibrozil. Gastroenterol
Hepatol 1998; 21: 419-20.
de Diego Lorenzo A, Catalina V, García Sánchez A, Escudero M, Cos
E, Clemente G. Cholestatic hepatitis caused by gemfibrozil. Rev Esp
Enferm Dig 2001; 93; 610-1.
Grubisić-Cabo F, Vrdoljak E. Drug-induced hepatitis in a patient with
malignant melanoma treated with interferon alfa 2b adjuvantly who
had been administered gemfibrozil in therapy. Med Oncol 2006; 23:
121-4.
Andrade RJ, Lucena MI, Kaplowitz N, García-Muņoz B, Borraz Y,
Domínguez Tordera P, Comellas Alabern JF, Ronda Rivero F.
Gemfibrozil hepatotoxicity: a case report. Int J Clin Pharm 2011;
33: 730-2.
pii: S0016-5085(15)00311-X.
GLIMEPIRIDE
Dusoleil A, Condat B, Sobesky R, Pelletier G, Buffet C. [Glimepirideinduced acute hepatitis] Gastroenterol Clin Biol 1999; 23: 1096-7.
French.
Sitruk V, Mohib S, Grando-Lemaire V, Ziol M, Trinchet JC. [Acute
cholestatic hepatitis induced by glimepiride] Gastroenterol Clin Biol
2000; 24: 1233-4. French.
Heurgué A, Bernard-Chabert B, Higuero T, Lukas-Croisier C, Caron
J, Cadiot G, Thiéfin G. [Glimepiride-induced acute cholestatic
hepatitis] Ann Endocrinol(Paris) 2004; 65: 174-5. French.
Chounta A, Zouridakis S, Ellinas C, Tsiodras S, Zoumpouli C,
Kopanakis S, Giamarellou Hl. Cholestatic liver injury after
glimepiride therapy. J Hepatol 2005; 42: 944-6.
GLIPIZIDE
Clementsen P, Hansen CL, Høegholm A. [Glipizide induced toxic
hepatitis] Ugeskr Laeger 1986; 148: 771-2. Danish.
Ilario MJ, Turyan HV, Axiotis CA. Glipizide treatment with shortterm alcohol abuse resulting in subfulminant hepatic failure.
Virchows Arch 2003; 443: 104-5.
HYDROXYUREA
Heddle R, Calvert AF. Hydroxyurea induced hepatitis. Med J Aust
1980; 1: 121.
Westerman DA, Schwarer A, Grigg AP. Hydroxyurea-induced fever
and hepatitis. Aust N Z J Med 1998; 28: 657-9.
Weissman SB, Sinclair GI, Green CL, Fissell WH. Hydroxyureainduced hepatitis in human immunodeficiency virus-positive
patients. Clin Infect Dis 1999; 29: 223-4.
Shimizu T, Mori T, Karigane D, Kikuchi T, Koda Y, Toyama T,
Nakajima H, Okamoto S. [Hydroxyurea (hydroxycarbamide)induced hepatic dysfunction confirmed by drug-induced lymphocyte
stimulation test]. Rinsho Ketsueki. 2014 Jan;55(1):125-9.
INDOMETHACIN
Pina R, Lopez-Aldeguer J, Navarro JR, Perez Agullar F, Berenguer J.
[Acute hepatitis due to indomethacin] Gastroenterol Hepatol 1981;
4: 49-51.
Lopez Vivancos J, Vilaseca J, Arnau JM, Allende E. [Acute cholestatic
hepatitis caused by indomethacin] Gastroenterol Hepatol 1985; 8:
165-6.
Balduck N, Otten J, Verbruggen L, Bougatef A, Ramet J, Piepsz A.
Sudden death of a child with juvenile chronic arthritis, probably due
to indomethacin. Eur J Pediatr 1987; 146: 620.
López Navidad A, Cadafalch Arpa J, Vehi Gasol C, Espinos Pérez J.
[Acute hepatitis caused by indomethacin] Rev Esp Enferm Apar Dig
1987; 71: 358-9. Spanish.
Cappell MS, Kozicky O, Competiello LS. Indomethacin-associated
cholestasis. J Clin Gastroenterol 1988; 10: 445-7.
Suárez González A, Rodríguez García M, González González M,
Alvarez Navascues C, González Sotorrio N, Rodrigo Sáez L. [Acute
indomethacin-induced hepatitis in a female patient with
asymptomatic primary biliary cirrhosis] An Med Interna 1994; 11:
549-50. Spanish.
Abraham C, Hart J, Locke SM, Baker AL. A case of indometacin-
induced acute hepatitis developing into chronic autoimmune
hepatitis. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 172-6.
IRBESARTAN
Hariraj R, Stoner E, Jader S, Preston DM. Drug points: prolonged
cholestasis associated with irbesartan. BMJ. 2000 Sep
2;321(7260):547
Andrade RJ, Lucena MI, Fernández MC, Vega JL, García-Cortés M,
Casado M, Guerrero-Sanchez E, Pulido-Fernandez F. Cholestatic
hepatitis related to use of irbesartan: a case report and a literature
review of angiotensin II antagonist-associated hepatotoxicity. Eur J
Gastroenterol Hepatol. 2002 Aug;14(8):887-90.
Foruny Olcina JR, Moreira Vicente VF, Gómez García M, Morell Hita
JL.
[Irbesartan-induced acute hepatitis]. Gastroenterol Hepatol. 2004
Feb;27(2):71-2. Spanish.
Péron JM, Robic MA, Bureau C, Vinel JP.[Irbesartan induced acute
hepatitis: one case]. Gastroenterol Clin Biol. 2005 Jun-Jul;29(67):747-8
Annicchiarico BE, Siciliano M. Could irbesartan trigger autoimmune
cholestatic hepatitis? Eur J Gastroenterol Hepatol. 2005
Feb;17(2):247-8.
pii: S0016-5085(15)00311-X.
ISOTRETINOIN
Vahlquist A, Lööf L, Nordlinder H, Rollman O, Vahlquist C.
Differential hepatotoxicity of two oral retinoids (etretinate and
isotretinoin) in a patient with palmoplantar psoriasis. Acta Derm
Venereol. 1985;65(4):359-62.
Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S.
Incidence, Presentation and Outcomes in Patients with DrugInduced Liver Injury in the General Population of Iceland.
KETOPROFEN
Rambaud S, Nores JM, Rémy JM. [Jaundice related to the ingestion
of ketoprofen] Ann Med Interne (Paris) 1990; 141: 278. French.
Dutertre J-P, Bastides F, Jonville A-P, De Muret A, Sonneville A,
Larrey D, Autret E. Microvesicular steatosis after ketoprofen
administration. Eur J Gastroenterol Hepatol 1991; 3: 953-4.
Flamenbaum M, Abergel A, Marcato N, Zénut M, Kémény JL, Cassan
P. [Regressive fulminant hepatitis, acute pancreatitis and renal
insufficiency after taking ketoprofen]. Gastroenterol Clin Biol 1998;
22: 975-6.
Bonaventure C, Nancey S, Pont E, Michalet V, Chevalier M, Vial T,
Taieb S, et al. [Ketoprofen-induced acute hepatitis] Gastroenterol
Zabala S, Calpe MJ, Pérez G, Lerín FJ, Mouronval L. Neutropenia,
thrombocytopenia and hepatic injury associated with dexketoprofen
trometamol therapy in a previously healthy 35-year-old woman. J
Clin Pharm Ther 2008; 33: 79-81.
Famularo G, Gasbarrone L, Minisola G. Probable ketoprofenassociated nonalcoholic fatty liver disease and steatohepatitis. Ann
LABETALOL
Thiele DL. Labetalol hepatotoxicity. Am J Med. 1989 Sep;87(3):361.
Douglas DD, Yang RD, Jensen P, Thiele DL.Fatal labetalol-induced
hepatic injury. Am J Med. 1989 Aug;87(2):235-6.
Clark JA, Zimmerman HJ, Tanner LA. Labetalol hepatotoxicity.
Ann Intern Med. 1990 Aug 1;113(3):210-3.
Stumpf JL. Fatal hepatotoxicity induced by hydralazine or labetalol.
Pharmacotherapy. 1991;11(5):415-8.
Stronkhorst A, Bosma A, van Leeuwen DJ. A case of labetalolinduced hepatitis. Neth J Med. 1992 Apr;40(3-4):200-2.
Chon EM, Middleton RK. Labetalol hepatotoxicity.
Ann Pharmacother. 1992 Mar;26(3):344-5.
Marinella MA. Labetalol-induced hepatitis in a patient with chronic
hepatitis B infection. J Clin Hypertens (Greenwich). 2002 MarApr;4(2):120-1.
Long RC, Wofford MR, Harkins KG, Minor DS.Hepatocellular necrosis
associated with labetalol. J Clin Hypertens (Greenwich). 2007
Apr;9(4):287-90.
Vicuña-Arregui M, Ruiz-Clavijo-García D, Zozaya-Urmeneta JM,
Bolado-Concejo F, Nantes-Castillejo O.[Cholestatic síndrome due to
labetalol]. Rev Esp Enferm Dig. 2010 Apr;102(4):287. Spanish.
pii: S0016-5085(15)00311-X.
LANSOPRAZOLE
Viana de Miguel C, Alvarez García M, Sánchez Sánchez A, Carvajal
García-Pando A. [Lansoprazole-induced hepatitis]. Med Clin (Barc)
1997; 108: 599. Spanish.
Baudot S, Milpied-Homsi B, Andres P, Poirier Y, Larousse C.
[Lansoprazole hypersensitivity syndrome]. Therapie 1999; 54: 4913. French.
García-Cortés M, Lucena MI, Andrade RJ, Romero-Gómez M,
Fernández MC. Lansoprazole-induced hepatic dysfunction. Ann
pii: S0016-5085(15)00311-X.
LENALIDOMIDE/THALIDOMIDE
Fowler R, Imrie K. Thalidomide-associated hepatitis: a case report.
Am J Hematol 2001; 66: 300-2.
Hanje AJ, Shamp JL, Thomas FB, Meis GM. Thalidomide-induced
severe hepatotoxicity. Pharmacotherapy 2006; 26: 1018-22.
Hamadani M, Benson DM Jr, Copelan EA. Thalidomide-induced
fulminant hepatic failure. Mayo Clin Proc 2007; 82: 638.
Hussain S, Browne R, Chen J, Parekh S. Lenalidomide-induced
severe hepatotoxicity. Blood 2007; 110: 3814.
Dabak V, Kuriakose P. Thalidomide-induced severe hepatotoxicity.
Cancer Chemother Pharmacol. 2009; 63: 583-5.
Levesque E, Bradette M. Hepatotoxicity as a rare but serious side
effect of thalidomide. Ann Hematol 2009; 88: 183-4.
Zanella MC, Rubbia-Brandt L, Giostra E, Chalandon Y, Hadengue A,
Spahr L. A Case of drug-induced hepatitis due to lenalidomide. Case
Rep Gastroenterol 2011; 5: 217-22.
Vilas-Boas F, Gonçalves R, Sobrinho Simões M, Lopes J, Macedo G.
Thalidomide-induced acute cholestatic hepatitis: Case report and
review of the literature. Gastroenterol Hepatol 2012; 35: 560-6.
Nojkov B, Signori C, Konda A, Fontana RJ. Lenalidomide-associated
hepatotoxicity--a case report and literature review. Anticancer Res
2012; 32: 4117-9.
LEVETIRACETAM
Tan TC, de Boer BW, Mitchell A, Delriviere L, Adams LA, Jeffrey GP,
Macquillan G. Levetiracetam as a possible cause of fulminant liver
failure. Neurology 2008; 71: 685-6.
Xiong N, Hou L, Lu N, Mohamed AA, Wang T, Huang Y. Probable
levetiracetam-related serum alkaline phosphatase elevation. BMC
Neurol 2012; 12: 97.
Azar NJ, Aune P. Acute pancreatitis and elevated liver
transaminases after rapid titration of oral levetiracetam. J Clin
Neurosci 2013 Oct 18. [Epub ahead of print]
Sethi NK, Sethi PK, Torgovnick J, Arsura E, Cukierwar F.
Asymptomatic elevation of liver enzymes due to levetiracetam: a
case report. Drug Metabol Drug Interact. 2013;28(2):123-4.
Gómez-Zorrilla S, Ferraz AV, Pedrós C, Lemus M, Peña C.
Levetiracetam-induced drug reaction with eosinophilia and systemic
symptoms syndrome. Ann Pharmacother. 2012 Jul-Aug;46(78):e20
Lens S1, Crespo G, Carrión JA, Miquel R, Navasa M. Severe acute
hepatitis in the DRESS syndrome: Report of two cases. Ann
Hepatol. 2010 Apr-Jun;9(2):198-201.
Gavilán JC, Bermúdez F, Romero M, González Santos P.
[Levetiracetam hepatitis]. Med Clin (Barc). 2004 Jan 17;122(1):38.
Spanish.
LEVOCETIRIZINE/CETIRIZIN
Bera F, Siproudhis JP, Jonville-Bera AP, Martin MP, Autret
E.[Cytolytic hepatic involvement after administration of cetirizine
(Zyrtec)].Gastroenterol Clin Biol. 1993;17(10):770-1. French.
Fong DG, Angulo P, Burgart LJ, Lindor KD. Cetirizine-induce
cholestasis. J Clin Gastroenterol 2000; 31: 250-3.
Watanabe M, Kohge N, Kaji T.Severe hepatitis in a patient taking
cetirizine.Ann Intern Med. 2001 Jul 17;135(2):142-3.
Sánchez-Lombraña JL, Alvarez RP, Sáez LR, Oliva NP, Martínez
RM.Acute hepatitis associated with cetirizine intake. J Clin
Gastroenterol. 2002 Apr;34(4):493-5.
Pompili M, Basso M, Grieco A, Vecchio FM, Gasbarrini G, Rapaccini
GL.Recurrent acute hepatitis associated with use of cetirizine. Ann
Pharmacother. 2004 Nov;38(11):1844-7.
Rodríguez-Gómez SJ, Zamora-Martínez T, Bailador-Andrés C,
Fuentes-Coronel AM, Martín-Arribas MI.[Severe intrahepatic
cholestasis associated with cetirizine].Gastroenterol Hepatol. 2009
May;32(5):383-4.
Jurawan R, Smith A.Severe hepatitis in a primary sclerosing
cholangitis patient receiving recent cetirizine therapy. N Z Med J.
2010 Feb 19;123(1309):106-7.
Díaz-Sánchez A, Marín-Jiménez I, Aldeguer M.[Benign recurrent
intrahepatic cholestasis simulating cetirizine-induced toxic
hepatitis].Gastroenterol Hepatol. 2010 Jan;33(1):68-9. Spanish.
Ekiz F, Yüksel I, Ekiz O, Coban S, Basar O, Yüksel O.Levocetirizine
induced hepatotoxicity in a patient with chronic urticaria. Ann
Hepatol. 2011 Apr-Jun;10(2):237-8.
Prieto de Paula JM, Franco Hidalgo S, Nalotto L, Ginés Santiago
A.[Cetirizine hepatotoxicity]. Med Clin (Barc). 2011 Sep
10;137(6):283-4.
LINEZOLID
Savard S, Desmeules S, Riopel J, Agharazii M. Linezolid-Associated
Acute Interstitial Nephritis and Drug Rash With Eosinophilia and
Systemic Symptoms (DRESS) Syndrome. Am J Kidney Dis 2009;
54: e17-20.
De Bus L, Depuydt P, Libbrecht L, Vandekerckhove L, Nollet J,
Benoit D, Vogelaers D, Van Vlierberghe H. Severe drug-induced
liver injury associated with prolonged use of linezolid. J Med Toxicol
2010; 6: 322-6.
Kraleti S, Soultanova I. Pancytopenia and lactic acidosis associated
with linezolid use in a patient with empyema. J Ark Med Soc 2013;
110: 62-3.
Holmaas G, Lærum JH, Schjøtt J, Leiva RA. A man in his seventies
with a long-term infection and severe acid-base imbalance. Tidsskr
Nor Laegeforen 2014; 134: 315-319.
LOSARTAN
Nygaard B, Strandgaard S.Marked hepatotoxicity associated with
losartan treatment. Blood Press. 1996 May;5(3):190-1.
Bosch X. Losartan-induced hepatotoxicity. JAMA 1997; 278: 1572.
Tabak F, Mert A, Ozaras R, Biyikli M, Ozturk R, Ozbay G, Senturk H,
Aktuglu Y. Losartan-induced hepatic injury.
J Clin Gastroenterol. 2002 May-Jun;34(5):585-6.
Andrade RJ, Lucena MI, Santalla F.Hepatic injury associated with
losartan. Ann Pharmacother. 1998 Dec;32(12):1371.
pii: S0016-5085(15)00311-X.
MELOXICAM
Staerkel P, Horsmans Y. Meloxicam-induced liver toxicity. Acta
Gatroenterol Belg 1999; 62: 255-6.
Gierer IM, Abdala O, Calderón C, Risoli E, Cravero A, Pinchuk L.
[Meloxican-induced cholestasis] Acta Gastroenterol Latinoam 2000;
30: 511-4. Spanish.
Martinez-Odriozola P, et al. Meloxicam as a Cause of Drug-Induced
Autoimmune Hepatitis. Dig Dis Sci 2010; 55: 1191-1192.
MESALAMINE/BALSALAZIDE/OLSALAZINE
Pineda JR, Leal JC, de la Morena E, Abreu L.[Hepatotoxicity: a new
side effect of 5-aminosalicylic acid]. Med Clin (Barc). 1989 Oct
28;93(13):516. Spanish.
Hautekeete ML, Bourgeois N, Potvin P, Duville L, Reynaert H, Devis
G, Adler M, Klöppel G. Hypersensitivity with hepatotoxicity to
mesalazine after hypersensitivity to sulfasalazine.
Gastroenterology. 1992 Dec;103(6):1925-7.
Stoschus B, Meybehm M, Spengler U, Scheurlen C, Sauerbruch T.
Cholestasis associated with mesalazine therapy in a patient with
Crohn's disease. J Hepatol 1997; 26: 425-8.
Braun M, Fraser GM, Kunin M, Salamon F, Tur-Kaspa R.
Mesalamine-induced granulomatous hepatitis. Am J Gastroenterol
1999; 94: 1973-4.
Barroso N, Leo E, Guil A, Larrauri J, Tirado C, Zafra C, Gavilán F,
Reina FR. [Non-immunoallergic hepatotoxicity due to mesalazine].
Deltenre P, Berson A, Marcellin P, Degott C, Biour M, Pessayre D.
Mesalazine(5-aminosalicylic acid) induced chronic hepatitis. Gut
1999; 44: 886-8.
Hartleb M, Biernat L, Kochel A. Drug-induced liver damage--a threeyear study of patients from one gastroenterological department.
Med Sci Monit 2002; 8: CR292-6.
Nayar M, Cunliffe W, Cross P, Oppong K. Mesalazine-induced
jaundice, eosonophilia, and thrombocytopenia. Inflamm Bowel Dis.
2008 Sep;14(9):1320-1.
METHOXASALEN
Bjellerup M, Bruze M, Hanssen A, Krook G, Ljunggren JB. Liver
injury following administration of 8-methoxypsoralen during PUVA
therapy. Acta Derm Venereol (Stockh) 1979; 59: 371-2.
Pariser DM, Wyles RJ. Toxic hepatitis from oral methoxsalen
phototherapy(PUVA). J Am Acad Dermatol 1980; 3: 248-50.
Freeman K, Warin AP. Deterioration of liver function during PUVA
therapy. Photodermatol Photoimmunol Photomed 1984; 1: 147-8.
Markin RS, Donovan JP, Shaw BW Jr, Zetterman RK. Fulminant
hepatic failure after methotrexate and PUVA therapy for psoriasis. J
Clin Gastroenterol 1993; 17: 311-3.
Park YM, Kim TY, Kim CW. Reproducible elevation of liver
transaminases by topic 8-methoxypsoralen. Photodermatol
Photoimmunol Photomed 1994; 10: 261-3.
Stephens RB, Cooper A. Hepatitis from 5-methoxypsoralen
occurring in a patient with previous flucloxacillin hepatitis. Australas
J Dermatol 1999; 40: 217-9.
METHYLPHENIDATE
Goodman CR. Hepatotoxicity due to methylphenidate hydrochloride.
N Y State J Med 1972; 72: 2339-40.
Mehta H, Murray B, LoIudice TA. Hepatic dysfunction due to
intravenous abuse of methylphenidate hydrochloride. J Clin
Stecyk O, Loludice TA, Demeter S, Jacobs J. Multiple organ failure
resulting from intravenous abuse of methylphenidate hydrochloride.
Ann Emerg Med 1985; 14: 597-9.
Lewis JJ, Iezzoni JC, Berg CL. Methylphenidate-induced autoimmune
pii: S0016-5085(15)00311-X.
METRONIDAZOLE
Appleby DH, Vogtland HD. Suspected metronidazole hepatotoxicity.
Clin Pharm 1983; 2: 373-4.
Uchihara M, Maeda M, Koyama W, Sakamoto S, Kanayama M. A
case of metronidazole-induced liver injury. Acta Hepatol Jpn 1984;
25: 1612-5.
Hestin D, Hanesse B, Frimat L, Trechot P, Netter P, Kessler M.
Metronidazole-associated hepatotoxicity in a hemodialyzed patient.
Nephron 1994; 68: 286.
Björnsson E, Nordlinder H, Olsson R. Metronidazol as a probable
cause of severe liver injury. Hepatogastroenterology 2002; 49: 2524.
Hussein R, El-Halabi M, Ghaith O, Jurdi N, Azar C, Mansour N,
Sharara AI. Severe hepatotoxicity associated with the combination
of spiramycin plus metronidazole. Arab J Gastroenterol 2011; 12:
44-7..
Kancherla D, Gajendran M, Vallabhaneni P, Vipperla K.
Metronidazole induced liver injury: a rare immune mediated drug
reaction. Case Rep Gastrointest Med 2013; 2013: 568193.
MEXILETINE
Pernot C, Netter P, Marcon F, Weber JL. [Reversible hepatic
anomalies during treatment with mexiletine]. Presse Med 1983; 12:
1938. French.
Geisler C, Keiding S. [Cholestatic hepatitis during treatment with
mexiletine/lidocaine]. Ugeskr Laeger 1984; 146: 1212-3. Danish.
Higa K, Hirata K, Dan K. Mexiletine-induced severe skin eruption,
fever, eosinophilia, atypical lymphocytosis, and liver dysfunction.
Pain 1997; 73: 97-9.
Higa K, Hirata K, Dan K. Mexiletine-induced severe skin eruption,
fever, eosinophilia, atypical lymphocytosis, and liver dysfunction.
Pain. 1997 Oct;73(1):97-9.
Seino Y, Yamauchi M, Hirai C, Okumura A, Kondo K, Yamamoto M,
Okazaki Y. A case of fulminant Type 1 diabetes associated with
mexiletine hypersensitivity syndrome. Diabet Med 2004; 21: 11567.
Sekiguchi A, Kashiwagi T, Ishida-Yamamoto A, Takahashi H,
Hashimoto Y, Kimura H, Tohyama M, et al. Drug-induced
hypersensitivity syndrome due to mexiletine associated with human
herpes virus 6 and cytomegalovirus reactivation. J Dermatol 2005;
32: 278-81.
MIRTAZEPINE
Hui CK, Yuen MF, Wong WM, Lam SK, Lai CL. Mirtazapine-induced
hepatotoxicity. J Clin Gastroenterol. 2002; 35: 270-1.
Adetunji B, Basil B, Mathews M, Osinowo T. Mirtazapine-associated
dose-dependent and asymptomatic elevation of hepatic enzymes.
Ann Pharmacother 2007; 41: 359.
Rodriguez-Pecci MS, Fuente-Aguado Jde L, Montero-Tinnirello J,
Fernandez-Fernandez FJ. [Mirtazapine-associated hepatotoxicity].
Med Clin (Barc) 2010; 135: 625-6. Spanish.
Kang SG, Yoon BM, Park YM. Mirtazapine-induced hepatocellulartype liver injury. Ann Pharmacother 2011; 45: 825-6.
MITOMYCIN
Lazarus HM, Gottfried MR, Herzig RH, Phillips GL, Weiner RS, Sarna
GP, Fay J, et al. Veno-occlusive disease of the liver after high-dose
mitomycin C therapy and autologous bone marrow transplantation.
Cancer 1982; 49: 1789-95.
Gottfried MR, Sudilovsky O. Hepatic veno-occlusive disease after
high-dose mitomycin C and autologous bone marrow
transplantation therapy. Hum Pathol. 1982 Jul;13(7):646-50.
MONTELUKAST
Margery J, Dot JM, Bredin C, Bonnichon A, Romand F, Guigay J,
Vaylet F, L'Her P. [Montelukast induced cytolytic acute hepatitis]
Romero-Gómez M, Sánchez-Muñoz D, Castilla L, Castro M. [Acute
hepatitis due to montelukast] Med Clin(Barc) 2003; 120: 239.
Spanish.
Russmann S, Iselin HU, Meier D, Zimmermann A, Simon HU, Caduff
P, Reichen J. Acute hepatitis associated with montelukast. J
Hepatol. 2003; 38: 694-5.
Sass DA, Chopra KB, Wu T. A case of montelukast-induced
Goldstein MF, Anoia J, Black M. Montelukast-induced hepatitis. Ann
Intern Med. 2004; 140: 586-7.
Incecik F, Onlen Y, Sangun O, Akoglu S. Probable montelukastinduced hepatotoxicity in a pediatric patient: case report. Ann Saudi
Med 2007; 27: 462-3.
Harugeri A, Parthasarathi G, Sharma J, D'Souza GA, Ramesh M.
Montelukast induced acute hepatocellular liver injury. J Postgrad
Med 2009; 55: 141-2.
4 DILIN cases
pii: S0016-5085(15)00311-X.
NAFCILLIN
Miller WI, Souney PF, Chang JT.Hepatic dysfunction following
nafcillin and cephalothin therapy in a patient with a history of
oxacillin hepatitis. Clin Pharm. 1983 Sep-Oct;2(5):465-8.
Lestico MR, Vick KE, Hetsko CM. Hepatic and renal dysfunction
following nafcillin administration. Ann Pharmacother. 1992 JulAug;26(7-8):985-90.
Mazuryk H, Kastenberg D, Rubin R, Muñoz SJ.Cholestatic hepatitis
associated with the use of nafcillin. Am J Gastroenterol. 1993
Nov;88(11):1960-2.
Schuman R, Miskovitz P.Nafcillin-associated jaundice.
Am J Gastroenterol. 1994 Jun;89(6):952.
Presti ME, Janney CG, Neuschwander-Tetri BA. Nafcillin-associated
hepatotoxicity. Report of a case and review of the literature. Dig Dis
Sci. 1996 Jan;41(1):180-4.
Mian Bilal Alam, Amin Kadoura, Magesh Sathaiah. A Fatal Case of
Nafcillin-Induced Hepatotoxicity: A Case Report and the Literature
Review. Case Reports in Medicine
2012;2012:953714
NATALIZUMAB
Bezabeh S, Flowers CM,Kortepeter C, Avigan M. Clinically significant
liver injury in patients treated with natalizumab. Aliment Pharmacol
Ther 2010; 31: 1028-35.
André MC, Pacheco D, AntunesJ, Silva R, Filipe P, Soares de
Almeida LM. Generalized skin drug eruption to natalizumab in a
patient with multiple sclerosis. Dermatol Online J 2010; 16: 14.
Lisotti A, AzzaroliF, Brillanti S, Mazzella G. Severe acute
autoimmune hepatitis after natalizumab treatment. Dig Liver Dis
2012; 44: 356-7.
NEFAZODONE
Lucena MI, Andrade RJ, Gomez-Outes A, Rubio M, Cabello MR.
Acute liver failure after treatment with nefazodone. Dig Dis Sci
1999; 44: 2577-9.
Aranda-Michel J, Koehler A, Bejarano PA, Poulos JE, Luxon BA, Khan
CM, Ee LC, et al. Nefazodone-induced liver failure: report of three
cases. Ann Intern Med 1999; 130: 285-8.
Schirren CA, Baretton G. Nefazodone-induced acute liver failure. Am
Eloubeidi MA, Gaede JT, Swaim MW. Reversible nefazodone-induced
liver failure. Dig Dis Sci 2000; 45:1036-8.
Ehrentraut S, Rothenhäusler HB, Gerbes AL, Rau HG, Thiel M,
Schirren CA, Kapfhammer HP. [Acute liver failure in nefazodone
therapy? A case report]. Nervenarzt 2002; 73: 686-9.
Conway CR, McGuire JM, Baram VY. Nefazodone-induced liver
failure. J Clin Psychopharmacol 2004; 24: 353-4.
pii: S0016-5085(15)00311-X.
NILUTAMIDE
Hammel P, Ducreux M, Bismuth E, et al. [Nilutamide-induced acute
hepatitis] Gastroenterol Clin Biol 1991; 15: 557. French.
Pescatore P, Hammel P, Durand F, et al. [Fatal fulminant hepatitis
induced by nilutamide (Anandron)] Gastroenterol Clin Biol 1993;
17: 499-501. French.
Marty F, Godart D, Doermann F, Mérillon H. [Fatal fulminating
hepatitis caused by nilutamide. A new case] Gastroenterol Clin Biol
1996; 20: 710-1.
Edouard A, Robinel R, Rat C, Lombard F, Lorinet C, Escarmant P.
[Fatal fulminating hepatitis induced by nilutamide] Gastroenterol
Merwat SN, Kabbani W, Adler DG. Fulminant hepatic failure due to
nilutamide hepatotoxicity. Dig Dis Sci 2009; 54: 910-3.
NORFLOXACIN
López-Navidad A, Domingo P, Cadafalch J, Farrerons J. Norfloxacininduced hepatotoxicity. J Hepatol 1990; 11: 277-8.
Davoren P, Mainstone K. Norfloxacin-induced hepatitis. Med J Aust
1993; 159: 423, 426.
Lucena MI, Andrade RJ, Sanchez-Martinez H, Perez-Serrano JM,
Gomez-Outes A. Norfloxacin-induced cholestatic jaundice. Am J
Romero-Gómez M, Suárez García E, Fernández MC. Norfloxacininduced acute cholestatic hepatitis in a patient with alcoholic liver
cirrhosis. Am J Gastroenterol. 1999; 94: 2324-5.
Björnsson E, Olsson R, Remotti H. Norfloxacin-induced eosinophilic
necrotizing granulomatous hepatitis. Am J Gastroenterol 2000; 95:
3662-4.
ORLISTAT
Montero JL, Muntané J, Fraga E, Delgado M, Costán G, Serrano M,
Padillo J, et al. Orlistat associated subacute hepatic failure. J
Hepatol 2001; 34: 173.
Kim DH, Lee EH, Hwang JC, Jeung JH, Kim do H, Cheong JY, Cho
SW, et al. [A case of acute cholestatic hepatitis associated with
Orlistat]. Taehan Kan Hakhoe Chi 2002; 8: 317-20. Korean.
Thurairajah PH, Syn WK, Neil DA, Stell D, Haydon G.
Orlistat(Xenical)-induced subacute liver failure. Eur J Gastroenterol
Hepatol 2005; 17: 1437-8.
Umemura T, Ichigo T, Matsumoto A, Kiyosawa K. Severe hepatic
injury caused by orlistat. Am J Med 2006; 119; 37.
OXAPROZIN
Purdum PP 3rd, Shelden SL, Boyd JW, Shiffman ML. Oxaprozininduced fulminant hepatitis. Ann Pharmacother 1994; 28: 1159-61.
Kethu SR, Rukkannagari S, Lansford CL. Oxaprozin-induced
symptomatic hepatotoxicity. Ann Pharmacother 1999; 33: 942-4.
pii: S0016-5085(15)00311-X.
PANTOPRAZOLE
Yusoff IF, Nairn P, Morgan CA. Multiple organ failure related to
pantoprazole. Aust N Z J Med 1999; 9: 33-4.
Cordes A, Vogt W, Maier KP. [Pantoprazole-induced hepatitis].
Dtsch Med Wochenschr 2003; 128: 611-4. German.
Darabi K. Proton-pump-inhibitor-induced hepatitis. South Med J
2005; 98: 844-5.
Sandig C, Flechtenmacher C, Stremmel W, Eisenbach C.
Pantoprazole induces severe acute hepatitis. Z Gastroenterol 2011;
49: 207-10.
PENICILLIN G AND V
Girard JP, Haenni B, Bergoz R, Kapanci Y, Cruchaud A. Lupoid
hepatitis following administration of penicillin. Case report and
immunological studies. Helv Med Acta 1967; 34: 23-35.
Goldstein LI, Ishak KG. Hepatic injury associated with penicillin
therapy. Arch Pathol 1974; 98: 114-7.
Beeley L, Gourevitch A, Kendall MJ. Jaundice after oral penicillin.
Lancet 1976; 2: 1297.
Oñate J, Montejo M, Aguirrebengoa K, Ruiz-Irastorza G, González
de Zárate P, Aguirre C. Hepatotoxicity associated with penicillin V
therapy. Clin Infect Dis 1995; 20: 474-5.
Bauer TM, Bircher AJ. Drug-induced hepatocellular liver injury due
to benzylpenicillin with evidence of lymphocyte sensitization. J
Hepatol 1997; 26: 429-32.
Andrade RJ, Guilarte J, Salmerón FJ, Lucena MI, Bellot V.
Benzylpenicillin-induced prolonged cholestasis. Ann Pharmacother
2001; 35: 783-4.
2013; 144: 1419-25.
pii: S0016-5085(15)00311-X.
PHENELZINE
Holdswoth CD, Atkinson M, Goldie W. Hepatitis caused by the newer
amine-oxidase-inhibiting drugs. Lancet 1961; 2: 621-23.
Cook GC, Sherlock S. Jaundice and its relation to therapeutic
agents. Lancet 1965; 1: 175-9.
Daneshmend TK, Scott GL, Bradfield JW. Angiosarcoma of liver
associated with phenelzine. Br Med J 1979;1: 1679.
Bonkovsky HL, Blanchette PL, Schned AR. Severe liver injury due to
phenelzine with unique hepatic deposition of extracellular material.
Am J Med 1986; 80: 689-92
Gomez-Gil E, Salmeron JM, Mas A. Phenelzine-induced fulminant
hepatic failure. Ann Intern Med 1996; 124: 692-3.
PIOGLITAZONE
Pinto AG, Cummings OW, Chalasani N. Severe but reversible
cholestatic liver injury after pioglitazone therapy. Ann Intern Med.
2002 Nov 19;137(10):857.
Nagasaka S, Abe T, Kawakami A, Kusaka I, Nakamura T, Ishikawa
S, Saito T, Ishibashi S. Pioglitazone-induced hepatic injury in a
patient previously receiving troglitazone with success.
Diabet Med. 2002 Apr;19(4):347-8.
Chase MP, Yarze JC. Pioglitazone-associated fulminant hepatic
failure. Am J Gastroenterol. 2002 Feb;97(2):502-3.
May LD, Lefkowitch JH, Kram MT, Rubin DE. Mixed hepatocellularcholestatic liver injury after pioglitazone therapy. Ann Intern Med
2002; 136: 449-52.
Hisamochi A, Kumashiro R, Koga Y, Tanaka E, Ide T, Hino T,
Murashima S, Ogata K, Kuwahara R, Koga H, Shishido S, Ueno T,
Sata M, Eguchi T.[A case of drug induced liver injury related
pioglitazone].Nihon Shokakibyo Gakkai Zasshi. 2003
Mar;100(3):333-6. Japanese.
Farley-Hills E, Sivasankar R, Martin M. Fatal liver failure associated
with pioglitazone. BMJ. 2004 Aug 21;329(7463):429.
Arotçarena R, Bigué JP, Etcharry F, Pariente A.[Pioglitazone-induced
acute severe hepatitis]. Gastroenterol Clin Biol. 2004 Jun-Jul;28(6-7
Pt 1):610-1. French.
Martínez Odriozola P, Ibarmia Lahuerta J, Gutiérrez Macías A, de la
Villa FM. [A new case: pioglitazone hepatotoxicity].Med Clin (Barc).
2007 Jun 23;129(4):158-9. Spanish.
PRAVASTATIN
Hartleb M, Rymarczyk G, Januszewski K. Acute cholestatic hepatitis
associated with pravastatin. Am J Gastroenterol 1999; 94:1388-90.
Heuer T, Gerards H, Pauw M, Gabbert HE, Reis HE. [Toxic liver
damage caused by HMG-CoA reductase inhibitor]. Med Klin(Munich)
2000; 95: 642-4. German.
Punthakee Z, Scully LJ, Guindi MM, Ooi TC. Liver fibrosis attributed
249-54.
Batey RG, Harvey M. Cholestasis associated with the use of
pravastatin sodium. Med J Aust 2002; 176: 561.
Hartleb M, Biernat L, Kochel A. Drug-induced liver damage--a threeyear study of patients from one gastroenterological department.
Med Sci Monit 2002; 8: CR292-6.
Hepatol 2012; 56:374-80.
4 DILIN cases
PREGABALIN
Crespo Pérez L, Moreira Vicente V, Manzano Fernández R, García
Aguilera XA. [Cholestasis associated with pregabalin treatment] Med
Clin (Barc) 2008; 130: 157-8. Spanish.
Einarsdottir S, Björnsson E. Pregabalin as a probable cause of acute
liver injury. Eur J Gastroenterol Hepatol 2008; 20: 1049.
Doğan S, Ozberk S, Yurci A. Pregabalin-induced hepatotoxicity. Eur
J Gastroenterol Hepatol 2011; 23: 628.
Sendra JM, Junyent TT, Pellicer MJ. Pregabalin-induced
hepatotoxicity. Ann Pharmacother 2011; 45: e32. Epub 2011 Jun 7.
Bamanikar A, Dhobale S, Lokwani S. Pregabalin hypersensitivity in a
patient treated for postherpetic neuralgia. Indian J Pharmacol 2013;
45: 522-3.
pii: S0016-5085(15)00311-X.
PROCAINAMIDE
Zimmerman HJ. Antiarrhythmics. Drugs used in cardiovascular
disease. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of
drugs and other chemicals on the liver. 2nd ed. Philadelphia:
Lippincott, 1999, pp. 642-4.
Farber HI. Fever, vomiting, and liver dysfunction with procainamide
therapy. Postgrad Med 1974; 56: 155-6.
Rotmensch HH, Yust I, Siegman-Igra Y, Liron M, Ilie B, Vardinon N.
Granulomatous hepatitis: a hypersensitivity response to
procainamide. Ann Intern Med 1978; 89: 646-7.
Ahn CS, Tow DE. Intrahepatic cholestasis due to hypersensitivity
reaction to procainamide. Arch Intern Med 1990; 150: 2589-90.
Worman HJ, Ip JH, Winters SL, Tepper DC, Gomes AJ.
Hypersensitivity reaction associated with acute hepatic dysfunction
following a single intravenous dose of procainamide. J Intern Med
1992; 232: 361-3.
Chuang LC, Tunier AP, Akhtar N, Levine SM. Possible case of
procainamide-induced intrahepatic cholestatic jaundice. Ann
PROCHLORPERAZINE
Case records of the Massachusetts General Hospital. Case 32-1967.
N Engl J Med 1967; 277: 255-62.
Ishak KG, Irey NS. Hepatic injury associated with the
phenothiazines. Clinicopathologic and follow-up study of 36
patients. Arch Pathol 1972; 93: 283-304.
Lok AS, Ng IO. Prochlorperazine-induced chronic cholestasis. J
Hepatol 1988; 6: 369-73.
Bach N, Thung SN, Schaffner F, Tobias H. Exaggerated cholestasis
and hepatic fibrosis following simultaneous administration of
chlorpromazine and sodium valproate. Dig Dis Sci 1989; 34: 13037.
years experience. NZ Med J 1996; 109: 315-9.
Mindikoglu AL, Anantharaju A, Hartman GG, Li SD, Villanueva J, Van
Thiel DH. Prochlorperazine-induced cholestasis in a patient with
alpha-1 antitrypsin deficiency. Hepatogastroenterology 2003; 50:
1338-40.
PYRIMETHAMINE
Selby CD, Ladusans EJ, Smith PG.Fatal multisystemic toxicity
associated with prophylaxis with pyrimethamine and sulfadoxine
(Fansidar). Br Med J (Clin Res Ed). 1985 Jan 12;290(6462):113-4.
Wejstal R, Lindberg J, Malmvall BE, Norkrans G. Liver damage
associated with fansidar. Lancet. 1986 Apr 12;1(8485):854-5.
Zitelli BJ, Alexander J, Taylor S, Miller KD, Howrie DL, Kuritsky JN,
Perez Th, Van Thiel DH. Fatal hepatic necrosis due to Fansidar. Ann
Intern Med 1987; 106: 393-5.
Gersch K, Bröker HJ, Mörl H, Waldherr R. [Drug-induced hepatitis
caused by Fansidar]. Schweiz Med Wochenschr. 1987 Oct
3;117(40):1544-8. German.
Okazaki Y, Watanabe N, Uchiyama J, Nakano A, Nishizaki Y, Kagawa
T, Matsuzaki S.[A case of hypersensitivity type of liver injury
induced by pyrimetamine and sulfadoxin (Fansidar)].
Nihon Shokakibyo Gakkai Zasshi. 1997 Feb;94(2):129-32.
Japanese.
Meier P, Schmid M, Stäubli M.[Acute hepatitis following
administration of fansidar]. Schweiz Med Wochenschr. 1990 Feb
17;120(7):221-5. German.
QUIETAPINE
El Hajj I, Sharara AI, Rockey DC. Subfulminant liver failure
associated with quetiapine. Eur J Gastroenterol Hepatol 2004; 16:
1415-8.
Wright TM, Vandenberg AM. Risperidone- and quetiapine-induced
cholestasis. Ann Pharmacother 2007; 41: 1518-23.
Shpaner A, Li W, Ankoma-Sey V, Botero RC. Drug-induced liver
injury: hepatotoxicity of quetiapine revisited. Eur J Gastroenterol
Hepatol 2008; 20: 1106-9.
Naharci MI, Karadurmus N, Demir O, Bozoglu E, Ak M, Doruk H.
Fatal hepatotoxicity in an elderly patient receiving low-dose
quetiapine. Am J Psychiatry 2011; 168: 212-3.
Al Mutairi F, Dwivedi G, Al Ameel T. Fulminant hepatic failure in
association with quetiapine: a case report. J Med Case Rep 2012; 6:
418.
Lin CH, Liu CM, Huang WL. Quetiapine-induced hepatocellular
damage. Psychosomatics 2012; 53: 601-2.
Sistanizad M, Peterson GM. Drug-induced liver injury in the
Australian setting. J Clin Pharm Ther 2013; 38: 115-20.
3 DILIN cases
RAMIPRIL
Douros A, Kauffmann W, Bronder E, Klimpel A, Garbe E, Kreutz R.
Ramipril-induced liver injury: case report and review of the
literature. Am J Hypertens. 2013 Sep;26(9):1070-5. n=3
Yeung E, Wong FS, Wanless IR, Shiota K, Guindi M, Joshi S,
Gardiner G.Ramipril-associated hepatotoxicity.
Arch Pathol Lab Med. 2003 Nov;127(11):1493-7.
RISPERIDONE
Fuller MA, Simon MR, Freedman L. Risperidone-associated
hepatotoxicity. J Clin Psychopharmacol 1996; 16: 84-5.
Phillips EJ, Liu BA, Knowles SR. Rapid onset of risperidone-induced
hepatotoxicity. Ann Pharmacother 1998; 32: 843-4.
Cordeiro Q Jr, Elkis H. Pancreatitis and cholestatic hepatitis induced
by risperidone. J Clin Psychopharmacol 2001; 21: 529-30.
Llinares Tello F, Hernández Prats C, Bosacoma Ros N, Pérez
Martínez E, Climent Grana E, Navarro Polo JN, Ordovás Baines JP.
Acute cholestatic hepatitis probably associated with risperidone. Int
J Psychiatry Med 2005; 35: 199-205.
Esposito D, Brocvielle H, Becquemont L, Hardy P, Chouinard G,
Corruble E. Risperidone-induced immunoallergic hepatitis. Am J
Psychiatry 2005; 162: 1984.
Legaz Huidobro ML, González Carro P, Pérez Roldán F, Soto
Fernández S, de Pedro Esteban A, Cuesta Domínguez R.
[Autoimmune hepatitis after risperidone-induced cholestatic
hepatitis]. Gastroenterol Hepatol 2005; 28: 135-6. Spanish.
RITONAVIR
Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B
infection in HIV-infected patient on protease inhibitor. Lancet 1997;
349: 995-6
Picard O, Rosmorduc O, Cabane J. Hepatotoxicity associated with
ritonavir (letter). Ann Intern Med 1998; 129: 670-1.
John M, Flexman J, French MA. Hepatitis C virus-associated
hepatitis following treatment of HIV-infected patients with HIV
protease inhibitors: an immune restoration disease? AIDS 1998;
12: 2289-93.
Vandercam B, Moreau M, Horsmans C, Gala JL. Acute hepatitis in a
patient treated with saquinavir and ritonavir: absence of crosstoxicity with indinavir. Infection. 1998 Sep-Oct;26(5):313. No
abstract available.
Arribas JR, Ibáñez C, Ruiz-Antoran B, Peña JM, Esteban-Calvo C,
Frías J, Vázquez JJ, González-García JJ. Acute hepatitis in HIVinfected patientsduring ritonavir treatment. AIDS. 1998
Sep10;12(13):1722-4.
Benveniste O, Longuet P, Duval X, Le Moing V, Leport C, Vildé JL.
Two episodes of acute renal failure,rhabdomyolysis, and severe
hepatitis in an AIDS patient successively treated with ritonavir and
indinavir. Clin Infect Dis. 1999 May;28(5):1180-1.
Cozza KL, Swanton EJ, Humphreys CW. Hepatotoxicity with
combination of valproicacid, ritonavir, and nevirapine: a case
report. Psychosomatics.2000 Sep-Oct;41(5):452-3. No abstract
available.
PaiVB, Koranyi K, Nahata MC. Acute hepatitis and bleeding possibly
induced by zidovudine andritonavir in an infant with HIV infection.
Pharmacotherapy 2000 Sep;20(9):1135-40.
ROSIGLITAZONE
Al-Salman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury
in a patient receiving rosiglitazone. A case report. Ann Intern Med
2000; 132: 121-4.
Isley WL, Oki JC. Rosiglitazone and liver failure.
Ann Intern Med. 2000 Sep 5;133(5):393-4.
Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient
taking rosiglitazone. Ann Intern Med. 2000 Jan 18;132(2):118-21.
Gouda HE, Khan A, Schwartz J, Cohen RI.Liver failure in a patient
treated with long-term rosiglitazone therapy. Am J Med. 2001
Nov;111(7):584-5.
Bonkovsky HL, Azar R, Bird S, Szabo G, Banner B.Severe
cholestatic hepatitis caused by thiazolidinediones: risks associated
with substituting rosiglitazone for troglitazone. Dig Dis Sci. 2002
Jul;47(7):1632-7.
Dhawan M, Agrawal R, Ravi J, Gulati S, Silverman J, Nathan G,
Raab S, Brodmerkel G Jr. Rosiglitazone-induced granulomatous
hepatitis. J Clin Gastroenterol. 2002 May-Jun;34(5):582-4.
Menees SB, Anderson MA, Chensue SW, Moseley RH.
Hepatic injury in a patient taking rosiglitazone. J Clin Gastroenterol.
2005 Aug;39(7):638-40.
Su DH, Lai MY, Wu HP.Liver failure in a patient receiving
rosiglitazone therapy. Diabet Med. 2006 Jan;23(1):105-6. No
abstract available.
SALSALATE
Juluri R, Gupta S, Vuppalanchi R. Serum concentration dependent
hepatoxicity in individuals receiving oral salsalate. Dig Dis Sci 2009;
54: 1375-6.
pii: S0016-5085(15)00311-X.
SORAFENIB
Schramm C, Schuch G, Lohse AW. Sorafenib-induced liver failure.
Am J Gastroenterol. 2008 Aug;103(8):2162-3.
Llanos L, Bellot P, Zapater P, Pérez-Mateo M, Such J.
Acute hepatitis in a patient with cirrhosis and hepatocellular
carcinoma treated with sorafenib. Am J Gastroenterol. 2009
Jan;104(1):257-8.
Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger
M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ,
Brose MS. Phase II trial of sorafenib in advanced thyroid cancer. J
Clin Oncol. 2008 Oct 10;26(29):4714-9.
Van Hootegem A, Verslype C, Van Steenbergen W. Sorafenibinduced liver failure: a case report and review of the literature.
Case Reports Hepatol. 2011;2011:941395.
Mancuso A, Zavaglia C, Bai F, Puoti M, Belli LS.Letter: Sorafenib
hepatotoxicity may be enhanced during treatment of advanced
hepatocellular carcinoma in HIV-infected patients. Aliment
Pharmacol Ther. 2013 Dec;38(11-12):1414-6
Fairfax BP, Pratap S, Roberts IS, Collier J, Kaplan R, Meade AM,
Ritchie AW, Eisen T, Macaulay VM, Protheroe A.
Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the
adjuvant treatment of a patient with renal cell carcinoma.
BMC Cancer. 2012 Dec 11;12:590.
TEMOZOLOMIDE
Goldbecker A, Tryc AB, Raab P, Worthmann H, Herrmann J,
Weissenborn K. Hepatic encephalopathy after treatment with
temozolomide. J Neurooncol 2011; 103: 163-6.
Dixit S, Hingorani M, Afzal P, Campbell AP. Temozolomide induced
liver injury. Acta Neurol Belg 2011; 111: 249-51.
Sarganas G, Orzechowski HD, Klimpel A, Thomae M, Kauffmann W,
Herbst H, Bronder E, Garbe E. Severe sustained cholestatic hepatitis
following temozolomide in a patient with glioblastoma multiforme:
case study and review of data from the FDA adverse event reporting
system. Neuro Oncol 2012; 14: 541-6.
Grant LM, Kleiner DE, Conjeevaram HS, Vuppalanchi R, Lee WM.
Clinical and histological features of idiosyncratic acute liver injury
caused by temozolomide. Dig Dis Sci 2013; 58: 1415-21
Becker F, Hecht M, Schmidtner J, Semrau S, Fietkau R.
Temozolomide-induced liver damage. A case report.
Strahlenther Onkol. 2014 Apr;190(4):408-10.
Case 1. Severe mixed-hepatocellular-cholestatic hepatitis due to
temozolomide. [Clinical Center, National Institutes of Health]
TOLCAPONE
Korri H, Awada A. [Serious tolpcapone-induced hepatitis 17 months
after commencing treatment]. Rev Neurol (Paris). 2005
Nov;161(11):1113-5
Spahr L, Rubbia-Brandt L, Burkhard PR, Assal F, Hadengue A.
Tolcapone-related fulminant hepatitis: electron microscopy shows
mitochondrial alterations. Dig Dis Sci. 2000 Sep;45(9):1881-4.
Martignoni E, Cosentino M, Ferrari M, Porta G, Mattarucchi E, Marino
F, Lecchini S, Nappi G. Two patients with COMT inhibitor-induced
hepatic dysfunction and UGT1A9 genetic polymorphism.
Neurology. 2005 Dec 13;65(11):1820-2.
TOPIRAMATE
Bjøro K, Gjerstad L, Bentdal O, Osnes S, Schrumpf E. Topiramate
and fulminant liver failure. Lancet 1998; 352: 1119.
Doan RJ, Clendenning M. Topiramate and hepatotoxicity. Can J
Psychiatry 2000; 45: 937-8.
Longin E, Teich M, Koelfen W, König S. Topiramate enhances the
risk of valproate-associated side effects in three children. Epilepsia
2002; 43: 451-4.
pii: S0016-5085(15)00311-X.
TRASTUZUMAB
Vucicevic D, Carey EJ, Karlin NJ.Trastuzumab-induced
hepatotoxicity: a case report. Breast Care (Basel). 2013
May;8(2):146-8.
Srinivasan S, Parsa V, Liu CY, Fontana JA. Trastuzumab-induced
hepatotoxicity. Ann Pharmacother. 2008 Oct;42(10):1497-501.
Force J, Saxena R, Schneider BP, Storniolo AM, Sledge GW Jr,
Chalasani N, Vuppalanchi R. Nodular Regenerative Hyperplasia After
Treatment With Trastuzumab Emtansine. J Clin Oncol. 2014 May 12.
TRAZODONE
Chu AG,Gunsolly BL, Summers RW, Alexander B, McChesney C,
Tanna VL. Trazodone and liver toxicity. Ann Intern Med 1983; 99:
128-9.
Sheikh KH, Nies AS. Trazodone and intrahepatic cholestasis. Ann
Intern Med 1983; 99: 274-5.
LongstrethGF, Hershman J. Trazodone-induced hepatotoxicity and
leukonychia. J Am Acad Dermatol 1985; 13: 149-50.
Rongioletti F, Rebora A. Drug eruption from trazodone. J Am Acad
Dermatol 1986; 14: 274-5.
Beck PL,Bridges RJ, Demetrick DJ, Kelly JK, Lee SS. Chronic active
hepatitis associated with trazodone therapy. Ann Intern Med 1993;
118: 791-2.
Fernandes NF, Martin RR, Schenker S. Trazodone-induced
hepatotoxicity: a case report with comments on drug-induced
Carvajal García-Pando A, García del Pozo J, Sánchez AS, Velasco
MA, Rueda de Castro AM, Lucena MI. Hepatotoxicity associated with
the new antidepressants. J Clin Psychiatry 2002; 63: 135-7.).
Sánchez Ruiz JC, González López E, Aparicio Tijeras C, Ezquerra
Gadea J. [Hepatotoxicity due to trazodone]. Aten Primaria 2004;
34: 104.
pii: S0016-5085(15)00311-X.
TRIMETOPRIM
Lindgren A, Olsson R. Liver reactions from trimethoprim.
J Intern Med. 1994 Sep;236(3):281-4.
VANCOMYCIN
Yazganoglu KD, Ozkaya E, Ergin-Ozcan P, Cakar N. Vancomycininduced drug hypersensitivity syndrome. J Eur Acad Dermatol
Venereol 2005; 19: 648-50.
Mennicke M, Zawodniak A, Keller M, Wilkens L, Yawalkar N, Stickel
F, Keogh A, et al. Fulminant liver failure after vancomycin in a
sulfasalazine-induced DRESS syndrrome: fatal recurrence after liver
transplantation. Am J Transplant 2009; 9: 2197-2202.
Vinson AE, Dufort EM, Willis MD, Eberson CP, Harwell JI.Drug rash,
eosinophilia, and systemic symptoms syndrome: Two pediatric
cases demonstrating the range of severity in presentation--A case
of vancomycin-induced drug hypersensitivity mimicking toxic shock
syndrome and a milder case induced by minocycline. Pediatr Crit
Care Med 2010; 11: e38-43.
O'Meara P, Borici-Mazi R, Morton AR, Ellis AK. DRESS with delayed
onset acute interstitial nephritis and profound refractory
eosinophilia secondary to Vancomycin. Allergy Asthma Clin Immunol
2011; 7: 16.
Song SM,Cho MS, Oh SH, Kim KM, Park YS, Kim DY, Lee SG. Liver
transplantation in a child with acute liver failure resulting from drug
rash with eosinophilia and systemic symptoms syndrome. Korean J
Pediatr 2013; 56: 224-6.
Della-Torre E, Yacoub MR, Pignatti P, Della-Torre F, Sabbadini MG,
Colombo G, Tresoldi M. Optimal management of DRESS syndrome
in course of infectious endocarditis. Ann Allergy Asthma Immunol
2013; 110: 303-5.
VERAPAMIL
Brodsky SJ, Cutler SS, Weiner DA, Klein MD. Hepatotoxicity due to
treatment with verapamil. Ann Intern Med 1981; 94:490-1.
Nash DT, Feer TD. Hepatic injury possibly induced by verapamil.
JAMA 1983; 249:395-6.
Guarascio P, D’Amato C, Sette P, Conte A, Visco G. Liver damage
from verapamil. Br Med J 1984; 288: 362-3.
Hare DL, Horowitz JD. Verapamil hepatotoxicity: a hypersensitivity
reaction. Am Heart J 1986; 111:160-1.
Burgunder JM, Abernethy DR, Lauterburg BH. Liver injury due to
verapamil. Hepatogastroenterology 1988; 35: 169-70.
De Arriba G, Garcia-Martin F, Sanchez-Heras M, Aldeguer M, Tejero
E, Jarillo MD. Hepatotoxicity due to verapamil hydrochloride. Eur J
Med 1993; 2: 179-81.
Kumar KL, Colley CA. Verapamil-induced hepatotoxicity. West J Med
1994; 160: 485-6.
Odeh M, Oliven A. Verapamil-associated liver injury. Harefuah
1998; 134: 36-7 [Hebrew].
Case 1. Asymptomatic elevations in serum enzymes during
verapamil therapy. [Modified from a case in the data base of the
Drug-Induced Liver Injury Network]
VINCRISTINE
Hansen MM, Ranek L, Walbom S, Nissen NI. Fatal hepatitis following
irradiation and vincristine. Acta Med Scand 1982; 212: 171-4.
el Saghir NS, Hawkins KA. Hepatotoxicity following vincristine
therapy. Cancer 1984; 54: 2006-8.
Uygun K , Kocak Z , Cicin I , Caloglu M . Fatal hepatic venoocclusive disease in an adult patient with Wilms' tumour. Clin Oncol
(R CollRadiol). 2003 Sep;15(6):366.
Boula AM, Mantadakis E, Xilouri IM, Christoforidou AV, Foudoulakis
AM, Samonis G. Veno-occlusive disease of the liver associated with
chronic myelomonocytic leukemia treated with vincristine and
standard doses of cytarabine. Am J Hematol.2005 Jul;79(3):216-9.
Ishaqi MK, Jamil A, Khanani M, Baroudi M, Trad O, El-Hayek M,
Bouffet E. Hepatic Sinusoidal Obstruction Syndrome in a child after
chemotherapy for medulloblastoma. J Neurooncol. 2010
Mar;97(1):137-41.
Cecen E, Uysal KM, Ozguven A, Gunes D, Irken G, Olgun N. Venoocclusive disease in a child withrhabdomyosarcoma after
conventional chemotherapy: report of a case and review of the
literature. Pediatr Hematol Oncol. 2007 Dec;24(8):615-21.
WARFARIN
Adler E, Benjamin SB, Zimmerman HJ. Cholestatic hepatic injury
related to warfarin exposure. Arch Intern Med 1986; 146: 1837-9.
Matsukawa R, Uemura S, Fukuchi S, Tsuruta Y, Murakami S.
[Thrombosed St. Jude Medical prosthesis with drug induced
hepatitis due to warfarin potassium.a case report]. Nippon Kyobu
Geka Gakkai Zasshi 1994; 42: 413-5. Japanese.
Chaudhry S, Oelsner D. Cholestatic reaction to warfarin.
Am J Gastroenterol. 1995 May;90(5):853.
Höhler T, Schnütgen M, Helmreich-Becker I, Mayet WJ,Mayer zum
Büschenfelde KH. Drug-induced hepatitis: a rare complication of
oral anticoagulants. J Hepatol 1994; 21: 447-9.
Bamanikar A, Hiremath S.Hepatotoxic reaction to warfarin in a
recovering hepatitis patient with hypoalbuminenia. J Assoc
Physicians India. 2002 Nov;50:1456
ZAFIRLUKAST
Grieco AJ, Burstein-Stein J. Oral montelukast versus inhaled
salmeterol to prevent exercise-induced bronchoconstriction. Ann
Intern Med 2000; 133: 392.
Reinus JF, Persky S, Burkiewicz JS, Quan D, Bass NM, Davern TJ.
Severe liver injury after treatment with the leukotriene receptor
antagonist zafirlukast. Ann Intern Med 2000; 133: 964-8.
Actis GC, Morgando A, Lagget M, David E, Rizzetto M. Zafirlukastrelated hepatitis: report of a further case [Letter]. J Hepatol 2001;
35: 539-41.
Danese S, De Vitis I, Gasbarrini A. Severe liver injury associated
with zafirlukast [Letter]. Ann Intern Med 2001; 135: 930.
Molés JR, Primo J, Fernández JM, Hinojosa JE. Acute hepatocellular
injury associated with zafirlukast. J Hepatol 2001; 35: 541-2.
Torres M, Reddy KR. Severe liver injury. Ann Intern Med. 2001;
135: 550.
Su CW, Wu JC, Huang YH, Huang YS, Chang FY, Lee SD.
Zafirlukast-induced acute hepatitis. Zhonghua Yi Xue Za Zhi(Taipei)
2002; 65: 553-6.
ACETAZOLAMIDE
Basar O, Basar N, Tuna Y, Yuksel H, Coban S. Azetazolamide induced sever
hepatotoxicity. Wiener Klinische Wochenschript 2013; 125: 223-224.
ACETOHEXAMIDE
Duncan TG, Smith BS, Duncan GG. The comprative clinical effects of
tolbutamide and acethoxamide. Metabolism 1965; 17: 218-25.
Goldstein MJ, Rothenberg AJ. Jaundice in a patient receiving acetohexamide.
N Engl J Med. 1966 Jul 14;275(2):97-9.
Rank JM, Olson RC. Reversible cholestatic hepatitis caused by
acetohexamide.Gastroenterology. 1989 Jun;96(6):1607-8.
ALSKIREN
Crepin S, Godet B, Carrier P, Villeneuve C, Merle L, Laroche ML. Probable
drug-induced liver injury associated with aliskiren: case report and review of
adverse event reports from pharmacovigilance databases. Am J Health Syst
Pharm 2014; 71: 643-7.
Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J. Features
and Outcomes of 889 Patients with Drug-induced Liver Injury: The DILIN
Prospective Study. Gastroenterology. 2015 Mar 6. [Epub ahead of print].
ALOSETRON
Turgeon DK, Tayeh N, Fontana RJ. Acute hepatitis associated with
alosetron(Lotronex). J Clin Gastroenterol 2005; 39: 641-2.
ALPRAZOLAM
Judd FK, Norman TR, Marriott PF, Burrows GD. A case of alprazolam-related
hepatitis. Am J Psychiatry 1986; 143: 388-9.
ANASTROZOLE
Zapata E, Zubiaurre L, Bujanda L, Piérola A. Anastrozole - induced
hepatotoxicity. Eur J Gastroenterol Hepatol. 2006 Nov;18(11):1233-4.
de la Cruz L, Romero-Vazquez J, Jiménez-Sáenz M, Padron JR, HerreriasGutierrez JM.Severe acute hepatitis in a patient treatedwith anastrozole.
Lancet. 2007 Jan6;369(9555):23-4.
Inno A , Basso M , Vecchio FM , Marsico VA , Cerchiaro E , D'Argento E ,
Bagalà C , Barone C. Anastrozole-related acute hepatitis with
autoimmunefeatures: a case report. BMC Gastroenterol. 2011 Mar 31;11:32.
ATANAZAVIR
Eholié SP, Lacombe K, Serfaty L, Wendum D, Girard PM. Acute hepatic
cytolysis in an HIV-infected patient taking atazanavir. AIDS 2004; 18: 16101.
ATENOLOL
Yusuf SW, Mishra RM. Hepatic dysfunction associated with atenolol. Lancet.
1995 Jul 15;346(8968):192.
Dumortier J, Guillaud O, Gouraud A, Pittau G, Vial T, Boillot O, Scoazec JY.
Atenolol hepatotoxicity: report of a complicated case. Ann Pharmacother.
2009 Oct;43(10):1719-23.
Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR,
Watkins PB, Navarro V, Barnhart H, Gu J, Serrano J Features and Outcomes of 889
Patients with Drug-induced Liver Injury: The DILIN Prospective Study.
Gastroenterology. 2015 Mar 6. pii: S0016-5085(15)00311-X.
BACLOFEN
BENAZEPRIL
Palta R, Thobani S, Donovan JA, Kanel GC, Gutierrez G, Fong TL.Prolonged
cholestasis associated with benazepril therapy. Am J Gastroenterol. 2009
Jan;104(1):245-6.
BICALUTAMIDE
Dawson LA, Chow E, Morton G. Fulminant hepatic failure associated with
bicalutamide. Urology 1997; 49: 283-4.
O'Bryant CL, Flaig TW, Utz KJ. Bicalutamide-associated fulminant
hepatotoxicity. Pharmacotherapy 2008; 28: 1071-5.
BORTEZUMIB
Rosiñol L, Montoto S, Cibeira MT, Bladé. Bortezomib-induced severe hepatitis
in multiple myeloma: a case report. Arch Intern Med 2005; 165: 464-5.
Cornelis T, Beckers EA, Driessen AL, van der Sande FM, Koek GH.
Bortezomib-associated fatal liver failure in a haemodialysis patient with
multiple myeloma. Clin Toxicol (Phila) 2012; 50: 444-5.
Wilson N, Surati M, Walker BF, Kaufman JL, Harvey RD. Bortezomib
administration with severe hyperbilirubinemia caused by hepatic plasma cell
infiltration: a case report. Clin Lymphoma Myeloma Leuk. 2013
Apr;13(2):159-61
BROMOCRIPTINE
Liberato NL, Poli M, Bollati P, Chiofalo F, Filipponi M. Bromocriptine-induced
acute hepatitis. Lancet. 1992 Oct 17;340(8825):969-70.
CANAKINUMAB
Banse C, Vittecoq O, Benhamou Y, Gauthier-Prieur M, Lequerré T, Lévesque
H. Reactive macrophage activation syndrome possibly triggered by
canakinumab in a patient with adult-onset Still's disease. Joint Bone Spine
2013; 80: 653-5.
CARBENICILLIN
Gump DW. Elevated SGOT levels after carbenicillin. N Engl J Med 1970; 282:
1489-90.
CARBOPLATIN
Hruban RH, Sternberg SS, Meyers P, Fleisher M, Menendez-Botet C, Boitnott
JK. Fatal thrombocytopenia and liver failure associated with carboplatin
therapy. Cancer Invest. 1991;9(3):263-8.
Carvedilol
Hagmeyer KO, Stein J. Hepatotoxicity associated with carvedilol. Ann
Pharmacother. 2001 Nov;35(11):1364-6.
CEFACLOR
Bosio M. Cholestatic jaundice and hematuria due to hypersensitivity to
cefaclor in a child. Clin Toxicol 1983; 20: 79.
Alqahtani SA, Kleiner DE, Ghabril M, Gu J, Hoofnagle JH, Rockey DC.
Identification and Characterization of Cefazolin-induced Liver Injury. Clin
Gastroenterol Hepatol. 2014 Dec 17. pii: S1542-3565(14)01824-2
CEFADROXIL
CEFDINIR
Chen J, Ahmad J. Cefdinir-induced hepatotoxicity: potential hazards of
inappropriate antibiotic use. J Gen Intern Med. 2008 Nov;23(11):1914-6.
Gastroenterol Hepatol. 2014 Dec 17. pii: S1542-3565(14)01824-2.
CEFEPIME
Gastroenterol Hepatol. 2014 Dec 17. pii: S1542-3565(14)01824-2.
CEFOPERAZONE
Wolf A, Schomerus H, Berg P.[Severe liver damage as a drug-allergy
reaction to cefoperazone].Z Gastroenterol. 1985 Apr;23(4):198-202.
German.
CEFOTAXIM
CEFPROZIL
Bilici A, Karaduman M, Cankir Z. A rare case of hepatitis associated with
cefprozil therapy. Scand J Infect Dis. 2007;39(2):190-2.
CEFTAZIDIME
Incidence, presentation and outcomes in patients with drug-induced liver
injury in the general population of Iceland. Gastroenterology 2013; 114:
1419-25.
CEFUROXIME
Ekiz F, Uskudar O, Simsek Z, Yuksel I, Basar O, Altinbas A, Yuksel O.
Cefuroxime axetil-induced liver failure. Annals of Hepatology 2010; 9: 306.
CHLORAMBUCIL
Morgano G, Patrone E, Muratore A. [Atypical aspects of leukoses. Venous
thrombosis; jaundice]. Minerva Med 1969; 60: 1106-11.
Patel SP, Nast CC, Adler SG.Chlorambucil-induced acute hepatic failure in a
patient with membranous nephropathy.Am J Kidney Dis. 2000
Aug;36(2):401-4.
Pichon N, Debette-Gratien M, Cessot F, Paraf F, Labrousse F, Sautereau D,
Pillegand B. [Acute cholestatic hepatitis caused by chlorambucil].
Gastroenterol Clin Biol 2001; 25: 202-3. PubMed Citation]
CHLORDIAZEPOXIDE
Lo KJ, Eastwood IR, Eidelman S. Cholestatic jaundice associated with
chlordiazepoxide hydrochloride (Librium) therapy. Report of a case and
review of the literature. Am J Dig Dis 1967; 12: 845-9.
Kratzsch KH, Buttner W, Reinhardt G. [Intrahepatic cholestasis following
chlordiazepoxide-contribution to the differential diagnosis of drug jaundice]
Z Gesamte Inn Med 1972; 27: 408-11.
CHLOROQUINE/ HYDROXYCHLOROQUINE
Makin AJ, Wendon J, Fitt S, Portmann BC, Williams R. Fulminant hepatic
failure secondary to hydroxychloroquine. Gut 1994; 35: 569-70.
Wielgo-Polanin R, Lagarce L, Gautron E, Diquet B, Lainé-Cessac P.
Hepatotoxicity associated with the use of a fixed combination of chloroquine
and proguanil. Int J Antimicrob Agents 2005; 26: 176-8.
CISPLATIN
Cavalli F, Tschopp L, Sonntag RW, Zimmermann A. A case of liver toxicity
following cis-dichlorodiammineplatinum (II) treatment. Cancer Treat Rep
1978; 62: 2125-6.
Cersosimo RJ. Hepatotoxicity associated with cisplatin chemotherapy. Ann
Pharmacother. 1993 Apr;27(4):438-41.
CLOFIBRATE
Jacobs WH. Intrahepatic cholestasis following the use of Atromid-S. Am J
Pierce EH, Chesler DL. Possible association of granulomatous hepatitis with
clofibrate therapy. N Engl J Med 1978; 299: 314.
Migneco G, Mascarella A, La Ferla A, Attianese R. [Clofibrate hepatitis. A
case report] Minerva Med 1986; 77: 799-800.
CLOMIPRAMINE
Alderman CP, Atchison MM, McNeece JI. Concurrent agranulocytosis and
hepatitis secondary to clomipramine therapy. Br J Psychiatry 1993; 162:
688-9.
CLONAZEPAM
Olsson R, Zettergren L. Anticonvulsant-induced liver damage.
Gastroenterol. 1988 May;83(5):576-7.
Am J
CLOTRIMAZOLE
Clerig Arnau U, García Rodríguez J, Pérez Lidón G, Palacios Vaca
F.[Cholestatic hepatitis secondary to clotrimazole]. Med Clin (Barc). 1992
May 16;98(19):757.
CROMOLYN
Rosenberg JL, Edlow D, Sneider R. Liver disease and vasculitis in a patient
taking cromolyn. Arch Intern Med. 1978 Jun;138(6):989-91.
CYCLOSPORINE
Moore RA, Greenberg E, Tangen L.Cyclosporine-induced worsening of
hepatic dysfunction in a patient with Crohn's disease and enterocutaneous
fistula. South Med J. 1995 Aug;88(8):843-4.
Ngo MD, Hagège H, Rosa I, Cartier VA, Lons T, Gordin J, Chousterman M.
[Acute hepatitis in the course of cyclosporine therapy of Crohn's disease].
Presse Med. 1999 Nov 6;28(34):1873-5. French.
.
DABIGATRAN
Rochwerg B, Xenodemetropoulos T, Crowther M, Spyropoulos A. Dabigatraninduced acute hepatitis. Clin Appl Thromb Hemost 2012; 18: 549-50.
Fulcrand J, Lerooy A, Giraud J, Cailliau A, Delrot C, Petitpain N, Auffret M; le
réseau des Centres régionaux de Pharmacovigilance. [Cytolysis in an elderly
patient treated with dabigatran etexilate]. Therapie 2013; 68: 332-4.
DALTEPARIN
Levinson P, Glaumann H, Söderberg M. Probable dalteparin-induced
hepatotoxicity in a man with alpha-1-antitrypsin deficiency. J Clin
Pharmacol. 2012 Nov;52(11):1764-7
DAREPOETIN ALFA
Dumortier J, Boucher A, Scoazec JY, Vial T.[Cytolytic hepatitis induced by
darbepoetin alpha treatment]. Gastroenterol Clin Biol. 2004 May;28(5):5067.
DEFIRASIROX
Aslam N, Mettu P, Marsano-Obando LS, Martin A. Deferasirox induced liver
injury in haemochromatosis. J Coll Physicians Surg Pak 2010; 20: 551-3.
DEFEROXAMINE
Gratadour P, Fouque D, Chevalier P, Vial T, Chossegros P, Laville M,
Labeeuw M, et al. [Acute hepatitis induced by deferoxamine in a patient
under chronic hemodialysis]. Therapie 1992; 47: 555. French.
DOCETAXIL
Tomassini E, Muhizi J, al Raheb K, Steinbach G, Bemer M, Platini C.
[Fulminant hepatocellular necrosis following administration of docetaxel].
Presse Med 2001; 30: 634. French.
DONEPEZIL
Dierckx RIR, Vandewoude MFJ. Donepezil-related toxic hepatitis. Acta Clinica
Belg 2008; 63: 339-42.
DOXEPINE
Keegan AD. Doxepin-induced recurrent acute hepatitis. Aust N Z J Med
1993; 23: 523.
ENOXAPARIN
Hui CK, Yuen MF, Ng IO, Tsang KW, Fong GC, Lai CL.Low molecular weight
heparin-induced liver toxicity. J Clin Pharmacol. 2001 Jun;41(6):691-4.
Baker EL, Loewenthal T, Salerno E, Baker WL. Probable enoxaparin-induced
hepatotoxicity. Am J Health Syst Pharm. 2009 Apr 1;66(7):638-41.
Carlson MK, Gleason PP, Sen S.Elevation of hepatic transaminases after
enoxaparin use: case report and review of unfractionated and lowmolecular-weight heparin-induced hepatotoxicity. Pharmacotherapy. 2001
Jan;21(1):108-13.
ENTACAPONE
Entacapone-induced hepatotoxicity and hepatic dysfunction.
Fisher A, Croft-Baker J, Davis M, Purcell P, McLean AJ.
Mov Disord. 2002 Nov;17(6):1362-5; discussion 1397-1400.
ETHAMBUTOL
Guilliford M, MacKay AD, Prawse K. Cholestatic jaundice caused by
ethambutol. Br Med J 1986; 292: 866.Rechallenge.
ETRAVIRINE
EXEMESTANE
Bao T, Fetting J, Mumford L, Zorzi J, Shahverdi K, Jeter S, Herlong F, et al.
Severe prolonged cholestatic hepatitis caused by exemestane. Breast Cancer
Res Treat 2010; 121: 789-91.
FEBUXOSTAT
Vuppalanchi R, Chalasani N. Febuxostat-induced acute liver injury.
Hepatology 2015. In press.
FLECAINIDE
Hopmann G, Surmann T. [Cholestatic jaundice during flecainide therapy].
Dtsch Med Wochenschr 1984; 109: 1863. German.
Mikloweit P, Bienmüller H. [Drug-induced intrahepatic cholestasis caused by
flecainide acetate and enalapril]. Internist(Berl) 1987; 28: 193-5. German.
Kühlkamp V, Haasis R, Seipel L. [Flecainide-induced hepatitis]. Z Kardiol
1988; 77: 678-80.
FLURAZEPAM
Fang MH, Ginsberg AL, Dobbins WO 3rd. Cholestatic jaundice associated with
flurazepam hydrochloride. Ann Intern Med 1978; 89: 363-4.
Reynolds R, Lloyd DA, Slinger RP. Cholestatic jaundice induced by
flurazepam hydrochloride. Can Med Assoc J 1981; 124: 893-4.
FONDAPARINUX
Orostegui L, Medejel N, Kone-Paut I, Dreyfus M, Benhamou D. Fondaparinux
(Arixtra *) hepatotoxicity in a 6 year-old child. J Hepatol 2013; 58: 195-8.
FOSFOMYCIN
Wang YP, Shi B, Chen YX, Xu J, Jiang CF, Xie WF. Drug-induced liver
disease: an 8-year study of patients from one gastroenterological
department. J Dig Dis. 2009 Aug;10(3):195-200.
Matsumori A, Yoneda S, Kobayashi Y, Takeda K, Andoh M, Yamane Y,
Nishimura K, Kojima H, Fukui H.[A case of acute severe hepatitis induced by
fosfomycin]. Nihon Shokakibyo Gakkai Zasshi. 2005 Sep;102(9):1207-11.
Durupt S, Josserand RN, Sibille M, Durieu I. Acute, recurrent fosfomycininduced liver toxicity in an adult patient with cystic fibrosis. Scand J Infect
Dis. 2001;33(5):391-2
FOSINORIL
Nunes AC, Amaro P, Maçias F, et al. Fosinopril-induced prolonged cholestatic
jaundice and pruritus: first case report. Eur J Gastroenterol Hepatol 2001;
13: 279-82.
Chou JW, Yu CJ, Chuang PH, Lai HC, Hsu CH, Cheng KS, Peng CY, Chiang IP.
Successful treatment of fosinopril-induced severe cholestatic jaundice with
plasma exchange. Ann Pharmacother. 2008 Dec;42(12):1887-92.
Romero-Gómez M, Miralles EJ, García Díaz E, Robles A, Suárez E, Castro M.
Hepatotoxicity induced by fosinopril. J Hepatol. 2001 Aug;35(2):309-10.
GEMIFLOXACIN
Kilincalp S, Deveci M, Coban S, Basar O, Yuksel O. A new cause of acute
hepatitis: gemifloxacin. Acta Gastroenterol Belg 2012; 75: 460-1.
GLICLAZIDE
Chitturi S, Le V, Kench J, Loh C, George J.Gliclazide-induced acute hepatitis
with hypersensitivity features. Dig Dis Sci 2002; 47: 1107-10.
Dourakis SP, Tzemanakis E, Sinani C, Kafiri G,Hadziyannis SJ. Gliclazideinduced acute hepatitis. Eur J Gatroenterol Hepatol 2000; 12: 119-121.
HYDROCHLORTIAZIDE
Anez MS, Dickson G, Zabala R, Zabaleta P, Pacheco A, Briceno D. [Acute
hepatitis due to hydrochlorothiazide: report of a case]. Gastroenterol
Hepatol 1981; 4: 476-8.
Valhovd M, Kildahl-Andersen O.[Drug-induced severe jaundice].
Tidsskr Nor Laegeforen. 2003 May 1;123(9):1202-3.Hydrochlortiazide
+amilorid
IMIPENEM
Quattropani C, Schneider M, Helbling A, Zimmermann A, Krähenbühl S.
Cholangiopathy after short-term administration of piperacillin and
imipenem/cilastatin. Liver. 2001 Jun;21(3):213-6.
Schreiber C, May B.[Cholestasis in imipenem/cilastatin treatment].Z
Gastroenterol. 1993 Feb;31 Suppl 2:76-7. German.
IPRONIAZID
Gollini C, Dallari R, Cervi F, Mengoli M.[Iproniazid-induced acute hepatitis].
Recenti Prog Med. 1992 Jun;83(6):354-5. Italian.
IVERMECTIN
Veit O, Beck B, Steuerwald M, Hatz C. First case of ivermectin-induced
severe hepatitis. Trans R Soc Trop Med Hyg 2006; 100: 795-7. ………….was
treated with a single dose of ivermectin (15 mg orally).
Sparsa A, Bonnetblanc JM, Peyrot I, Loustaud-Ratti V, Vidal E, Bédane C.
[Systemic adverse reactions with ivermectin treatment of scabies]. Ann
Dermatol Venereol 2006; 133: 784-7. French.
LAPATINIB
Peroukides S, Makatsoris T, Koutras A, Tsamandas A, Onyenadum A,
Labropoulou-Karatza C, Kalofonos H. Lapatinib-induced hepatitis: a case
report. World J Gastroenterol 2011; 17: 2349-52.
LETROZOLE
LOMUSTINE
de Labarthe B, Chahinian P, Gosselin M, Goasguen J, Ferrand B, Danrigal A,
Israel L. [Hepatic damage during treatment with C.C.N.U]. Sem Hop Ther
1975; 51: 309-14.
LOPINAVIR
Zell SC. Clinical vignette in antiretroviral therapy: jaundice. J Int Assoc
Physicians AIDS Care 2003; 2: 133-9.
MEBENDAZOLE
Seitz R, Schwerk W, Arnold R. [Hepatocellular drug reaction caused by
mebendazole therapy in cystic echinococcosis]. Z Gastroenterol 1983; 21:
324-9. German.
Bekhti A, Pirotte J. Hepatotoxicity of mebendazole. Relationship with serum
concentrations of the drug. Gastroenterol Clin Biol 1987; 11: 701-3.
Colle I, Naegels S, Hoorens A, Hautekeete M. Granulomatous hepatitis due
to mebendazole. J Clin Gastroenterol 1999; 28: 44-5.
MEFENAMIC ACID
Chan JCN, Lai FM, Critchley JAJH. A case of Stevens-Johnson syndrome,
cholestatic hepatitis and haemolytic anaemia associated with use of
mefenamic acid. Drug Saf 1991; 6: 230-4.
Schwartz D, Gremmel F, Kurz R, Tragl KH, Gellner B, Pausch V. Case report:
acute renal failure, thrombocytopenia and nonhemolytic icterus probably
caused by mefenamic acid(Parkemed)-dependent antibodies. Beitr
Infusionsther 1992; 30: 413-5.
MEFLOQUINE
Bruguera M, Herrera S. [Acute hepatitis associated with mefloquine
therapy]. Gastroenterol Hepatol 2007; 30: 102-3. Spanish.
MEMANTINE
Ferrara N, Corbi G, Capuano A, Filippelli A, Rossi F. Memantine-induced
hepatitis with cholestasis in a very elderly patient. Ann Intern Med. 2008 Apr
15;148(8):631-2.
MEROPENEM
Schumaker AL, Okulicz JF. Meropenem-induced vanishing bile duct
syndrome. Pharmacotherapy 2010; 30: 335e-338e.
METHAZOLAMIDE
Krivoy N, Ben-Arieh Y, Carter A, Alroy G. Methazolamide-induced hepatitis
and pure RBC aplasia. Arch Intern Med. 1981 Aug;141(9):1229-30.
MICAFUNGIN
King KY, Edwards MS, Word BM. Hepatitis associated with micafungin use in
a preterm infant. J Perinatol 2009; 29: 320-2.
MILNACRIPIN
de Widerspach-Thor A, Dubois F, Bacq Y. [Acute hepatitis associated with
milnacipran treatment]. Gastroenterol Clin Biol 2004; 28: 191-2. French.
MITOXANTRONE
Caruso A, Vecchio R, Patti F, Neri S. Drug rash with eosinophilia and
systemic signs syndrome in a patient with multiple sclerosis. Clin Ther 2009;
31: 580-4.
MITHRAMYCIN
Fraisse F, Marche C, Gibert C, Coquin Y, Vachon F. [Acute hepatic necrosis
and hemorrhagic syndrome leading to a fatal outcome during treatment of
hypercalcemia with mithramycin (author's transl)]. Ann Med Interne (Paris)
1980; 131: 281-4.
Hémon Y, Martin C, Auffray JP, Bonneru JJ, Brunet C, Farisse J. [Acute fatal
hepatorenal failure during treatment with mithramycin]. Ann Fr Anesth
Reanim 1985; 4: 301-3. French.
Case submitted to Livertox (http://livertox.nih.gov).
MOLINDONE
Bhatia SC, Banta LE, Ehrlich DW. Molindone and hepatotoxicity. Drug Intell
Clin Pharm 1985; 19: 744-6.
MYCOPHENOLATE
Dourakis SP, Boki K, Soultati A, Cherouvim E, Delladetsima I. Acute hepatitis
following mycophenolate mofetil administration for ANCA-positive vasculitis.
Scand J Rheumatol. 2007 May-Jun;36(3):237-9.
Loupy A, Anglicheau D, Mamzer-Bruneel MF, Martinez F, Thervet E, Legendre
C, Serpaggi J, Pol S.Mycophenolate sodium-induced hepatotoxicity: first
report. Transplantation. 2006 Aug 27;82(4):581.
NELARABINE
Iino M. [Severe liver injury following nelarabine chemotherapy for T-cell
lymphoblastic lymphoma]. Rinsho Ketsueki 2009; 50: 49-51. Japanese.
NELFINAVIR
Stohl HE, Silva AM, Argani CH, Anderson JR. Fulminant hepatic failure
associated with antiretroviral therapy in a pregnant woman. Int J Gynaecol
Obstet. 2009 Sep;106(3):260-1.
NIZATIDINE
Chey WD, Kochman ML, Traber PG, Appelman HD, Gumucio JJ. Possible
nizatidine-induced subfulminant hepatic failure. J Clin Gastroenterol 1995;
20: 164-7. Cirrhosis.
NORTRYPTILINE
Berkelhammer C, Kher N, Berry C, Largosa A. Nortriptyline-induced
fulminant hepatic failure. J Clin Gastroenterol 1995; 20: 54-6.
Pedersen AMB, Enevoldsen HK, Kohler H. Nortriptyline-induced hepatic
failure. Ther Drug Monit 1996; 18: 100-2.
ONDANSETRON
Verrill M, Judson I. Jaundice with ondansetron. Lancet 1994; 344(8916):
190-1.
Lewandowski MJ, Chapman SA. Ondansetron-induced aminotransferase level
elevation: case report and review of the literature. Pharmacotherapy 2008;
28: 1542-6.
OXCARBAZEPINE
Bosdure E, Cano A, Roquelaure B, Reynaud R, Boyer M, Viard L, Sarles
J. [Oxcarbazepine and DRESS syndrome: a paediatric cause of acute liver
failure]. Arch Pediatr 2004; 11: 1073-7. French.
Hsu HF, Huang SY. Severe hepatitis associated with administration
of oxcarbazepine. Pediatr Int 2010; 52: 677-8.
PENTAMIDINE
Picon M, Causse X, Gelas P, Retornaz G, Trépo C, Bouletreau P.
[Pentamidine-related acute hepatitis during pneumocystosis treatment in
acquired immunodeficiency syndrome]. Gastroenterol Clin Biol 1991; 15:
463-4.
PENTOSTATIN
Dang-Vu AP, Olsen EA, Vollmer RT, Greenberg ML, Hershfield MS. Treatment
of cutaneous T cell lymphoma with 2'-deoxycoformycin(pentostatin). J Am
Acad Dermatol 1988; 19: 692-8.
PRASUGREL
Fernández-Ruiz M, Carbonell-Porras A, García-Reyne A, López-Medrano F.
Management of a hypersensitivity reaction to thienopyridines: prasugrel-
induced fever and hepatitis resolved after switching to clopidogrel. Rev Esp
Cardiol 2012; 65: 773-4.
PROCARBAZINE
Fesler MJ, Becker-Koepke S, Di Bisceglie AM, Petruska PJ. Procarbazineinduced hepatotoxicity: case report and review of the literature.
Pharmacotherapy 2010; 30: 540.
PROPOFOL
Anand K, Ramsay MA, Crippin JS. Hepatocellular injury following the
administration of propofol. Anesthesiology 2001; 95: 1523-4.
Kneiseler G, Bachmann HS, Bechmann LP, Dechene A, Heyer T, Baba H,
Saner F, et al. A rare case of propofol-induced acute liver failure and
literature review. Case Rep Gastroenterol 2010; 4: 57-65.
Asai A, Yagi M, Tsuchimoto Y, Fukunishi S, Takeshita A, Tsuda Y, Fukuda A,
et al. A rare case of propofol-induced liver injury during modified
electroconvulsive therapy in an elderly woman. Intern Med 2013; 52: 761-5.
RABEPRAZOLE
Aktaş B, Başar Ö, Altinbaş A, Ekiz F, Yüksel O. Rabeprazole-induced
acute cholestatic liver injury. Turk J Gastroenterol 2012; 23: 309-10.
RALTEGRAVIR
Fleischbein E, O'Brien J, Martelino R, Fenstersheib M. Elevated alkaline
phosphatase with raltegravir in a treatment experienced HIV patient. AIDS
2008; 22: 2404-5.
REPAGLINIDE
Jaiswal S, Mehta R, Musuku M, Tran L, McNamee W Jr. Repaglinide induced
acute hepototoxicity. JNMA J Nepal Med Assoc. 2009 Apr-Jun;48(174):1624.
López-García F, Borrás J, Verdú C, Salazar VR, Ruiz JA, Sales J, Lucena MI,
Andrade RJ. Cholestatic hepatitis associated with repaglinide. Diabetes Care.
2005 Mar;28(3):752-3.
Nan DN, Hernández JL, Fernández-Ayala M, Carrascosa M. Acute
hepatotoxicity caused by repaglinide. Ann Intern Med. 2004 Nov
16;141(10):823.
RIFABUTIN
Horne DJ, Spitters C, Narita M. Experience with rifabutin replacing rifampin
in the treatment of tuberculosis. Int J Tuberc Lung Dis 2011; 15: 1485-9.
RILPIVIRIN
Ahmed Y, Siddiqui W, Enoch CB, Albrecht H, Bookstaver PB. Rare case of
rilpivirine-induced severe allergic hepatitis. J Antimicrob Chemother 2012
Oct 12
RILUZOLE
Castells LI, Gamez J, Cervera C, Guardia J. Icteric toxic hepatitis associated
with riluzole. Lancet 1998; 351: 648.
Remy A-J, Camu W, Ramos J, Blanc P, Larrey D. Acute hepatitis after riluzole
administration. J Hepatol 1999; 30: 527-30.
Henderson RD, McCombe PA. Riluzole: a glimmer of hope in the treatment of
motor neurone disease. Med J Aust 2005; 183: 164; author reply 164-5.
RIVASTIGMINE
Mumoli N, Carmignani G, Luschi R, Cei M, Chiavistelli P.Hepatitis with
cholestasis caused by rivastigmine transdermal patch. Am J Gastroenterol.
2009 Nov;104(11):2859-60.
ROPINIROLE
Navacerrada F, González-Alonso MR, Alonso-Navarro H, Pilo-de-la-Fuente B,
Plaza-Nieto JF, Jiménez-Jiménez FJ. Liver toxicity possibly related with
ropinirole use in the treatment of restless legs syndrome. Eur J Neurol. 2011
Jun;18(6):e65.
SAQUINAVIR
Vandercam B, Moreau M, Horsmans C, Gala JL. Acute hepatitis in a patient
treated with saquinavir and ritonavir: absence of cross-toxicity with
indinavir. Infection. 1998 Sep-Oct;26(5):313.
SIBUTRAMINE
Chounta A, Tsiodras S, Zouridakis S, Doumas M, Giamarellou H. Sibutramine use
associated with reversible hepatotoxicity. Ann Intern Med 2005; 143: 763-4.
SILDENADIL
Wolfhagen FH, Vermeulen HG, de Man RA,Lesterhuis W. Initially obscure
hepatotoxicity attributed to sildenafil. Eur J Gastroenterol Hepatol 2008; 20:
710-2.
Enomoto M, Sakaguchi H, Ominami M, Iwai S, Morikawa H, Tamori A,
Kawada N. Sildenafil -induced severe cholestatic hepatotoxicity. Am J
Gastroenterol. 2009 Jan;104(1):254-5.
SITAGLIPTIN
Gross BN, Cross LB, Foard J, Wood Y.Elevated hepatic enzymes potentially
associated with sitagliptin. Ann Pharmacother. 2010;44:394-5.
SIROLIMUS
Jacques J, Dickson Z, Carrier P, Essig M, Guillaudeau A, Lacour C,
Bocquentin F, Aldigier JC, Rerolle JP. Severe sirolimus-induced acute
hepatitis in a renal transplant recipient. Transpl Int. 2010 Sep;23(9):967-70.
SPIRONOLACTONE
Shuck J, Shen S, Owensby L, Leftik M, Cucinell S.Spironolactone hepatitis in
primary hyperaldosteronism. Ann Intern Med. 1981 Dec;95(6):708-10.
Renkes P, Gaucher P, Tréchot P. Spironolactone and hepatic toxicity. JAMA.
1995 Feb 1;273(5):376-7.
Thai KE, Sinclair RD. Spironolactone-induced hepatitis. Australas J Dermatol.
2001 Aug;42(3):180-2.
SUNITINIB
Weise AM, Liu CY, Shields AF. Fatal liver failure in a patient on
acetaminophen treated with sunitinib malate and levothyroxine. Ann
TACROLIMUS
Yadav DK, Gera DN, Gumber MR, Kute VB, Patel MP, Vanikar AV, Trivedi HL.
Tacrolimus-induced severe cholestasis complicating renal transplantation.
Ren Fail. 2013;35(5):735-7.
Sacher VY, Bejarano PA, Pham SM. Tacrolimus induced hepatotoxicity in a
patient with bilateral lung transplant. Transpl Int. 2012 Oct;25(10):e111-2.
TAMSULOSIN
Fremond L, Diebold MD, Thiefin G. [Acute pseudoangiocholitic hepatitis
probably induced by tamsulosin]. Gastroenterol Clin Biol. 2006
Oct;30(10):1224-5.[Article in French].
TERBUTALINE
Quinn PG, Sherman BW, Tavill AS, Gibas AL. Terbutaline hepatitis in
pregnancy: report of two cases and literature review. Am J Gastroenterol
1994; 89: 781-4.
Suzuki M, Inagaki K, Kihira M, Matsuzawa K, Ishikawa K, Ishizuka T.
Maternal liver impairment associated with prolonged high-dose
administration of terbutaline for premature labor. Obstet Gynecol 1985;
66(3 Suppl): 14S-15S.
THIOTEPA
Lee JL, Gooley T, Bensinger W, Schiffman K, McDonald GB. Veno-occlusive
disease of the liver after busulfan, melphalan, and thiotepa conditioning
therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant.
1999;5(5):306-15.
Blanco Sampascual S, de Las Heras Niño B, Cabezudo Gil P, Ruiz Eguiluz P, Orive
Cura V. [Tibolone-induced hepatotoxicity]. Gastroenterol Hepatol 2002; 25: 274.
Rigato I, Cravatari M, Avellini C, Ponte E, Crocè SL, Tiribelli C. Drug-induced acute
cholestatic liver damage in a patient with mutation of UGT1A1. Nat Clin Pract
THYROXINE (LEVOTHYROXINE)
Inui A, Ishikawa K, Mizuno N, Oimomi M, Baba S.[Case of Hashimoto's disease with
thyroxine induced allergic hepatitis]. Nihon Naika Gakkai Zasshi. 1983
Oct;72(10):1407-13.
Ohmori M, Harada K, Tsuruoka S, Sugimoto K, Kobayashi E, Fujimura A.
Levothyroxine-induced liver dysfunction in a primary hypothyroid patient. Endocr J.
1999 Aug;46(4):579-83.
Kawakami T, Tanaka A, Negoro S, Morisawa Y, Mikami M, Hojo M, Yamamoto T,
Uegaki S, Aiso M, Kawasaki T, Ishii T, Kuyama Y, Fukusato T, Takikawa H. Liver
injury induced by levothyroxine in a patient with primary hypothyroidism. Intern
Med. 2007;46(14):1105-8.
TIBOLONE
Etogo-Asse F, Boemer F, Sempoux C, Geubel A. Acute hepatitis with prolonged
cholestasis and disappearance of interlobular bile ducts following tibolone and
Hypericum perforatum(St. John's wort). Case of drug interaction? Acta
Gastroenterol Belg 2008; 71: 36-8.
Blanco Sampascual S, de Las Heras Niño B, Cabezudo Gil P, Ruiz Eguiluz P, Orive
Cura V. [Tibolone-induced hepatotoxicity]. Gastroenterol Hepatol 2002; 25: 274.
Rigato I, Cravatari M, Avellini C, Ponte E, Crocè SL, Tiribelli C. Drug-induced acute
cholestatic liver damage in a patient with mutation of UGT1A1. Nat Clin Pract
Etogo-Asse F, Boemer F, Sempoux C, Geubel A. Acute hepatitis with prolonged
cholestasis and disappearance of interlobular bile ducts following tibolone and
Hypericum perforatum(St. John's wort). Case of drug interaction? Acta
Gastroenterol Belg 2008; 71: 36-8.
TIZANIDINE
de Graaf EM, Oosterveld M, Tjabbes T, Stricker BH. A case of tizanidineinduced hepatic injury. J Hepatol 1996; 25: 772-3.
Afonso Pérez E, Pego Reigosa R, Lancho Seco A, Brañas Fernández F.
[Tizanidine-induced toxic hepatitis] Med Clin(Barc) 1999; 112: 478-9.
Spanish.
TOBRAMYCIN
Nisly SA, Ray SM, Moye RA. Tobramycin-induced hepatotoxicity. Ann
TOLAZAMIDE
Rotolo V. [Jaundice in diabetics treated with sulfonylureas. On a clinical case
of jaundice caused by tolazamide] Friuli Med 1968; 23: 257-75. Italian.
LoIudice TA, Lang JA. Tolazamide-induced hepatic dysfunction. Am J
Bridges ME, Pittman FE. Tolazamide-induced cholestasis. South Med J 1980;
73: 1072-4.
TOLMETIN
Shaw GW, Anderson R. Multisystem failure and hepatic microvesicular fatty
metamorphosis associated with tolmetin ingestion. Arch Pathol Lab Med
1991; 115: 818-21.
TOLVAPTAN
Cases submitted to Livertox (http://livertox.nih.gov).
Cabello Muriel A, Marín Pozo JF, Alcalá Sanz A, Carrillo Ortiz D. Hepatic
alteration after treatment using tolvaptan. Farm Hosp 2011; 35: 94-6.
TRANYLCYPROMINE
Bandt C, Hofbauer FW. Liver injury associated with tranylcypromine therapy.
JAMA 1964 188: 752-3.
TRIAMTERENE
Nolan PJ, D’Arcy G. Triamterene drug fever andhepatitis. Med J Aust 1987;
147: 262.
VALACYCLOVIR
Renkes P, Trechot P, Blain H. Valaciclovir-induced hepatitis. Acta Clin Belg
1999; 54: 17-8.
Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J,
Yang H, et al.; Drug Induced Liver Injury Network(DILIN). Causes, clinical
features, and outcomes from a prospective study of drug-induced liver injury
in the United States. Gastroenterology 2008; 135: 1924-34.
VALSARTAN
Kiykim A, Altintas E, Sezgin O, Sezer K, Tiftik N, Akbay E, Seyrek E, Konca
K.Valsartan-induced hepatotoxicity in a HBs-Ag-Positive patient. Am J
Gastroenterol. 2003 Feb;98(2):507.
Reñé JM, Buenestado J, Sesé E, Miñana JM.[Acute hepatitis induced by
valsartan]. Med Clin (Barc). 2001 Nov 17;117(16):637-8. Spanish.
VARENICLINE
Sprague D, Bambha K. Drug-induced liver injury due to varenicline: a case
report. BMC Gastroenterol 2012; 12: 65.
Franck AJ1, Sliter LR. Acute hepatic injury associated with varenicline in a
patient with underlying liver disease. Ann Pharmacother. 2009
Sep;43(9):1539-43.
Mogensen H, Bjornsson ES. Varenicline induced jaundice. Hepatology 2015
VISMODEGIB
Ash MM, Jolly PS. Cholestatic hepatic injury associated with vismodegib,
aspirin, and naproxen use: a case study and review of vismodegib safety. Int
J Dermatol. 2015 Mar;54(3):370-4.
ZILEUTON
Watkins PB, Dube LM, Walton-Bowen K, Cameron CM, Kasten LE. Clinical
pattern of zileuton-associated liver injury: results of a 12-month study in
patients with chronic asthma. Drug Saf 2007; 30: 805-15.
ZONISAMIDE
Vuppalanchi R, Chalasani N, Saxena R. Restoration of bile ducts in druginduced vanishing bile duct syndrome due to zonisamide. Am J Surg Pathol
2006; 30: 1619-23.
ZIPRASIDONE
Tsai CF, Tsai SJ, Hwang JP. Ziprasidone-induced hypersensitivity syndrome
in an aged schizophrenia patient. Int J Geriatr Psychiatry 2005; 20: 797-9.
Gordon JS, Neyman KM, Wells RD, Chen SC. Drug rash with eosinophilia and
systemic symptoms (DRESS syndrome). Cutis 2012; 89: 180-2.
Kim MS, Kim SW, Han TY, Son SJ, Lee JH, Kim EJ. Ziprasidone-induced
hypersensitivity syndrome confirmed by reintroduction. Int J Dermatol 2014;
53: e267-8.
References DILI high doses
Acetaminophen
http://livertox.nih.gov
Aspirin and salicylates
Manso C, Taranta A, Nydick I. Effect of aspirin administration on serum
glutamic oxaloacetic and glutamic pyruvic transaminases in children. Proc
Soc Exp Biol Med 1956; 93: 84-88.
Reye R, Morgan G, Baral J. Encephalopathy and fatty degeneration of the
viscera. A disease entity in childhood. Lancet 1963; 2: 749-52.
Okumura H, Takayama K, Obayashi K, Ichikawa T, Aramaki T. [Chronic
toxic hepatitis caused by aspirin] Nippon Rinsho 1965; 23: 1633-6.
Japanese.
Norman MG. Encephalopathy and fatty degeneration of the viscera in
childhood: I. Review of cases at the Hospital for Sick Children,
Toronto (1954-1966). Can Med Assoc J 1968; 99: 522-6.
Norman MG, Lowden JA, Hill DE, Bannayne RM. Encephalopathy and fatty
degeneration of the viscera in childhood: II. Report of a case with isolation
of influenza B virus. Can Med Assoc J 1968; 99: 522-6.
Iancu T. Serum transaminases and salicylate therapy. Br Med J 1972; 2:
167.
Athreya BH, Gorske AL, Myers AR. Aspirin-induced abnormalities of liver
function. Am J Dis Child 1973; 126: 638-41.
Rich RR, Johnson JS. Salicylate hepatotoxicity in patients with juvenile
rheumatoid arthritis. Arthritis Rheum 1973; 16: 1-9.
Gitlin N, Dietrich B, Spektor F. Salicylate hepatitis. A case report. S Afr
Med J 1974; 48: 1998-2000.
Koppes GM, Arnett FC. Salicylate hepatotoxicity. Postgrad Med 1974; 56:
193-5.
Seaman WE, Ishak KG, Plotz PH. Aspirin-induced hepatotoxicity in
patients with systemic lupus erythematosus. Ann Intern Med 1974; 80: 18.
Goldenberg DL. Letter: Aspirin hepatotoxicity. Ann Intern Med 1974; 80:
773.
Wolfe JD, Metzger AL, Goldstein RC. Aspirin hepatitis. Ann Intern Med
1974; 80: 74-6.
Garber E, Craig RM, Bahu RM. Letter: Aspirin hepatotoxicity. Ann Intern
Med 1975; 82: 592-3.
Linnemann CC, Shea L, Partin JC, Schubert WK, Schiff GM. Reye's
syndrome: epidemiologic and viral studies, 1963-1974. Am J Epidemiol
1975; 101: 517-526.
Sillanpaa M, Makela AL, Koivikko A. Acute liver failure and encephalopathy
(Reye's syndrome?) during salicylate therapy. Acta Paediatr Scand 1975;
64: 877-80.
Zucker P, Daum F, Cohen MI. Aspirin hepatitis. Am J Dis Child 1975; 129:
1433-4.
Barone R, Chase PH, Wallace SL. Letter: Salicylate-induced hepatic injury.
Ricks WB. Letter: Salicylate hepatotoxicity in Reiter's syndrome. Ann
Intern Med 1976; 84: 52-3.
Saltzman DA, Gall EP, Robinson SF. Aspirin-induced hepatic dysfunction in
a patient with adult rheumatoid arthritis. Am J Dig Dis 1976; 21: 815-20.
Wilson JR. Aspirin hepatotoxicity in adults with rheumatoid arthritis. Ohio
State Med J 1976; 72: 577-8.
O'Gorman T, Koff RS. Salicylate hepatitis. Gastroenterology 1977; 72 (4
Pt 1): 726-8.
Sbarbaro JA, Bennett RM. Aspirin hepatotoxicity and disseminated
intravascular coagulation. Ann Intern Med 1977; 86: 183-5.
Kanada SA, Kolling WM, Hindin BI. Aspirin hepatotoxicity. Am J Hosp
Pharm 1978; 35: 330-6.
Petty BG, Zahka KG, Bernstein MT. Aspirin hepatitis associated with
encephalopathy. J Pediatr 1978; 93: 881-2.
Ulshen MH, Grand RJ, Crain JD, Gelfand EW. Hepatotoxicity with
encephalopathy associated with aspirin therapy in rheumatoid arthritis. J
Pediatr 1978; 93: 1034-7.
Bulugahapitiya DT, Hebron B, Beck PR. Salicylate hepatitis with acidosis in
an infant. Lancet 1979; 1: 1295-6.
Lahaie RG, Blondin C, Huet PM. Salicylate hepatitis in a case of juvenile
dermatomyositis. Can Med Assoc J 1979; 120: 1399-400.
Makela AL, Lang H, Korpela P. Toxic encephalopathy with
hyperammonaemia during high-dose salicylate therapy. Acta Neurol Scand
1980; 61: 146-56.
Mastaglia GL. Salicylate hepatotoxicity in rheumatoid arthritis. Med J Aust
1980; 2: 341.
Bertino JS Jr, Willis ED, Reed MD, Speck WT. Salicylate hepatitis: a
complication of the treatment of Kawasaki's disease. Am J Hosp Pharm
1981; 38: 1171-2.
von Muhlendahl KE. [Salicylate induced disturbances of liver function
(author's transl).] Dtsch Med Wochenschr 1982; 107: 101-3. German.
Hamdan JA, Ahmad MS, Sa'di AR. Salicylate hepatotoxicity in rheumatic
fever. Ann Trop Paediatr 1983; 3: 89-91.
Starko KM, Mullick FG. Hepatic and cerebral pathology findings in children
with fatal salicylate intoxication: further evidence for a causal relation
between salicylate and Reye's syndrome. Lancet 1983; 1 (Feb 12): 326-9.
Bhabha FS, Kshirsagar NA, Pohujani S, Dastur P, Joshi MU, Kandoth P,
Satoskar
R S . E ffe ct o f
suffering from juvenile rheumatoid arthritis and rheumatic fever. Indian J
Pediatr 1984; 51: 317-21.
Partin JS, Daugherty CC, McAdams AJ, Partin JC, Schubert WK. A
comparison of liver ultrastructure in salicylate intoxication and Reye's
syndrome. Hepatology 1984; 4: 687-90.
Young RSK, Torretti D, Williams R, Hendriksen D, Woods M. Reye's
syndrome associated with long-term aspirin therapy. JAMA 1984; 251:
754-6.
Hansen JR, McCray PB, Bale JF Jr, Corbett AJ, Flanders DJ. Reye syndrome
associated with aspirin therapy for systemic lupus erythematosus.
Pediatrics 1985; 76: 202-5.
Everson GW, Krenzelok EP. Chronic salicylism in a patient with juvenile
rheumatoid arthritis. Clin Pharm 1986; 5: 334-41.
Peters LJ, Wiener GJ, Gilliam J, Van Noord G, Geisinger KR, Roach ES.
Reye's syndrome in adults: a case report and review of the literature. Arch
Intern Med 1986; 146: 2401-3.
De Leeuw P, Lefebvre C, Tomasi JP, Rahier J, Geubel A. [Severe hepatitis
with encephalopathy induced by acetylsalicylic acid in a case of lupus
erythematosus disseminatus] Gastroenterol Clin Biol 1992; 16: 359-61.
Nadkarni MM, Peller CA, Retig J. Eosinophilic hepatitis after ingestion of
choline magnerium trisalicylate. Am J Gastroenterol 1992; 87: 151-3.
Mallet EC, Gestas P, Vic P, Arnaud JP. [Fulminant hepatitis with
encephalopathy in acute articular rheumatism treated with acetylsalicylic
acid]. Arch Fr Pediatr 1993; 50: 272-3.
Caksen H, Guler E, Alper M, Ustunbas HB. A fatal case of Reye syndrome
after varicella and ingestion of aspirin. J Dermatol 2001; 28: 286-7.
Chen TC, Ng KF, Jeng LB, Yeh TS, Chen CM. Aspirin-related hepatotoxicity
in a child after liver transplant. Dig Dis Sci 2001; 46: 486-8.
McGovern MC, Glasgow JF, Stewart MC. Lesson of the week: Reye's
syndrome and aspirin: lest we forget. BMJ 2001; 322: 1591-2.
Da Silveira EBV, Young K, Rodriguez M, Ameen N. Reye's syndrome in a
17-year-old male: is this disease really disappearing? Dig Dis Sci 2002;
47: 1959-61.
Bhutta AT, Savell VH, Schexnayder SM. Reye's syndrome: down but not
out. South Med J 2003; 96: 43-45.
Chow EL, Cherry JD, Harrison R, McDiarmid SV, Bhuta S. Reassessing
Reye Syndrome. Arch Pediatr Adolesc Med 2003; 157: 1241-2.
BUPRENORFIN
Hirschauer C, Guillemot F, Héud M, Mathieu-Chandelier C, Cortot A, Paris
JC. [Is buprenorphine hepatotoxic?]. Gastroenterol Clin Biol 1989; 13:
636. French.
Houdret N, Asnar V, Szostak-Talbodec N, Leteurtre E, Humbert L,
Lecomte-Houcke M, Lhermitte M, et al. [Hepatonephritis and massive
ingestion of buprenorphine]. Acta Clin Belg Suppl 1999; 1: 29-31. French.
Berson A, Gervais A, Cazals D, Boyer N, Durand F, Bernuau J, Marcellin P,
et al. Hepatitis after intravenous buprenorphine misuse in heroin addicts. J
Hepatol 2001; 34: 346-50.
Wisniewski B, Perlemuter G, Buffet C. [Acute hepatitis following
intravenous buprenorphine injection as a substitute drug in a drugaddict]. Gastroenterol Clin Biol 2001; 25: 328-9. French.
Hervé, Riachi G, Noblet C, Guillement N, Tanasescu S, Goria O, Thuillez C,
et al. Acute hepatitis due to buprenorphine administration. Eur J
Zuin M, Giorgini A, Selmi C, Battezzati PM, Cocchi CA, Crosignani A,
Benetti A, et al. Acute liver and renal failure during treatment with
buprenorphine at therapeutic dose. Dig Liver Dis 2009; 41: e8-e10.
Peyriere H, Tatern L Bories C, Pageua G-P, Blayac J-P, Larrey D. Hepatitis
after intravenous injection of sublingual buprenorphine in acute hepatitis C
carriers: report of two cases of disappearance of viral replication after
acute hepatitis. Ann Pharmacother 2009; 43: 973-7.
Upadhyay A, Xueming Y. Buprenorphine-induced elevated liver enzymes in
an adolescent patient. J Child Adolesc Psychopharmacol 2010; 20: 545-6.
Eiden C, Ripault MP, Larrey D, Faillie JL, Pinzani V, Pageaux GP, Peyrière
H.Acute hepatitis and renal failure related to intranasal buprenorphine
misuse: case report and analysis of cases reported to the French network
for drug monitoring. Ann Pharmacother. 2013 Dec;47(12):1721-6.
Methylprednisone
Steinberg H, Webb WM, Rafsky HA. Hepatomegaly with fatty infiltration
secondary to cortisone therapy: case report. Gastroenterology 1952; 21:
304-9.
Iancu TC, Shiloh H, Dembo L. Hepatomegaly following short-term highdose steroid therapy. J Pediatr Gastroenterol Nutr 1986; 5: 41-6.
Wald JA, Farr RS. Abnormal liver-function tests associated with long-term
systemic corticosteroid use in subjects with asthma. J Allergy Clin
Immunol 1991; 88: 277-8.
Gerolami R, Mambrini P, Barthet M, Jean-Pastor MJ, Salducci J, Grimaud
JC. [Acute hepatitis caused by Solupred in a patient with Crohn disease].
Weissel M, Hauff W. Fatal liver failure after high-dose glucocorticoid pulse
therapy in a patient with severe thyroid eye disease. Thyroid 2000; 10:
521.
Dourakis SP, Sevastianos VA, Kaliopi P. Acute severe steatohepatitis
related to prednisolone therapy. Am J Gastroenterol 2002; 97: 1074-5.
Salvi M, Vannucchi G, Sbrozzi F, Del Castello AB, Carnevali A, Fargion S,
Beck-Peccoz P. Onset of autoimmune hepatitis during intravenous steroid
therapy for thyroid-associated ophthalmopathy in a patient with
Hashimoto's thyroiditis: case report. Thyroid 2004; 14: 631-4.
Marinò M, Morabito E, Altea MA, Ambrogini E, Oliveri F, Brunetto MR,
Pollina LE, et al. Autoimmune hepatitis during intravenous glucocorticoid
pulse therapy for Graves' ophthalmopathy treated successfully with
glucocorticoids themselves. J Endocrinol Invest 2005; 28: 280-4.
Hofstee HM, Nanayakkara PW, Stehouwer CD. Acute hepatitis related to
prednisolone. Eur J Intern Med 2005; 16: 209-210.
Das D, Graham I, Rose J. Recurrent acute hepatitis in patient receiving
pulsed methylprednisolone for multiple sclerosis. Indian J Gastroenterol
2006; 25: 314-6.
Topal F, Ozaslan E, Akbulut S, Küçükazman M, Yüksel O, Altiparmak E.
Methylprednisolone-induced toxic hepatitis. Ann Pharmacother 2006; 40:
1868-71.
Reuss R, Retzlaff K, Vogel S, Franke FE, Oschmann P. Autoimmune
hepatitis after high-dose intravenous methylprednisolone pulse in RR-MS.
CEJ Med 2007; 2: 356-9.
Le Moli R, Baldeschi L, Saeed P, Regensburg N, Mourits MP, Wiersinga
WM. Determinants of liver damage associated with intravenous
methylprednisolone pulse therapy in Graves' ophthalmopathy. Thyroid
2007; 17: 357-62.
Takahashi A, Kanno Y, Takahashi Y, Sakamoto N, Monoe K, Saito H, Abe
K, et al. Development of autoimmune hepatitis type 1 after pulsed
methylprednisolone therapy for multiple sclerosis: a case report. World J
Rivero Fernández M, Riesco JM, Moreira VF, Moreno A, López San Román
A, Arranz G, Ruiz Del Arbol L. [Recurrent acute liver toxicity from
intravenous methylprednisolone]. Rev Esp Enferm Dig 2008; 100: 720-3.
Loraschi A, Banfi P, Mauri M, Sessa F, Bono G, Cosentino M.
Hepatotoxicity after high-dose methylprednisolone for demyelinating
disease. Clin Neuropharm 2010; 33: 52-4.
Gutkowski K, Chwist A, Hartleb M. Liver injury induced by high-dose
methylprednisolone therapy: a case report and brief review of the
literature. Hepat Mon 2011; 11: 656-61.
Furutama D, Kimura F, Shinoda K, Maeda T, Tanaka T, Ohsawa N.
Recurrent high-dose intravenous methylprednisolone succinate pulse
therapy-induced hepatopathy in a patient with multiple sclerosis. Med
Princ Pract 2011; 20: 291-3.
Carrier P, Godet B, Crepin S, Magy L, Debette-Gratien M, Pillegand B,
Jacques J, et al. Acute liver toxicity due to methylprednisolone: consider
this diagnosis in the context of autoimmunity. Clin Res Hepatol
D'Agnolo HM, Drenth JP. High-dose methylprednisolone-induced hepatitis
in a patient with multiple sclerosis: a case report and brief review of
literature. Neth J Med 2013; 71: 199-202.
Melamud B, Lurie Y, Goldin E, Levi I, Esayag Y. Methylprednisoloneinduced liver injury: a diagnostic challenge. Isr Med Assoc J 2014; 16:
180-1.
Niacin
Rivin AU. Jaundice occurring during nicotinic acid therapy for
hypercholesterolemia. JAMA 1959; 170: 2088-9.
Christensen NA, Achor RW, Berge KG, Mason HL. Nicotinic acid treatment
of hypercholesteremia. Comparison of plain and sustained-action
preparations and report of two cases of jaundice. JAMA 1961; 177: 54650.
Pardue WO. Severe liver dysfunction during nicotinic acid therapy. JAMA
1961; 175: 137-8.
Kohn RM, Montes M. Hepatic fibrosis following long acting nicotinic acid
therapy: a case report. Am J Med Sci 1969; 258:94-9.
Winter SL, Boyer JL. Hepatic toxicity from large doses of Vitamin
B(nicotinamide). N Engl J Med 1973; 289: 1180-2.
Sugerman AA, Clark CG. Jaundice following the administration of niacin.
JAMA 1974; 228: 202.
Einstein N, Baker A, Galper J, Wolfe H. Jaundice due to nicotinic acid
therapy. Am J Dig Dis 1975; 20: 282-286.
Patterson DJ, Dew EW, Gyorkey F, Graham DY. Niacin hepatitis. South
Med J 1983; 76: 239-41.
Clememntz GL, Holmes AW. Nicotinic acid-induced fulminant hepatic
failure. J Clin Gastroenterol 1987; 9: 582-4.
Ferenchick G, Rovner D. Hepatitis and hematemesis complicating nicotinic
acid use. Am J Med Sci 1989; 298: 191-3.
Mullin GE, Greenson JK, Mitchell MC. Fulminant hepatic failure after
ingestion of sustained release nicotinic acid. Ann Intern Med 1989; 111:
253-5.
Henkin Y, Johnson KC, Segrest JP. Rechallenge with crystalline niacin after
drug-induced hepatitis from sustained-release niacin. JAMA 1990; 264:
241-3.
Hodis HN. Acute hepatic failure associated with the use of low-dose
sustained release niacin. JAMA 1990; 264: 181.
Henkin Y, Oberman A, Hurst Dc, Segrest JP. Niacin revisited: clinical
observations on an important but underutilized drug. Am J Med 1991; 91:
239-46.
Etchason JA, Miller TD, Squires RW, Allison TG, Gau GT, Martilla JK, Kottke
BA. Niacin-induced hepatitis: a potential side effect with low-dose timerelease niacin. Mayo Clin Proc 1991; 66: 23-8.
Schwab RA, Bachhuber BH. Delirium and lactic acidosis caused by ethanol
and niacin coingestion. Am J Emerg Med 1991; 9: 363-5.
Fischer DJ, Knight LL, Vestal RE. Fulminant hepatic failure following lowdose sustained release niacin therapy in hospital. West J Med 1991; 155:
410-2.
Dalton TA, Berry RS. Hepatotoxicity associated with sustained-release
niacin. Am J Med 1992; 93: 102-4.
Dearing BD, Lavie CJ, Lohmann TP, Genton E. Niacin-induced clotting
factor synthesis deficiency with coagulopathy. Arch Intern Med 1992; 152:
861-3.
Lawrence SP. Transient focal hepatic defects related to sustained-release
niacin. J Clin Gastroenterol 1993; 16: 234-6.
Coppola A, Brady PG, Nord HJ. Niacin-induced hepatotoxicity: Unusual
presentations. South Med J 1994; 87: 30-2.
Patel SD, Taylor HC. Intrahepatic cholestasis during nicotinic acid therapy.
Cleve Clin J Med 1994; 61: 70-5.
Schwenk TL, Fisher M. Hepatitis caused by low-dose sustained-release
niacin. J Am Board Fam Pract 1994; 7: 242-4.
Reimund E, Ramos A. Niacin-induced hepatitis and thrombocytopenia after
10 years of niacin use. J Clin Gastroenterol 1994; 18: 270-1.
Rourk RM, Rehman NU. Niacin. Help for your cholesterol--harm for your
liver. N C Med J 1998; 59: 87-8.
Kristensen T, Olcott EW. Effects of niacin therapy that simulate neoplasia:
hepatic steatosis with concurrent hepatic dysfunction. J Comput Assist
Tomogr 1999; 23: 314-7.
Scheer MS, Perlmutter S, Ross W, Katz DS. Ultrasonographic findings in
niacin-induced hepatitis. J Ultrasound Med 1999; 18: 321-3.
Gavilán JC, Bermúdez FJ, Belmonte A, González-Santos P. [Niacin-induced
hepatitis]. Med Clin(Barc) 2002; 118: 558.
Tetracycline
Lepper MH, Wolfe CK, Zimmerman HJ, Cladwell ER Jr, Spies HW, Dowling
HF. Effect of large doses of aureomycin on human liver. Arch Intern Med
1951; 88: 271-83.
Schultz JC, Adamson JS Jr, Workman WW, Norman TD. Fatal liver disease
after intravenous administration of tetracycline in high dosage. N Engl J
Med 1963; 269: 999-1004.
Horwitz ST, Marymont JH Jr. Fatal liver disease during pregnancy
associated with tetracycline therapy. Report of a case. Obstet Gynecol
1964; 23: 826-9.
Norman TD, Schultz JC, Hoke RD. Fatal liver disease following the
administration of tetracycline. South Med J 1964; 57: 1038-42.
Whalley PJ, Adams RH, Combes B. Tetracycline toxicity in pregnancy.
Liver and pancreatic dysfunction. JAMA 1964; 189: 357-62.
Finn WF, Horwitz ST. Maternal death due to fatty metamorphosis of liver
following tetracycline therapy. N Y State J Med 1965; 65: 662-7.
Ichida F, Watanabe K, Ishiwara S, Inoue K, Tanabe Y. [A case of
cholestatic jaundice due to tetracycline-triacetyloleandomycin] Nippon
Naika Gakkai Zasshi 1965; 54:142-7. Japanese. PubMed Citation
Kunelis CT, Peters JL, Edmondson HA. Fatty liver of pregnancy and its
relationship to tetracycline therapy. Am J Med 1965; 38: 359-77.
Winterling AN, Goldman RL. Hepatic and renal lesions in a case of
tetracycline toxicity during long-term estrogen therapy after orchiectomy.
Calif Med 1965; 102: 314-6.
Wruble LD, Ladman AJ, Britt LG, Cummins AJ. Hepatotoxicity produced by
tetracycline overdosage. JAMA 1965; 192: 6-8.
Davis JS, Kaufman RH. Tetracycline toxicity. A clinicopathologic study with
special reference to liver damage and its relationship to pregnancy. Am J
Obstet Gynecol 1966; 95: 523-9.
Schiffer MA. Fatty liver associated with administration of tetracycline in
pregnant and nonpregnant women. Am J Obstet Gynecol 1966; 96: 32632.
Aach R, Kissane J eds. Clinicopathologic conference. A seventeen-year-old
girl with fatty liver of pregnancy following tetracycline therapy. Am J Med
1967; 43: 274-83.
Peters RL, Edmondson HA, Mikkelsen WP, Tatter D. Tetracycline-induced
fatty liver in nonpregnant patients. A report of six cases. Am J Surg 1967;
113: 622-32.
Damjanov I, Arnold R, Faour M. Tetracycline toxicity in a nonpregnant
woman. JAMA 1968; 204: 934.
Breitenbucher RB, Crowley LV. Hepatorenal toxicity of tetracycline. Minn
Med 1970; 53: 949-55.
Robinson MJ, Rywlin AM. Tetracycline-associated fatty liver in the male.
Report of an autopsied case. Am J Dig Dis 1970; 15: 857-62.
Breen KJ, Perkins KW, Mistilis SP, Shearman R. Idiopathic acute fatty liver
of pregnancy. Gut 1970; 11: 822-5.
Pride GL, Cleary RE, Hamburger RJ. Disseminated intravascular
coagulation associated with tetracycline-induced hepatorenal failure
during pregnancy. Am J Obstet Gynecol 1973; 115: 585-6.
Lloyd-Still JD, Grand RJ, Vawter GF. Tetracycline hepatotoxicity in the
differential diagnosis of postoperative jaundice. J Pediatr 1974; 84: 36670.
Wenk RE, Gebhardt FC, Bhagavan BS, Lustgarten JA, McCarthy EF.
Tetracycline-associated fatty liver of pregnancy, including possible
pregnancy risk after chronic dermatologic use of tetracycline. J Reprod
Med 1981; 26: 135-41.
Hunt CM, Washington K. Tetracycline-induced bile duct paucity and
prolonged cholestasis. Gastroenterology 1994; 107: 1844-7.
Glenn C, Feldman SR. Letter: Tetracycline-induced hepatotoxicity.
Dermatol Online J 2011; 17: 14.
VITAMIN A
Shaw EW, Niccoli JT. Hypervitaminosis A: report of a case in an adult
male. Ann Intern Med 1954; 39: 131-4.
Soler-Bechara J, Soscia JL. Chronic hypervitaminosis A: report of a case in
an adult. Arch Intern Med 1963; 112: 462-6.
Rubin E, Florman AL, Degnan T, Diaz J. Hepatic injury in chronic
hypervitaminosis A. Am J Dis Child 1970; 119: 132-8.
Muenter MD, Perry HO, Ludwig J. Chronic vitamin A intoxication in adults.
Hepatic, neurologic and dermatologic complications. Am J Med 1971; 50:
129-36.
Katz CM, Tzagournis M. Chronic adult hypervitaminosis A with
hypercalcemia. Metabolism 1972; 21: 1171-6.
Leicht E, Strunz J, von Seebach HB, Meiser RJ, Mäle E. [Acute vitamin A
intoxication with hemolytic anemia, hypercalcemia and toxic hepatosis].
Med Klin 1973; 68: 54-9. German.
Frame B, Jackson CE, Reynolds WA, Umphrey JE. Hypercalcemia and
skeletal effects in chronic vitaminosis A. Ann Intern Med 1974; 80: 44-8.
Russell RM, Boyer JL, Bagheri SA, Hruban Z. Hepatic injury from chronic
hypervitaminosis A resulting in portal hypertension and ascites. N Engl J
Med 1974; 291: 435-40.
Farrell GC, Bhathal PS, Powell LW. Abnormal liver function in chronic
hypervitaminosis A. Am J Dig Dis 1977; 22: 724-8.
Kistler HJ, Pluer S, Dickenmann W, Pirozynski W. [Portal hypertension
without cirrhosis due to chronic vitamin A intoxication]. Schweiz Med
Wschr 1977; 107: 825-32.
Fleischmann R, Schlote W, Schomerus H, Wolburg H, CastrillonOberndorfter WL, Hoensch H. [Small-nodular liver cirrhosis with marked
portal hypertension due to vitamin A intoxication resulting from psoriasis
treatment]. Dtsch Med Wochenschr 1977; 102: 1637-40.
Babb RR, Kieraldo JH. Cirrhosis due to hypervitaminosis A. West J Med
1978; 128: 244-6.
Tholen W, Paquet KJ, Rohner HG, Albrecht M. [Cirrhosis of the liver and
esophageal bleeding after chronic vitamin A intoxication(author's transl)].
Leber Magen Darm 1980; 10: 193-7. German.
Mahoney CP, Margolis MT, Knauss TA, Labbe RF. Chronic vitamin A
intoxication in infants fed chicken liver. Pediatr 1980; 65: 893-6.
Lippe B, Hensen L, Mendoza G, Finerman M, Welch M. Chronic vitamin A
intoxication. A multisystem disease that could reach epidemic proportions.
Am J Dis Child 1981; 135: 634-6.
Hatoff DE, Gertler SL, Miyai K, Parker BA, Weiss JB. Hypervitaminosis A
unmasked by acute viral hepatitis. Gastroenterology 1982; 82: 124-8.
Weber FL Jr, Mitchell GE Jr, Powell DE, Reiser BJ, Banwell JG. Reversible
hepatotoxicity associated with hepatic vitamin A accumulation in a
protein-deficient patient. Gastroenterology 1982; 82: 118-23.
Farris WA, Erdman JW Jr. Protracted hypervitaminosis A following longterm, low-level intake. JAMA 1982; 247: 1317-8.
Le Marchand P, Benatre A, Metman EH, CouëC, Arbeille-Brassart B,
Monegier du Sorbier C, Danquechin-Dorval E, et al. [Cirrhosis induced by
vitamin A]. Gastroenterol Clin Biol 1984; 8: 116-20. French.
Verneau A, Rosenbaum J, Zafrani ES, Roudot-Thoraval F, Leclercq M,
Dhumeaux D. [Hepatic fibrosis and portal hypertension in chronic vitamin
A poisoning]. Gastroenterol Clin Biol 1984; 8: 121-5. French.
Zafrani ES, Bernuau D, Feldmann G. Peliosis-like ultrastructural changes
of the hepatic sinusoids in human chronic hypervitaminosis A: report of
three cases. Hum Pathol 1984; 15: 1166-70.
Yamamoto M. [Toxic hepatitis induced by vitamin A]. Nippon Rinsho 1985;
43: 1187-91. Japanese. PubMed Citation
Inkeles SB, Connor WE, Illingworth DR. Hepatic and dermatologic
manifestations of chronic hypervitaminosis A in adults. Report of two
cases. Am J Med 1986; 80: 491-6.
Minuk GY, Kelly JK, Hwang WS. Vitamin A hepatotoxicity in multiple family
members. Hepatology 1988; 8: 272-5.
Mendoza FS, Johnson F, Kerner JA, Tune BM, Shochat SJ. Vitamin A
intoxication presenting with ascites and a normal vitamin A level. West J
Med 1988; 148: 88-90.
Smith JW. Vitamin A toxicity presenting as jaundice. Postgrad Med 1989;
85: 53-4, 56.
Baker H, ten Hove W, Kanagasundaram N, Zaki G, Leevy CB, Frank O,
Leevy CM. Excess vitamin A injures the liver. J Am Coll Nutr 1990; 9: 5039.
Belaiche J, Gast P, Lambinet N, Etienne M, Fridman V, Vivario M, Boniver
J. [Hepatic fibrosis with cirrhogenous development in chronic vitamin A
poisoning]. Rev Med Liege 1990; 45: 381-9. French.
Sarles J, Scheiner C, Sarran M, Giraud F. Hepatic hypervitaminosis A: a
familial observation. J Pediatr Gastroenterol Nutr 1990; 10: 71-6.
Fallon MB, Boyer JL. Hepatic toxicity of vitamin A and synthetic retinoids. J
Geubel AP, De Galocsy C, Alves N, Rahier J, Dive C. Liver damage caused
by therapeutic vitamin A administration: estimate of dose-related toxicity
in 41 cases. Gastroenterology 1991; 100: 1701-9.
Dubois A, Balducchi JP, Barbuat C, Fabre J, Flaisler F, Joujoux JM,
Pignodel C, et al. [Portal hypertension and hypervitaminosis A. Apropos of
2 cases and review of the literature]. Rev Med Interne 1991; 12: 295-8.
Oren R, Ilan Y. Reversible hepatic injury induced by long-term vitamin A
ingestion. Am J Med 1992; 93: 703-4.
Scoazec JY, Bouma ME, Roche JF, Blache D, Verthier N, Feldmann G, Gay
G. Liver fibrosis in a patient with familial homozygous
hypobetalipoproteinaemia: possible role of vitamin supplementation. Gut
1992; 33: 414-7.
Theiler R, Wirth HP, Flury R, Hanck A, Michel BA. [Chronic vitamin A
poisoning with musculoskeletal symptoms and morphological changes of
the liver: a case report]. Schweiz Med Wochenschr 1993; 123: 2405-12.
Kowalski TE, Falestiny M, Furth E, Malet PF. Vitamin A hepatotoxicity: a
cautionary note regarding 25,000 IU supplements. Am J Med 1994; 97:
523-8.
Croquet V, Pilette C, Lespine A, Vuillemin E, Rousselet MC, Oberti F, Saint
AndréP, et al. Hepatic hyper-vitaminosis A: importance of retinyl ester
level determination. Eur J Gastroenterol Hepatol 2000; 12: 361-4.
Miksad R, de Lénghen V, McDougall C, Fiel I, Rosenberg H. Hepatic
hydrothorax associated with vitamin A toxicity. J Clin Gastroenterol 2002;
34: 275-9.
Castano G, Etchart C, Sookoian S. Vitamin A toxicity in a physical culturist
patient: a case report and review of the literature. Ann Hepatol 2006; 5:
293-5.
Ramanathan VS, Hensley G, French S, Eysselein V, Chung D, Reicher S,
Pham B. Hypervitaminosis A inducing intra-hepatic cholestasis - a rare
case report. Exp Mol Pathol 2010; 88: 324-5.
Category C
Adalimumab
Feau S, Causse X, Corondan A, Michenet P, Autret-Leca F. Acute druginduced hepatitis during adalimumab and ibuprofen treatment. Gastroenterol
Clin Biol 2010; 34: 420-2.
Amphotericin B
Carnecchia B, Kurtzke J. Fatal toxic reaction toamphotericin B in cryptococcal
meningo-encephalitis. Ann Intern Med 1960; 53: 1027-36.
Olin JL, Spooner LM. Amphotericin B-associatedhyperbilirubinemia: case
report and review of the literature. Pharmacotherapy 2006; 26: 1011-7.
Akyol Erikci A, Ozyurt M, Terekeci H, Ozturk A,Karabudak O, Oncu K.
Oesophageal aspergillosis in a case of acute lymphoblastic leukaemia
successfully treated with caspofungin alone due to liposomalamphotericin B
induced severe hepatotoxicity. Mycoses 2009; 52: 84-6.
Michot JM, Gubavu C, Fourn E, Maigne G, Teicher E, Angoulvant A, Blanche
S, et al. Very prolonged liposomal amphotericin B use leading to a lysosomal
storage disease. Int J Antimicrob Agents 2014 Apr 12. pii: [Epub ahead of
print]
Amphicillin
Köklü S, Köksal AS, Asil M, Kiyici H, Coban S, Arhan M. Probable
sulbactam/ampicillin-associated prolonged cholestasis. Ann Pharmacother
2004; 38: 2055-8.
Anakinra
Mahamid M, Paz K, Reuven M, Safadi R. Hepatotoxicity due to tocilizumab
and anakinra in rheumatoid arthritis: two case reports. Int J Gen Med 2011;
4: 657-60.
Bupropion
Carlos Titos-Arcos J, Hallal H, Collados V, Plaza-Aniorte J. [Acute hepatitis
secondary to bupropion]. Gastronterol Hepatol 2008; 31: 549.
Cyproheptadine
Larrey D, Geneve J, Pessayre D, Machayekhi JP, Degott C, Benhamou JP.
Prolonged cholestasis after cyproheptadine-induced acute hepatitis.
J Clin Gastroenterol. 1987 Feb;9(1):102-4.
Cytarabine
Pizzuto J, Avilés A, Ramos E, Cervera J, Aguirre J.Cytosine arabinoside
induced liver damage: histopathologic demonstration. Med Pediatr Oncol
1983; 11: 287-90.
George CB, Mansour RP, Redmond J 3rd, Gandara DR. Hepatic dysfunction
and jaundice following high-dose cytosine arabinoside. Cancer 1984; 54:
2360-2.
Kirtley DW, Votaw ML, Thomas E. Jaundice and hepatorenal syndrome
associated with cytosine arabinoside. J Natl Med Assoc 1990; 82: 209, 213,
217-8.
NachbaurK, Dietze O, Herold M, Thaler J, Braunsteiner H, Vogel W.
Fulminant hepatic failure after high-dose cytosine arabinoside and
mitoxantrone treatment for relapse of acute myelogenous leukaemia. Eur J
Haematol 1992; 49: 221-3.
Altundag O, Altundag K, Celik I, Turker A, Kars A. Isolated
hyperbilirubinemia following standard dose cytosine arabinoside in a patient
with relapsed acute myeloid leukemia. Am J Hematol 2004; 75: 263-4.
Babaoglu MO, Karadag O, Saikawa Y, Altundag K, Elkiran T, Yasar U, Bozkurt
A. Hepatotoxicity due to a possible interaction between cytosine arabinoside
and dipyridamole: a case report. Eur J Clin Pharmacol 2004; 60: 455-6.
Coutsouvelis J, Corallo CE. The management of prolonged, isolated
hyperbilirubinemia following cytarabine-based chemotherapy for acute
myeloid leukaemia. J Oncol Pharm Pract 2009; 15: 107-10.
Desflurane
Katz J, Magee J, Baker B, Eger EI 2nd. Hepatic necrosisassociated with
herpesvirus after anesthesia with desflurane and nitrous oxide. Anesth Analg
1994; 78: 1173-6.
Diltiazem
Traverse JH, Swenson LJ, McBride JW. Acute hepaticinjury after treatment
with diltiazem. Am Heart J 1994; 127: 1636-9.
Lewin JJ 3rd, Nappi JM, Taylor MH. Rhabdomyolysis withconcurrent
atorvastatin and diltiazem. Ann Pharmacother 2002; 36: 1546-9.
Disopyramide
Tonkin AM, Joel SE, Reynolds JL. Unusual hepatocellular and cardiovascular
complications of disopyramide. Chest 1980; 77:125.
ScheinmanSJ, Poll DS, Wolfson S. Acute cardiac failure and hepatic ischemia
induced by disopyramide phosphate. Yale J Biol Med 1980; 53: 361-6.
Doody PT. Disopyramide hepatotoxicity and disseminated intravascular
coagulation. South Med J 1982; 75: 496-8.
Antonelli D, Koltun B, Barzilay J. Acute hepatotoxic effect of disopyramide.
Chest 1984; 86: 274.
Etodolac
Cunha PD, Lord RS, Johnson ST, Wilker PR, Aster RH,Bougie DW. Immune
hemolytic anemia caused by sensitivity to a metabolite of etodolac, a
nonsteroidal anti-inflammatory drug. Transfusion 2000; 40: 663-8.
Ezetimibe
Stolk MF, Becx MC, Kuypers KC, Seldenrijk CA. Severe hepatic side effects of
ezetimibe. Clin Gastroenterol Hepatol 2006; 4: 908-11.
Ritchie SR, Orr DW, Black PN. Severe jaundice followingtreatment with
ezetimibe. Eur J Gastroenterol Hepatol 2008; 20: 572-3.
Fluoxetine
Castiella A, Arenas JI. Fluoxetine-hepatotoxicity. Am JGastroenterol 1994;
89: 458-9.
Cosme A,Barrio J, Lobo C, Gil Y, Castiella A, Arenas JI. Acute cholestasis by
fluoxetine. Am J Gastroenterol 1996; 91: 2449-50.
Johnston DE, Wheeler DE. Chronic hepatitis related to use of fluoxetine. Am
Gabapentin
Ragucci MV, Cohen JM. Gabapentin-induced hypersensitivity syndrome. Clin
Neuropharmacol 2001; 24: 103-5.
Bureau C, Poirson H, Péron JM, Vinel JP. [Gabapentine-induced acute
hepatitis] Gastroenterol Clin Biol 2003; 27: 1169-70. French.
Gemcitabine
Robinson K, Lambiase L, Li J, Monteiro C, Schiff M.Fatal cholestatic liver
failure associated with gemcitabine therapy. Dig Dis Sci 2003; 48: 1804-8.
Saif MW, Shahrokni A, Cornfeld D. Gemcitabine - induced liver fibrosis in a
patient with pancreatic cancer. JOP. 2007 Jul9;8(4):460-7.
Gemfibrozil
Akoglu H, Yilmaz R, Kirkpantur A, Arici M Altun B, Turgan C. Combined organ
failure with combination antihyperlipidemic treatment: a case of hepatic
injury and acute renal failure. Ann Pharmacother 2007; 41: 143-7
Indomethacin
Fenech FF, Bannister WH, Grech JL. Hepatitis with biliverdinaemia in
association with indomethacin therapy. Br Med J 1967; 3: 155-6.
Kelsey WM, Scharyj M. Fatal hepatitis probably due to indomethacin. JAMA
1967; 199: 586-7.
Siegmund H. [Intrahepatic cholestasis following treatment with Dpenicillamine and indomethacin] Med Welt 1976; 27: 172-3. German.
Borbás B, Kiss E, Varga M. [2 cases of acute liver damage caused by
indomethacin] Orv Hetil 1980; 121: 459-60. Hungarian.
de Kraker-Sangster M, Bronkhorst FB, Brandt KH, Boersma JW. [Massive
liver cell necrosis following administration of indomethacin in combination
with aminophenzone] Ned Tijdschr Geneeskd 1981; 125: 1828-31. Dutch.
Lenalidomide/Thalidomide
Trojan A, Chasse E, Gay B, Pichert G, Taverna C. Severehepatic toxicity due
to thalidomide in relapsed multiple myeloma. Ann Oncol 2003; 14: 501-2.
Levetiracetam
Skopp G, Schmitt HP, Pedal I. [Fulminant liver failure in a patient on
carbamazepine and levetiracetam treatment associated with status
epilepticus]. Arch Kriminol 2006; 217: 161-75. German.
Broli M, Provini F, Naldi I, Bisulli F, Sama C, Baruzzi A, Tinuper P, Riva
R. Unexpected gamma glutamyltransferase rise increase during
levetiracetam monotherapy. Epileptic Disord 2010; 12: 81-2.
Gutiérrez-Grobe Y, Bahena-Gonzalez JA, Herrera-Gomar M, Mendoza-Diaz P,
García-López S, González-Chon O. Acute liver failure associated with
levetiracetam and lacosamide combination treatment for unspecified
epileptic disorder. Case Rep Emerg Med 2013; 2013: 634174.
Gómez-Zorrilla S, Ferraz AV, Pedrós C, Lemus M, Peña C. Levetiracetaminduced drug reaction with eosinophilia and systemic symptoms syndrome.
Ann Pharmacother. 2012 Jul-Aug;46(7-8):e20
Broli M, Provini F, Naldi I, Bisulli F, Sama C, Baruzzi A, Tinuper P, Riva R.
Unexpected gamma glutamyltransferase rise increase during levetiracetam
monotherapy. Epileptic Disord. 2010 Mar;12(1):81-2.
Losartan
Nygaard B, Strandgaard S. Marked hepatotoxicity associated with losartan
treatment. Blood Press. 1996 May;5(3):190-1.
Metronidazole
Lam S, Bank S. Hepatotoxicity caused by metronidazoleoverdose. Ann Intern
Med 1995; 122: 803.
Fagin ID. Jaundice associated with metronidazole. JAMA 1965; 193: 1128.
Mefenamic acid
Imoto S, Matsumoto H, Fujii M. Drug-related hepatitis. Ann Intern Med
1979; 91: 129.
Mexiletine
SasakiK, Yamamoto T, Kishi M, Yokozeki H, Nishioka K. Acute
exanthematous pustular drug eruption induced by mexiletine. Eur J
Dermatol 2001; 11: 469-71.
Yagami A, Yoshikawa T, Asano Y, Koie S, Shiohara T,Matsunaga K. Druginduced hypersensitivity syndrome due to mexiletine hydrochloride
associated with reactivation of human herpesvirus 7. Dermatology 2006;
213: 341-4.
Lee SP, Kim SH, Kim TH, Sohn JW, Shin DH, Park SS, Yoon HJ. A case of
mexiletine-induced hypersensitivity syndrome presenting as eosinophilic
pneumonia. J Korean Med Sci 2010; 25: 148-51.
Montelukast
Actis GC, Bugianesi E, Ottobrelli A, Rizzetto M. Fatal liver failure following
food supplements during chronic treatment with montelukast. Dig Liver Dis
2007; 39: 953-5.
Nafcillin
Lestico MR, Vick KE, Hetsko CM. Hepatic and renal dysfunction
followingnafcillin administration. Ann Pharmacother. 1992 Jul-Aug;26(78):985-90.
Nilutamide
Gomez JL, Dupont A,Cusan L, Tremblay M, Tremblay M, Labrie F.
Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen
nilutamide (Anandron): a case report. Am J Med 1992; 92: 563-6.
Penicillin G/V
Vardivia-Barriga V, FeldmanA, Orellana J. Generalized hypersensitivity with
hepatitis and jaundice after the use of penicillin and streptomycin.
Williams CN, Malatjalian DA. Severe penicillin-induced cholestasis in a 91year-old woman. Dig Dis Sci 1981; 26: 470-3.
Phenelzine
Daneshmend TK, Scott GL, Bradfield JW. Angiosarcoma of liver associated
with phenelzine. Br Med J 1979;1: 1679.
Pioglitazone
Floyd JS, Barbehenn E, Lurie P, Wolfe SM. Case series of liver failure
associatedwith rosiglitazone and pioglitazone. Pharmacoepidemiol Drug Saf.
2009 Dec;18(12):1238-43.
Maeda K. Hepatocellular injury in a patient receiving pioglitazone. Ann Intern
Med. 2001 Aug 21;135(4):306.
PRAVASTATIN
Hartleb M, Biernat L, Kochel A. Drug-induced liver damage--a three-year
study of patients from one gastroenterological department. Med Sci Monit
2002; 8: CR292-6.
RISPERIDONE
Fuller MA, Simon MR, Freedman L. Risperidone-associated hepatotoxicity. J
Clin Psychopharmacol 1996; 16: 84-5.
Kumra S, Herion D, Jacobsen LK, Briguglia C, Grothe D. Case study:
risperidone-induced hepatotoxicity in pediatric patients. J Am Acad Child
Adolesc Psychiatry 1997; 36: 701-5.
Benazzi F. Risperidone-induced hepatotoxicity. Pharmacopsychiatry 1998;
31: 241.
Whitworth AB, Liensberger D, Fleischhacker WW. Transient increase of liver
enzymes induced by risperidone: two case reports. J Clin Psychopharmacol
1999; 19: 475-6.
Krebs S, Dormann H, Muth-Selbach U, Hahn EG, Brune K, Schneider HT.
Risperidone-induced cholestatic hepatitis. Eur J Gastroenterol Hepatol 2001;
13: 67-9.
Holtmann M, Kopf D, Mayer M, Bechtinger E, Schmidt MH. Risperidoneassociated steatohepatitis and excessive weight-gain. Pharmacopsychiatry
2003; 36: 206-7.
Wright TM, Vandenberg AM. Risperidone- and quetiapine-induced
cholestasis. Ann Pharmacother 2007; 41: 1518-23.
Paulzen M, Orfanos S, Gründer G. Remission of drug-induced hepatitis after
switching from risperidone to paliperidone. Am J Psychiatry 2010; 167: 3512.
ROSIGLITAZONE
Floyd JS, Barbehenn E, Lurie P, Wolfe SM. Case series of liver failure
associated with rosiglitazone and pioglitazone.
Pharmacoepidemiol Drug Saf. 2009 Dec;18(12):1238-43.
Slavin DE, Schlichting CL, Freston JW.Rating the severity of the medical
consequences of drug-induced liver injury.
Regul Toxicol Pharmacol. 2005 Nov;43(2):134-40.
TEMOZOLOMIDE
Chheda MG, Drappatz J, Greenberger NJ, Kesari S, Weiss SE, Gigas DC,
Doherty LM, et al. Hepatitis B reactivation during glioblastoma treatment
with temozolomide: a cautionary note. Neurology 2007; 68: 955-6.
Topiramate
Bumb A, Diederich N, Beyenburg S. Adding topiramate to valproate therapy
may cause reversible hepatic failure. Epileptic Disord 2003; 5: 157-9.
Del Val Antoñana A, Ortiz Polo I, Andrade Bellido RJ. [Topiramate-induced
acute hepatitis]. Gastroenterol Hepatol 2010; 33: 148-9. Spanish.
TRAZODONE
Hull M, Jones R, Bendall M. Fatal hepatic necrosis associated with trazodone
and neuroleptic drugs. BMJ 1994; 309: 378.
Detry O, Delwaide J, De Roover A, Hans MF, Delbouille MH, Monard J,
Honore P. Fulminant hepatic failure induced by venlafaxine and trazodone
therapy: a case report. Transplant Proc 2009; 41: 3435-6.
VANCOMYCIN
Hauben M, Adler C. Acute hepatitis, interstitial nephritis, and eosinophilia.
Ann Intern Med 1995; 122: 555-6.
Alexander II, Greenberger PA. Vancomycin-inducedStevens-Johnson
syndrome. Allergy Asthma Proc 1996; 17: 75-8.
Zuliani E, Zwahlen H, Gilliet F, Marone C. Vancomycin-induced
hypersensitivity reaction with acute renal failure: resolution following
cyclosporine treatment. Clin Nephrol 2005; 64: 155-8.
Cadle RM, Mansouri MD, Darouiche RO. Vancomycin-induced elevation of
liver enzyme levels. Ann Pharmacother 2006; 40: 1186-9.
Tamagawa-Mineoka R, Katoh N, Nara T, Nishimura Y, Yamamoto S,
Kishimoto S. DRESS syndrome caused by teicoplanin and vancomycin,
associated with reactivation of human herpesvirus-6. Int J Dermatol 2007;
46: 654-5.
Fleming P, Marik PE. The DRESS syndrome: the great clinical mimicker.
Pharmacotherapy 2011; 31: 332.
VERAPAMIL
Stern EH, Pitchon R, King BD, Wiener I. Possible hepatitis from verapamil. N
Engl J Med 1982; 306: 612-3.
Veluvolu P, Whalen JP, Collier DC, Friedman B. Scintigraphic demonstration
of hepatocellular damage after verapamil toxicity. Clin Nucl Med 1988; 13:
368.
VINCRISTINE
Green DM, Finklestein JZ, Norkool P, D'Angio GJ. Severe hepatic toxicity
after treatment with single-dose dactinomycin and vincristine. A report of
the National Wilms' Tumor Study. Cancer 1988; 62: 270-3.
LeGuellec C, Benz-de Bretagne I, Jonville-Bera AP, Tarfaoui N, Andres CR,
Gendrot C, Jourdain A. A case of severe toxicity during coadministration of
vincristine and piperacillin: are drug transporters involved in vincristine
hypersensitivity and drug-drug interactions? J Pediatr Hematol Oncol. 2012
Nov;34(8):e341-3.
WARFARIN
Rehnqvist N. Intrahepatic jaundice due to warfarin therapy. Acta Med Scand
1978; 204: 335-6.
Jones DB, Makepeace MC, Smith PM. Jaundice following warfarin therapy.
Postgrad Med J 1980; 56: 671.
ZIDOVUDINE
Chen SC, Barker SM, Mitchell DH, Stevens SM, O’Neill P, Cunningham AL.
Concurrent zidovudine-induced myopathy and hepatotoxicity in patients
treated for human immunodeficiency virus(HIV) infection. Pathology 1992;
24: 109-11.
Aggarwal A, al Talib K, Alabrash M. Type B lactic acidosis in an AIDS patient
treated with zidovudine. Md Med J 1996; 45: 929-31.
In category D
Acetazolamide:
Kristinsson A. Fatal reaction to acetazolamide. Brit J Opthalamology
1967;51:348-349.
Alprazolam
Roy-Byrne P, Vittone BJ, Uhde TW. Alprazolam-related hepatotoxicity.
Lancet. 1983; 2: 786-7.
Anastrazole
Carlini P , Papaldo P , Fabi A , Felici A , Ruggeri EM , Milella M , Ciccarese M ,
Nuzzo C , Cognetti F , Ferretti G . Liver toxicity after treatment with gefitinib
andanastrozole: drug-drug interactions through cytochrome p450? J Clin
Oncol. 2006 Dec10;24(35):e60-1.
Atazanavir
Jacques AC, Giguère P, Zhang G, Touchie C, la Porte CJ. Atazanavir associated choledocholithiasis leading to acute hepatitis in an HIV-infected
adult. Ann Pharmacother. 2010 Jan;44(1):202-6.
Atenolol
Schwartz MS, Frank MS, Yanoff A, Morecki R. Atenolol-associated
cholestasis. Am J Gastroenterol. 1989 Sep;84(9):1084-6.
Anastrozole
Carlini P , Papaldo P , Fabi A , Felici A , Ruggeri EM , Milella M , Ciccarese M ,
Nuzzo C , Cognetti F , Ferretti G . Liver toxicity after treatment with gefitinib
andanastrozole: drug-drug interactions through cytochrome p450? J Clin
Oncol. 2006 Dec10;24(35):e60-1.
Benazepril
Hourmand-Ollivier I, Dargere S, Cohen D, Galais MP, Mosquet B, Rousselot
P, Dao T.
[Fatal subfulminant hepatitis probably due to the combination benazeprilhydrochlorothiazide (Briazide)]. Gastroenterol Clin Biol. 2000 Apr;24(4):464.
Bicalutamide
Castro Beza I, Sánchez Ruiz J, Peracaula Espino FJ, Villanego Beltrán MI.
Drug-related hepatotoxicity and hepatic failure following combined androgen
blockade. Clin Transl Oncol 2008; 10: 591-2.
Carbenicillin
Graft DF, Chesney PJ. Use of ticarcillin following carbenicillin-associated
hepatotoxicity. J Pediatr. 1982; 100: 497-9.
Neu HC, Swarz H. Carbenicillin: clinical and laboratory experience with a
parenterally administered penicillin for treatment of Pseudomonas infections.
Ann Intern Med. 1969 Nov;71(5):903-1
Cefadroxil
Ammann R, Neftel K, Hardmeier T, Reinhardt M. Cephalosporin-induced
cholestatic jaundice. Lancet 1982; 2: 337.
Cefuroxime
Yossepowitch O, Amir G, Safadi R, Lossos IS. Ischemic hepatitis associated
with toxic epidermal necrolysis in a cirrhotic patient treated with cefuroxime.
Eur J Med Res 1997;2 : 182-184.
Chlorambucil
Koler RD, Forsgren AL. Hepatotoxicity due to chlorambucil; report of a case.
JAMA 1958; 167: 316-7.
Jick H, Walker AM, Porter J. Drug-induced liver disease. J Clin Pharmacol
1981; 21: 359-64.
Chlordiazepoxide
Cacioppo J, Merlis S. Chlordiazepoxide hydrochlordie (Librium) and
jaundice: report of a case. Am J Psychiatry 1961; 117: 1040-1.
Pickering D. Hepatic necrosis after chlordiazepoxide therapy. N Engl J Med
1966; 274: 1449.
Abbruzzese A, Swanson J. Jaundice after therapy with chlordiazepoxide
hydrochloride. N Engl J Med 1965; 273; 321-2.
Chloroquine
Makin AJ, Wendon J, Fitt S, Portmann BC, Williams R.Fulminant hepatic
failure secondary to hydroxychloroquine. Gut 1994; 35: 569-70.
Giner Galvañ V, Oltra MR, Rueda D, Esteban MJ, Redón J. Severe acute
hepatitis related to hydroxychloroquine in a woman with mixed connective
tissue disease. Clin Rheumatol 2007; 26: 971-2.
CISPLATIN
Nagai H, Matsui T, Kanayama M, Momiyama K, Shizawa K, Wakui N,
Shinohara M, Watanabe M, Iida K, Ishii K, Igarashi Y, Sumino Y.
Hepatotoxicity of intra-arterial combination chemotherapy in patients with
liver cirrhosis and advanced hepatocellular carcinoma. Cancer Chemother
Pharmacol. 2010 Nov;66(6):1123.
Cyclosporin
Taniai N, Akimaru K, Ishikawa Y, Kanada T, Kakinuma D, Mizuguchi Y,
Mamada Y, Yoshida H, Tajiri T. Hepatotoxicity caused by both tacrolimus
andcyclosporine after living donor liver transplantation. J Nippon Med
Sch.2008 Jun;75(3):187-91.
Videla C, Vega J, Borja H. Hepatotoxicity associated with
cyclosporinemonitoring using C2 recommendations in adults renal recipients
receiving ketoconazole. Transplant Proc.2005 Apr;37(3):1574-6.
KaramehićJ, Ascerić M, Tulumović T, Kabil E, Uzeirbegović M, Hadzibegić N.
[Hepatotoxicity of cyclosporine in patientswith kidney transplants]. Med
Arh.1999;53(4):193-5. Croatian.
Myara A, Cadranel JF, Dorent R, Lunel F, Bouvier E, Gerhardt M, Bernard B,
Ghoussoub JJ, Cabrol A, Gandjbakhch I, Opolon P, Trivin F. Cyclosporin Amediated cholestasis in patients with chronic hepatitis after heart
transplantation. Eur J Gastroenterol Hepatol. 1996 Mar;8(3):267-71.
Horina JH, Wirnsberger GH, Kenner L, Holzer H, Krejs GJ. Increased
susceptibility for CsA- induced hepatotoxicity inkidney graft recipients with
chronic viral hepatitis C. Transplantation. 1993 Nov;56(5):1091-4.
Vinot O, Cochat P, Dubourg-DerainL, Bouvier R, Vial T, Philippe N. Jaundice
associated with concomitant use ofnorethandrolone and cyclosporine.
Transplantation. 1993 Aug;56(2):470-1.
Bluhm RE, Rodgers WH, Black DL, Wilkinson GR, Branch R. Cholestasis in
transplant patients--what is the role of cyclosporin? Aliment Pharmacol
Ther. 1992 Apr;6(2):207-19.
Docetaxel
Sundar S, Chan SY. Cholestatic jaundice and pseudomembranous colitis
following combination therapy with doxorubicin and docetaxel. Anticancer
Drugs 2003; 14: 327-9.
Ohlmann CH, Kohlmorgen S, Sahi D, Engelmann U, Heidenreich A. [Lethal
course after chemotherapy with docetaxel. Acute liver failure with
accompanying erythema multiforme major]. Urologe A 2007; 46: 1425-7.
German.
Donepezil
Verrico MM, Nace DA, Towers AL.Fulminant chemical hepatitis possibly
associated with donepezil and sertraline therapy. J Am Geriatr Soc. 2000
Dec;48(12):1659-63.
Enoxaparin
Carlson MK, Gleason PP, Sen S. Elevation of hepatic transaminases after
enoxaparin use: case report and review of unfractionated and lowmolecular-weight heparin-induced hepatotoxicity. Pharmacotherapy. 2001
Jan;21(1):108-13.
Entacapone
Fisher A, Croft-Baker J, Davis M, Purcell P, McLean AJ. Entacapone - induced
hepatotoxicity and hepatic dysfunction. Mov Disord. 2002 Nov;17(6):13625.
[No authors listed]. Entacapone : hepatitis (continued). The risk of liver
damage is being confirmed. It is better not to expose parkinsonian patients
to this drug . Prescrire Int.2008 Jun;17(95):113-4.
Ethambutol
Younossian AB, Rochat T, Ketterer JP, Wacker J, Janssens JP. High
hepatotoxicity of pyrazinamide and ethambutol for treatment of latent
tuberculosis. Eur Respir J. 2005 Sep;26(3):462-4.
Kurokawa I, Nakahigashi Y, Teramachi M. Erythema multiforme-type drug
eruption due to ethambutol with eosinophilia and liver dysfunction.
Int J Antimicrob Agents. 2003 Jun;21(6):596-7.
EXEMESTANE
Rabaglio M, Ruepp B; Soft/Text/Perche Steering Committee. Death due to
liver failure during endocrine therapy for premenopausal breast cancer. Acta
Oncol 2010; 49: 874-6.
Fosinopril
SchoondykeJW, Mohan R, Kelly JL, Ponder MA, Iskandar S, Douglas JE.
Fosinopril- induced hepatotoxicity in acomplex medical patient. Tenn Med.
2002Apr;95(4):155-6.
Gliclazide
Caksen H, Kendirci M, Tutus A, Uzüm K, Kurtoglu S. Gliclazide-induced
hepatitis, hemiplegia and dysphasia in a suicide attempt. J Pediatr Endocrinol
Metab 2001; 14: 1157-9.
Hydrochorothiazide
Arinzon Z, Alexander P, Berner Y. Hydrochlorothiazide induced hepatocholestatic liver injury. Age Ageing 2004; 33: 509-10.
Lapatinib
Shah RR, Morganroth J, Shah DR.Hepatotoxicity of tyrosine kinase
inhibitors:clinical and regulatory perspectives. Drug Saf. 2013
Jul;36(7):491-503.
Spraggs CF, Parham LR, Hunt CM, Dollery CT. Lapatinib - induced liver injury
characterized byclass II HLA and Gilbert's syndrome genotypes. Clin
Pharmacol Ther. 2012 Apr;91(4):647-52.
LOPINAVIR
Kottilil S, Polis MA, Kovacs JA. HIV Infection, hepatitis C infection, and
HAART: hard clinical choices. JAMA 2004; 292:243-50.
Mefloquine
Gotsman I, Azaz-Livshits T, Fridlender Z, Muszkat M, Ben-Chetrit E.
Mefloquine-induced acute hepatitis. Pharmacotherapy 2000; 20: 1517-9.
Mithramycin
Green L, Donehower RC. Hepatic toxicity of low doses of mithramycin in
hypercalcemia. Cancer Treat Rep. 1984 Nov;68(11):1379-81.
Nelfinavir
Trapé M, Barnosky S. Nelfinavir in expanded postexposure prophylaxis
causing acute hepatitis with cholestatic features: two case reports.
Infect Control Hosp Epidemiol. 2001 Jun;22(6):333-4.
Pentostatin
Sanchez M, Orero M, Marco J, Simó, Linares M, Carbonell F. Fulminant
hepatic failure after 2'-deoxycoformycin(pentostatin). Br J Haematol 1999;
105: 316.
Propofol
Motsch J, Schmidt H, Bach A, Böttiger BW, Böhrer H. Long-term sedation
with propofol and green discolouration of the liver. Eur J Anaesthesiol 1994;
11: 499-502.
Müller C, Jelinek T, Endres S, Loeschke K. [Severe protracted cholestasis
after general anesthesia in a patient with Alagille syndrome]. Z
Orsini J, Nadkarni A, Chen J, Cohen N. Propofol infusion syndrome: case
report and literature review. Am J Health Syst Pharm 2009; 66: 908-15.
Polo-Romero FJ. Propofol is not so safe for ERCP. Hepatobiliary Pancreat Dis
Int 2006; 5: 314; author reply 315.
Nguyen HD, Borum ML. Acute hepatitis in a patient given propofol during
colonoscopy. South Med J 2009; 102: 333-4.
RABEPRAZOLE
Johnstone D, Berger C, Fleckman P. Acute fulminant hepatitis after
treatment with rabeprazole and terbinafine. Arch Intern Med 2001; 161:
1677-8.
RALTEGRAVIR
Mateo-Carrasco H, Gálvez-Contreras MC, Fernández-Ginés FD, Nguyen TV.
Elevated liver enzymes resulting from an interaction between Raltegravir
and Panax ginseng: a case report and brief review.
Drug Metabol Drug Interact. 2012;27(3):171-5.
Sirolimus
Yaich S, El Aoud N, Zaghdane S, Charfeddine K, Kharrat M, Masmoudi M,
Hachicha J. Fatal outcome due to sirolimus-induced acute hepatitis,
myelosuppression and fever in a kidney allograft recipient. Saudi J Kidney
Dis Transpl. 2013 May;24(3):580-2.
Niemczyk M, Wyzgał J, Perkowska A, Porowski D, Paczek L. Sirolimusassociated hepatotoxicity in the kidney graft recipient. Transpl Int. 2005
Nov;18(11):1302-3.
Neff GW, Ruiz P, Madariaga JR, Nishida S, Montalbano M, Meyer D, Levi DM,
Tzakis AG, O'Brien CB. Sirolimus-associated hepatotoxicity in liver
transplantation.
Ann Pharmacother. 2004 Oct;38(10):1593-6.
Sunitinib
Mueller EW, Rockey ML, Rashkin MC. Sunitinib-related fulminant hepatic
failure: case report and review of the literature. Pharmacotherapy 2008; 28:
1066-70.
Lee NR, Yhim HY, Yim CY, Kwak JY, Song EK. Sunitinib-induced
hyperammonemic encephalopathy in gastrointestinal stromal tumors. Ann
Pharmacother 2011; 45: e56.
Shea YF, Chiu WY, Mok MY, Hung IF, Yau CC. Sunitinib-induced
hyperammonaemia in a patient with pancreatic neuroendocrine tumour. J
Clin Pharm Ther 2013; 38: 327-9.
Mermershtain W, Lazarev I, Shani-Shrem N, Ariad S. Fatal liver failure in a
patient treated with sunitinib for renal cell carcinoma. Clin Genitourin Cancer
2013; 11: 70-2.
SILDENAFIL
Daghfous R, El Aidli S, Zaiem A, Loueslati MH, Belkahia C. Sildenafilassociated hepatotoxicity. Am J Gastroenterol. 2005 Aug;100(8):1895-6.
TACROLIMUS
Kusumi E, Kami M, Kanda Y, Murashige N, Seki K, Fujiwara M, Koyama R,
Komatsu T, Hori A, Tanaka Y, Yuji K, Matsumura T, Masuoka K, Wake A,
Miyakoshi S, Taniguchi S.Hepatic injury following reduced intensity unrelated
cord blood transplantation for adult patients with hematological diseases.
Biol Blood Marrow Transplant. 2006 Dec;12(12):1302-9.
Shah S, Budev M, Blazey H, Fairbanks K, Mehta A. Hepatic veno-occlusive
disease due to tacrolimus in a single-lung transplant patient. Eur Respir J.
2006 May;27(5):1066-8.
Ganschow R, Albani J, Grabhorn E, Richter A, Burdelski M. Tacrolimusinduced cholestatic syndrome following pediatric liver transplantation and
steroid-resistant graft rejection. Pediatr Transplant. 2006 Mar;10(2):220-4.
Taniai N, Akimaru K, Ishikawa Y, Kanada T, Kakinuma D, Mizuguchi Y,
Mamada Y, Yoshida H, Tajiri T. Hepatotoxicity caused by both tacrolimus and
cyclosporine after living donor liver transplantation. J Nippon Med Sch. 2008
Jun;75(3):187-91.
Tümgör G, Ankan C, Nart D, Kihiç M, Aydoğdu S. Fatty liver due to high
levels of serum tacrolimus after liver transplantation. Turk J Pediatr. 2007
Apr-Jun;49(2):223-5.
Oto T, Okazaki M, Takata K, Egi M, Yamane M, Toyooka S, Sano Y, Snell GI,
Goto K, Miyoshi S. Calcineurin inhibitor-related cholestasis complicating lung
transplantation. Ann Thorac Surg. 2010 May;89(5):1664-5.
Thiotepa
Lee JL, Gooley T, Bensinger W, Schiffman K, McDonald GB. Veno-occlusive
disease of the liver after busulfan, melphalan, and thiotepa conditioning
therapy: incidence, risk factors, and outcome. Biol Blood Marrow
Transplant. 1999;5(5):306-15.
Triazolam
Cobden I, Record CO, White RWB. Fatal intrahepatic cholestasis associated
with triazolam. Postgrad Med J 1981; 57: 730-1
Valsartan
Gómez NA, Mejillón JL, Zapatier JA, Vargas PE.[Biliary stenosis, hepatitis A
and valsartan: multifactorial hepatotoxicity in a surgical patient]. Cir Esp.
2006 Mar;79(3):189-91. Spanish.
Zonisamide
Fujita Y, Hasegawa M, Nabeshima K, Tomita M, Murakami K, Nakai S,
Yamakita T, Matsunaga K. Acute kidney injury caused byzonisamide-induced
hypersensitivity syndrome. Intern Med 2010; 49: 409-13.
Amoxapine
Patterson JP. Amoxapine associated with hepatotoxicity. J Clin
Psychopharmacol 1987; 7: 50-1.
Amprenavir/Fosamprenavir
Pavel S, Burty C, Alcaraz I, de la Tribonnière X, Baclet V, Ajana F, Mouton
Y, et al. Severe liver toxicity in postexposure prophylaxis for HIV infection
with a zidovudine, lamivudine and fosamprenavir/ritonavir regimen. AIDS
2007; 21: 268-9.
Anidualfungin
Hayes D Jr, McConnell PI, Preston TJ, Nicol KK.
Hyperbilirubinemia complicating plasma-free hemoglobin and antifactor Xa
level monitoring on venovenous extracorporeal membrane oxygenation.
World J Pediatr Congenit Heart Surg. 2014 Apr;5(2):345-7.
Aripiprazole
Mahapatra S, Belgrad JL, Adeoye MA. Psychotropic drug-related
eosinophilia with systemic symptoms after acute caffeine ingestion.
Pediatrics. 2011 Jan;127(1):e235-8.
Atovaquone
Grieshaber M, Lämmli J, Marcus L. Acute hepatitis and
atovaquone/proguanil. J Travel Med 2005; 12: 289-90. Other drug.
BLEOMYCIN
Hubbard SP, Chabner BA, Canellos GP, Young RC, DeVita VT Jr. High dose
intravenous bleomycin in the treatment of advanced lymphomas. Eur J
Cancer 1975; 11: 623-6.
Aleem A, Al-Katari M, Alsaleh K, AlSwat K, Al-Sheikh A. Vanishing bile
duct syndrome in a Hodgkin's lymphoma patient with fatal outcome
despite lymphoma remission. Saudi J Gastroenterol 2013; 19: 286-9.
Capecitabine
Gurzu S1, Jung I, Comsulea M, Kadar Z, Azamfirei L, Molnar C. Lethal
cardiotoxicity, steatohepatitis, chronic pancreatitis, and acute enteritis
induced by capecitabine and oxaliplatin in a 36-year-old woman. Diagn
Pathol. 2013 Sep 16;8:150. doi: 10.1186/1746-1596-8-150.
Carmustine
Lokich JJ, Drum DE, Kaplan W. Hepatic toxicity ofnitrosourea analogues.
Clin Pharmacol Ther 1974; 16: 363-7.
McIntyre RE, Magidson JG, Austin GE, Gale RP. Fatal veno-occlusive
disease of the liver following high dose1,3-bis(2-chloroethyl)-1nitrosurea(BCNU) and autologus bone marrow transplantation. Am J Clin
Pathol 1981; 75: 614-6.
Ceftibuten
Combe C, Banas B, Zoller WG, Manns MP, Schlöndorff D. [Antibioticinduced prolonged cholestasis: suspected induction by ceftibuten]. Z
CLOFARABINE
Johnston DL, Mandel KM. Fatal skin and liver toxicity in a patient treated
with clofarabine. Pediatr Blood Cancer 2008; 50: 1082.
CLORAZEPATE
PROBABLY UNLIKELY: HEP A, B AND C NOT INCLUDED
Parker JLW. Potassium clorazepate (Tranxene)-induced jaundice. Acute
hepatitis-like injury due to clorazepate. Postgrad Med J 1979; 55: 908910.
Desipramine
Powell WJ, Koch-Weser J, Williams RA. Lethal hepatic necrosis after
therapy with imipramine and desipramine. JAMA 1968; 206: 642-5.
Price LH, Nelson JC, Waltrip RW. Desipramine-associated hepatitis. J Clin
Psychopharmacol. 1983 Aug;3(4):243-6. Blood transfusion 6 months
earlier in case 1, parenteral drug use in case 2.
Remy AL, Larrey D, Pageaux GP, Desprez D, Ramos J, Michel H. Cross
hepatotoxicity between tricyclic antidpressants and phenothiazines. Eur J
Diazepam
Fors B, Nilsson F. [Hepatitis probably induced by diazepam medication]
Cunningham ML. Acute hepatic necrosis following treatment with
amitriptyline and diazepam. Brit J Psychiat 1965; 111: 1107-9.
Dydrogesterone
Altintaş E, Oğuz D, Kaçar S, Ozderin Y, Sezgin O, Zengin NI.
Dydrogesterone-induced hepatitis and autoimmune hemolytic anemia.
Turk J Gastroenterol. 2004 Mar;15(1):49-52.
Ethosuximide
Coulter DL. Ethosuximide-induced liver dysfunction. Arch Neurol 1983;
40: 393-4.
Conilleau V, Dompmartin A, Verneuil L, Michel M, Leroy D.
Hypersensitivity syndrome due to 2 anticonvulsant drugs. Contact
Dermatitis 1999; 41: 141-4.
Flucytosine
Record CO, Skinner JM, Sleight P, Speller DCE. Candida endocarditis
treated with 5-fluorocytosine. Br Med J 1971; 1: 262-4.
Fluphenazine
Walters GM, Terrence C, Steckel R. Jaundice followingadministration of
fluphenazine dihydrochloride. Am J Psychiatry 1963; 120: 81-2.
Snyder S. Fluphenazine jaundice. Report of a case. Am J Gastroenterol
1980; 73: 336-40.
Holt RJ. Fluphenazine decanoate-induced cholestatic jaundice and
thrombocytopenia. Pharmacotherapy 1984; 4: 227-9.
Aruna AS, Murungi JH. Fluphenazine-induced neuroleptic malignant
syndrome in a schizophrenic patient. Ann Pharmacother 2005; 39: 11315.
Fluvoxamine
Lam KS, Blanchi A, Chavaillon JM. [Hepatitis probably secondary to the
massive ingestion of fluvoxamine]. Gastroenterol Clin Biol 1988; 12: 3989.
Indinavir
Bräu N, Leaf HL, Wieczorek RL, Margolis DM. Severe hepatitis in three
AIDS patients treated with indinavir. Lancet. 1997 Mar
29;349(9056):924-5.
Vergis E, Paterson DL, Singh N. Indinavir-associated hepatitis in patients
with advanced HIV infection. Int J STD AIDS 1998; 9:53.
Lithium
Warick LH. Lithium poisoning. Report of a case with neurologic, cardiac
and hepatic sequelae. West J Med 1979; 130: 259-63.
Kosson H, Chou JC-Y. Abnormal liver function tests associated with lithium
treatment. J Clin Psychopharmacol 1992; 12: 216-7.
Isocarboxazid
Knight JA. Drug-induced hepatic injury. Marplan hepatitis. Am J Psychiatry
1961; 118: 73-4.
Maraviroc
Horster S, Goebel FD. Serious doubts on safety and efficacy of CCR5
antagonists: CCR5 antagonists teeter on a knife-edge. Infection 2006; 34;
110-3.
Mangiafico L, Perja M, Fusco F, Riva S, Mago D, Gringeri A. Safety and
effectiveness of raltegravir in patients with haemophilia and anti-HIV
multidrug resistance. Haemophilia 2012; 18: 108-11.
Minoxidil
David J. DiSantis, John Flanagan. Minoxidil-induced Stevens-Johnson
syndrome. Arch Intern Med 1981; 141: 1515.
Piperacillin
Schneider M, Helbling A, Zimmermann A, Krähenbühl S. Cholangiopathy
after short-term administration of piperacillin and imipenem/cilastatin.
Liver 2001; 21: 213-6).
Dietze MA, Martin P, Schaaf-Lafontaine N. [Clinical case of the
month. Cholestatic hepatitis after administration of piperacillin]. Rev Med
Liege 2002; 57: 571-4. French.
PROBENEZID
Reynolds ES, Schlant RC, Gonick HC, Dammin GJ. Fatal massive necrosis
of the liver as a manifestation of hypersensitivity to probenecid. N Engl J
Med 1957; 256: 592-6.
Proguanil
Grieshaber M, Lämmli J, Marcus L. Acute hepatitis and
atovaquone/proguanil. J Travel Med 2005; 12: 289-90.
Wielgo-Polanin R, Lagarce L, Gautron E, Diquet B, Lainé-Cessac P.
Hepatotoxicity associated with the use of a fixed combination of
chloroquine and proguanil. Int J Antimicrob Agents 2005; 26: 176-8.
Propranolol
Epeirier JM, Pageaux GP, Coste V, Perrigault PF, Banc P, Larrey D, Michel
H. Fulminant hepatitis after carbimazole and propranolol administration.
Eur J Gastroenterol Hepatol. 1996 Mar;8(3):287-8.
Kunze KD, Porst H, Tschöpel L.[Morphology and pathogenesis of liver
injury produced by dihydralazine , propranolol and ketophenylbutazone].
Zentralbl Allg Pathol. 1985;130(6):509-18. German.
RISEDRONATE
Phillips MB. Risedronate-induced hepatitis. Am J Med 2007; 120: e1-2.
Sumatriptan
Deixler E, Helmke K. [Extrahepatic cholestasis during therapy with
zolmitriptan (AscoTop)]. Z Gastroenterol 2005; 43: 1045-9. German.
Tolbutamide
Baird RW, Hull JG. Cholestatic jaundice from tolbutamide. Ann Intern Med
1960; 53: 194.
McMahon TF. Cholestatic jaundice, liver decompensation, and shock
resulting from tolbutamide: report of a case. Med Ann DC 1963; 509.
Balodimos MC, Camerini-Dávalos RA, Marble A. Nine years. experience
with tolbutamide in the treatment of diabetes. Metabolism 1966; 15: 95770.
Gregory DH, Zaki GF, Sarosi GA, Carey JB Jr. Chronic cholestasis following
prolonged tolbutamide administration. Arch Pathol 1967; 84: 194.
Ananth JV, Ban TA, Lehmann HE. Tolbutamide jaundice associated with
multiple drug therapy. Can Med Assoc J 1970; 103: 1194.
Tipranavir
Jülg B, Bogner JR, Goebel FD. Severe hepatotoxicity associated with the
combination of enfuvirtide and tipranavir/ritonavir: case report. AIDS
2006; 20:1563.
Tramadol
Loughrey MB, Loughrey CM, Johnston S, O'Rourke D. Fatal hepatic failure
following accidental tramadol overdose. Forensic Sci Int 2003; 134: 2323.
De Decker K, Cordonnier J, Jacobs W, Coucke V, Schepens P, Jorens PG.
Fatal intoxication due to tramadol alone: case report and review of the
literature. Forensic Sci Int. 2008 Feb 25;175(1):79-82.
Triazolam
Cobden I, Record CO, White RWB. Fatal intrahepatic cholestasis
associated with triazolam. Postgrad Med J 1981; 57: 730-1.
Lewis JH, Zimmerman HJ. Drug- and chemical-induced cholestasis. Clin
Liver Dis 1999; 3: 433-64, vii. Erratum in: Clin Liver Dis 1999; 3: 917.
Trifluoperazine
Kohn N, Myerson RM. Cholestatic hepatitis associated with trifluoperazine.
N Engl J Med 1961; 264: 549-50.
Margulies AI, Berris B. Jaundice associated with the administration of
trifluoperazine. Can Med Assoc J 1968; 98: 1063-4.
Valganciclovir
Shea BF, Hoffman S, Sesin GP, Hammer SM. Ganciclovir hepatotoxicity.
Vardenafil
Shea BF, Hoffman S, Sesin GP, Hammer SM. Ganciclovir hepatotoxicity.
Zolmitriptan
Deixler E, Helmke K. Recurrent jaundice in a patient taking zolmitriptan
for migraine headaches. [Extrahepatic cholestasis during therapy with
zolmitriptan (AscoTop)]. Z Gastroenterol 2005; 43: 1045-9. German
Zolpidem
Karsenti D, Blanc P, Bacq Y, Metman EH. Hepatotoxicity associated with
zolpidem treatment. BMJ 1999; 318(7192): 1179.
No
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
Ingredient
Abatacept*
Acamprosate
Acrivastine
Adefovir
Albuterol
Alefacept*
Alemtuzumab
Alendronic acid
Almotriptan
Altretamine*
Amantadine
Ambrisentan
Amikacin
Amiloride
Aminophylline
Amobarbital
Amoxapine
Amprenavir/Fosamprenavir
Anidulafungin
Apomorphine
Aprepitant/Fosaprepitant
Aripiprazole*
Artemether*
Atovaquone*
Atropine
Azacitidine*
Aztreonam*
Basiliximab
Bendroflumethiazide
Benzphetamine
Benztropine
Betaxolol
Bevacizumab
Biperiden
Bisacodyl
Bisoprolol
Bitolterol
Bleomycin*
Brompheniramine/Dexbrompheniramine
Bumetanide
Buspirone*
Butalbital
Butobarbital
Butorphanol
Caffeine
Capecitabine*
Capreomycin
Year
2005
2004
1994
2002
1981
2001
1995
2003
2001
1990
1968
2007
1981
1986
1940
<1980
1992
1999
2006
2004
2003
2002
2008
1992
<1960
2004
1986
1998
1959
1960
1954
1985
2004
1959
2004
1992
<1980
1973
1971
1983
1986
1990
<1980
1978
1998
1971
Classification
Immunomodulatory
Substance abuse agent
Respiratory
Antimicrobial
Respiratory
Immunomodulatory
Immunomodulatory
Endocrine
CNS
Antineoplastic
CNS
Respiratory
Antimicrobial
Cardiovascular
Respiratory
CNS
CNS
Antimicrobial
Antimicrobial
CNS
Gastrointestinal
CNS
Antimicrobial
Antimicrobial
Cardiovascular
Antineoplastic
Antimicrobial
Immunomodulatory
Cardiovascular
Weight loss agent
CNS
Cardiovascular
Antineoplastic
CNS
Gastrointestinal
Cardiovascular
Respiratory
Antineoplastic
Respiratory
Cardiovascular
CNS
CNS
CNS
Analgesic
CNS
Antineoplastic
Antimicrobial
No
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
Ingredient
Carbidopa
Carbinoxamine
Carisoprodol
Carmustine*
Caspofungin
Cefditoren*
Cefixime*
Cefoxitin*
Cefpodoxime*
Ceftibuten*
Ceftizoxime*
Cephradine*
Certolizumab pegol*
Cetuximab
Chloral hydrate
Chlorpheniramine/Dexchlorpheniramine
Chlortetracycline*
Chlorthalidone
Cholestyramine*
Cidofovir
Cilastatin
Cisapride
Cladribine
Clemastine
Clonidine
Clorazepate
Cobicistat
Codeine
Colchicine
Colesevelam
Colestipol
Cyclobenzaprine
Darifenacin
Darunavir*
Daunorubicin*
Decitabine*
Delavirdine*
Demeclocycline*
Desipramine*
Desirudin
Diazepam
Dicyclomine
Diethylpropion
Dihydroergotamine
Dimenhydrinate
Dimercaprol
Diphenhydramine
Year
1966
<1980
1959
1977
2001
2001
1989
1991
1995
1998
1971
1974
2008
2002
<1960
1971
<1960
1960
1973
1996
1985
1993
1977
1974
1972
2012
<1960
1961
2000
1977
1977
2004
2003
1979
2006
1997
1960
1964
2003
1963
1996
1959
1946
2004
1946
1946
Classification
CNS
Respiratory
CNS
Antineoplastic
Antimicrobial
Antimicrobial
Antimicrobial
Antimicrobial
Antimicrobial
Antimicrobial
Antimicrobial
Antimicrobial
Immunomodulatory
Antineoplastic
CNS
Respiratory
Antimicrobial
Cardiovascular
Cardiovascular
Antimicrobial
Antimicrobial
Gastrointestinal
Antineoplastic
Respiratory
Cardiovascular
CNS
Antimicrobial
Analgesic
Rheumatologic
Cardiovascular
Cardiovascular
CNS
Urologic
Antimicrobial
Antineoplastic
Antineoplastic
Antimicrobial
Antimicrobial
CNS
Hematologic
CNS
Gastroinestinal
Weight loss agent
CNS
CNS
Toxicology
CNS
No
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
Ingredient
Diphenoxylate
Docusate
Dolasetron
Doxazosin
Doxylamine
Dronabinol
Dutasteride
Eletriptan
Emtricitabine
Enfuvirtide
Entecavir
Epirubicin*
Eplerenone
Eprosartan
Ergotamine
Ertapenem*
Esmolol
Estazolam
Eszopiclone
Ethacrynate
Ethosuximide
Etidronate
Everolimus
Famciclovir
Felodipine
Fentanyl
Fesoterodine
Fexofenadine
Finasteride
Flavoxate
Flucytosine
Fludarabine*
Fluphenazine*
Fluvoxamine*
Formoterol
Foscarnet
Fosfestrol*
Frovatriptan
Furosemide
Galantamine
Ganciclovir/Valganciclovir
Gentamicin
Glycopyrrolate
Golimumab*
Granisetron
Griseofulvin
Guanethidine
Year
1960
<1980
1997
2007
1948
1985
2001
2002
2006
2003
2005
1999
2002
1997
<1960
2001
1986
1991
2004
1967
1960
1977
2009
1994
1991
1968
2008
1996
1992
1970
1971
1991
1972
1994
2006
1991
2001
1966
2001
1994
1970
1961
2009
1993
2007
1960
Classification
Gastrointestinal
Gastrointestinal
Gastrointestinal
Cardiovascular
CNS
Gastrointestinal
Urologic
CNS
Antimicrobial
Antimicrobial
Antimicrobial
Antineoplastic
Cardiovascular
Cardiovascular
CNS
Antimicrobial
Cardiovascular
CNS
CNS
Cardiovascular
CNS
Endocrine
Immunomodulatory
Antimicrobial
Cardiovascular
Analgesic
Urologic
Respiratory
Urologic
Urologic
Antimicrobial
Antineoplastic
CNS
CNS
Respiratory
Antimicrobial
Antineoplastic
CNS
Cardiovascular
CNS
Antimicrobial
Antimicrobial
Respiratory
Immunomodulatory
Gastrointestinal
Antimicrobial
Cardiovascular
No
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
Ingredient
Homatropine
Hydrocodone
Hydromorphone
Hydroxyzine
Hyoscyamine
Ibandronate
Idarubicin*
Indapamide
Indinavir*
Ipratropium
Isocarboxazid*
Isradipine
Ketorolac*
Lamivudine
Levamisole*
Levodopa
Levorphanol
Liraglutide
Lithium
Lomefloxacin
Loperamide
Loratadine/Desloratadine
Lorazepam
Loxapine
Lubiprostone
Maraviroc*
Mechlorethamine*
Meclizine
Mepenzolate
Meperidine
Meprobamate
Metaproterenol
Metaxalone
Methadone
Methocarbamol
Methscopolamine
Methysergide
Metoclopramide*
Metolazone
Mezlocillin*
Midazolam
Miglitol
Minoxidil
Modafinil/Armodafinil
Moexipril
Morphine
Muromonab-CD3
Year
<1980
1998
1984
1956
<1980
2003
1990
1983
1996
1986
1959
1990
1991
1994
1990
1970
1953
2010
1970
1992
1976
1991
1977
1975
2006
2007
1949
1957
1956
1942
1952
1987
1962
1947
1957
1953
1962
1980
1973
1981
1985
1996
1979
1998
1995
Old
1999
Classification
Gastrointestinal
Analgesic
Analgesic
Respiratory
Gastrointestinal
Endocrine
Antineoplastic
Cardiovascular
Antimicrobial
Respiratory
CNS
Cardiovascular
Analgesic
Antimicrobial
Antimicrobial
CNS
Analgesic
Endocrine
CNS
Antimicrobial
Gastrointestinal
Respiratory
CNS
CNS
Gastrointestinal
Antimicrobial
Antineoplastic
Respiratory
Gastrointestinal
Analgesic
CNS
Respiratory
CNS
CNS
Respiratory
CNS
Gastrointestinal
Cardiovascular
Antimicrobial
CNS
Endocrine
Cardiovascular
CNS
Cardiovascular
Analgesic
Immunomodulatory
No
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
Ingredient
Nabilone
Nabumetone*
Nadolol
Nalmefene
Naloxone
Naltrexone
Naratriptan
Nateglinide
Nebivolol*
Neomycin
Nicardipine
Nicotine
Nilotinib*
Nimodipine
Nisoldipine
Nitazoxanide
Nitroprusside
Nystatin
Ofatumumab*
Olmesartan
Omalizumab
Orphenadrine
Oseltamivir
Oxazepam
Oxybutynin
Oxycodone
Oxytetracycline*
Paclitaxel*
Palonosetron
Pamidronate
Panitumumab
Pegaptanib
Penbutolol
Pentazocine
Pergolide
Perindopril
Phentermine
Phenyltoloxamine
Pimozide
Pindolol
Piperacillin*
Pirbuterol
Polythiazide
Posaconazole*
Pramipexole
Pramlintide
Praziquantel
Year
1985
1991
1979
1995
1971
2006
1976
2004
2000
1970
1988
OTC
2007
1998
1995
2004
1981
1971
2009
2002
2003
1959
1999
1965
1975
1991
<1960
1992
2003
1991
2006
2004
1987
1967
1988
1993
1983
Old
1984
1982
1981
1986
1961
2006
1997
2005
1982
Classification
Gastrointestinal
Analgesic
Cardiovascular
CNS
Endocrine
Cardiovascular
Antimicrobial
Cardiovascular
Antineoplastic
Cardiovascular
Cardiovascular
Antimicrobial
Cardiovascular
Antimicrobial
Antineoplastic
Cardiovascular
Respiratory
CNS
Antimicrobial
CNS
Urologic
Analgesic
Antimicrobial
Antineoplastic
Gastrointestinal
Endocrine
Antineoplastic
Ophthalmologic
Cardiovascular
Analgesic
CNS
Cardiovascular
Weight loss agent
Respiratory
CNS
Cardiovascular
Antimicrobial
Respiratory
Cardiovascular
Antimicrobial
CNS
Endocrine
Antimicrobial
No
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
269
269
270
271
272
273
274
275
276
277
278
279
280
281
282
Prazosin
Primaquine*
Primidone*
Probenecid
Proguanil*
Promazine*
Promethazine
Propantheline
Propranolol
Protriptyline*
Pyrantel
Quazepam
Quinapril
Ramelteon
Ranibizumab
Rasagiline*
Remifentanil
Reserpine
Ribavirin
Rifapentine*
Rifaximin
Rilonacept
Rimantadine
Risedronate*
Rizatriptan
Salbutamol
Salmeterol
Saxagliptin*
Scopolamine
Secobarbital
Selegiline*
Silodosin
Solifenacin
Sotalol
Succimer
Sufentanil
Sulbactam
Sumatriptan
Tadalafil
Tazobactam
Tegaserod
Telbivudine
Telmisartan
Temazepam
Temsirolimus
Teniposide*
Tenofovir
Ingredient
Year
1976
1952
1954
1951
2000
1957
1957
1953
1967
1967
Old
1985
1991
2005
2006
2006
1996
1955
1985
1998
2004
2010
1993
1998
2007
1981
1997
2009
1979
1950
2006
2007
2004
1992
1991
1984
1986
1997
2003
1993
2002
2006
1998
1981
2007
1992
2001
Classification
Cardiovascular
Antimicrobial
CNS
Rheumatologic
Antimicrobial
CNS
Gastrointestinal
Gastrointestinal
Cardiovascular
CNS
Antimicrobial
CNS
Cardiovascular
CNS
Ophthalmologic
CNS
Analgesic
Cardiovascular
Antimicrobial
Antimicrobial
CNS
Immunomodulatory
Antimicrobial
Endocrine
CNS
Respiratory
Respiratory
Endocrine
Gastrointestinal
CNS
CNS
Urologic
Urologic
Cardiovascular
Toxicology
Analgesic
Antimicrobial
CNS
Urologic
Antimicrobial
Gastrointestinal
Antimicrobial
Cardiovascular
CNS
Antineoplastic
Antineoplastic
Antimicrobial
No
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
Ingredient
Terazosin
Theophylline
Thiopental
Thyroid extract
Tiagabine
Ticarcillin*
Tigecycline*
Timolol
Tinidazole
Tinzaparin*
Tiotropium
Tipranavir*
Tolbutamide*
Tolterodine
Topotecan*
Torsemide
Tramadol
Trandolapril
Triazolam*
Trientine
Trifluoperazine*
Trihexyphenidyl*
Triiodothyronine*
Trimethobenzamide
Triprolidine
Trospium
Vardenafil
Vinblastine*
Vinorelbine
Zalcitabine
Zaleplon
Zanamivir
Zoledronic acid
Zolmitriptan*
Zolpidem
Year
1987
1982
<1980
<1960
1997
2005
2005
1995
2004
2000
2004
2005
1961
1998
2007
1993
1995
1996
1982
1985
1959
1949
1956
1974
<1980
2004
2003
1965
1994
1992
1999
1999
2001
1997
1992
Classification
Urologic
Respiratory
CNS
Endocrine
CNS
Antimicrobial
Antimicrobial
Cardiovascular
Antimicrobial
Hematologic
Respiratory
Antimicrobial
Endocrine
Urologic
Antineoplastic
Cardiovascular
Analgesic
Cardiovascular
CNS
Toxicology
CNS
CNS
Endocrine
Gastrointestinal
Respiratory
Urologic
Urologic
Antineoplastic
Antineoplastic
Antimicrobial
CNS
Antimicrobial
Endocrine
CNS
CNS
*These agents have been suspected of having hepatotoxicity or were implicated in published cases
that did not meet the criteria of being possibly causalitive using the RUCAM method.

REFERENCES FOR DRUGS IN CATEGORY A ALLOPURINOL

Transcription

Similar documents

Kurikulum Vitae Nama : Prof Dr. Nurul Akbar SpPD KGEH Riwayat

Hepatic diseases related to migratory flows

HCV - Microbiologia TorVergata

Terapia cellulare

SIMPOSIO AIRO-AIMN Trattamento delle metastasi ossee nel

Adsorption Desalination and its hybrids

Diete a diverso contenuto di carboidrati

Instrucciones de instalación Riviera

Wetrok Monomatic LS/I/DS/HS/US

manual

Manuels

2213 - Eheim

Weber Charcoal Grill Owner`s Guide